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Abstract 
 
Introduction 
Multimorbidity is common.  The gaps in multimorbidity research are in the measurement of 
the prevalence, the levels of multimorbidity and its associated outcomes.   
 
Objectives 
This thesis aimed to provide a uniform definition for multimorbidity, identify instruments for 
measuring the level of multimorbidity, and describe patient-reported outcomes for different 
levels of multimorbidity. 
 
Methods 
Three studies were conducted.  The first determined the prevalence rates of multimorbidity and 
explored whether there were differences among the different age, sex and ethnic groups in the 
primary care population.  Common dyads and triads of conditions were described.  The 
systematic review updated the list of instruments for measuring the level of multimorbidity for 
community-dwelling adults.  The third study determined the association of different levels of 
multimorbidity with depression, anxiety and quality of life.  The agreement between patients’ 
self-reported conditions and conditions recorded in their electronic medical records (EMR) 
were reported. 
 
Results 
Increasing age was associated with a higher prevalence of multimorbidity.  The commonest 
dyad was hyperlipidaemia/hypertension, and triad was hyperlipidaemia/hypertension/diabetes.  
Disease count and weighted indices were the most commonly used instruments for measuring 
the level of multimorbidity.  Self-reported disease count was positively associated with 
depression and anxiety, and negatively associated with quality of life.  Stroke was the only 
condition that showed substantial agreement between patients’ self-reported medical 
conditions and the EMR. 
  
 
 
ii 
 
Conclusion 
We identified a practical definition of multimorbidity in the Singapore primary care population, 
described the commonly used instruments for measuring the level of multimorbidity, and 
reported the disparity of multimorbidity outcomes between patients’ self-reported chronic 
conditions and EMR. 
 
(249 words) 
 
Keywords 
 
Anxiety, chronic condition, concordance, depression, level of multimorbidity, measurement of 
multimorbidity, patterns of multimorbidity, patient-reported outcomes, prevalence, quality of 
life.  
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1 Introduction 
 
Epidemiologically, we are in the age of degenerative and human-made diseases whereby 
overall mortality continues to decline1.  This is mainly due to demographic changes in many 
developed societies and public health improvement.  During this transition, a long-term shift 
occurs in mortality and disease patterns whereby degenerative diseases gradually displace 
pandemic infections as the chief form of morbidity and primary death. 
  
In 2015, the Global Burden of Disease study reported that chronic conditions like heart disease, 
stroke, diabetes, chronic kidney disease and Alzheimer’s disease caused seven out of every ten 
deaths in 20142.  This occurred at the same time that death rates from communicable diseases 
like HIV/AIDS and malaria were falling. 
 
The report also revealed that people’s average life spans had risen by 6.1 years over the last 15 
years steadily in 191 countries, resulting in a significant overall increase in life expectancy.  
Not only does a longer life expectancy increase the chance of developing a chronic condition, 
but the likelihood of having multiple chronic conditions (i.e., multimorbidity) also increases.  
As the population ages in many societies worldwide, an increasing number of people are living 
with multimorbidity. 
 
Multimorbidity was an important but often ignored medical phenomenon until recently.  Until 
ten years ago, the disease-centred approach to research has led to a predominant focus on the 
index disease and resulted in a dearth of information about multimorbidity and its complexity3.  
In this chapter, we discussed the salient issues on what is currently known on the subject matter 
and highlighted the gaps in the body of knowledge.  We provided the context of multimorbidity 
in Singapore next as the accompanying research activities were all conducted in the country.  
Finally, we described the research studies we had undertaken to help close this gap and add to 
the body of knowledge on the subject matter. 
 
2 What is multimorbidity? 
 
The concept of multimorbidity was first published in 1976 in Germany, and since the 1990s, 
the concept has spread widely and has been researched by many worldwide4.  The World Health 
3 
 
 
Organization (WHO) defines multimorbidity as the co-occurrence of two or more chronic 
medical conditions in one person5.  
 
However, the term ‘comorbidity’ has been used interchangeably with the term ‘multimorbidity’ 
for a long time even up to now.  Comorbidity was described in a seminal paper in 1970 by 
Feinstein6 for ‘any distinct additional clinical entity that has existed, or that may occur during 
the clinical course of a patient who has the index disease under study’.  Since 1996, van den 
Akker et al. has addressed the conceptual confusion between the two terms7,8.  The consensus 
is that comorbidity describes the simultaneous presence of multiple health conditions when 
there is an index condition and other unrelated conditions whereas multimorbidity describes 
the co-occurrence of two or more chronic medical conditions without specifying which is the 
index condition.  For comorbidity, health outcomes are evaluated in the context of the index 
condition.  For multimorbidity, health outcomes are interpreted in the context of the interaction 
and burden of all the co-existing chronic conditions. 
 
Although comorbidity is not a comprehensive way to design research interventions and care 
delivery programs for the whole person, it is a concept commonly used by secondary and 
tertiary care clinicians.  Advocates of the concept of multimorbidity tend to focus on primary 
care where the identification of an index disease is often neither obvious nor useful9.  
 
There is an explosion of interest in multimorbidity in the last decade10,11. In 2013, the European 
General Practice Research Network (EGPRN) defined multimorbidity as any combination of 
chronic disease with at least one other disease (acute or chronic) or biopsychosocial factor 
(associated or not) or physical risk factor.  Any biopsychosocial factor, any physical risk factor, 
the social network, the burden of diseases, the healthcare consumption and the patient’s coping 
strategies may function as modifiers (of the effects of multimorbidity).  Multimorbidity may 
modify the health outcomes and lead to an increased disability or a decreased quality of life or 
frailty12. 
 
PubMed, the free search engine provided by the United States National Library of Medicine at 
the National Institutes of Health, adopted multimorbidity as a medical subject heading (MeSH) 
term in January 2018 and defined it as ‘the complex interactions of several co-existing 
diseases’. These complex interactions have profound implications on individuals with 
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multimorbidity,  their health care providers, and accounts for most of the expenditures of the 
healthcare system, putting pressure on its sustainability13. 
  
3 Epidemiology of multimorbidity 
 
A chronic disease does not occur in isolation14.  A study on multimorbidity in the primary care 
setting reported that more than half of individuals with a chronic condition had at least two, 
and frequently more, other conditions15. The overall estimates of the prevalence of 
multimorbidity varied widely in the literature and ranged from 12.9% in participants aged 18 
years and older to 95.1% in those aged 65 years and older16.  Public health studies tend to use 
hospital validated definition of chronic diseases to estimate population prevalence of 
multimorbidity.  There are very few validated conditions and in one such studies, there were 
only five conditions17. 
 
Age and lower socioeconomic status are consistently associated with multimorbidity10,16,18.  
Sex and the presence of mental health problems also show associations with multimorbidity, 
but the evidence is less consistent across studies16.  Other risk factors for multimorbidity 
include health behaviours such as smoking, obesity, and inactivity10.  
 
Two types of patterns of multimorbidity are reported in prevalence studies14.  The first pattern 
is the most frequent combinations of specific conditions based on the frequency of all possible 
combinations of two or three conditions (dyads and triads).  Descriptive statistics showed that 
the commonest dyad was the combination of hypertension and osteoarthritis followed by 
different combinations of cardiovascular conditions16.  The combination of hyperlipidaemia, 
hypertension and diabetes was the commonest triad19,20. 
 
The second pattern is to identify groups of conditions with the highest degree of non-random 
associations using analytical statistics such as cluster or factor analysis10,16.  Three distinct 
patterns were commonly reported21.  The first being a combination of cardiovascular and 
metabolic conditions, the second pattern included mental health conditions, and the third 
pattern included musculoskeletal conditions. 
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Kanesarajah et al.22 suggested that from an epidemiological and health planning perspective, 
using disease count to describe multimorbidity is useful to establish the prevalence of 
multimorbidity.  However, for clinical practice and health policy, patterns of conditions that 
tend to co-occur are more useful.  Public health studies tend to use hospital validated definition 
of chronic diseases to estimate population prevalence of multimorbidity.  There are very few 
validated conditions and in one such studies, there were only five conditions.  
4 Problems of multimorbidity 
 
4.1 From the patients’ perspective 
 
Multimorbidity affects individuals to varying degrees.  Living with multimorbidity is a state of 
complexity that goes beyond counts of conditions and symptom burden23.  Patient’s 
perspectives of living with multimorbidity speak more to psychological and functional 
challenges leading to poorer quality of life than to disease-specific issues24.  
 
The risk of psychological distress increased five times for individuals with a high level of 
multimorbidity compared to those with no multimorbidity, after controlling for age, sex, social 
support and economic status25.  Clinical depression was two to three times more likely in people 
with multimorbidity compared to people without multimorbidity or those who had no chronic 
physical condition26.   However, clinically depressed patients with chronic physical conditions 
were inconsistently picked up in primary care27.    
 
The functional challenges of individuals with multimorbidity included coping with managing 
the complexity of multiple chronic conditions, physical limitations experienced such as pain or 
fatigue, financial constraints, complexity of communication with healthcare providers, 
inadequate or inappropriate family and social support, logistical challenges in managing the 
scheduling of different appointments or coordination of medications, lifestyle changes, and the 
burden of treatment imposed28,29. 
 
4.2 From the care providers’ perspective 
 
Generally, medical and public health programs targeting commonly defined chronic conditions 
have been fixated on individual chronic conditions without considering the broader context of 
6 
 
 
co-occurring chronic conditions.  Clinical practice guidelines are written by committees 
dominated by specialists, mainly drawing on research in selected individuals without other co-
occurring medical conditions30.  The applicability of existing disease management guidelines  
to individuals with multimorbidity is limited, particularly for those with discordant* 
combinations31,32.  Medical interventions may be less effective in individuals with 
multimorbidity than in individuals with no other comorbidities included in clinical trials.  Even 
if treatments were effective, older individuals with multimorbidity might have less to gain 
because of their reduced life expectancy33. 
 
Basing standards for quality of care and pay for performance on existing practice guidelines 
could lead to inappropriate management and create perverse incentives that emphasise the 
wrong aspects of care for individuals with multimorbidity and diminish the quality of their 
care33.  The struggle most family physicians experience is in finding the balance of promoting 
autonomy for individuals with multimorbidity in self-management and for professional 
autonomy in straying away safely from clinical guidelines to provide individualised care34.  In 
an attempt to achieve this patient-centred care, this can lead to potential conflicts with specialist 
services and confuse patients. 
 
4.3 From the health system’s perspective 
 
There is a global consensus that multimorbidity is a growing concern for healthcare 
policymakers trying to provide optimal healthcare services within resource-constrained 
environments11.  Multimorbidity is associated with higher levels of utilisation across almost all 
resource types including medications, primary care, specialist outpatient consultations, 
emergency department presentations and hospitalizations11,35.  Moreover, it appears that 
spending more money is not always better for health in healthcare36.  This puts into doubt the 
sustainability of healthcare services for managing the complexity of multimorbidity using the 
current model of care.  A revamped and better model of care will need to be developed and 
implemented for managing the inevitable increase in the number of patients with 
multimorbidity. More thoughtful care for individuals with multimorbidity and shifting the 
                                                 
* Conditions that are not directly related in either their pathogenesis or management and do not share an underlying 
predisposing factor (31. Lugtenberg M, Burgers JS, Clancy C, et al. Current guidelines have limited applicability to patients 
with comorbid conditions: a systematic analysis of evidence-based guidelines. PLoS ONE 2011;6(10):e25987. doi: 
10.1371/journal.pone.0025987) 
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goals towards medical care that is less disruptive to their lives may be the solution to the ever-
increasing health care spending and achieve better patient/provider satisfaction37. 
 
5 Multimorbidity interventions and their outcomes 
 
Most of the interventional studies for multimorbidity are relatively recent, reflecting the fact 
that research to date has focused on description and impact rather than the evaluation of the 
effectiveness of the intervention.  Many of these studies were not robust methodologically and 
most had no control groups for comparison38-40.  In general, none of the intervention studies 
fully supported the implementation of the following modes of interventions – chronic care 
model41, promotion of self-management39, comprehensive care management38, nurse-led case 
management40, and general case-management42.   
 
Interventions that targeted well-defined conditions like depression and diabetes or focused on 
specific problems experienced by individuals such as functional status were more effective 
than interventions with a broader focus43.  Therefore, attention to particular issues, risk factors 
or practical difficulties using a nuanced management approach rather than a one-size-fits-all 
general approach may be superior39. 
 
6 Gaps in knowledge – prevalence, levels, and outcomes of 
multimorbidity 
 
Measurements are the foundation of medical research and clinical practice44,45.  The major gaps 
in multimorbidity research are in the measurement of the prevalence of multimorbidity, the 
measurement of the different levels of multimorbidity, and the measurement of outcomes 
associated with multimorbidity.  And the fundamental reason for these gaps is in the 
contentious issues related to the definition of multimorbidity.  Even though the World Health 
Organization (WHO) defines multimorbidity as the co-occurrence of two or more chronic 
medical conditions in one person5, many other different definitions of multimorbidity exist as 
described in Section 2 (p2-4). 
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6.1 Prevalence and definition of multimorbidity 
 
Disease count is the most typical approach to measure the prevalence of multimorbidity46.  
However, even using the simple count of chronic conditions resulted in a wide range of 
prevalence estimates being reported in epidemiological studies.  Estimates of multimorbidity 
prevalence vary widely from 12.9% to 95.1% internationally16.     
 
Using disease count to determine prevalence estimates is greatly influenced by five 
components in the definition of multimorbidity : a) the types of conditions selected to form the 
multimorbidity list; b) the total number of conditions considered in the multimorbidity list; c) 
the data sources of the conditions; d) the cut-points used to define multimorbidity; and e) the 
reference population being measured47-49. 
 
6.1.1 The type of conditions selected to form the multimorbidity list of conditions 
 
There is a lot of controversy in the types of conditions that are selected to form the list of 
conditions used in multimorbidity research.  Primarily, the conditions included in the list of 
conditions are chronic diseases or noncommunicable diseases as defined by the World Health 
Organisation, i.e., they are not passed from person to person, of long duration and generally 
slow in progression50.  However, it is not so apparent what a ‘chronic disease’ is.    
 
Bernell and Howard51 described many variations in the diseases that are included under the 
umbrella term ‘chronic disease’ and also the variation in the time a disease must be present for 
it to be referred to as chronic from different professional and academic bodies.  To add to the 
confusion, the European professional body included both acute and chronic medical conditions 
and also social conditions like poverty12, the National Institute for Health and Care Excellence 
(NICE) guideline on multimorbidity included symptoms experienced by individuals like 
frailty52, and a multimorbidity study in Ghana excluded mental health conditions53.   
 
While it is idealistic to bring into focus all the possible needs of individuals with 
multimorbidity, there are concerns of including acute conditions in the primary care context 
and operationalisation of social factors10,54.  Concerning the inclusion of mental health 
conditions, Fortin et al.55 emphasised that excluding psychiatric diagnoses in primary care for 
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counting towards multimorbidity is unacceptable.  Two recommendations were suggested for 
the progress of research in multimorbidity - either unrestricted eligibility of health conditions 
or an agreement on a defined list of key conditions43. 
 
6.1.2 The total number of conditions considered in the multimorbidity list 
 
The number of conditions used in multimorbidity prevalence studies ranged from 4 to 14754.  
It has been reported that studies that included a higher number of conditions would report a 
higher prevalence rate of multimorbidity compared to studies using a lower number of 
conditions47,48. 
 
6.1.3 The data sources of chronic conditions 
 
Data sources could be from chart reviews, administrative data, or self-reports from patients49.  
Fortin et al.56 reported that health administrative data based on the billing system 
underestimated the prevalence of multimorbidity when compared to self-reported chronic 
conditions.  However, other studies have raised concerns about the reliability of self-reporting 
of medical conditions due to biases, including respondent recall and poor respondent 
understanding57,58. 
   
6.1.4 The cut-points used to define multimorbidity 
 
Holzer et al.59 reported that the cut-points of two or three chronic conditions provide essentially 
the same information on prevalence.   However, Fortin et al.47 reported that ‘three or more’ 
conditions better identify patients with higher needs that is more meaningful for primary care 
physicians. 
 
6.1.5 The reference population 
 
Generally, prevalence estimates of multimorbidity for the family practice-based population 
were higher than those for the general population48.  The prevalence estimates of 
multimorbidity also increase with age with the prevalence in older persons almost reaching 
100%10. 
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Although the prevalence of multimorbidity increases with age, the absolute number of 
individuals with multimorbidity is higher in those aged less than 65 years old15,60.   
Multimorbidity is not uniquely an ageing-related phenomenon as one would expect.  Research 
emphasis should also be on understanding the optimal health systems for younger people with 
multimorbidity49. 
 
In summary, there is no common lexicon amongst stakeholders in the definition, and therefore 
the measurement of the prevalence of multimorbidity.   The definition of multimorbidity needs 
further clarification and consensus.  Most researchers agree that a precise definition of 
multimorbidity to allow for generalisability or applicability of studies is lacking.  While waiting 
for the broad consensus of the definition and measurement of multimorbidity to materialise, 
Fortin et al.47 suggested that future studies should include two operational definitions of 
multimorbidity, i.e., for two or more and three or more chronic conditions.  The authors also 
urged researchers to carefully consider the specific diagnoses included in the list of chronic 
conditions and to state the recruitment and data collection methods clearly.   
 
Comparing different definitions of multimorbidity and determining the prevalence of 
multimorbidity are key goals of the thesis described later in this chapter. 
 
6.2 Measurement of the different levels of multimorbidity 
 
For measurement of the level of multimorbidity, Lefevre et al.14 listed four common methods.  
They are: by simple counts of chronic diseases from a list of individual conditions (i.e., disease 
count), by grouping chronic diseases into dyads or triads (i.e., dyad and triad patterns), by 
identifying groups of people with common disease and characteristics that occur more often 
than by chance, and by using an index of variable complexity (i.e., weighted indices). However, 
this does not clearly explain the different purposes of measuring multimorbidity45.  According 
to de Vet et al.61, the three main purposes of measurement in medicine are for diagnosis, 
evaluation of intervention, and prediction of outcome.  The instrument for each of the above 
purpose is called a discriminant measurement, an evaluation measurement, aobjectivesnd a 
prediction measurement respectively.  Each of these four measurement methods described by 
Lefevre et al.14 can be used for any of the three different purposes described by de Vet et al.61 
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The first three methods described by Lefevre et al.14 are usually used for measuring the 
prevalence or patterns of multimorbidity (consistent with the purpose of diagnosis described 
above).  All three methods have already been described in Section 3 (p4).  The three methods 
of measurements help to differentiate between those who have multimorbidity and those 
without multimorbidity, or those with a certain pattern of multimorbidity from those without. 
One major criticism of these three methods is that the severity of individual conditions is not 
usually specified47.  Only 23% of multimorbidity studies reported the severity of individual 
conditions and they were reported in many different ways54.   A concern on the lack of reporting 
on severity is that common conditions in the population like hypertension and hyperlipidaemia 
are not necessarily those with the most significant impact on individuals’ functional status or 
quality of life54.  Relying too much on these conditions without indicating their severity when 
describing the prevalence of multimorbidity will shift the focus to awareness of future illness 
rather than the actual disease burden and functional status of individuals with multimorbidity. 
 
The fourth method described by Lefevre et al.14 of using indices of variable complexity (i.e., 
weighted indices) is usually used for measuring the different levels of multimorbidity in 
association with specific outcomes either for evaluation of intervention or for prediction of an 
outcome.  Disease count†, which is the first method described by Lefevre et al.14, is also 
commonly used for the same purpose.  When a group of individuals with multimorbidity has 
already been identified, these two methods help to categorise these individuals into different 
levels of the overall multimorbidity.  The systematic review by Huntley et al.46 described theses 
two methods as indices for the measurement of the morbidity burden of multimorbidity.   
 
In this same systematic review, seventeen different indices used for measuring the morbidity 
burden for multimorbidity in the primary care and the general population were found.  The 
most common index was ‘disease count’.  Other common indices for measuring multimorbidity 
in relation to a particular outcome include the Charlson Index, Adjusted Clinical Groups 
System, and Cumulative Illness Rating Scale46.   In general, these indices weighted individual 
conditions differently and then added the scores up to provide a total score.  Even though most 
of these indices were initially developed and validated in the hospital setting, many of them 
have been adapted for use in the primary care and the community populations. 
                                                 
† ‘Disease count’ as a measuring instrument has two purposes here.  One is for measuring the prevalence of multimorbidity, 
and the other is for measuring the different levels of multimorbidity. 
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The systematic review by Huntley et al.46 included original articles only till the end of 2009, 
and there has not been any update on the use of the existing measurement indices or new 
measurement indices created since then.  Getting a summary update of the measurement 
instruments used for measuring the different levels of multimorbidity for specific outcomes for 
community-dwelling individuals is the next key goal of the thesis described later in this chapter. 
 
6.3 Measurement of the outcomes associated with multimorbidity 
 
The use of clinical outcomes has always been the norm in medical research.  However, there 
is increasing recognition of involving patients in clinical research, evaluation of health care 
service delivery, and quality improvement62.  Good clinical care requires patients to provide 
information regarding how they are feeling, their symptoms, and any effects of treatment.   
 
A patient-reported outcome is directly reported by the patient without interpretation of the 
patient’s response by a clinician or anyone else and pertains to the patient’s health, quality of 
life, or functional status associated with health care or treatment62.  However, heterogeneity in 
the choice of outcome measures in multimorbidity research has led to a lack of consistent 
evidence for multimorbidity intervention research63. 
 
Sasseville et al.64 compiled a list of patient-reported outcomes used in multimorbidity 
intervention research into six domains including general health, psycho-social health, disease 
management, health-associated behaviours, functional, and health services.  The most universal 
three outcomes reported in their scoping review were depression under psychosocial health, 
quality of life under general health, and self-efficacy under disease management.  However, 
these outcomes were rarely reported together.  Care satisfaction, goal assessment, social health 
and communication with the providers were the least frequently reported patient-reported 
outcomes. 
 
Core outcome sets (COS) represent the minimum that should be measured and reported in all 
clinical trials of a specific condition or conditions65.  This is in relation to the recognition that 
outcomes measured in clinical trials were not always relevant to health service users and 
policymakers66.  The widespread adoption of COS can help improve the uniformity in outcome 
measurement and reduce outcome reporting bias67.  In accordance with the above, the long-
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awaited set of core outcomes of multimorbidity (COSmm) was recently published in 2017 by 
Smith et al.68 after consulting a Delphi panel of experts.  Seventeen core outcomes were 
identified, and the three essential core outcomes were quality of life, mental health outcomes, 
and mortality. 
 
Obtaining patient-reported outcomes and relating them to the different levels of multimorbidity 
is another key goal of the thesis described later in this chapter. 
 
7 Conceptual frameworks 
 
Theories are integral to healthcare practice and research69.  Making explicit the theoretical 
assumptions is vital as they can offer a generalisable framework for engaging with the concept 
of multimorbidity, a concept that is still unclear and inconsistent as shown in the previous 
sections.    More theory-driven research should help us decide on the best approaches to provide 
solutions to the challenges generated by multimobidity70.  
 
Realistically, it is impossible to pile on the recommendations from the Clinical Practice 
Guidelines of each of the single chronic diseases for patients with multimorbidity as doing so 
would overburden them and render the health system unsustainable.  As such, we adopted two 
conceptual frameworks for the research work done for this thesis.  One is the Patient Centred 
Clinical Method71 (PCCM) that focuses on building a positive interaction between clinicians 
and their patients at both the personal and practice level.   
 
“Patient-centred care is the willingness to become involved in the full range of difficulties 
individuals bring to their doctors, and not just their biomedical problems.”72 
 
The PCCM framework outlines four components for the clinician to combine medical science 
with knowledge of patients as people, their experiences, their values and their beliefs within 
their context, with an ongoing and affirmative relationship. 
 
The other framework is applicable at the personal, practice and policy levels.  Minimally 
disruptive medicine (MDM) draws attention to the impact of treatment burden, imposed by the 
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clinician and the health care system, on patients’ capacity to cope with their medical conditions 
on top of their other life demands73. 
 
“Minimally disruptive medicine is a patient-centred approach to care that focuses on achieving 
patient goals for life and health while imposing the smallest possible treatment burden on 
patients’ lives. It is particularly appropriate for patients who are at risk of being (or who 
already are) overwhelmed by the demands of life, illness, and health care. Such patients include 
the expanding group of vulnerable individuals with multiple chronic conditions.”74 
 
The MDM framework is a theory-based, patient-centred, and context-sensitive approach to 
care that focuses on achieving patients’ goals while imposing the smallest possible burden on 
their lives74.  The four principles for MDM are to establish the weight of the burden, encourage 
coordination in clinical practice, acknowledge multimorbidity in clinical evidence, and 
prioritise treatment from the patient perspective73.   
 
The two theories work in tandem at the personal, practice and policy levels.  PCCM will 
promote the holistic patient-centred care tailored to the overall needs of individuals with 
multimorbidity in an ongoing, positive relationship over the long term.  MDM is designed to 
provide comprehensive, evidence-based, supportive care that fits into the patient’s life.  Both 
PCCM and MDM are approaches used in the intervention and management of multimorbidity 
and will be used in interpreting the results of the proposed studies which are non-interventional.   
 
8 Family medicine and multimorbidity 
 
There is debate in the medical community as to who should coordinate all the medical 
conditions an individual with multimorbidity faces.  Articles and editorials in the specialty 
literature advocate shifting the care of chronically ill persons from primary to specialty care75.  
The argument for such a shift can be found in the growing body of evidence demonstrating that 
specialists are more knowledgeable on the specific condition and are more likely to follow 
disease-specific  guidelines76.  Arguments opposing the shift of chronic illness care from 
generalists to specialists include concerns about the receipt of preventive care, the care of 
comorbid conditions outside of the specialty focus, and cost75. 
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In 2009, Stange and Ferrer77 described the paradox of primary care.  They observed that 
primary care is associated with low levels of evidence-based care for individual diseases.  
However, healthcare systems based on primary care have healthier populations, use fewer 
resources, and have less health inequality.  Homa et al.78 explored the above observation further 
by developing an agent-based computer simulation model with a participatory group model-
building process.  Primary care in the model is less effective than specialty care in treating 
single diseases, but it has the ability to manage multiple diseases at once78.  Primary care also 
can provide disease prevention, help improve individuals’ health behaviours and lower their 
threshold for seeking care.  In a model simulation with primary care features turned off, 
individuals have poorer health.  In a model simulation with all primary care features turned on, 
better population health was observed, with significant improvements in individuals who are 
disadvantaged or those with multimorbidity. 
 
However, Rothman and Wagner reasoned that most studies of the quality of chronic disease 
care had not differentiated the sources of care or the specialty of the primary clinician75.  The 
few available comparative studies of primary and specialty care made it clear that the quality 
gap pertains to both.  They suggested that the practice environment and system determine the 
quality of chronic disease care far more prominently than whether the care provider is a 
specialist or a generalist. 
 
Primary care practices offer an ideal setting to study individuals with diverse patterns of 
multimorbidity79.  It is the best setting for studying the causality of seemingly unrelated chronic 
diseases and including individuals with multimorbidity into clinical trials.  Family medicine is 
more patient-centred and less disease-focused.  The rationale for the discipline is based on the 
health of people and populations, not the one-by-one counting of diseases, their diagnoses, and 
their management80.  In concordance with the way multimorbidity is described in PubMed as 
‘the complex interactions of several co-existing diseases’, the goal is not to manage each 
disease separately but to provide holistic care and to improve both clinical and patient-reported 
outcomes instead.  Family physicians who adopt the patient centred clinical method (PCCM) 
will be the most likely professionals to lead collaborative work with other professionals in 
primary, secondary and tertiary healthcare; together with policymakers, the patients themselves 
and their caregivers to achieve the above aims.  Afterall, the patients they serve traverse through 
the whole health care system, and it is myopic to make the artificial divide between primary 
and specialty care for individuals with multimorbidity.  The crux is in the formation of a 
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practice environment and system that allows coordination and continuity of healthcare to 
happen with minimal disruption to the patients. 
 
9 Multimorbidity in Singapore 
 
Singapore is a city-state country in southeast Asia with a population of 5.6 million, of which 
close to 4.0 million are Singapore residents81.  The rest comprises permanent residents and non-
residents, including foreign workers, their dependants and international students.  Singapore is 
a multi-ethnic society where the Chinese formed 74% of the resident population, the Malay at 
13% and the Indian at 9.2% according to the 2010 Census82.  According to the Bloomberg 
Healthiest Country Index which ranks 169 economies according to factors that contribute to 
overall health, Singapore was ranked fourth position in 2017 and eighth position in 2019. 
  
One in four Singaporeans aged 40 years and older have at least one chronic condition and the 
risk increases with age.  By 2030, one in four adults will be 65 and above, up from one in eight 
today and many of them will have multimorbidity83.  Total life expectancy at birth rose from 
65.8 years in 1970 to 82.5 years in 2013.  Life expectancy at age 65 rose from 8.4 years to 20.6 
years over the same period.  Therefore, not only has the elderly population grown but the 
elderly, as a group, are themselves getting older with longer life expectancy, many of them 
with multimorbidity84.  Longevity is not equivalent to good health.  A local study projected 
that the number of seniors who require assistance with daily activities would increase from 
31,738 in 2010 to 82,968 in 2030, and more women than men will require assistance85. 
 
Unfortunately, only four studies could be found in Singapore looking at multimorbidity 
specifically86-89.   Subramaniam et al.86 reported that 16.3% of the Singapore general population 
has two or more chronic conditions.  Those who were older, economically inactive, 
unemployed, overweight or obese had higher odds of having multimorbidity.  Individuals from 
the Malay ethnic group had significantly lower odds of multimorbidity as compared to the 
Chinese ethnic group.  Picco et al.87 reported that the prevalence of multimorbidity was 51.5% 
for those aged 60 years and above in the general population of Singapore.  The authors also 
found that the total societal cost of multimorbidity equated to SGD‡15,148 per person annually 
for those with multimorbidity while those with one or no chronic conditions, the total annual 
                                                 
‡ SGD – Singapore Dollar (1.00 SGD is equivalent to 0.99 Canadian dollar) 
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societal costs per person were SGD5,610 and SGD2,806 respectively.  Quah et al.88 conducted 
a study on older adults in the primary care setting and found that the prevalence of 
multimorbidity was 89.4% for those above 65 years old and was associated with poorer quality 
of life.  Ge et al.89 interviewed community-dwelling adults aged 21 years and above and 
reported that the prevalence of multimorbidity was 35.0%.  They also reported that there was 
no difference in the prevalence rates between the two sexes. 
 
Among the four multimorbidity studies conducted in Singapore, different lists of chronic 
medical conditions were used.  Subramaniam et al.86 used eight conditions, Picco et al.87 used 
ten, Quah et al.88 used fourteen, and Ge et al.89 used seventeen.  None of the studies described 
clearly how and why they chose the list of chronic conditions in their study.  All four studies 
used data sources from patients’ self-report. All the studies used two or more chronic conditions 
as the cut-point to define multimorbidity.  Three of the reference populations were from the 
general population, and one was from a practice-based population.  Two of the studies were 
for all adults while the other two were for older adults.  Only one out of the four studies 
measured the levels of multimorbidity using disease count and drug count. The different 
characteristics of the four studies are summarised in Table 1-1. 
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Table 1-1. A summary of the different characteristics of measuring prevalence, levels, and 
outcomes of multimorbidity of studies conducted in Singapore 
 
 Subramaniam et al.86 
(Published in 2014) 
Picco et al.87  
(Published in 2016) 
Quah et al.88  
(Published in 2016) 
Ge et al.89  
(Published in 2018) 
Definition of 
chronic disease 
(Section 6.1.1) 
No 
 
 
No No 
 
 
Diseases that are 
irreversible and 
persistent throughout 
adulthood 
No. of 
conditions 
(Section 6.1.2) 
 
8 
 
10 
 
14 
 
17 
     
Source of list of 
chronic 
conditions 
(Section 6.1.2) 
Modified Composite 
International 
Diagnostic Interview 
(CIDI) 
Not mentioned Conditions from the 
Singapore Mental 
Health Study 2011 
Not mentioned 
Sources of data 
(Section 6.1.3) 
Self-reported Self-reported Self-reported At least one of the 
sources from self-
reported or from 
chronic disease 
management system 
database 
Cut-point 
(Section 6.1.4) 
2 conditions 2 conditions 2 conditions 2 conditions 
Reference 
population 
(Section 6.1.5) 
General population General population Practice-based 
population 
General population 
Age group 
(Section 6.1.5) 
≥ 18 years old ≥ 60 years old ≥ 65 years old ≥ 21 years old 
Measured 
levels of 
multimorbidity 
(Section 6.2) 
No No Yes 
 
1. Disease Count 
2. Drug Count 
 
No 
Patient-
reported 
Outcomes 
(Section 6.3) 
 
 
 
 
 
 
Yes 
 
Health-related quality 
of life 
 
 
 
 
 
 
No 
 
Health care utilisation 
and costs 
 
 
 
 
 
Yes 
 
1. Health-related 
quality of life 
2. Functional 
disability 
3. Chronic 
musculoskeletal 
pain 
Yes  
 
Physical function 
 
 
 
 
 
 
10    Proposed studies 
 
In 2015, Le Reste et al.4 established a research agenda for multimorbidity and suggested that 
the highest priorities should be given to the measurement of multimorbidity and the impact of 
multimorbidity on the different stakeholders.   This agenda has been supported by many 
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investigators.  However, the unintended consequence was a marked variation among studies of 
the prevalence of multimorbidity concerning both methodologies and findings90.   Furthermore, 
observational studies of multimorbidity were generally not done well with questionable 
generalisability relating to issues of sampling, attrition and non-response91.    
 
The key message for this chapter is the immaturity of the different measurements of 
multimorbidity: prevalence, levels of morbidity burden, and outcomes.   This thesis aimed to 
provide a uniform definition for multimorbidity, identify a list of instruments to measure the 
levels of multimorbidity and explore some patient-reported outcomes for different levels of 
multimorbidity. 
 
As primary care practices offer an ideal setting to study individuals with diverse patterns of 
multimorbidity79, the following three studies for this thesis were all conducted in the primary 
care setting.  The research activities were focused on clarifying the definitions, measurements 
and the impact of multimorbidity.  No attempt was made to conduct intervention trials for the 
current management of multimorbidity in this thesis. 
 
As with most research in multimorbidity, acute, social and non-medical conditions were not 
included in the list of conditions for multimorbidity in this thesis.  Only chronic conditions 
were used.  Frailty is interrelated with multimorbidity as they are both age-related and highly 
correlated but they are two different concepts or clinical conditions92.  Frailty will not be 
considered and discussed further in this thesis.  However, as described in Section 6.1.1 (p8), 
defining what constitutes a chronic condition is not simple51.  N’Goran et al.93 described a four-
step study in family medicine in Switzerland to define the list of conditions family doctors 
coded in their medical records which were deemed to be considered ‘chronic’.  A similar 
approach, on a smaller scale, was conducted to emulate their study to create a master list of 
chronic conditions in Singapore. 
 
The three studies are briefly described below. 
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10.1 The prevalence and the common patterns of multimorbidity in 
Singapore: An epidemiology study based on administrative data 
 
This was a cross-sectional epidemiology study looking at the prevalence of multimorbidity in 
the primary care setting by using administrative data.  We used two multimorbidity lists (one 
local source and the other from an international source) and compared two different cut-offs of 
‘two or more’ or ‘three or more’ chronic conditions to define multimorbidity.  We used the full 
age range for the study to look at the changes from early adulthood to the older age group. We 
hypothesised that the standardised prevalence rate of multimorbidity might differ between the 
different sex and among different age and ethnic groups.   
 
Violan et al.16 encouraged studying the patterns of the clustering of chronic diseases because it 
helps to identify what makes certain conditions co-occur from the aetiological perspective; 
tailors special care to a stratified stratum of people who are at high risks with a familiar pattern 
from the clinical perspective; and prevent multimorbidity and its associated risks from the 
policy perspective.  As such, we also described the most common dyads and triads of 
multimorbidity for those ages 45 years old and above and reported the crude prevalence rates 
of the dyads and triads for the different ethnic groups and sex. 
 
The study aimed to describe the epidemiology of chronic conditions in primary care, establish 
the standardised prevalence rates of multimorbidity in the primary care population, compare 
the standardised prevalence rates among different age, sex and ethnic groups, and describe the 
most common dyads and triads for those 45 years and older by each sex/ethnic groups.  We 
explicitly reported all the definitions of the variables so that the study could be easily replicated. 
 
10.2 A systematic review of the instruments used for measuring the 
level of multimorbidity 
 
This was a systematic review that used three electronic databases to provide an update from 
Huntley et al.’s 46 review on the current instruments used for measuring the level of 
multimorbidity in the primary care or general population setting.  The other objectives were to 
report the advantages and disadvantages of using selected instruments, provide the details of 
the data sources and resources required to use the instruments, and compile a list of 
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corresponding instruments for measuring the level of multimorbidity for the three essential 
core outcomes identified for multimorbidity (COSmm)68. 
The study aimed to provide a useful and handy resource for researchers and clinicians who can 
easily choose an instrument for measuring the level of multimorbidity for a specific outcome. 
 
10.3 A cross-sectional study on the level of multimorbidity and its 
association with depression, anxiety and quality of life 
 
Based on the common triads of multimorbidity noted in the polyclinics, we targeted the group 
of patients with the most common triad of chronic conditions in Singapore and looked at how 
the levels of multimorbidity were associated with depressive symptoms, anxiety symptoms, 
and quality of life.  We also looked at what other sociodemographic factors were associated 
with the same outcomes.  The outcomes were chosen as they were part of the patient-centred 
COSmm outcomes.   This was a cross-sectional study using interviewer-administered 
questionnaires where we took into account the rigour for research design, population and 
sampling, data definition, and outcome measures used in cross-sectional studies as suggested 
by Stewart et al.90  A concordance study on patient self-report of the presence or absence of 
chronic condition with those recorded in the clinical notes was also conducted. 
 
The main study aim was to describe the baseline patient-reported outcomes of patients with the 
most common triad of chronic conditions seen in primary care for different levels of 
multimorbidity. 
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1 Introduction 
 
Chapter One has clearly demonstrated that individuals with multimorbidity are the rule in 
primary care1.  The overall estimates of the prevalence of multimorbidity varied widely in the 
literature and ranged from 12.9% in participants aged 18 years and older to 95.1% in those 
aged 65 years and older2.  
 
Even though multimorbidity is a common phenomenon, there were only four studies3-6  done 
in Singapore that looked at it so far.  The prevalence rates of multimorbidity in these four 
studies ranged from 16.3% to 89.4%, which was not too different from the range reported in 
the literature.  The reason for the wide range is due to varying standards of measuring 
multimorbidity7. 
    
Issues with multimorbidity studies in Singapore included the the lack of proper definition of 
chronic disease, the total number of conditions considered in the multimorbidity list, the data 
source, and the reference population (Chapter One Table 1-1 p18).  Subramaniam et al.3 used 
a list of eight chronic conditions, Picco et al.4 used ten, Quah et al.5 used fourteen, and Ge et 
al.6 used seventeen conditions.  Out of the four studies, only Ge et al.6 gave a brief description 
of what chronic disease was while the other three did not provide any definition.  The data 
source for the chronic conditions was self-reported in three of the studies while the data source 
for the fourth study was from a combination of self-report and administrative data. The 
reference population for three of the studies was from the general population3,4,6 whereas the 
reference population for Quah et al.5 was from the primary care population.  Two of the studies 
included younger adults (≥18 years old3 and ≥21 years old6) whereas the other two studies only 
targeted older adults (≥60 years old4 and ≥65 years old5). 
 
Subramaniam et al.3 reported that the prevalence of multimorbidity was 16.3% in the Singapore 
general population.  Her team also reported that individuals from the Malay ethnic group had 
significantly lower odds of multimorbidity as compared to the Chinese ethnic group.  Picco et 
al.4 reported that the prevalence of multimorbidity was 51.5% in those aged 60 years and above 
in the general population of Singapore.  Quah et al.5 conducted a study on older adults aged 65 
years and above in the primary care setting and reported that 89.4% of them had two or more 
chronic conditions.  Ge et al.6 interviewed community-dwelling adults aged 21 years and above 
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and reported that the prevalence of multimorbidity was 35.0%.  They also reported that there 
was no difference in the prevalence rates between the two sexes. The only similarity in these 
four studies was that multimorbidity was defined by the unweighted count of two or more 
chronic conditions.  
  
Primary care practices offer an ideal setting to study individuals with diverse patterns of 
multimorbidity8.  Studies using primary care as their source population can provide insights on 
the optimal intervention of care for individuals with multimorbidity as compared to using 
information from the general population which are more desirable for surveillance and public 
health analysis9.    
 
An increased understanding of the epidemiology of multimorbidity is needed to inform how 
health care in Singapore should be organised and delivered to patients with multimorbidity.  
However, efforts to manage and study multimorbidity in Singapore are hampered by a lack of 
basic, up-to-date, and consistent epidemiologic data.  The lack of consensus on the definition 
of multimorbidity makes it difficult to compare the magnitude of the problem internationally 
and among different health care settings in Singapore. 
 
We proposed to measure the prevalence of multimorbidity in the primary care setting by using 
a local list of chronic conditions for defining multimorbidity and an internationally-
recommended list from the literature. We also adopted Fortin et al.’s10 suggestion to include 
two operational definitions of multimorbidity, that is, multimorbidity defined as a cut-off of 
‘two or more’ and ‘three or more’ chronic conditions.  As the prevalence of multimorbidity is 
dependent on the prevalence of each of the individual chronic conditions that made up the list, 
the epidemiology of the chronic conditions belonging to each list were also described.   
 
Most studies found that the proportion of individuals with multimorbidity tended to increase 
rapidly in the fourth decade of life10.  As such, we described the most common patterns of 
multimorbidity (i.e., dyads and triads) stratified by sex and ethnicity for patients who were 45 
years and older that visited primary care.  This would provide evidence for primary care 
physicians to create meaningful multimorbidity guidelines for the common patterns of 
multimorbidity seen in primary care that occur at high frequency. 
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The objectives of the study were to: (1) describe the epidemiology of chronic conditions 
depicted in the two lists for the sample population; (2) determine the overall prevalence rates 
of multimorbidity (crude and standardised) in the National Healthcare Group polyclinics based 
on two different lists of chronic conditions and two different definitions of multimorbidity in 
terms of cut-points; (3) determine whether there were differences in standardised prevalence 
rates among the different age, sex and ethnic groups; and (4) describe the common dyads and 
triads of chronic conditions, stratified by ethnicity and sex in primary care patients who were 
45 years and above with multimorbidity.  We hypothesised that there were differences in sex2, 
ethnicity3 and age11 based on existing literature. 
 
2 Methods 
 
This was a cross-sectional study determining the prevalence and common patterns of 
multimorbidity amongst all patients who consulted a doctor in the National Healthcare Group 
Polyclinics (NHGP) between 1st Jul 2015 and 30th Jun 2016.  We received approval from the 
ethics review board (National Healthcare Group Domain Specific Review Board Reference 
number 2018/00466) on 18 June 2018.  We followed the reporting of studies conducted using 
observational routinely-collected health data (RECORD) statement as a guideline in preparing 
the report12.  There was no funding for this project. 
 
2.1 Setting and study population 
 
There are eighteen polyclinics spread over the island of Singapore.  Each polyclinic serves as 
a primary care safety net providing government-funded subsidised primary care.  Each 
polyclinic offers a one-stop health centre for chronic disease management, National Childhood 
Immunisation program, children development assessment, women’s cancer screening, 
antenatal care, health promotion, education and disease prevention, medical education and 
training, and National emergency planning and mobilisation. 
 
The primary health care services in Singapore underwent a major restructuring on 1st October 
2000 and was reorganised into two clusters – National Healthcare Group Polyclinics (NHGP) 
and SingHealth Polyclinics (SHP)13.  This clustering and reorganisation provided a platform 
for consolidation and integration in order to bring about better health outcomes and greater 
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efficiency while maintaining some competition.  NHGP consisted of nine polyclinics and they 
were located geographically in the central, western and northern parts of Singapore.  SHP also 
consisted of nine polyclinics and they were located geographically in the central and eastern 
parts of Singapore. 
 
About 300 primary care doctors work in the eighteen polyclinics (public primary care) 
compared to another 2,700 primary care doctors who work in 1,700 private general practitioner 
clinics14,15.    Although the private clinics provided about 80% of the total primary care clinical 
load, they only provided about 55% of the demand for primary care chronic disease 
management.  As such, the 10% of primary care doctors in the eighteen polyclinics managed 
45% of all the patients with chronic diseases in primary care. 
 
This study included all the patients who visited the nine polyclinics of NHGP. 
 
2.2 Data Source 
 
The source population of this study were all patients who visited National Healthcare Group 
Polyclinics (NHGP). Data were collected from the National Healthcare Group Polyclinics 
(NHGP) Business Informatics (BI) system that is an administrative database that captures all 
the consultation episodes, clinical parameters from structured data fields within the electronic 
medical records (EMR) e.g., blood pressure readings, body mass index, diagnoses codes, 
pharmacy data, laboratory data, and billing16.  All the data collected were linked using patients’ 
National Registration Identity Card (NRIC) number.  We de-identified all patient information 
according to the personal data protection act (PDPA).  A separate ‘patient key’ was created for 
each patient for de-identification by the Office of Clinical Informatics (OCI).  Subsequently, 
NRICs were removed from the dataset prior to being made available to the research team.  OCI 
cut the data for this research study on 14th September 2018.  Data cleaning was then conducted 
by the research team based on the de-identified list before the analysis was performed. 
 
The National Healthcare Group Polyclinics (NHGP) BI system is used for generating reports 
to the Singapore Ministry of Health regularly.  System integration and user acceptance tests 
were implemented before any new information request from the NHGP BI system to ensure 
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completeness and accuracy of data.  Regular surveillance is also scheduled by the OCI to rectify 
any anomalies detected. 
 
For this study, the study population was the total unique number of patients of age ranging 
from 0 to 99 years old who had consulted a family physician at least once in NHGP between 
1st Jul 2015 and 30th Jun 2016 for any reason documented with an ICD-10 diagnosis code.  We 
excluded all patient encounters in the polyclinic that did not include an ICD-10 diagnosis code 
by a physician, for example, well-child visit and vaccination. 
 
2.3 Determining the denominator and numerator for the prevalence 
rate 
 
2.3.1 Denominator 
 
Epidemiology is the study of disease about populations17.  The ‘population at risk’ (PAR) is a 
basic concept of epidemiology and denotes the ‘denominator’ used for calculating the 
prevalence of a condition where the cases with the condition observed are used as the 
numerator. 
 
In the 1970-80s, there was a lot of discussion in the family medicine literature on the 
ascertainment of the PAR, i.e., the denominator problem.  Six methods have been proposed, 
each with its limitations18.  These include the: (1) Census method where a single medically 
isolated practice serving a well-defined community could estimate its denominator by 
obtaining the community census; (2) Registration by intent method where every patient informs 
the practice about which members of their family considers the practice to be their regular 
source of care; (3)  De facto registration method where the denominator is determined by the 
number of individuals who have visited a practice one or more times during a specified time 
period; (4) Indicator disease method where a disease of relatively constant frequency across 
all patient populations is identified, and the number of patients seen with that disease annually 
is then used to extrapolate the total population (i.e., the denominator); (5) Episodes of illness 
method where the frequency of episodes of illness was assumed to follow a negative binomial 
distribution. Hence, if the practice was able to determine the annual number of episodes of 
illness for each of their patients, the practice denominator could be derived from that number; 
and (6) Utilisation correction factor method where the denominator is estimated by assuming 
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that relatively constant proportions of the populations served will visit the practice during a 
particular time period.    Only the ‘de facto registration’ and ‘Utilisation correction factor’ 
methods are the widely acceptable ascertainment methods18. 
 
Bass19 argued that, although the ‘de facto registration’ method was useful in describing the 
workload of the practice, the method resulted in too many sources of variability to allow 
adequate comparisons of incidence and prevalence rates across practices.  He suggested that 
the most acceptable denominator for office morbidity studies was best done by the ‘utilisation 
correction factor’ which could be determined by a separate study or through analysis of health 
insurance statistics19. 
 
However, not many investigators have used the ‘utilisation correction factor’ as a denominator.  
Recent examples included a Belgium primary care database that consisted of 43 practices20 and 
a research team in Australia that has consistently used this method to adjust for the PAR from 
publications dating from 2008 to 2017 on the prevalence of chronic disease or multimorbidity21-
24. 
 
For those using a capitation model, investigators used the register list25,26 for their primary care 
service.  For those in a fee-for-service model, many investigators used the ‘de facto 
registration’ method by using the number of patients seen over a pre-defined time-frame in a 
health-care setting and excluded disease-free persons who were not seeking health care9.  , .  
The pre-defined time-frame ranged from at least once a year for three consecutive years27, one 
visit within a time-frame of six months28, to as short as one visit in three weeks29.  Most studies 
used unique patients seen in one year as their denominators21,23,24,30,31. 
   
Perusing the Singapore National Health Survey 201032, the percentage of the general 
population who visited the polyclinic was not captured and therefore the ‘utilisation correction 
factor’ is unknown.  A separate study needs to be conducted in the general population to derive 
the PAR by including both groups of persons who visited and did not visit the polyclinics.  This 
is not permissible in the timeline for the PhD study and is not within the scope of work of the 
thesis. 
 
This study was conducted in a fee-for-service primary care environment in the polyclinic 
setting.  As such, no listing or practice register can be used.  Therefore, the study team decided 
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to use the ‘de facto registration’ method by including all patients who had consulted a doctor 
in National Healthcare Group Polyclinics (NHGP) at least once between 1st Jul 2015 and 30th 
Jun 2016 as the denominator. 
 
2.3.2 Numerator 
 
Four senior family physicians in the National Healthcare Group Polyclinics (NHGP) worked 
together to provide a full list of chronic conditions based on our local clinical practice and 
doctors’ coding practices that fulfilled the criteria of the definition of chronicity.   We 
simplified and adopted the steps used by N’Goran et al.33 to create a master list of chronic 
conditions used in the local context that were deemed suitable for a study of multimorbidity in 
Singapore.  We used O’Halloran and colleagues’ definition of chronicity of a disease as lasting 
at least six months, having a documented pattern of recurrence or deterioration, and having an 
impact on an individual’s quality of life34. 
   
As there was no consensus among the four senior family physicians on which multimorbidity 
list of chronic conditions to use, the study team adopted two lists where one was readily 
available locally, and another was from an international source.  The local list, which consisted 
of 20 conditions, was the Chronic Disease Management Programme (CDMP) list35 from the 
Ministry of Health whereby the government subsidised medical costs for Singaporeans with 
these conditions.  The international list, which also consisted of 20 conditions, was 
recommended by Fortin et al.36  These two lists will hereafter be referred to as the CDMP list 
and the Fortin list respectively.  Using the International Statistical Classification of Diseases 
and Related Health Problems revision 10 (ICD-10), we subsequently matched all NHGP 
chronic conditions diagnosis codes with the CDMP list (Appendix 2-1) and Fortin list 
(Appendix 2-2) to determine the number of patients with any of those conditions in the NHGP 
database. 
  
The study team was also unable to come to a consensus on which cut-point to select for the 
definition of multimorbidity.  We followed the recommendation of Fortin et al.10 of using two 
operational definitions of multimorbidity.  Therefore, we included both cut-offs of ‘two or 
more’ chronic conditions (hereafter referred to as MM2+) and ‘three or more’ chronic 
conditions (hereafter referred to as MM3+). 
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The numerator was therefore, the number of patients who consulted a family physician in the 
specified period who had ‘two or more’ or ‘three or more’ chronic conditions based on the 
CDMP and Fortin lists. 
 
This resulted in four numerators used with the same denominator: 
a. The number of patients who visited the polyclinic with at least one doctor visit and at 
least two chronic conditions based on the CDMP list 
b. The number of patients who visited the polyclinic with at least one doctor visit and at 
least two chronic conditions based on the Fortin list 
c. The number of patients who visited the polyclinic with at least one doctor visit and at 
least three chronic conditions based on the CDMP list 
d. The number of patients who visited the polyclinic with at least one doctor visit and at 
least three chronic conditions based on the Fortin list 
 
2.4  Outcome variables 
 
For objective 1 (p31), the outcomes for the epidemiology of chronic conditions were the crude 
prevalence rates of single chronic conditions or single categories as described by the CDMP 
and Fortin lists.  The outcomes for objective 2 were the crude prevalence rates and standardised 
prevalence rates of multimorbidity.  For objective 3, the standardised prevalence rates of 
different age, sex and ethnic groups were compared.  Finally, objective 4 described the most 
common dyads and triads for patients age 45 years and older.  The most common dyads and 
triads of each sex and ethnic groups were determined by the crude prevalence rates. 
 
2.4.1 Crude prevalence rate 
 
The crude prevalence rate was expressed as a numeral with the numerator as the number of 
patients with multimorbidity and the denominator as the total number of unique patients who 
had consulted a doctor in National Healthcare Group Polyclinics (NHGP) at least once between 
1st Jul 2015 and 30th Jun 2016.  There were four crude prevalence rates due to four numerators 
as described in Section 2.3.2 above. 
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2.4.2 Standardised prevalence rate 
 
As it was likely that different prevalence rates may occur in different sub-populations, a 
comparison of crude prevalence rates would be misleading since it would not be reflective of 
the population.  Therefore, we used the standardised prevalence rate as a summary measure. 
We used the direct standardisation method as detailed by Bains38.  Confidence intervals of 95% 
were calculated using the Poisson approximation around the standardised rates39.  To determine 
whether prevalence rates of multimorbidity differ among age, sex and ethnic groups, the 
standardised prevalence rates were altered to 1) age-stratified, sex-and-ethnicity standardised 
prevalence rate; 2) sex-stratified, age-and-ethnicity standardised prevalence rate; and 3) 
ethnicity-stratified, age-and-sex standardised prevalence rate respectively. 
 
We used superscripts ‘a’ for age-stratified, sex-and-ethnicity standardised prevalence rate, ‘g’ 
for sex-stratified, age-and-ethnicity standardised prevalence rate, and ‘e’ for ethnicity-
stratified, age-and-sex standardised prevalence rate attached to the phrase ‘standardised 
prevalence rate’ in the results section to clearly describe the different rates used.  The 
standardised prevalence rate with a superscript ‘t’ attached provides the weighted average of 
the prevalence rate where the weights were the proportions of persons in the corresponding 
age/sex/ethnic groups according to the 2016 Singapore population37 (Appendix 2-3).  It will be 
termed age-sex-ethnicity standardised prevalence rate for short. 
 
2.4.3 Dyads and Triads 
 
Dyads were created by summing every combination of two chronic conditions separately from 
the CDMP and Fortin lists respectively.  Triads were created by summing every combination 
of three chronic conditions.   
 
For the most common dyads and triads of the total population, the number of unique patients 
age 45 years and above with the specified dyad (or triad) of each list was denoted the numerator. 
The denominator was all patients age 45 years and above who had consulted a doctor in 
National Healthcare Group Polyclinics (NHGP) at least once between 1st Jul 2015 and 30th Jun 
2016.  We chose ‘45 years old and above’ as the 45-49 years old age group was found to be 
the age group with the steepest rise of multimorbidity shown in Fig 2-2 (p44).  
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For the most common dyads and triads of a specific sub-population, the numerator and 
denominator would be altered accordingly.  For example, for the most common dyads of the 
Chinese male population within the study population, the numerator would be the number of 
unique Chinese male patients age 45 years and above with the specified dyads of each list; and 
the denominator would be all Chinese male patients age 45 years and above who had consulted 
a doctor in NHGP at least once between 1st Jul 2015 and 30th Jun 2016.  For all cases, the most 
common dyads and triads were defined as a crude prevalence of 1.0% or more. 
 
2.5  Independent variables 
 
The independent variables (with no implication of causation) were age, sex and ethnicity.  Age 
was divided into four categories – ‘0-24’,‘25-44’, ‘45-64’, ’65-99’ following similar age groups 
used by Ashman et al.40 and Fortin et al.26. Sex was classified into male and female.  Ethnicity 
was categorised into Chinese, Malay, Indians, and Others. 
 
2.6 Analysis 
 
The sample size was determined by the number of patients aged 0 to 99 who visited the 
National Healthcare Group Polyclinics (NHGP) for at least one doctor consultation between 
1st Jul 2015 and 30th Jun 2016.  We used listwise deletion method for missing data41. 
 
For descriptive statistics, we described the mean for continuous variables and their respective 
standard deviation.  For categorical variables, we described proportions and their respective 
confidence intervals where appropriate. 
 
In objective 1 (p31) for describing the epidemiology of chronic conditions, the age group of 
patients (x-axis) was plotted against the proportion of patients with different number of chronic 
conditions (y-axis) in a line graph.  We calculated the gradient between consecutive age groups 
using the formula as follows: 
Gradienti = (yi+1 - yi) / (xi+1 - xi)
§ 
                                                 
§ Gradienti = gradient of age group i,  
  yi = prevalence of age grp i 
  xi = lower limit of age grp i 
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The highest gradient value indicated the sharpest rise in the percentage of patients with a 
specific number of chronic conditions within that specified age group. 
 
For the third objective (p31), we considered no overlap of the 95% confidence intervals for the 
standardised prevalence rates among the different age, sex and ethnic groups as statistically 
significant.  For multiple comparisons, we adjusted with Bonferroni adjustment by taking the 
statistically significant p value as less than 0.05 divided by the number of comparisons.  
However, we considered only an absolute difference between the different groups of 5.0% for 
clinical significance. 
 
For the fourth objective (p31), we used the crude prevalence rate to rank the most common 
dyads and triads of co-occurring chronic conditions for primary care patients who were 45 
years and above for the same population.  We listed only the common dyads and triads with an 
overall crude prevalence rate of at least 1.0% and above.  We next compared the dyads and 
triads among different sex and ethnic groups.  For multiple comparisons, we adjusted with 
Bonferroni adjustment by taking the statistically significant p value as less than 0.05 divided 
by the number of comparisons.  We considered an absolute difference between the subgroups 
of 10.0% or a relative difference of 300% for clinical significance. 
 
IBM SPSS version 21 and Microsoft Office Excel 2016 were used for all statistical calculations 
and analyses.   
 
2.7 Sub-group analysis 
 
As the crude prevalence rates of the common dyads and triads would likely be determined in a 
large part by the majority Chinese ethnic group for the overall population, a sub-group analysis 
was made by determining the common dyads and triads for each of the three major ethnic 
groups stratified by sex.  This sub-group analysis was performed using the multimorbidity list 
that gave a higher standardised prevalence rate between the two lists.  We listed only the 
common dyads and triads with crude prevalence rates of at least 1.0% and above. 
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3 Results 
 
3.1 Demographics of the study population 
 
This study included 787,447 unique patients who consulted a doctor in the National Healthcare 
Group Polyclinics (NHGP) at least once between 1st Jul 2015 and 30th Jun 2016.  We excluded 
one individual whose sex was not recorded. The final sample size was 787,446. 
 
Within this study population, there were more adults aged between 65-99 years and fewer 
adults aged 0-44 years who visited a family physician over the one-year period when compared 
to the national population (Table 2-1).  Using the CDMP list of conditions, the average number 
of chronic conditions increased from 0.1 for the ‘0-24’ year age group to 0.2 for the ‘25-44’ 
year age group to 1.3 for the ‘45-64’ year age group and to 2.4 for the ‘65-99’ year age group.  
Using the Fortin list, the average number of chronic conditions increased from 0.1 for the ‘0-
24’ year age group to 0.4 for the ‘25-44’ year age group to 1.7 for the ‘45-64’ year age group 
to 3.0 for the ‘65-99’ year age group. 
 
Patients under 25 years old had very low rates of chronic conditions for both the CDMP and 
Fortin lists.  The increase from the ‘25-44’ year age group to the ‘45-64’ year age group was 
6.5 times for CDMP list and 4.3 times for the Fortin list.  The average number of chronic 
conditions almost doubled from the ‘45-64’ year age group to the ‘65-99’ year age group for 
both lists. 
 
In terms of ethnicity, there were fewer Chinese, more Malays, Indians, and patients of other 
ethnicity** in this study population who visited a family physician over the one-year period 
compared to the national population.  The mean age of the different ethnic groups was very 
different compared to each other.  The Chinese were the oldest at 47.1 years old, followed by 
the Indians at 39.7 years old, the Others at 37.1 years old, and finally the Malays at 35.1 years 
old. 
 
                                                 
** Others included mainly Eurasians, Caucasians, Javanese. 
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For the CDMP list of conditions, the Chinese had an average of 1.1 chronic conditions, 
followed by the Indians with 0.9, the Malays at 0.7, and the Others at 0.6.  For the Fortin list 
of conditions, the Indians had the highest average of 1.2 chronic conditions, followed by the 
Chinese at 1.1, the Malays at 1.0, and the Others at 0.8.  
 
Compared to the national population, there were slightly fewer female (50.9% vs 51.2%) and 
more male (49.1% vs 48.8%) patients in the study population.  The mean age of the female 
patients was 2.9 years older than the male patients (45.3 vs 42.4).  The mean number of chronic 
conditions was the same for both sexes, 1.0 for CDMP conditions and 1.3 for Fortin conditions. 
 
Table 2-1. Demographics of the study population of patients (N=787,446) 
 
Number of 
patients 
(N) 
Percentage 
(%) 
National 
Proportion 
2016 (%) 
Age (years) 
Mean (SD) 
Number of 
CDMP 
Conditions, 
Mean (SD) 
Number of 
Fortin 
Conditions, 
Mean (SD) 
Age Group 
  0-24 201,839 25.6 26.9 12.9 (0.18) 0.1 (0.000) 0.1 (0.001) 
25-44 165,212 21.0 30.5 34.0 (0.02) 0.2 (0.001) 0.4 (0.002) 
45-64 252,206 32.0 29.3 55.4 (0.01) 1.3 (0.003) 1.7 (0.003) 
65-99 168,189 21.4 13.3 73.5 (0.02) 2.4 (0.004) 3.0 (0.004) 
Ethnic Group 
Chinese  537,234 68.2 74.3 47.1 (0.03) 1.1 (0.002) 1.1 (0.002) 
Malay 127,501 16.2 13.4 35.1 (0.06) 0.7 (0.004) 1.0 (0.005) 
Indian 78,452 10.0 9.1 39.7 (0.08) 0.9 (0.005) 1.2 (0.006) 
Others 44,529   5.6 3.2 37.1 (0.09) 0.6 (0.005) 0.8 (0.007) 
Sex 
Female 400,965 50.9 51.2 45.3 (0.04) 1.0 (0.002) 1.3 (0.003) 
Male  386,481 49.1 48.8 42.4 (0.04) 1.0 (0.002) 1.3 (0.003) 
 
3.2  The CDMP and Fortin lists of chronic conditions 
 
Sections 3.2 and 3.3 address objective 1, the epidemiology of chronic conditions depicted in 
the two lists for the sample population.  Table 2-2 lists the patient counts and crude prevalence 
rates of all the single chronic conditions of both the CDMP and Fortin lists. 
 
Four NHGP senior family physicians in the study team unanimously agreed that the ICD code 
for ‘back pain’ was not considered to be a chronic condition that was reliably coded in the 
context at our primary care setting for ‘chronic musculoskeletal conditions causing pain or 
limitation’ in the Fortin’s list.  As such, we only used 19 out of the 20 conditions in the Fortin 
list. 
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Table 2-2. Crude prevalence rates of chronic conditions - CDMP and Fortin lists 
(N=787,446) 
Rank CDMP Conditions 
Patient 
Count 
% Fortin Conditions 
Patient 
Count 
% 
1 Hyperlipidaemia 257,114 32.7 Hyperlipidaemia 257,114 32.7 
2 Hypertension 221,760 28.2 Hypertension 221,760 28.2 
3 Diabetes 125,058 15.9 Diabetes 124,954 15.9 
4 Ischaemic Heart Disease 36,401 4.6 Arthritis &/or Rheumatoid arthritis 100,838 12.8 
5 Asthma 28,778 3.7 Obesity 48,893 6.2 
6 
Chronic Kidney Disease 
21,638 2.7 
Cardiovascular disease (Angina, 
Myocardial infarction, Atrial 
fibrillation, poor circulation of lower 
limbs) 
43,559 5.5 
7 Osteoarthritis 18,378 2.3 
Asthma, COPD, or Chronic 
bronchitis 
32,611 4.1 
8 
Benign Prostate 
Hypertrophy 
13,031 1.7 Chronic hepatitis 25,918 3.3 
9 Osteoporosis 7,283 0.9 
Stroke and Transient Ischaemic 
Attack 
23,628 3.0 
10 
Stroke 
7,241 0.9 
Stomach problem 
(reflux, heartburn, or gastric ulcer) 
22,233 2.8 
11 Anxiety 6,085 0.8 Kidney disease or failure 22,221 2.8 
12 
Chronic Obstructive 
Pulmonary Disease 
(COPD) 
5,080 0.6 
Thyroid disorder 
20,781 2.6 
13 
Dementia 
3,571 0.5 
Heart failure 
(including valve problem or 
replacement) 
20,538 2.6 
14 Schizophrenia 2,889 0.4 Depression or anxiety 14,910 1.9 
15 Epilepsy 2,734 0.3 Chronic urinary problem 13,031 1.7 
16 Rheumatoid Arthritis 2,010 0.3 Any Cancer in the last 5 years 7,940 1.0 
17 Parkinson's 1,900 0.2 Osteoporosis 7,283 0.9 
18 Major Depression 1,700 0.2 Dementia or Alzheimer's disease 3,571 0.5 
19 Bipolar Disorder 51 0.0†† Colon problem (irritable bowel) 1,571 0.2 
20 Psoriasis 0 0    
 
The commonest three conditions for both lists were ‘hyperlipidaemia’, ‘hypertension’ and 
‘diabetes’ in descending order (Table 2-2).  There were three conditions in the CDMP list that 
were above 10.0% prevalence rate compared to four conditions in the Fortin list.  There were 
eight conditions altogether with a prevalence rate of above 1.0% in the CDMP list compared 
to 16 conditions in the Fortin list.   There was zero patient count for ‘psoriasis’ in the CDMP 
list. 
 
Five of the conditions in the CDMP list were not found in the Fortin list. They were a 
dermatological condition – ‘psoriasis’; two neurological conditions – ‘epilepsy’ and 
‘Parkinson’s disease’; and two psychiatric conditions – ‘bipolar disorder’ and ‘schizophrenia’.  
                                                 
†† Actual value is 0.006% 
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There was a total of four psychiatric conditions in the CDMP list (anxiety, schizophrenia, major 
depression, and bipolar disorder), and all of them recorded a prevalence rate of less than 1.0% 
each. 
 
Seven of the Fortin list conditions were not found in the CDMP list.  They were three 
gastrointestinal conditions – ‘chronic hepatitis’, ‘stomach problem’, and ‘colon problem’; two 
endocrine conditions – ‘thyroid disorder’ and ‘obesity’; one cardiovascular condition – ‘heart 
failure’; and ‘any cancer in the last five years’.  There was only one psychiatric condition 
(‘depression or anxiety’) in the Fortin list with a prevalence rate of more than 1.0%. 
 
3.3  Prevalence of chronic conditions 
 
Figures 2-1 and 2-2 report the percentage of patients with chronic conditions based on the 
standardised prevalence ratea for sex and ethnicity stratified by age.  The proportion of patients 
with chronic conditions increased with the advancement of age. 
 
For the CDMP list (Figure 2-1), the steepest gradient occurred at age 50-54 for those with two 
conditions; and for those with three conditions, the steepest gradient occurred at age 65-69 
(Appendix 2-4). According to the CDMP list, 50% of the population in primary care would 
have one chronic condition in their 50s, two conditions in their 60s and three conditions in their 
70s. 
 
For the Fortin list (Figure 2-2), the steepest gradient occurred at age 45-49 for those with two 
conditions; and for those with three conditions, the steepest gradient occurred at age 50-54 
(Appendix 2-4).  According to the Fortin list, 50% of the population in primary care would have 
one chronic condition in their 40s, two conditions in their 50s, three conditions in their 60s, 
and four conditions in their 80s. 
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Figure 2-1. Number of chronic conditions by age-group (CDMP list)  
 
 
 
 
Figure 2-2. Number of chronic conditions by age-group (Fortin list) 
 
  
45 
 
 
3.4 Prevalence rates of multimorbidity  
 
Section 3.4 addresses objective 2, the prevalence of multimorbidity using two different lists 
and two different cut-points.  The standardised prevalence ratest of multimorbidity using the 
CDMP list were lower than that of the Fortin list (Table 2-3).  The standardised prevalence 
ratest were also lower than that of the crude prevalence rate.  The standardised prevalence ratet 
of multimorbidity was lower when MM3+ was used to define multimorbidity as compared to 
MM2+. 
 
Table 2-3. Prevalence rates of multimorbidity 
 CDMP MM2+ 
% (CI) 
Fortin MM2+ 
% (CI) 
CDMP MM3+ 
% (CI) 
Fortin MM3+ 
% (CI) 
Prevalence (Crude) 29.6 33.9 17.3 23.7 
Age-sex-ethnicity 
standardised 
prevalence rate 
21.9 
(21.8, 22.0)  
25.9 
(25.8, 26.0) 
12.0 
(12.0, 12.1)  
17.2 
(17.2, 17.3) 
t Age-sex-ethnicity standardised prevalence rate  
 
3.5 Comparing the standardised prevalence rates of multimorbidity 
among age, sex and ethnic groups 
 
Section 3.5 addresses objective 3, to determine whether there were differences in the standard 
prevalence rates among different age, sex, and ethnic groups. 
 
3.5.1 Age 
 
The prevalence rate of multimorbidity increased with age as shown in Table 2-4.  The 
standardised prevalence ratesa were generally lower than the crude prevalence rate for those in 
the ‘0-24’ year age group.  The standardised prevalence ratesa were generally higher than the 
crude prevalence rate for those in the ‘25-44’ year age group, lower for those in the ‘45-64’ 
year age group, and about the same for those in the ‘65-99’ year age group. 
  
Patients under 25 years old had very low standardised prevalence ratesa (range from 0.01% to 
0.61%) of multimorbidity for both the CDMP and Fortin lists.  Using the CDMP list and MM2+ 
                                                 
a Age-stratified, sex-and-ethnicity standardised prevalence rate 
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definition, the standardised prevalence ratea of multimorbidity increased by more than six times 
from the ‘25-44’ year age group (5.7%) to the ‘45-64’ year age group (37.6%) and more than 
12 times from the ‘25-44’ year age group to the ‘65-99’ year age group (72.3%). 
 
Using the CDMP list and MM3+ definition, the standardised prevalence ratea of multimorbidity 
increased by more than 10 times from the ‘25-44’ year age group (1.8%) to the ‘45-64’ year 
age group (18.4%) and more than 26 times from the ‘25-44’ year age group to the ‘65-99’ year 
age group (48.5%). 
 
Using the Fortin list and MM2+ definition, the standardised prevalence ratea of multimorbidity 
increased by more than five times from the ‘25-44’ year age group (8.9%) to the ‘45-64’ year 
age group (45.3%) and more than eight times from the ‘25-44’ year age group to the ‘65-99’ 
year age group (77.3%). 
 
Using the Fortin list and MM3+ definition, the standardised prevalence ratea of multimorbidity 
increased by more than seven times from the ‘25-44’ year age group (4.0%) to the ‘45-64’ year 
age group (28.5%) and more than 15 times from the ‘25-44’ year age group to the ‘65-99’ year 
age group (60.9%). 
 
There were clinically and statistically significant differences (after Bonferroni adjustment) 
among the standardised prevalence ratesa of multimorbidity among all the four different age 
groups as there were no overlap of the confidence intervals and the absolute difference between 
them were at least 5.0% or more. 
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Table 2-4. Prevalence rates of multimorbidity stratified by age-groups 
 
 
0-24 25-44 45-64 65-99 
Crude 
Prevalence 
% 
Age-
stratified, 
sex-and-
ethnicity-
standardised 
prevalence 
% (CI) 
Crude 
Prevalence 
% 
Age-
stratified, 
sex-and-
ethnicity-
standardised 
prevalence 
% (CI) 
Crude 
Prevalence 
% 
Age-
stratified, 
sex-and-
ethnicity-
standardised 
prevalence 
% (CI) 
Crude 
Prevalence 
% 
Age-
stratified, 
sex-and-
ethnicity-
standardised 
prevalence 
% (CI) 
 
CDMP 
MM2+ 
 
0.16 
0.13 
(0.12, 0.15) 
5.2 
5.7 
(5.6,5.8) 
40.4 
37.6 
(37.4, 37.9) 
72.5 
72.3 
(71.9, 72.7) 
 
CDMP 
MM3+ 
 
0.02 
0.01 
(0.01, 0.02) 
1.7 
1.8 
(1.8, 1.9) 
20.3 
18.4 
(18.3, 18.6) 
48.8 
48.5 
(48.2, 48.9) 
 
Fortin 
MM2+ 
 
0.73 
0.61 
(0.58, 0.65) 
8.1 
8.9 
(8.7, 9.0) 
48.2 
45.3 
(45.1, 45.6) 
77.5 
77.3 
(76.9, 77.7) 
 
Fortin 
MM3+ 
 
0.11 
0.08 
(0.07, 0.10) 
3.7 
4.0 
(3.9, 4.1) 
30.9 
28.5 
(28.3, 28.7) 
61.1 
60.9 
(60.5, 61.2) 
a Age-stratified, sex-and-ethnicity standardised prevalence rate 
 
3.5.2 Sex 
 
The standardised prevalence ratesg of multimorbidity were higher for male patients when 
compared to female patients for both the CDMP and Fortin lists and both multimorbidity 
definitions (MM2+ and MM3+ cut-offs) as shown in Table 2-5.  Although there were no 
overlaps between the confidence intervals indicating that the difference between the sexes were 
statistically significant (after Bonferroni adjustment), the difference in standardised prevalence 
rates between the two sexes were less than 5.0% and was therefore deemed not to be clinically 
significant. 
Table 2-5.  Prevalence rates of multimorbidity stratified by sex 
 Female Male 
Crude 
Prevalence % 
Sex-stratified, age-and-
ethnicity-standardised 
prevalence 
% (CI) 
Crude 
Prevalence % 
Sex-stratified, age-and-
ethnicity-standardised 
prevalence 
% (CI) 
CDMP 
MM2+ 
29.4 
20.4 
(20.3, 20.5) 
29.7 
23.4 
(23.3, 23.6) 
CDMP 
MM3+ 
16.5 
10.9 
(10.8, 11.0) 
18.1 
13.2 
(13.1, 13.3) 
Fortin 
MM2+ 
34.6 
25.0 
(24.8, 25.1) 
33.2 
26.8 
(26.7, 27.0) 
Fortin 
MM3+ 
24.0 
16.5 
(16.4, 16.6) 
23.4 
18.0 
(17.9, 18.1) 
g Sex-stratified, age-and-ethnicity standardised prevalence rate 
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3.5.3 Ethnicity 
 
We next compared the standardised prevalence ratese of multimorbidity among the different 
ethnic groups (Table 2-6).  Using the CDMP list and MM2+ definition, the standardised 
prevalence ratee of multimorbidity in decreasing order for each ethnic group was Chinese 
(22.6%), Indian (21.1%), Malay (20.2%), followed by Others (14.3%).  The order changed 
when the MM3+ definition was used.  In decreasing order, the Indian ethnic group had the 
highest standardised prevalence ratee of multimorbidity at 12.9%, followed by Malay at 12.4%, 
then Chinese at 12.1%, and finally Others at 7.5%. 
 
For CDMP MM2+, the differences in standardised prevalence ratese of multimorbidity were 
statistically different (after Bonferroni adjustment) among all ethnic groups but only the 
differences between the Others ethnic group and each of the three major ethnic groups were 
clinically significant.  For CDMP MM3+, clinically significant difference (an absolute 
difference of 5% between standardised prevalence rates) was noted between the Others ethnic 
group and the Indian ethnic group only. 
 
The ranking order of the ethnic groups based on the standardised prevalence ratee of the Fortin 
list was consistent for both MM2+ and MM3+ definitions.  They were Chinese (MM2+ 26.8%, 
MM3+ 17.5%‡‡), followed by Indian (MM2+ 24.9%, MM3+ 17.5%§§), then Malay (MM2+ 
23.5%, MM3+ 16.8%), and finally Others (MM2+ 17.3%, MM3+ 11.1%). 
 
There were statistically significant differences (after Bonferroni adjustment) in the 
standardised prevalence ratese of the Fortin list among all the four ethnic groups except between 
the Chinese and Indian ethnic groups (Chinese – 17.5%, CI 17.4% - 17.6%; Indians – 17.5%, 
CI 17.3% - 17.8%) where the confidence intervals overlapped.  Similar to the CDMP MM2+ 
list, only the differences between the Others ethnic group and each of the three major ethnic 
groups were clinically significant for both Fortin MM2+ and MM3+ cut-offs. 
  
                                                 
‡‡ Actual standardised prevalence ratee was 17.548% 
§§ Actual standardised prevalence ratee was 17.545%. 
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Table 2-6. Prevalence rates of multimorbidity stratified by ethnicity 
 Chinese Malay Indian Others 
Crude 
Prevalence 
% 
Ethnicity-
stratified, 
age-and-sex 
standardised 
prevalence 
% (CI) 
Crude 
Prevalence 
% 
Ethnicity-
stratified, 
age-and-sex 
standardised 
prevalence 
% (CI) 
Crude 
Prevalence 
% 
Ethnicity-
stratified, 
age-and-sex 
standardised 
prevalence 
% (CI) 
Crude 
Prevalence 
% 
Ethnicity-
stratified, 
age-and-sex 
standardised 
prevalence % 
(CI) 
CDMP 
MM2+ 
32.8 
22.6 
(22.5, 22.7) 
21.7 
20.2 
(20.0, 20.5) 
27.1 
21.1 
(20.8, 21.4) 
16.7 
14.3 
(14.0, 14.7) 
CDMP 
MM3+ 
18.7 
12.1 
(12.0, 12.2) 
13.7 
12.4 
(12.2, 12.5) 
17.4 
12.9 
(12.7, 13.1) 
9.4 
7.5 
(7.3, 7.7) 
Fortin 
MM2+ 
37.6 
26.8 
(26.7, 26.9) 
24.9 
23.5 
(23.2, 23.8) 
31.1 
24.9 
(24.6, 25.2) 
19.7 
17.3 
(16.9, 17.7) 
Fortin 
MM3+ 
26.0 
17.5 
(17.4, 17.6) 
18.2 
16.8 
(16.6, 17.0) 
23.0 
17.5 
(17.3, 17.8) 
13.3 
 
11.1 
(10.8, 11.4) 
 
e Ethnicity-stratified, age-and-sex standardised prevalence rate 
 
3.6 The most common dyads and triads 
 
Sections 3.6 and 3.7 address objective 4 regarding the dyads and triads of chronic conditions. 
Table 2-7 to 2-10 show a list of common dyads and triads for patients age 45 years and above 
for the overall population (n=420,395) for each of the multimorbidity lists and cut-points.  The 
most common dyads and triads were defined by a crude prevalence of 1.0% or more.  The list 
of common dyads and triads obtained was further stratified into different groups based on their 
ethnicity and sex.   The Others ethnic group did not have any dyads or triads with a crude 
prevalence rate that exceeded any of the three major ethnic groups.  As such, for the rest of this 
section, we described the patterns of multimorbidity among the three major ethnic groups only. 
 
The dyad or triad with the highest crude prevalence rate among the different ethnic/sex groups 
would have a superscript ‘#’ symbol tagged next to it.  We considered an absolute difference in 
crude prevalence rates among the different subgroups of 10.0% or a relative difference of 300% 
for clinical significance.  An asterisk was put next to a crude prevalence rate if it was lower 
than the highest crude prevalence rate for the specific dyad or triad based on the above two 
criteria. 
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3.6.1 CDMP Dyads 
 
Table 2-7.  The most common dyads using the CDMP list – Crude prevalence rates 
15,043 participants were excluded from the Others Ethnic Group.  Highest crude prevalence rate in that row;  Clinically 
significant lower crude prevalence rate than the prevalence rate that was tagged with # in the same row;  Ischaemic Heart 
Disease;  Chronic Kidney Disease 
 
There were eleven CDMP dyads with a crude prevalence rate of 1.0% and above for the overall 
population (n=420,395) (Table 2-7).  The CDMP dyads consisted of different combinations of 
the seven most prevalent CDMP chronic conditions (hyperlipidaemia, hypertension, diabetes, 
IHD, asthma, CKD and osteoarthritis) listed in Table 2-2. 
 
The top two dyads were hyperlipidaemia/hypertension (44.1%) and hypertension/diabetes 
(23.3%) with a crude prevalence rate of more than 10.0%.  These two dyads were also the top 
two dyads for all the subgroups stratified by sex and ethnicity with a crude prevalence rate of 
more than 10.0%.  In addition to these two dyads, the Indian females had one more dyad 
(hyperlipidaemia/diabetes), and the Indian males had two more dyads 
(hyperlipidaemia/diabetes and diabetes/IHD) with a crude prevalence rate of more than 10.0%.  
 
The Chinese had three dyads with crude prevalence rates that surpassed the other ethnic groups, 
and the Malays and Indians had four dyads each. 
 
Rank CDMP Dyads 
Overall  
(n = 420,395) 
Chinese 
(n=323,941) 
Malay 
(n=47,541) 
Indian 
(n=33,870) 
Female 
(n = 174,750) 
Male 
(n=149,191) 
Female 
(n=25,338) 
Male 
(n=22,203) 
Female 
(n=17,633) 
Male 
(n=16.237) 
1 
Hyperlipidaemia/ 
Hypertension 
44.1% 41.4% 47.4% 47.9% 43.1% 44.3% 43.9% 
2 
Hypertension/ 
Diabetes 
23.3% 20.0%* 23.7% 31.4% 26.5% 32.1% 31.8% 
3 
Hyperlipidaemia/ 
Diabetes 
5.1% 3.6%* 4.8% 6.0% 7.0% 10.7% 12.7% 
4 Diabetes/IHD 4.6% 2.6%* 5.8% 3.7%* 7.5% 5.9% 11.6% 
5 Hypertension/IHD 3.4% 1.9% 5.3% 1.5%* 4.5% 1.7%* 4.5% 
6 Diabetes/CKD 2.3% 1.8% 2.5% 4.1% 3.5% 2.0% 1.9% 
7 Hypertension/CKD 1.4% 1.1% 2.0% 1.1% 1.8% 0.5%* 0.7% 
8 IHD/CKD 1.3% 0.8%* 1.7% 1.3% 2.4% 1.0% 1.7% 
9 
Hypertension/ 
Osteoarthritis 
1.1% 1.5% 0.8% 1.2% 0.7% 1.1% 0.5% 
10 Hypertension/Asthma 1.1% 0.9% 0.8% 2.2% 1.4% 2.1% 1.0% 
11 Diabetes/Asthma 1.0% 0.7%* 0.5%* 2.8% 1.2%* 4.3% 2.1% 
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The Chinese females had five dyads with crude prevalence rates that were clinically 
significantly lower than other ethnic/sex groups.  The Indian males had no dyads with crude 
prevalence rates that were clinically significantly lower than the other ethnic/sex groups. 
 
3.6.2 CDMP Triads 
 
Table 2-8. The most common triads using the CDMP list – Crude prevalence rates 
Rank CDMP Triads 
Overall  
(n = 420,395) 
Chinese 
(n=323,941) 
Malay 
(n=47,541) 
Indian 
(n=33,870) 
Female 
(n = 174,750) 
Male 
(n=149,191) 
Female 
(n=25,338) 
Male 
(n=22,203) 
Female 
(n=17,633) 
Male 
(n=16.237) 
1 Hyperlipidaemia/ 
Hypertension/ 
Diabetes 
21.9% 19.0%* 22.1% 29.7% 24.8% 30.2% 29.8% 
2 Hypertension/ 
Diabetes/ 
IHD 
4.2% 2.5%* 5.2% 3.5% 6.7% 5.4% 9.8% 
3 Hyperlipidaemia/ 
Hypertension/IHD 
3.1% 1.8% 5.0% 1.4%* 4.3% 1.5%* 4.3% 
4 Hypertension/ 
Diabetes/CKD 
2.2% 1.8% 2.4% 4.0% 3.3% 1.9% 1.8% 
5 Hyperlipidaemia/ 
Hypertension/CKD 
1.2% 0.9% 1.6% 0.9% 1.4% 0.4%* 0.6% 
15,043 participants were excluded from the Others Ethnic Group.  Highest crude prevalence rate in that row;  Clinically 
significant lower crude prevalence rate than the prevalence rate that was tagged with # in the same row;  Ischaemic Heart 
Disease;  Chronic Kidney Disease 
 
There were five CDMP triads with a crude prevalence rate of 1.0% and above for the overall 
population (n=420,395) (Table 2-8).  The CDMP triads consisted of different combinations of 
the four most prevalent and the sixth most prevalent CDMP chronic conditions 
(hyperlipidaemia, hypertension, diabetes, IHD, CKD) listed in Table 2-2.  ‘Asthma’ (fifth most 
prevalent CDMP chronic condition) was not included in the top five CDMP triads. 
 
Hyperlipidaemia/hypertension/diabetes was the top triad for all the ethnic groups for both 
sexes.  Hypertension/diabetes/IHD was the second most common triad for all the ethnic groups 
for both sexes except the Malay females, where hypertension/diabetes/CKD (4.0%) was more 
common than hypertension/diabetes/IHD (3.5%).  When comparing the crude prevalence rates, 
both the Chinese and Indians had two triads each that surpassed the other ethnic groups and the 
Malays had one.  The males of all the three ethnic groups had no triads with crude prevalence 
rates that were clinically significantly lower than the other ethnic/sex groups. 
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3.6.3 Fortin Dyads 
 
There were 19 dyads with a crude prevalence of rate of 1.0% and above for the overall 
population (n=420,395) (Table 2-9).  The Fortin dyads consisted of different combinations 
from the most prevalent Fortin chronic conditions as listed in Table 2-2.  They included all the 
top eleven single chronic conditions (hyperlipidaemia, hypertension, diabetes, arthritis &/or 
rheumatoid arthritis, obesity, cardiovascular disease, chronic hepatitis, stroke/transient 
ischaemic attack, and kidney disease or failure) except ‘asthma/COPD or chronic bronchitis’ 
and ‘stomach problems’ (i.e., nine single conditions in total). 
 
The top two dyads were hyperlipidaemia/hypertension (42.9%) and hypertension/diabetes 
(22.8%) with a crude prevalence rate of more than 10.0%.  These two dyads were also the top 
two dyads for all the subgroups stratified by sex and ethnicity with a crude prevalence rate of 
more than 10.0%.  In addition to these two dyads, Malay females had one more dyad 
(diabetes/obesity), Indian females had one more dyad (diabetes/arthritis), and Indian males had 
one more dyad (hyperlipidaemia/diabetes) with a crude prevalence rate of more than 10.0%. 
The Indians had nine dyads with crude prevalence rates that surpassed the other ethnic groups, 
and both the Chinese and Malays had five dyads each. 
 
The Malay females had four dyads with crude prevalence rates that were clinically significantly 
lower than other ethnic/sex groups.  The Malay males had no dyads with crude prevalence rates 
that were clinically significantly lower than the other ethnic/sex groups. 
  
                                                 
 Chronic Obstructive Pulmonary Disease 
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Table 2-9. The most common dyads using the Fortin list – Crude prevalence rates 
Rank Fortin Dyads 
Overall  
(n = 420,395) 
Chinese 
(n=323,941) 
Malay 
(n=47,541) 
Indian 
(n=33,870) 
Female 
(n = 174,750) 
Male 
(n=149,191) 
Female 
(n=25,338) 
Male 
(n=22,203) 
Female 
(n=17,633) 
Male 
(n=16.237) 
1 Hyperlipidaemia/ 
Hypertension 
42.9 43.2% 45.9% 46.6% 41.0% 43.3% 41.7% 
2 Hypertension/ 
Diabetes 
22.8 21.3%* 23.1% 30.6% 25.4% 31.3% 30.3% 
3 Hypertension/Arthritis 6.8 7.1%
 5.8% 6.5% 4.8% 6.8% 4.1% 
4 Diabetes/Arthritis 6.3 5.5% 4.7%* 8.5% 6.1% 14.7%
 9.6% 
5 Hyperlipidaemia/ 
Diabetes 
4.6 3.8% 4.4% 5.2% 6.0% 9.3% 10.4% 
6 Diabetes/Obesity 4.1 3.0%* 3.1%* 11.9%
 6.6% 8.3% 6.0% 
7 Diabetes/ 
Cardiovascular 
3.5 3.3% 4.9% 2.3%* 5.3% 3.1% 7.9% 
8 Arthritis/ Obesity 3.1 2.2%* 1.5%* 8.2% 3.6% 9.6%
 3.4% 
9 Hypertension/ 
Cardiovascular 
2.8 3.0% 4.6% 1.1%* 3.5% 0.9%* 3.1% 
10 Hyperlipidaemia/ 
Arthritis 
2.5 2.6% 1.7% 2.4% 1.5% 3.4% 2.0% 
11 Hypertension/Obesity 2.1 1.8% 1.9% 5.0%
 2.8% 2.8% 1.5%* 
12 Arthritis/ 
Cardiovascular 
1.9 1.8% 2.2% 1.0%* 2.1% 2.2% 3.7% 
13 Obesity/ 
Cardiovascular 
1.3 1.0% 1.3% 2.3% 2.9% 2.6% 2.9% 
14 Hypertension/Stroke 1.3 1.5% 2.0%
 0.6%* 1.0% 0.4%* 0.8% 
15 Cardiovascular/Stroke 1.3 1.3% 1.7% 1.0% 1.7% 0.9% 1.9%
 
16 Diabetes/Stroke 1.2 1.3% 1.5%
 1.1% 1.3% 0.8% 1.4% 
17 Cardiovascular/ 
Kidney 
1.2 1.1% 1.4% 1.4% 2.3% 1.0% 1.6% 
18 Diabetes/Kidney 1.1 1.1% 1.3% 1.5% 1.6%
 0.8% 0.9% 
19 Diabetes/ 
Chronic Hepatitis 
1.1 1.2% 1.4% 0.5% 0.7% 0.8% 1.1% 
15,043 participants were excluded from the Others Ethnic Group.  Highest crude prevalence rate in that row;  Clinically 
significant lower crude prevalence rate than the prevalence rate that was tagged with # in the same row 
 
 
3.6.4 Fortin Triads 
 
There were 12 triads with a crude prevalence rate of 1.0% and above for the overall population 
(n=420,395) (Table 2-10).  The Fortin triads included the top eleven single chronic conditions 
(hyperlipidaemia, hypertension, diabetes, arthritis &/or rheumatoid arthritis, obesity, 
cardiovascular disease, stroke and transient ischaemic attack, and kidney disease or failure) 
except ‘asthma, COPD, or chronic bronchitis’, ‘stomach problem’, and ‘chronic hepatitis’ 
(i.e., eight single conditions in total). 
  
                                                 
 Chronic Obstructive Pulmonary Disease 
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Table 2-10. The most common triads using the Fortin list – Crude prevalence rates 
Rank Fortin Triads 
Overall  
(n = 420,395) 
Chinese 
(n=323,941) 
Malay 
(n=47,541) 
Indian 
(n=33,870) 
Female 
(n = 174,750) 
Male 
(n=149,191) 
Female 
(n=25,338) 
Male 
(n=22,203) 
Female 
(n=17,633) 
Male 
(n=16.237) 
1 Hyperlipidaemia/ 
Hypertension/Diabetes 
21.9% 18.9%* 22.1% 29.7% 24.8% 30.2% 29.8% 
2 Hyperlipidaemia/ 
Hypertension/Arthritis 
5.5% 6.7% 4.7% 5.3% 4.0% 5.6% 3.3% 
3 Hypertension/Diabetes/ 
Arthritis 
5.2% 5.3% 3.9% 7.1% 5.1% 11.4% 7.1% 
4 Hypertension/Diabetes/ 
Obesity 
3.8% 2.7%* 3.1%* 11.1% 6.3% 6.9% 5.2% 
5 Hypertension/Diabetes/ 
Cardiovascular 
3.2% 1.9%* 4.4% 2.2%* 4.5% 2.7% 6.7% 
6 
Hyperlipidaemia/ 
Hypertension/ 
Cardiovascular 
2.5% 1.4%* 4.2% 1.0%* 3.3% 0.7%* 2.9% 
7 Hyperlipidaemia/ 
Hypertension/Obesity 
2.0% 1.6% 1.8% 4.4% 2.7% 2.3% 1.5% 
8 Diabetes/Arthritis/ 
Obesity 
1.7% 1.4%* 0.8%* 4.5% 2.1% 5.9% 2.5% 
9 Hyperlipidaemia/ 
Hypertension/Stroke 
1.2% 1.0% 1.8% 0.5%* 0.9% 0.3%* 0.7% 
10 Hypertension/Arthritis/ 
Obesity 
1.1% 1.2% 0.6%* 2.9% 1.4% 2.5% 0.8% 
11 Hypertension/Diabetes/ 
Stroke 
1.1% 1.0% 1.4% 1.0% 1.2% 0.7% 1.2% 
12 Hypertension/Diabetes/ 
Kidney 
1.0% 0.8% 1.2% 1.4% 1.5% 0.8% 0.9% 
15,043 participants were excluded from the Others Ethnic Group.  Highest crude prevalence rate in that row;  Clinically 
significant lower crude prevalence rate than the prevalence rate that was tagged with # in the same row 
 
Hyperlipidaemia/hypertension/diabetes was the top triad for all the ethnic groups for both sexes 
with a crude prevalence rate of 10.0% and above.  These top triad was also the top triad for all 
the subgroups stratified by sex and ethnicity with a crude prevalence rate of more than 10.0%.  
In addition to this triad, Malay females had one more triad (hypertension/diabetes/obesity), and 
Indian females had one more triad (hypertension/diabetes/arthritis) with a crude prevalence 
rate of more than 10.0%.  In terms of the crude prevalence rate, each of the three ethnic groups 
had four triads that surpassed the other ethnic groups. 
 
The Chinese females had five triads with crude prevalence rates that were clinically 
significantly lower than other ethnic/sex groups.  Both the Malay and Indian males had no 
dyads with crude prevalence rates that were clinically significantly lower than other ethnic/sex 
groups. 
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3.7 Sub-group analysis of the common dyads and triads of 
multimorbidity 
 
The Fortin list was found to have a higher standardised prevalence ratet compared with the 
CDMP list in Section 3.4 (p44).  Therefore, we determined the common dyads and triads of 
the three major ethnic groups stratified by sex instead of the overall population using the Fortin 
list in this section.    Table 2-11, 2-12 and 2-13 show the most common dyads and triads based 
on the total Chinese, Malay, and Indian patients age 45 years and above respectively.  The most 
common dyads and triads were defined by a crude prevalence of 1.0% or more. 
 
3.7.1 Chinese ethnic group (Table 2-11) 
 
‘Hypertension’, ‘stroke and transient ischaemic attack’, and ‘chronic hepatitis’ tended to occur 
more in combination with other conditions to form a dyad or triad for Chinese males. 
‘Hypertension’ and ‘arthritis &/or rheumatoid arthritis’ tended to occur more in combination 
with other conditions to form a dyad or triad for Chinese females.  Although ‘asthma, COPD, 
or chronic bronchitis’, as a single condition, was ranked number seven in terms of prevalence 
rate (Table 2-2), it was not seen at all in the common dyads and triads of the Chinese ethnic 
group for both sexes. 
 
3.7.2 Malay ethnic group (Table 2-12) 
 
Both the Malay males and females tended to have more frequent occurrences of ‘kidney disease 
or failure’ in combination with other conditions to form a dyad or triad.  None of the other 
female ethnic groups had ‘kidney disease or failure’ found in any of the triads at all with a 
crude prevalence rate of 1.0% and above.  ‘Obesity’ was also a distinctly common condition in 
combination with other conditions to form a dyad or triad for the Malay females.  Out of the 
15 triads listed, nine of them consisted of ‘obesity’, of which six of the triads had the highest 
prevalence rate when compared to all the other subgroups (hypertension/diabetes/obesity, 
hyperlipidaemia/hypertension/obesity, hypertension/arthritis &/or rheumatoid 
arthritis/obesity, diabetes/obesity/chronic hepatitis, diabetes/obesity/kidney disease or failure, 
diabetes/obesity/asthma, COPD, or chronic bronchitis).   
                                                 
t Age-sex-ethnicity standardised prevalence rate 
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3.7.3 Indian ethnic group (Table 2-13) 
 
‘Diabetes’ and ‘cardiovascular disease’ tended to occur more frequently in combination with 
other conditions to form a dyad or triad for both sexes of the Indians.  Although ‘kidney disease 
or failure’, as a single condition, was ranked number eleven in terms of prevalence rate (Table 
2-2), it was not seen at all in the common triads of the Indian ethnic group for both sexes.  Only 
one dyad for Indian males had this condition.    Only the Indian females had ‘thyroid disorder’ 
in combination with other conditions to form a dyad, none of the other subgroups had this 
condition found in combination with other conditions with a crude prevalence rate of 1.0% and 
above. 
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Table 2-11. The most common dyads and triads for Chinese patients above 45 years old stratified by sex (Fortin List, n = 323,941) 
Rank 
Female (n = 174,750) Male (n=149,191) 
Dyad % Triad % Dyad % Triad % 
1 Hyperlipidaemia/Hypertension 40.9 Hyperlipidaemia/Hypertension/Diabetes 18.9 Hyperlipidaemia/Hypertension 45.9 Hyperlipidaemia/Hypertension/Diabetes 22.1 
2 Hypertension/Diabetes 19.7 Hyperlipidaemia/Hypertension/Arthritis 6.7# Hypertension/Diabetes 23.1 Hyperlipidaemia/Hypertension/Arthritis 4.7 
3 Hypertension/Arthritis 8.3# Hypertension/Diabetes/Arthritis 5.3 Hypertension/Arthritis 5.8 Hypertension/Diabetes/Cardiovascular 4.4 
4 Diabetes/Arthritis 6.2 Hypertension/Diabetes/Obesity 2.7 Diabetes/Cardiovascular 4.9 Hyperlipidaemia/Hypertension/Cardiovascular 4.2# 
5 Hyperlipidaemia/Arthritis 3.4# Hypertension/Diabetes/Cardiovascular 1.9 Diabetes/Arthritis 4.7 Hypertension/Diabetes/Arthritis 3.9 
6 Hyperlipidaemia/Diabetes 3.3 Hyperlipidaemia/Hypertension/Obesity 1.6 Hypertension/Cardiovascular 4.6# Hypertension/Diabetes/Obesity 3.1 
7 Diabetes/Obesity 2.8 Diabetes/Arthritis/Obesity 1.4 Hyperlipidaemia/Diabetes 4.4 Hyperlipidaemia/Hypertension/Obesity 1.8 
8 Arthritis/Obesity 2.8 Hyperlipidaemia/Hypertension/Cardiovascular 1.4 Diabetes/Obesity 3.1 Hyperlipidaemia/Hypertension/Stroke 1.8# 
9 Diabetes/Cardiovascular 2.0 Hypertension/Arthritis/Obesity 1.2 Arthritis/Cardiovascular 2.2 Hypertension/Diabetes/Stroke 1.4# 
10 Hypertension/Obesity 1.8  
 
Hypertension/Stroke 2.0# Hypertension/Diabetes/Kidney 1.2 
11 Hypertension/Cardiovascular 1.6 Hypertension/Obesity 1.9 Hypertension/Diabetes/Chronic Hepatitis 1.1# 
12 Arthritis/Cardiovascular 1.5 Hyperlipidaemia/Arthritis 1.7 
Hyperlipidaemia/Hypertension/Chronic 
Hepatitis 
1.1# 
13 Arthritis/Chronic Hepatitis 1.1# Cardiovascular/Stroke 1.7 Hypertension/Arthritis/Cardiovascular 1.0# 
14 Hypertension/Stroke 1.1 Cardiovascular/Kidney 1.6  
 
15 Diabetes/Stroke 1.0 Diabetes/Stroke 1.5# 
16  
 
Arthritis/Obesity 1.5 
17 Diabetes/Chronic Hepatitis 1.4# 
18 
Hypertension/Chronic 
Hepatitis 
1.3# 
19 Diabetes/Kidney 1.3 
20 Obesity/Cardiovascular 1.3 
21 Hypertension/Kidney 1.1# 
22 Hypertension/Urinary 1.0# 
# denotes the highest crude prevalence rate for that specific dyad or triad compared with other ethnic/sex subgroups across Table 2-11, Table 2-12 & Table 2-13. 
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Table 2-12. The most common dyads and triads for Malay patients above 45 years old stratified by sex (Fortin List, n = 47,541) 
Rank 
Female (n=25,338) Male (n=22,203) 
Dyad % Triad % Dyad % Triad % 
1 Hyperlipidaemia/Hypertension 46.6# Hyperlipidaemia/Hypertension/Diabetes 29.7 Hyperlipidaemia/Hypertension 41.0 Hyperlipidaemia/Hypertension/Diabetes 24.8 
2 Hypertension/Diabetes 30.6 Hypertension/Diabetes/Obesity 11.1# Hypertension/Diabetes 25.4 Hypertension/Diabetes/Obesity 6.3 
3 Diabetes/Obesity 11.9# Hypertension/Diabetes/Arthritis 7.1 Diabetes/Obesity 6.6 Hypertension/Diabetes/Arthritis 5.1 
4 Diabetes/Arthritis 8.5 Hyperlipidaemia/Hypertension/Arthritis 5.3 Diabetes/Arthritis 6.1 Hypertension/Diabetes/Cardiovascular 4.5 
5 Arthritis/Obesity 8.2 Diabetes/Arthritis/Obesity 4.5 Hyperlipidaemia/Diabetes 6.0 Hyperlipidaemia/Hypertension/Arthritis 4.0 
6 Hypertension/Arthritis 6.5 Hyperlipidaemia/Hypertension/Obesity 4.4# Diabetes/Cardiovascular 5.3 Hyperlipidaemia/Hypertension/Cardiovascular 3.3 
7 Hyperlipidaemia/Diabetes 5.2 Hypertension/Arthritis/Obesity 2.9# Hypertension/Arthritis 4.8 Hyperlipidaemia/Hypertension/Obesity 2.7 
8 Hypertension/Obesity 5.0# Hypertension/Diabetes/Cardiovascular 2.2 Arthritis/Obesity 3.6 Diabetes/Arthritis/Obesity 2.1 
9 Obesity/Asthma 2.4 Hyperlipidaemia/Diabetes/Obesity 1.6 Hypertension/Cardiovascular 3.5 Diabetes/Obesity/Cardiovascular 1.7# 
10 Hyperlipidaemia/Arthritis 2.4 Hypertension/Diabetes/Kidney 1.4 Obesity/Cardiovascular 2.9 Hypertension/Diabetes/Kidney 1.5# 
11 Obesity/Cardiovascular 2.3 Hyperlipidaemia/Diabetes/Arthritis 1.3 Hypertension/Obesity 2.7 Hypertension/Arthritis/Obesity 1.4 
12 Diabetes/Cardiovascular 2.3 Diabetes/Obesity/Cardiovascular 1.3 Cardiovascular/Kidney 2.3# Hypertension/Diabetes/Stroke 1.2 
13 Obesity/Chronic Hepatitis 1.9# Diabetes/Obesity/Kidney 1.2# Arthritis/Cardiovascular 2.1 Diabetes/Arthritis/Cardiovascular 1.1 
14 Obesity/Kidney 1.8# Diabetes/Obesity/Asthma 1.0# Cardiovascular/Stroke 1.7 Hyperlipidaemia/Diabetes/Arthritis 1.0 
15 Diabetes/Kidney 1.5 Diabetes/Obesity/Chronic Hepatitis 1.0# Diabetes/Kidney 1.6#   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
16 Cardiovascular/Kidney 1.4   
  
  
  
  
  
  
  
  
  
  
  
  
  
Hyperlipidaemia/Arthritis 1.5 
17 Hypertension/Cardiovascular 1.1 Diabetes/Stroke 1.3 
18 Diabetes/Stroke 1.1 Stroke/Kidney 1.1# 
19 Arthritis/Asthma 1.1 Obesity/Chronic Hepatitis 1.1 
20 Arthritis/Cardiovascular 1.0 Obesity/Kidney 1.0 
21 Cardiovascular/Stroke 1.0 Hypertension/Stroke 1.0 
22     Cardiovascular/Asthma 1.0 
# denotes the highest crude prevalence rate for that specific dyad or triad compared with other ethnic/sex subgroups across Table 2-11, Table 2-12 & Table 2-13. 
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Table 2-13. The most common dyads and triads for Indian patients above 45 years old stratified by sex (Fortin List, n = 33,870) 
Rank 
Female (n=17,633) Male (n=16.237) 
Dyad % Triad % Dyad % Triad % 
1 Hyperlipidaemia/Hypertension 43.3 Hyperlipidaemia/Hypertension/Diabetes 30.2# Hyperlipidaemia/Hypertension 41.7 Hyperlipidaemia/Hypertension/Diabetes 29.8 
2 Hypertension/Diabetes 31.3# Hypertension/Diabetes/Arthritis 11.4# Hypertension/Diabetes 30.3 Hypertension/Diabetes/Arthritis 7.1 
3 Diabetes/Arthritis 14.7# Hypertension/Diabetes/Obesity 6.9 Hyperlipidaemia/Diabetes 10.4# Hypertension/Diabetes/Cardiovascular 6.7# 
4 Arthritis/Obesity 9.6# Diabetes/Arthritis/Obesity 5.9# Diabetes/Arthritis 9.5 Hypertension/Diabetes/Obesity 5.2 
5 Hyperlipidaemia/Diabetes 9.3 Hyperlipidaemia/Hypertension/Arthritis 5.6 Diabetes/Cardiovascular 7.9# Hyperlipidaemia/Hypertension/Arthritis 3.3 
6 Diabetes/Obesity 8.3 Hyperlipidaemia/Diabetes/Arthritis 3.1# Diabetes/Obesity 6.0 Hyperlipidaemia/Hypertension/Cardiovascular 2.9 
7 Hypertension/Arthritis 6.8 Hypertension/Diabetes/Cardiovascular 2.7 Hypertension/Arthritis 4.1 Diabetes/Arthritis/Obesity 2.5 
8 Hyperlipidaemia/Arthritis 3.4 Hypertension/Arthritis/Obesity 2.5 Arthritis/Cardiovascular 3.7# Hyperlipidaemia/Diabetes/Arthritis 2.5 
9 Diabetes/Cardiovascular 3.1 Hyperlipidaemia/Hypertension/Obesity 2.3 Arthritis/Obesity 3.4 Diabetes/Arthritis/Cardiovascular 2.3# 
10 Hypertension/Obesity 2.8 Hyperlipidaemia/Diabetes/Obesity 1.8# Hypertension/Cardiovascular 3.1 Diabetes/Obesity/Cardiovascular 1.6 
11 Obesity/Cardiovascular 2.6 Diabetes/Arthritis/Cardiovascular 1.6 Obesity/Cardiovascular 2.9# Hyperlipidaemia/Hypertension/Obesity 1.5 
12 Obesity/Asthma 2.5# Arthritis/Obesity/Asthma 1.3# Hyperlipidaemia/Arthritis 2.0 Hyperlipidaemia/Diabetes/Obesity 1.4 
13 Arthritis/Cardiovascular 2.2 Diabetes/Obesity/Cardiovascular 1.2 Cardiovascular/Stroke 1.9# Hypertension/Diabetes/Stroke 1.2 
14 Arthritis/Asthma 2.0# Arthritis/Obesity/Cardiovascular 1.1# Cardiovascular/Kidney 1.6 Hyperlipidaemia/Diabetes/Cardiovascular 1.2# 
15 Obesity/Thyroid 1.7#   
  
  
  
  
  
  
  
  
  
  
  
  
  
Cardiovascular/Asthma 1.6# Hypertension/Arthritis/Cardiovascular 1.0 
16 Diabetes/Asthma 1.3# Hypertension/Obesity 1.5   
  
  
  
  
  
  
  
  
  
  
  
17 Arthritis/Thyroid 1.2# Diabetes/Stroke 1.4 
18 Diabetes/Thyroid 1.2# Diabetes/Asthma 1.1 
19 Asthma/Thyroid 1.1# Diabetes/Chronic Hepatitis 1.1 
20 Cardiovascular/Asthma 1.1   
  
  
  21 Obesity/Chronic Hepatitis 1.1 
# denotes the highest crude prevalence rate for that specific dyad or triad compared with other ethnic/sex subgroups across Table 2-11, Table 2-12 & Table 2-13. 
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4 Discussion 
 
4.1 Summary of results 
 
This study described the epidemiology of multimorbidity of Singapore’s primary care 
population.  Patients under 25 years old had very low rates of chronic conditions for both the 
CDMP and Fortin lists.  The prevalence of chronic conditions increased by several fold from 
the ‘25-44’ year age group to the ‘45-64’ year age group and with further increase to the ‘65-
99’ year age group for both the CDMP and Fortin lists.  There were different findings when 
using the two different lists to describe the prevalence of chronic conditions and multimorbidity 
in the sample population.  The two lists will be discussed in more detail in Section 4.3 (p64). 
 
The standardised prevalence ratet of multimorbidity using CDMP MM2+ was 21.9%, 25.9% 
for Fortin MM2+, 12.0% for CDMP MM3+, and 17.2% for Fortin MM3+ (Table 2-3).  The 
standardised prevalence ratesa of all the four age groups were statistically and clinically 
different from each other (Table 2-4).  There was no clinically significant difference in the 
standardised prevalence ratesg of multimorbidity between the sexes (Table 2-5).  There were 
also no clinically significant differences in the standardised prevalence ratese of multimorbidity 
among the three major ethnic groups in Singapore (Table 2-6). 
 
The two most common dyads of chronic conditions based on crude prevalence rates for those 
45 years old and above were hyperlipidaemia/hypertension and hypertension/diabetes for all 
the different ethnic groups and sexes (Table 2-7 & Table 2-9).  The most common triad of 
chronic conditions was hyperlipidaemia/hypertension/diabetes (Table 2-8 & Table 2-10). 
  
                                                 
t Age-sex-ethnicity standardised prevalence rate 
g Sex-stratified, age-and-ethnicity standardised prevalence rate 
e Ethnicity-stratified, age-and-sex standardised prevalence rate 
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4.2 Comparison with other studies 
 
4.2.1 Prevalence rate of multimorbidity 
 
Comparing our results with those of other studies is difficult due to the different conditions, 
different number of conditions selected to form the multimorbidity list, data sources, and 
reference populations.  When using two or more chronic conditions to define multimorbidity, 
most estimates from the primary care setting reported prevalence rates between 20-30% for the 
entire population and  50-90% for the elderly1,5,23,25,42,43.  Ours were 21.9% (CDMP list) and 
25.9% (Fortin list) for the entire population (Table 2-3), and 72.5% (CDMP list) and 77.5% 
(Fortin list) for the older adult population (age 65-99) (Table 2-4).  As such, our estimates of 
the standardised prevalence ratest of multimorbidity were comparable to the international 
literature. 
 
When using three or more chronic conditions to define multimorbidity, the age-standardised 
prevalence rate was 14.0-15.2% in the literature on practice-based populations39,44.  Our 
estimates of 12.0% (CDMP list) and 17.2% (Fortin list) were comparable to their findings 
(Table 2-3). 
 
4.2.2 Age and prevalence rate of multimorbidity 
 
Similar to the prevalence rates of chronic conditions, patients under 25 years old had very low 
standardised prevalence ratesa of multimorbidity for both the CDMP and Fortin lists.  The 
standardised prevalence ratesa of multimorbidity increased progressively from the ‘25-44’ year 
age group to the ‘45-64’ year age group and with further increase to the ‘65-99’ year age group 
for both the CDMP and Fortin lists.  Our findings confirmed the significant positive association 
between age and prevalence of multimorbidity, irrespective of the definitions used for 
multimorbidity, consistent with that found in a growing world literature1,21,25,26,39,42,45-51. 
  
                                                 
t Age-sex-ethnicity standardised prevalence rate 
a Age-stratified, sex-and-ethnicity standardised prevalence rate 
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4.2.3 Sex and prevalence rate of multimorbidity 
 
The association between sex and the prevalence of multimorbidity has been less consistent 
across studies2.  This study found no clinically statistically significant sex differences in the 
standardised prevalence rateg of multimorbidity. Other investigators who conducted 
multimorbidity studies in primary care also found no sex differences in the occurrences of 
multimorbidity21,28,22,40,42,51.  Fortin et al.44 observed that more females than males were found 
with multimorbidity were found in the general population, whereas the contrary was found in 
the practice-based population.  However, in the population health index survey (community-
dwelling individuals) conducted in Singapore, no sex differences were found in the prevalence 
rate of multimorbidity between males and females aged 21 years and above6.  Further 
comparison studies locally using the same list of multimorbidity conditions would need to be 
conducted to confirm whether there are sex differences between the two settings. 
 
Schafer et al.51 reported that the difference in prevalence rates of multimorbidity between the 
sexes depended on the type of multimorbidity conditions considered.  They explained that 
females seemed to be more vulnerable to anxiety, depression, somatoform disorders, and pain-
related morbidity while males appeared to be more vulnerable to cardiovascular and metabolic 
diseases.  In our study when we looked at the common dyads and triads of multimorbidity in 
Sections 3.6-3.7 (p49-59), the males also appeared to be more vulnerable to cardiovascular and 
metabolic diseases while the females were more vulnerable to arthritis. 
 
4.2.4  Patterns of multimorbidity 
 
The findings in our study showed that the most common dyads were 
hyperlipidaemia/hypertension and hypertension/diabetes.  The most common triad was 
hyperlipidaemia/hypertension/diabetes. These findings were consistent with results from 
international40,49,52 and local studies6.   
 
Hyperlipidaemia/hypertension/arthritis was found to be the second most common triad in the 
Chinese ethnic group (both males and females); for the Malay ethnic group, 
                                                 
g Sex-stratified, age-and-ethnicity standardised prevalence rate 
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hyperlipidaemia/hypertension/obesity took precedence; and hypertension/diabetes/arthritis 
took precedence for the Indian ethnic group.   
  
Salive9 in his review of multimorbidity in older adults stated that the most common 
combinations of chronic conditions could be predicted from the individual chronic condition 
prevalence rates.  In our study, the different combinations of the most prevalent single chronic 
conditions (Table 2-2) were also the common dyads and triads seen.  However, the condition 
‘asthma’ and ‘stomach problem’ were not included in the most common dyads and triads 
indicating that the most prevalent single chronic conditions may not always be able to predict 
the most common combinations. 
 
Furthermore, ‘depression’ and ‘anxiety’ were prominently not represented in all the patterns of 
this study compared to non-local studies.  The conspicuous absence of mental disorders in the 
patterns of multimorbidity in this study could be because there is a lower prevalence of mental 
illness in Singapore.  However, according to Chong et al.53, the prevalence of major depression 
in a local population-based mental health survey was 5.8%, bipolar disorder was 1.2%, and 
generalised anxiety disorder was 0.9%.  The prevalence rates of the above mental disorders 
were much lower in the present study – the crude prevalence rate of major depression was 
0.2%, bipolar disorder was 0.006%, and generalised anxiety disorder was 0.8% (Table 2-2). 
 
The other likely reason for the absence of mental disorders is the social stigma associated with 
these conditions resulting in the decreased help-seeking behaviour by the local population54.  
Chong et al.55 found that only 50.1% of respondents with severe disability across any mental 
disorder had sought help from some service in the past year.  Individuals with moderate or mild 
levels of mental disorder had lower rates of consultation. Their study found that the main 
sources of help were from religious or other non-medical healers rather than from family 
physicians or mental health specialists. 
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4.3 Comparison between CDMP and Fortin list with different cut-
points - addressing objective 2 
 
In this section, we discuss the advantages and disadvantages of the CDMP and Fortin lists of 
chronic conditions and also that of the different cut-points used for defining multimorbidity.  
We will address the controversial issues on multimorbidity research from Chapter One and 
attempt to make recommendations on lists and cut-points, based on this study. 
 
4.3.1 The CDMP vs Fortin list 
 
The CDMP list is based on the list of important chronic conditions that have a significant 
burden in the Singapore healthcare system where the Singapore Ministry of Health provides 
financial subsidy to patients who suffer from these conditions to help reduce their monetary 
burden.  Therefore, these conditions are chosen based on the country’s health burden and not 
strictly from the primary care perspective.  A good example is the zero-patient count for 
psoriasis from the 787,446 primary care patients in this study (Table 2-2). 
 
A team of well-established multimorbidity researchers developed the Fortin list after studying 
various multimorbidity lists used in several countries which targeted the primary healthcare 
system36.  Conceptually, the Fortin list is more suitable for measuring multimorbidity in 
primary care. 
 
Sixteen out of the 19 single conditions in the Fortin list had a prevalence rate of more than 
1.0% while only eight out of the 20 conditions in the CDMP list had a prevalence rate of more 
than 1.0% (Table 2-2).  The Fortin list consisted of categories of conditions and included 37 
ICD-10 codes used in NHGP (Appendix 2-2).  The CDMP list included 26 ICD-10 codes used 
in NHGP (Appendix 2-1).  So, even though there were only 19 conditions used in the Fortin 
list, more ICD-10 diagnoses were captured than in the CDMP list.  Using the Fortin list, the 
prevalence rate of multimorbidity was consistently higher than that of the CDMP list (Table 2-
3).  There were consistently more dyads and triads that had a prevalence rate of 1.0% and above 
when using the Fortin list than when using the CDMP list (Table 2-7 to 2-10).  The Fortin list 
is more intuitive as it combines conditions like ‘anxiety’ and ‘depression’ into one category 
recognising perhaps that about 85% of patients with depression have significant anxiety and 
vice versa56.  Therefore, in terms of practicality, the Fortin list picked up more chronic and 
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relevant conditions by merging frequently co-occurring conditions into one category in primary 
care than the CDMP list that kept all the conditions separate. 
 
Although we noticed differences between the gradients in the increase in proportion of patients 
with chronic conditions using the two different lists (Figures 2-1 & 2-2), it was evident that 
the sudden surge in the proportion (by age) of chronic conditions occurs around the middle-
age years of individuals.  The increase in the number of chronic conditions for the Fortin list 
was more gradual, i.e., the steepest slope for two conditions at age 45-49 and for three 
conditions at age 50-54 (Figure 2-2 & Appendix 2-4), when compared to the CDMP list.  The 
steepest slope for two conditions of the CDMP list was at age 50-54, and for three conditions 
at age 65-69 years old (Figure 2-1 & Appendix 2-4).  In terms of capturing the full breadth of 
multimorbidity across the ages, the Fortin list appears to be more sensitive when compared to 
the CDMP list. 
 
4.3.2 Cut-off for ‘two or more’ vs ‘three or more’ chronic conditions 
 
As mentioned in Chapter One, one of the concerns of using the cut-off for two conditions is 
that a large majority of patients would be classified as having multimorbidity, making the 
classification less clinically meaningful10. 
 
When using the CDMP list with an MM2+ cut-off, the standardised prevalence ratet of 
multimorbidity was similar to using the Fortin list (CDMP MM2+ 21.9%, Fortin MM2+ 
25.9%) (Table 2-3). As the surge in the proportion of chronic conditions occur around the 
middle-age years of an individual, we looked more carefully at the prevalence rates of 
multimorbidity for patients above 44 years old (Table 2-4).  
 
When using the CDMP list with an MM2+ cut-off, more than one in three (37.6% of patients 
age 45-64) and close to three in four (72.3% of patients age 65-99) patients were classified as 
having multimorbidity for the ‘45-64’ year and ‘65-99’ year age groups respectively.  When 
using the Fortin list with an MM2+ cut-off, almost one in two (45.3 % of patients age 45-64) 
patients and more than three in four (77.3% of patients age 65-99) patients were classified as 
                                                 
t Age-sex-ethnicity standardised prevalence rate 
66 
 
 
having multimorbidity.   In general, a large proportion of older adults would be classified as 
having multimorbidity when we use the MM2+ cut-off. 
 
When using CDMP list with an MM3+ cut-off, almost one in five (18.4% of patients age 45-
64) and close to one in two (48.5% of patients age 65-99) patients were classified as having 
multimorbidity for the ‘45-64’ year and ‘65-99’ year age groups respectively.  When using 
Fortin list with an MM3+ cut-off, more than one in four (28.5% of patients age 45-64) patients 
and about three in five (60.9% of patients age 65-99) patients were classified as having 
multimorbidity. 
 
Compared to MM2+, MM3+ results in a lower prevalence of multimorbidity and likely better 
identify patients with higher needs and hence may be more meaningful for clinicians than 
MM2+ which is less discriminating57. 
 
In summary, the Fortin list is conceptually more suitable for measuring multimorbidity in 
primary care, more practical as it reflects disease categories rather than single conditions like 
the CDMP list, and is more sensitive in capturing the full breadth of multimorbidity across the 
ages, when compared to the CDMP list.  Using MM3+ as the cut-off can identify a smaller 
number of patients with higher needs compared to MM2+.  Putting these two considerations 
together, it would seem that the Fortin list with MM3+ cut-off is the most suitable definition 
of multimorbidity in the Singapore primary care setting.  Further studies will need to be 
conducted to confirm this finding. 
 
4.4 Distinct patterns of chronic conditions and multimorbidity noted in 
the different ethnic and sex groups – addressing objective 4 
 
Using the Fortin list, the mean number of chronic conditions in descending order for each ethnic 
group was Indian (1.2), Chinese (1.1), Malay (1.0) and Others (0.8) (Table 2-1 Fortin 
Conditions).  Despite being younger than the Chinese, the Indians (mean age of Chinese = 47.1 
years old, Indians = 39.7 years old) had slightly more chronic conditions than the Chinese (1.2 
vs 1.1).  When looking at the overall dyads and triads with a crude prevalence rate of 1.0% and 
more (Table 2-9 & 2-10), the Indian ethnic group was also found to have the greatest number 
of dyads and triads with the highest crude prevalence rates when compared to the other ethnic 
groups.   
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Although the Malay males had the fewest number of dyads or triads that had the highest crude 
prevalence rate, they were also the only subgroup that did not differ significantly from all the 
other subgroups for every dyad and triad listed in Tables 2-9 and 2-10.  Moreover, despite 
being younger than the Others group (mean age of Malays = 35.1 years old, Others = 37.1 years 
old), the Malays had more chronic conditions than the Others ethnic group (1.0 vs 0.8) (Table 
2-1 Fortin Conditions). Therefore, the Malay males seemed to have the highest burden of 
multimorbidity compared to the other ethnic groups. 
 
The Chinese males had more dyads and triads with higher crude prevalence rates when 
compared to the Chinese females, in general.  For the other ethnic groups, it was usually the 
females who had more prevalent dyads and triads than the males.  Together with having more 
dyads and triads with clinically significant lower crude prevalence rates compared to the other 
subgroups, this suggests that Chinese females had the lowest burden of multimorbidity among 
the subgroups. 
 
The more frequent occurrences of ‘kidney disease or failure’ in combination with other 
conditions to form a dyad or triad for the Malay ethnic group is consistent with the findings in 
the National Health Survey 2010 where the Malay ethnic group was found to have a higher 
renal impairment prevalence (4.1%) compared with the Chinese (2.0%) and the Indians 
(2.0%)32. 
 
‘Obesity’ was also a distinctly common condition in combination with other conditions to form 
a dyad or triad for the Malay females.  This finding is also consistent with that reported by the 
Health Promotion Board of Singapore.  Among the ethnic groups in Singapore, 20.7% of 
Malays, 14.0% of Indians and 5.9% of Chinese were considered obese59. 
 
Looking at the different co-occurring conditions provides a fresh perspective and allows 
clinicians to see the fuller picture of the interactions of all these common chronic conditions.  
We summarised the overall picture of the patterns of multimorbidity seen in the three major 
ethnic groups of Singapore as follows. 
 
The Chinese ethnic group had a higher prevalence rate of hypertension as a risk factor with the 
brain being the major end-organ disease target (i.e., stroke and transient ischaemic attack).  The 
Malay ethnic group had a higher prevalence rate of obesity as a risk factor with the kidney 
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being the major end-organ disease target (i.e., kidney disease or failure).  The Indian ethnic 
group had a higher prevalence rate of diabetes as a risk factor with the heart being the major 
end-organ disease target (i.e., cardiovascular disease).  Hyperlipidaemia was the most prevalent 
single chronic condition and a significant risk factor for all ethnic groups.  These findings 
would need to be further confirmed by future studies. 
 
4.5 Strengths and Limitations 
 
4.5.1  Strengths 
 
There are several strengths in this study.  First, we used a large data set which included all the 
patients who visited the National Healthcare Group Polyclinics, which was a good 
representation of the primary care population in the public health setting in Singapore.  Second, 
we provided both crude and standardised rates that provided valuable information for both the 
burden of multimorbidity at the polyclinic level and possibly at the public health level.  Third, 
we used diagnoses from the electronic health records instead of self-reports where the latter 
have been found to be inaccurate due to under-reporting or forgetfulness60.  Last, we included 
the full age range of patients to describe multimorbidity across the whole age spectrum. 
 
4.5.2 Limitations 
 
This study also has several limitations.  The study was cross-sectional and the prevalence rate 
provided a snapshot of the burden of disease in the population over one year.  This may 
underestimate the actual prevalence of multimorbidity.   
 
Several reasons may lead one to consider that the prevalence rates were an underestimate.  The 
first is that patients who had chronic conditions but were seen at longer intervals than one year 
would not have been counted. 
 
A second possible reason for an underestimate may be that, like most prevalence studies, we 
can only provide information on those conditions already diagnosed.  There is a significant 
proportion of people in the community with undiagnosed chronic conditions.  For example, 
26.3% of patients with hypertension, 51.4% of patients with diabetes, and 44.1% of patients 
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with hyperlipidaemia were previously undiagnosed in the Singapore National Health Survey 
201032.  However, the setting of this study is in primary care and the proportion of the 
undiagnosed common chronic conditions should be lower than that found in the National 
Health Survey 2010 as asymptomatic participants gave consent and were screened for a few 
common chronic conditions in the survey hence increasing the chance of chronic condition 
detection.  In any case, this suggests that the estimates provided in this study may be 
conservative. 
 
Another possible reason for an underestimate may be because in all large database studies, the 
findings are dependent on the fidelity with which actual patient diagnoses were recorded.  Data 
from patients whose chronic conditons were treated outside the polyclinic were subjected to 
measurement error if the family physicians at National Healthcare Group Polyclinics did not 
update or include in the electronic medical records conditions treated by physicians outside of 
the polyclinics. Furthermore, there may be undetermined variation among physicians in the 
completeness and accuracy of their electronic medical record coding of chronic conditions10. 
 
Finally, an underestimate may have occurred as not all the ‘chronic’ conditions included may 
have been active or relevant for some patients during the study period.  For example, a patient 
with mild asthma that presents intermittently may not visit the polyclinic at all during the study 
period.   
 
Another limitation was the use of the ‘de facto registration’ method which excluded disease-
free persons who were not seeking health care.  We could not get the population at risk as the 
denominator because the study team did not have the utilisation correction factor.   We also 
used one-year window period and this time frame might underestimate the denominator 
because well patients did not visit in that year; it may overestimate the denominator because 
people have died or moved away.  
 
While the main limitation was a potential underestimate of the prevalence, another limitation 
may have been that this study did not provide any indication of the severity of individual 
chronic conditions.  A count of chronic conditions may not be adequate to assess how much 
burden an individual patient experience.  The lack of information on the severity of individual 
chronic conditions is common in prevalence studies and will be explored in the next chapter. 
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4.6 Clinical implications 
 
4.6.1 Policy and decision-makers 
 
Although the standardised prevalence rate of multimorbidity provides a good estimation of the 
burden of multimorbidity for primary care in Singapore, policymakers should be looking at the 
crude prevalence rate for better planning of services at the polyclinic level. 
 
For decision-makers tasked with resource allocation, prevalence estimates in samples from 
primary care practices are more informative than estimates from the general population.  This 
is because population prevalence has consistently been shown to be lower than primary care 
prevalence23,44.  The population-based study in Singapore by Subramaniam et al.3 (16.3%) 
supported this finding obviously.  However, whether the other two population studies in 
Singapore by Picco et al.4 (51.5%) and Ge et al.6 (35.0%) showed a higher or lower prevalence 
rate of multimorbidity compared to this study is difficult to ascertain.  This is due to the 
differences in the list of conditions used, the age of the reference population, and the 
methodology used among the studies.  A comparison study using the same list of conditions, 
similar reference population, and methods for the two population sources would be necessary 
to confirm the relationship between prevalence estimates from primary care and the general 
population in Singapore. 
 
The knowledge of the common patterns of multimorbidity will also allow delivery of care to 
be more targeted to ensure that the resources provided match the needs of patients with the 
same patterns of multimorbidity. 
 
4.6.2  Primary care clinicians and educators 
 
Up to nine single conditions were prominently featured when looking at the common dyads 
and triads of multimorbidity found in this study. Primary care practice guidelines could be 
developed for these common combinations of conditions to guide doctors in providing whole 
person care to patients with multimorbidity without dwelling on every single chronic condition 
individually and adding unnecessary treatment burden to patients. 
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These common dyads and triads included different combinations of conditions like 
hyperlipidaemia, hypertension, diabetes, arthritis, obesity, cardiovascular disease, kidney 
disease, stroke, and asthma.  With the distinct patterns noted in each ethnic group, emphasis 
could be put on managing hypertension, hyperlipidaemia and arthritis in Chinese females; 
hypertension, hyperlipidaemia and stroke prevention in Chinese males.  For the Malay ethnic 
group, emphasis could be put on weight management, hyperlipidaemia and kidney disease 
prevention.  For the Indian ethnic group, attention could be placed on diabetes prevention and 
control, hyperlipidaemia, and cardiovascular disease prevention.  Many of these conditions are 
cardiometabolic diseases and share common treatment goals.  Only arthritis and asthma add to 
the discordance of treatment goals with possible pharmacological interactions.  Special efforts 
involving the expertise of the specialists may be necessary to make the multimorbidity 
guidelines more complete. 
 
4.6.3 Researchers  
 
Including chronic diseases that are burdensome to the health care system but may not be 
prevalent to the list of conditions used in multimorbidity studies is debatable but essential.  In 
this study, mental disorders were found not to be prevalent, and asthma did not appear in many 
patterns of multimorbidity especially in the Chinese ethnic group.  It may be possible that the 
low prevalence of mental disorders is due to the social stigma attached to it54.   The reason for 
low prevalence rates of dyads or triads consisting of asthma is less evident. However, the 
undeniable fact is that asthma management in Singapore may need improvement as the 
country’s asthma mortality rate is three times that of other developed countries61. 
  
This emphasises the importance of the careful and precise documentation of chronic conditions 
by the family physician.  Without this, both the doctor and the patient may forget to take into 
account other co-occurring and important conditions during a typical episode of care.  The 
deliberate effort to register chronic conditions is a complex and laborious chore, but one that 
helps to make transparent the comprehensive reality of multimorbidity.  How to help busy 
family physicians to record and update all the chronic conditions a patient has is of critical 
importance in the area of health services research62. 
 
There are also other ways to look at the non-random associations of chronic conditions using 
statistical tools including factor analysis or cluster analysis 63.  Investigators should work 
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collaboratively with statisticians to explore other patterns of multimorbidity not discovered by 
using the current combinations of the most common conditions as was done in this study64. 
Understanding the common patterns of the non-random clustering of some chronic conditions 
for specific ethnic groups not only provides insights for public health clinicians to prevent their 
development in the first place, but also provides practical evidence for basic science researchers 
to look at the reasons for co-occurrence at the molecular level. 
 
4.7 Conclusion and future 
 
This is the first epidemiology study of multimorbidity on a large database of primary care 
patients in Singapore.  The standardised prevalence rate of multimorbidity based on Fortin’s 
list with a cut-off of three conditions was 17.2% for primary care patients age between 0-99. 
This study showed that age increases the standardised prevalence rate of multimorbidity.  
However, the standardised prevalence rates of multimorbidity between the sexes and among 
the three major ethnic groups were not clinically significant even though they were all 
statistically significant. 
 
This study has identified some distinct patterns of multimorbidity involving about nine 
conditions for the three major ethnic groups in Singapore.  Knowing these patterns can allow 
clinicians, administrators, researchers and policymakers to work collaboratively to look at the 
aetiology, prevention, clinical management, resource allocation, and future research for 
handling this monumental problem of multimorbidity. 
 
Since there is currently limited evidence of the effectiveness of interventions to improve care 
for patients with multimorbidity65, identifying these patients by consistently documenting all 
chronic conditions in the list of multimorbidity for each family practice is the first requisite.  
The development of minimally disruptive clinical guidelines for the management of the 
common patterns of multimorbidity in the local context should follow next. 
 
Although survivorship with minimal complications is the clinical aim of most clinicians 
managing patients with multimorbidity, the quality of life and psychological well-being of 
patients with multimorbidity are just as, if not more, important.  We will explore the quality of 
life and psychological distress of patients with multimorbidity in Chapter Four.  We have also 
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noted the limitation of this study by not including the severity of individual chronic conditions.  
This will be explored with a systematic review in Chapter Three.   
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6 Appendices 
Appendix 2-1. CDMP List of Conditions35 
S/No Category of Condition ICD10 Code & Description 
 
 
 
 
1 
 
Diabetes 
E10.9 (Type 1 diabetes mellitus without complication) 
E11.9 (Type 2 diabetes mellitus without complication) 
E14.2 (Diabetes mellitus with incipient diabetic nephropathy) 
E14.3 (Diabetes Mellitus with retinopathy) 
E14.31 (Unspecified diabetes mellitus with background retinopathy) 
E14.64 (Unspecified diabetes mellitus with hypoglycaemia) 
E14.73 (Unspecified diabetes mellitus with foot ulcer due to multiple causes) 
2 Hypertension I10 (Essential (primary) hypertension) 
3 Lipids E78.5 (Hyperlipidaemia, unspecified) 
4 Stroke I64 (Stroke, not specified as haemorrhage or infarction) 
5 Asthma J45.9 (Asthma, unspecified) 
6 COPD J44.9 (Chronic obstructive pulmonary disease, unspecified) 
7 Chronic Kidney Disease N18.9 (Chronic kidney disease, unspecified) 
8 Osteoporosis M81.99 (Other osteoporosis, site unspecified) 
9 Rheumatoid Arthritis M06.99 (Rheumatoid arthritis, unspecified, site unspecified) 
10 Osteoarthritis M15.9 Osteoarthritis (OA) - Generalised) 
11 
Major Depression 
F32.20 (Severe depressive episode without psychotic symptoms, not specified as 
arising in the postnatal period) 
12 Anxiety F41.1 (ANXIETY DISORDER, UNSPECIFIED) 
13 Dementia F03 (Unspecified dementia) 
14 Benign Prostate 
Hypertrophy 
N40 (Hyperplasia of prostate) 
15 Parkinson's G20 (Parkinson's disease) 
16 Epilepsy G40.90 (Epilepsy, unspecified, without mention of intractable epilepsy) 
17 Psoriasis L40.8 (Other psoriasis) 
18 Schizophrenia F20.9 (Schizophrenia, unspecified) 
19 Bipolar Disorder F31.9 (Bipolar affective disorder, unspecified) 
20 Ischaemic Heart Disease I25.9 (Chronic ischaemic heart disease, unspecified) 
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Appendix 2-2. Fortin List of Conditions36 
S/No Category of Condition ICD10 Code & Description 
1 Any cancer in the last 5 years C80 (Malignant neoplasm without specification of site) 
2 
Thyroid disorder 
E03.9 (Hypothyroidism, unspecified) 
E05.9 (Thyrotoxicosis, unspecified) 
3 
Diabetes 
E10.9 (Type 1 diabetes mellitus without complication) 
E11.9 (Type 2 diabetes mellitus without complication) 
E14.2 (Diabetes mellitus with incipient diabetic nephropathy) 
E14.64 (Unspecified diabetes mellitus with hypoglycaemia) 
E14.73 (Unspecified diabetes mellitus with foot ulcer due to multiple 
causes) 
4 Obesity E66.9 (Obesity, unspecified) 
5 Hyperlipidaemia E78.5 (Hyperlipidaemia, unspecified) 
6 
 
Dementia or Alzheimer's 
disease 
F03 (Unspecified dementia) 
7 
Depression or anxiety 
F32.20 (Severe depressive episode without psychotic symptoms, not 
specified as arising in the postnatal period) 
F32.90 (Depressive episode, unspecified, not specified as arising in the 
postnatal period) 
F41.1 (Anxiety disorder, unspecified) 
8 Hypertension  
(high blood pressure) 
I10 (Essential (primary) hypertension) 
9 
Cardiovascular disease  
(angina, MI, AF, poor 
circulation of lower limbs) 
I25.9 (Chronic ischaemic heart disease, unspecified) 
I48 (Atrial fibrillation and flutter) 
I70.20 (Atherosclerosis of arteries of extremities, unspecified) 
I73.9 (Peripheral vascular disease, unspecified) 
10 Heart failure  
(including valve problems or 
replacement) 
I50.0 (Congestive heart failure) 
I51.9 (Heart disease, unspecified) 
11 
Stroke and TIA 
G45.9 (Transient cerebral ischaemic attack, unspecified) 
I64 (Stroke, not specified as haemorrhage or infarction) 
12 Asthma, COPD, or  
chronic bronchitis 
J44.9 (Chronic Obstructive Pulmonary Disease, Unspecified) 
J45.9 (Asthma, unspecified) 
13 Stomach problem  
(reflux, heartburn, or gastric 
ulcer) 
K21.9 (Gastro-oesophageal reflux disease without oesophagitis) 
K27.9 (Peptic ulcer, unspecified as acute or chronic, without haemorrhage 
or perforation) 
14 Colon problem  
(irritable bowel) 
K58.9 (Irritable bowel syndrome without diarrhoea) 
15 
Chronic hepatitis 
K76.9 (Liver disease, unspecified) 
Z22.51 (Carrier of viral hepatitis B) 
16 
Arthritis &/or  
rheumatoid arthritis 
M06.99 (Rheumatoid arthritis, unspecified, site unspecified) 
M15.9 (Osteoarthritis (OA) - Generalised) 
M19.99 (Arthritis, Unspecified, Site Unspecified) 
17 Osteoporosis M81.99 (Other osteoporosis, site unspecified) 
18 
Kidney disease or failure 
N03.9 (Unspecified nephritic syndrome, unspecified) 
N18.9 (Chronic kidney disease, unspecified) 
19 Chronic urinary problem N40 (Hyperplasia of prostate) 
20 Chronic musculoskeletal 
condition causing pain or 
limitation 
No matching ICD code 
 
80 
 
 
 
Appendix 2-3. Singapore residents by age group, ethnic group and sex, June 201637 
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Appendix 2-4. Gradient calculation for Figure 2-1 and Figure 2-2 
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Abbreviations 
 
ACE-27   Adult Comorbidity Evaluation 
ACG   Adjusted Clinical Groups 
ACSH  Ambulatory Care Sensitive Hospitalisation 
ADG   Aggregated Diagnostic Groups 
ADL   Activities of daily living 
AUC  Area Under the Curve 
BI  Barthel Index 
CC-AM   Chronic conditions – additive modelling 
CCC (of ICD-9 Codes) Clinical Classification Categories 
CCC   Chronic Condition Count 
CCI    Charlson Comorbidity Index 
CCI-PSR   Charlson Comorbidity Index – Psychosocial Risk 
CC-MM   Chronic conditions – minimum modelling 
CC-MuM   Chronic conditions – multiplicative modelling 
CDS   Chronic Disease Count 
CGI-S   Clinical Global Impression – Severity scale 
CIRS   Cumulative Illness Rating Scale 
CLS   Comorbidity Linked Score 
CMI   Cornell Medical Index 
COSmm   Core Outcome Sets of multimorbidity 
CPRD   Clinical Practice Research Datalink 
DC    Disease Count 
ED    Emergency Department 
EDC  Expanded Diagnosis Clusters 
EI    Elixhauser Index 
EMR   Electronic Medical Record 
EQ-5D-5L   EuroQoL-5 Dimensions 
EQ-VAS   EuroQoL-Visual Analogue Scale 
ERA   Elders Risk Assessment 
GP    General Practice 
HCC   Hierachical Condition Categories 
HM    Hybrid Model (Minnesota Tiering and Elders Risk Assessment) 
HPFS Cohort  Health Professionals Follow-up Study Cohort 
HRQoL   Health-Related Quality of Life 
HSMI   Health Search Morbidity Index 
HUI3   Health Utility Index 
IADL   Instrumental Activities of Daily Living 
ICD-10   International Classification of Diseases, Tenth Revision 
ICD-9   International Classification of Diseases, Ninth Revision 
ICPC-2   International Classification of Primary Care – Second Edition 
M3 Index   Multi-Multimorbidity Measure Index 
mCCI   modified Charlson Comorbidity Index 
MDMS   Multidimensional Multimorbidity Score 
MeSH   Medical subject heading 
MM by ADL  Multimorbidity weighted by Activities of Daily Living scale 
MM by HUI3  Multimorbidity weighted by Health Utility Index 
MN Tier   Minnesota Tiering 
MWI   Multimorbidity-Weighted Index 
NHS   National Health Service 
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NHS II Cohort  Nurses’ Health Study II Cohort Study 
NOS   Newcastle-Ottawa Quality Assessment Scale 
NS    Not stated 
OARS   Older Americans Resources and Services 
Organ-CDC   Organ systems with chronic disease count 
Pra tool   Probability of repeated admission risk prediction tool 
QALY   Quality-Adjusted Life Year 
QOF  Quality and Outcomes Framework 
QOF-E   Extended Quality and Outcomes Framework 
QOF-S   Standard Quality and Outcomes Framework 
QoL   Quality of Life 
RoB   Risk of Bias 
RUB   Resource Utilisation Band 
RxRisk-V   A Veterans Association adapted pharmacy-based case-mix instrument 
SF-12   12-item Short Form Survey 
SF-36   36-item Short Form Survey 
SF-6D   Short Form Six Dimensions 
SRH   Self-Rated Health 
TRIPOD Transparent Reporting of Multivariable prediction models for individual 
prognosis or diagnosis 
UK    United Kingdom 
WHO-ATC World Health Organisation – The Anatomical Therapeutic Chemical 
Classification System 
Φc  Cramer’s V 
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1 Introduction  
 
Given the clinical significance of multimorbidity in primary care, it is essential to consider how 
we quantify multimorbidity in community-dwelling individuals.  We measured the prevalence 
and patterns of multimorbidity in Chapter Two.  Chapter Three will now address the 
measurement of the level of multimorbidity. 
 
Before moving on, it is pertinent to elucidate some terms used which are very similar but relate 
to different meanings and concepts.  The first two terms to clarify are the ‘severity of chronic 
condition’ and the ‘level of multimorbidity’.  The next two terms to clarify are ‘measuring 
multimorbidity’ and ‘measuring the level of multimorbidity’.  
 
A consideration of the complexity of multimorbidity should address the ‘severity of chronic 
condition’, that is, the severity of individual conditions and its impact of multimorbidity on 
health outcomes1.  However, less than a quarter of studies on multimorbidity reported the 
severity of individual conditions2.   Reporting the severity of individual conditions does not 
automatically lead to an understanding of the combined effects of multiple conditions.  The 
combined effect may be additive or multiplicative or may not even be synergistic at all3.  The 
‘severity of chronic condition’ refers to the severity of a single chronic condition which has 
been widely described in the medical literature and in daily clinical practice4.  Most of the time, 
it can be measured by well-established clinical guidelines like the New York Heart Association 
for functional classification of heart failure; or suggested clinical parameter cut-off like blood 
pressure control; or sometimes from patients’ self-reported severity of a condition2.  Therefore, 
the term ‘severity of chronic condition’ is not to be confused with the term ‘level of 
multimorbidity’ which measures the combined effects of the multiple conditions that an 
individual has. 
 
In scientific measurements, it is important to describe clearly the purpose of the measurement. 
According to de Vet et al.5, the three main purposes of measurement are for diagnosis 
(discriminant measurement), evaluation of intervention (evaluation measurement), and 
prediction of outcome (predictive measurement).  In Chapter Two, we used the term 
‘measuring multimorbidity’ for the purpose of describing the prevalence and patterns of 
multimorbidity in the primary care population.  For this systematic review, we searched for 
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studies that were ‘measuring the level of multimorbidity’.  The purpose was to describe the 
consequences, i.e., the prediction of future course5, with varying ‘levels of multimorbidity’.  
Referring to de Vet et al.’s5 classification, discriminant measurement of multimorbidity was 
performed in Chapter Two.  For Chapter Three, we looked at the predictive measurements of 
the different levels of multimorbidity that were described in the literature. 
 
Smith et al.6 published a list of 17 multimorbidity outcomes agreed to by international experts 
of multimorbidity intervention studies with quality of life, mental health outcomes, and 
mortality as the three essential core outcomes. These core outcome sets (COSmm) represent 
the minimum that should be measured and reported in all clinical studies of multimorbidity.  In 
this study, we looked at whether the purposes of measuring the level of multimorbidity 
concurred with the 17 COSmm recommended by international experts of multimorbidity 
intervention studies. 
 
Existing instruments for measuring the level of multimorbidity are heterogeneous in terms of 
the number, type, and weighting of conditions considered7.  Several instruments have also been 
developed from highly selective study populations and may not be suitable for individuals from 
a different setting.   
 
Multiple different opinions on what constitutes a useful instrument*** for measurement of the 
level of multimorbidity exist in the literature.  For example, counting diseases has been 
criticised for being less relevant compared to the disability connected with the level of the 
conditions when measuring multimorbidity8.  This was supported by a systematic review that 
reported that interventions for multimorbidity were shown to be most effective when focusing 
on functional difficulties rather than on the individual diseases9.  Other investigators argued 
that the number of conditions was associated with the number of consultations10 and was 
inversely associated with continuity of care11, highlighting that healthcare utilisation, costs, 
and patient satisfaction were just as important outcomes at both the system and patient levels.  
Some criticised that the reductive approaches based on the consequences, rather than the causes 
of multimorbidity, have led to an incorrect definition of the problem12.  There is currently no 
                                                 
*** We have used the term ‘instruments’ rather than ‘indices’ or ‘scales’ or ‘measures’ as a general term to encompass all the 
above in order not to create further confusion as some of the instruments are called a ‘scale’, an ‘index’, or a ‘measure’. 
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consensus on these disputes because of the conceptual differences in the understanding and a 
lack of standardisation in instruments that measure the level of multimorbidity13. 
 
However, prognostic information  (i.e., an outcome) has many meaningful uses14.  Patients and 
clinicians can use it to plan for treatment priorities.  Policy analysts can use it to evaluate the 
effectiveness of various treatment options.  Administrators can also use it to anticipate patients’ 
medical service utilisation and nursing needs.  This is the reason why this chapter will only 
look at instruments measuring the level of multimorbidity with at least a specific purpose or 
outcome in mind.  
 
Ideally, a single multimorbidity instrument should be able to predict a variety of relevant 
outcomes, such as death, hospital admission, and quality of life, in a variety of patient and 
population settings.  However, Byles et al.15 reported that no single instrument could predict a 
variety of outcomes.  For example, an instrument developed to measure mental health is 
unlikely to be applicable to measure the physical function outcome.  A range of different 
instruments for measuring different outcomes will be anticipated.    
 
Huntley et al.16 published a systematic review looking at the instruments for measuring 
morbidity burden used in the primary care and general population setting. They found 194 
articles describing 17 different measures.  Most instruments were diagnosis-based measures, 
but medication-based measures were also noted.  The measures that were most widely used 
and for which there was the most significant evidence of validity were the Charlson index, 
disease counts, and the ACG (Adjusted Clinical Groups) System16.  They concluded that the 
choice of an instrument would depend on the outcome (i.e., purpose) of interest and the type 
of data available (i.e., context).   
 
The systematic review by Huntley et al.16 has not been updated since 2009 and the amount of 
multimorbidity research has surged tremendously since 2010.  Therefore, we proposed an 
updated review to list the suitable instruments for the measurement of level of multimorbidity 
in community-dwelling individuals.  
 
This study aimed to perform a systematic review of relevant multimorbidity studies that 
measured the level of multimorbidity of patients from the primary care or general population 
to predict or explore the association with at least one specified outcome published from January 
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2010 onwards.  Specific objectives were to: (1) provide a list of measurement instruments for 
measuring level of multimorbidity in the primary care or general population setting; (2) report 
the advantages and disadvantages of using these instruments in predicting the multimorbidity-
related outcomes; (3) provide details of the data source(s) and resource(s) required by each of 
the instruments; and (4) compile a list of corresponding instruments for measuring the level of 
multimorbidity for the three essential core outcomes identified for COSmm6 (quality of life, 
mental health, and mortality). 
 
The systematic review will update investigators or clinicians targeting community-dwelling 
individuals with multimorbidity on the available instruments for the measurement of level of 
multimorbidity so that they can be better informed on the requirements, strengths and 
limitations of these instruments and select or develop one that matches their needs. 
 
2 Methods 
 
A protocol for the systematic review was developed using PRISMA-P guidelines17,18 and was 
published on PROSPERO website19.  CRD42018105297 dated 6th Sep 2018 is available at 
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=105297. 
 
We did not seek ethics approval as the review used published data from secondary sources and 
did not involve any interactions with human subjects.  We followed the PRISMA statement20 
and guidance on the conduct of narrative synthesis in systematic reviews21 for the reporting of 
this systematic review.  There was no funding for this project. 
 
2.1 Search Strategy 
 
We used OVID to search MEDLINE††† and EMBASE‡‡‡, and EBSCO for CINAHL§§§.  We 
also manually searched the Journal of Comorbidity for potential articles.  The search was from 
                                                 
††† A bibliographic database of life sciences and biomedical information. It includes bibliographic information for articles 
from academic journals covering medicine, nursing, pharmacy, dentistry, veterinary medicine, and health care from 1946 to 
present. 
‡‡‡ A biomedical research database that covers the most international biomedical literature from 1947 to the present day.  All 
articles are indexed in depth using Elsevier's Life Science thesaurus Embase Indexing and Emtree®. 
§§§ An index of English-language and selected other-language journal articles about nursing, allied health, biomedicine and 
healthcare from 1961 to present. 
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January 2010 to 14th August 2018.  A ‘snowball’ search, which is a hand search of the reference 
lists in the selected articles, was performed for comprehensiveness22.   
 
Several different search trials were performed before a structured search strategy that identified 
the best combination of Medical Subject Headings (MeSH) terms and keywords using 
proximity searching**** was developed23.  The final search strategy was developed between the 
principal investigator (LES) and a librarian trained in health sciences research (JC) after 
multiple iterations. 
 
The MeSH terms were different for each electronic database and the proximity searching terms 
were also different among them as reflected in Appendix 3-1.  For example, ‘multiple chronic 
conditions’ was a MeSH term in MEDLINE and EMBASE but not in CINAHL. 
 
2.2 Inclusion and Exclusion criteria 
 
The inclusion criteria were studies that included: (1) adult patients (ages 18 years and above) 
who visited primary care or were from the general population; (2) at least one specified 
outcome variable (e.g., mortality, quality of life) that was predicted by or associated with 
instruments used for measuring the level of multimorbidity; and (3) full-text articles published 
from January 2010 to August 2018. 
 
The exclusion criteria were studies that: (1) selected patients from the hospital or nursing home 
only or patient data that were drawn solely from the hospital or the nursing home; or (2) 
selected patients with a prerequisite to have certain conditions prior to recruitment; or (3) used 
level of multimorbidity as a covariate and not the main independent variable; or (4) were not 
written in English. 
  
                                                 
**** Proximity searching is a form of advanced search to specify two or more separately matching term occurrences are 
within a specified distance, where distance is the number of intermediate words or characters. 
 
91 
 
 
 
2.3  Study selection 
 
LES conducted a preliminary screen of titles and abstracts to exclude records that were 
irrelevant.  Records such as letters to editors, conference abstracts, protocols, editorials, 
reviews, qualitative research, and validation of questionnaires were removed.  Abstracts of the 
remaining records were screened independently by two reviewers (LES & EH) to identify 
potentially relevant articles. Disagreements were resolved through discussion until a consensus 
was reached.  The full-text articles were then retrieved for the agreed list and independently 
assessed for eligibility according to the inclusion and exclusion criteria as stated in Section 2.2 
(p90) by the same reviewers. 
 
The two reviewers used Covidence24 (a Systematic Review management tool) independently 
that allowed blinding to minimise bias while the article selections were assigned neatly from 
each stage of the review process to the next.  Disagreements at this stage were resolved through 
discussion with a third reviewer (TSH) until a consensus was reached.  After agreement on the 
list of articles, the reference lists of included articles were hand-searched for additional papers 
that adhered to the inclusion and exclusion criteria. 
 
2.4  Data Extraction 
 
Specific data extraction forms were developed, and after being pilot-tested (KHL, MZ & LES), 
were used with each article for assessment of study quality and evidence synthesis.  KHL and 
WFY performed the final data extraction.  Weekly meetings were held whereby all the data 
extracted were checked by LES.  Any discrepancies were discussed and rectified in meetings 
among LES, KHL and WFY.  Outstanding disagreements on data extracted among the three 
were resolved by involving EH and TSH. 
 
The extracted information from each article included (1) characteristics of participants 
(including population source, sample size, and the age range); (2) instruments used,  definition 
of chronic diseases used in the instrument, the cut-off number of chronic conditions for 
definition of multimorbidity, and the total number of chronic conditions considered in the 
multimorbidity list; (3) type of outcomes measured; (4) results; (5) data sources and resources 
used to conduct the study; and (6) other information like financial conflict of interest. We 
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collated data as much as possible when multiple articles of the same study were found to avoid 
double counting of measurement instruments. 
 
2.5 Assessment of risk of bias 
 
Several rounds of calibration exercises were conducted with extensive discussions and 
iterations on the selection of a suitable risk of bias assessment tool.  Pilot trials of potentially 
eligible articles were conducted by four of the team members – LES, MZ, KHL and EH.  
Eventually, the Newcastle-Ottawa Scale (NOS) was modified and used as the assessment tool 
to determine the risk of bias of each article25,26.  Risk of bias assessment was appraised by three 
reviewers (LES, EH & TSH) independently for each included article.  Each article was assessed 
as having good, fair or poor quality using the modified NOS which examined three broad 
categories: a) Selection; b) Comparability; and c) Outcome (Appendices 3-2 & 3-3). 
 
We contacted the authors, as needed, for additional information or clarification for a maximum 
of three times spaced one week apart.  The clarifications were mainly related to sampling and 
data analysis.  We contacted 25 authors, and 19 of them replied.  Any disagreements on the 
risk of bias were resolved among the three reviewers (LES, EH & TSH) through regular 
meetings.  KHL and WFY were responsible for tracking and updating the final risk of bias 
assessment outcome.   
 
2.6 Narrative synthesis of results 
 
It was anticipated that the studies would be heterogeneous and therefore the decision was made 
a priori not to combine them for meta-analysis.  Instead, we synthesised the evidence in tables 
and narrative text based on the data extracted. 
 
Upon completion of the systematic review, we compiled a list of instruments for measuring the 
level of multimorbidity that were described in studies with low risk of bias and the outcomes 
that were used in the studies with those instruments (Table 3-6).  We also compiled a list of the 
three essential core outcomes identified for COSmm6 (quality of life, mental health, and 
mortality) and listed the corresponding instruments for measuring the level of multimorbidity 
from those studies with low risk of bias (Table 3-7).  The intention was that the two lists 
93 
 
 
 
compiled from the findings of the systematic review would assist investigators in making 
informed choices in selecting appropriate instruments or outcomes for future research on level 
of multimorbidity. 
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3 Results 
 
3.1 Search Results 
 
A total of 67 studies involving 74 articles were identified for inclusion in the systematic review.  
The search of MEDLINE, EMBASE, CINAHL databases, and the Journal of Comorbidity 
provided a total of 9,122 records.  After adjusting for duplicates, the remaining records were 
screened by looking at the titles and abstracts only.  We then screened through the full text of 
all those articles that were selected from above.  This first round of screening resulted in 55 
articles.  This number was relevant to the first step but not the final step, so it is not shown in 
Figure 3-1. 
 
We hand-searched the lists of references of all the 55 included articles and added potentially 
eligible records to the ‘additional records identified through other sources’.  Many of these 
records were duplicates, but we went through the same process of screening the abstracts and 
titles, followed by full-text review and then hand-searching the list of references from the newly 
included articles.  We repeated the whole process until no more potentially eligible articles 
were identified.  A total of 134 articles were identified using this ‘snowballing’ process. 
 
Ultimately, 7,481 records were screened, and 7,351 records were discarded during the title and 
abstract screening.  The full text of all the 130 articles was found, and none was discarded 
during this screening process.  We perused the full text of 130 articles in detail, and 56 of them 
were excluded due to the various reasons stated in Figure 3-1.  The final number of included 
articles was 74 articles, representing 67 unique studies. 
 
Table 3-1 summarised the risk of bias appraisals for the 35 cohort articles and Table 3-2 
summarised the 39 cross-sectional articles.  Table 3-3 summarised the 53 articles with a good 
risk of bias judgement including a summary of the results.  Table 3-4 summarised the 21 articles 
with a fair or a poor risk of bias.  The summary of results was not provided for Table 3-4 due 
to the possibility of bias in the study design or methodology.  Table 3-5 described the unique 
instruments used for measuring the level of multimorbidity from the 74 included articles.  Table 
3-6 described the associated outcomes of each instrument that was reported in the 53 articles 
with a good risk of bias judgement.  Table 3-7 compiled the list of the instruments that were 
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used for the three essential core outcomes of multimorbidity identified for COSmm6 from the 
53 articles with a good risk of bias judgement. 
 
For the rest of the chapter, we describe the included 67 studies as much as possible rather than 
the 74 articles so as not to duplicate and confuse the reader. 
 
3.2  Description of the included studies 
 
There were 67 studies reported in 74 articles because 14 articles were from seven studies (two 
separate articles corresponding to each study) namely Barile et al.27,28, Boeckxstaens et al.29,30, 
Brilleman et al.31,32, Crooks et al.33,34, Formiga et al.35,36, Payne et al.37,38, and Wallace et al.39,40. 
 
Thirty studies selected participants from the general population and 37 studies selected 
participants from primary care. A majority of the studies were for participants 18 years old and 
above (n=28) and the second largest group was for older adults age 65 years old and above 
(n=20).  More than half of the studies were from Europe (n=35), and 14 of these came from the 
United Kingdom.  North America contributed 26 studies (the United States of America had 20 
and Canada had 6). There were two studies from Australia and one study each from Israel, 
Japan, New Zealand, and South Africa. 
   
Altogether, there were 117 instruments for measuring the level of multimorbidity used in  the 
67 studies, of which 33 were unique instruments.  The instruments were categorised based on: 
1) simple counts of individual conditions; 2) organ or system-based approaches; 3) conditions 
that have been weighted and combined into indices; and 4) other approaches including case -
mix and pharmaceutical-based approaches as described by Sarfati41,42. 
 
A total of 112 outcomes were reported from all the studies.  They were broadly categorised 
into eleven categories:  Activities of Daily Living; Costs; Health care use; Health-related 
Quality of life; Mental health; Mortality; Physical activity; Physical function; Quality health 
care; Self-rated health; and Others.  The top reported outcomes were health care use (n=34), 
mortality (n=14), and health-related quality of life (n=14). 
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The sample size of the 67 studies ranged from 11343 to more than 9 million44.  There were 28 
cohort studies, 36 cross-sectional studies, and three mixed studies (i.e., cross-sectional and 
cohort).  Twenty of these studies (23 articles) used prediction models. 
 
Figure 3-1. PRISMA Flow Diagram  
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Table 3-1 summarised the details of the risk of bias (RoB) assessment using the modified 
Newcastle Ottawa Scale (NOS) for 35 cohort articles and Table 3-2 summarised the 39 cross-
sectional articles.  Of the 35 cohort articles, 29 articles were rated ‘good’, four articles were 
rated ‘fair’, and two articles were rated ‘poor’.  Of the 39 cross-sectional articles, 24 articles 
were rated ‘good’, five articles were rated ‘fair’, and ten articles were rated ‘poor’.  In total, 
there were 47 studies (53 articles) that were rated ‘good’, eight studies (nine articles) that were 
graded ‘fair’, and 12 studies (12 articles) that were graded ‘poor’. (The articles are highlighted 
in light grey for combined studies and highlighted in dark grey for cohort studies in Tables 3-
1 and 3-2) 
 
All studies that were graded ‘fair’ were due to issues with the ‘selection’ criterion.  Studies 
graded ‘poor’ were due to issues with a variety of criteria but mainly on the ‘selection’ and 
‘comparability’ criteria.  A higher proportion of cohort studies compared to cross-sectional 
studies were graded ‘good’ with the RoB assessment. 
  
The justification for choosing a specific list of chronic conditions was not clearly stated in 
many of these studies.  We found only 23 studies (34.3%) that provided at least a brief 
statement of what a chronic condition was.  The total number of conditions in the 
multimorbidity list ranged from seven45-47 to 14710 conditions in this review but only slightly 
more than half of them, i.e., 38 studies (56.7%), provided the full list of the conditions.  Finally, 
only 23 studies (34.3%) stated clearly the cut-points they used to define multimorbidity.  A 
large majority of the studies used ‘two or more’ chronic conditions as the cut-off to define 
multimorbidity.  We identified two studies that used ‘three or more’ chronic conditions29,30,48 
and another two studies that used ‘four  or more’ conditions28,30 as the cut-offs to define 
multimorbidity.  In total, only 14 studies (20.9%) included all three components, i.e., the 
definition of chronic condition, list of conditions, and cut-points used to define multimorbidity.  
The data sources of the conditions and the reference populations were clearly stated in all the 
studies. 
 
Hand-searching by the snowball method contributed 25% (n=19) of the final selected articles.  
All the objectives stated in every one of the 67 studies were fully reported.  Only 15 articles 
declared financial sponsorship or funding from grants.  Thirty-six articles declared no financial 
support or funding, and 23 of the articles did not make any statement on financial conflict of 
interest.
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Table 3-1. Summary of risk of bias (RoB) appraisal of included cohort articles using the modified Newcastle-Ottawa Quality Assessment Scale 
(35 articles) 
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Selection Criteria                                    
Representativeness of the sample * * - * * * * * * * * * * * * * - * * * - * * * * * * * * * * - * * * 
Ascertainment of Multimorbidity - * * * * * - * * * * * * * * * * * - * - * * * * * * * * * * - * * - 
Demonstration that outcome of interest was 
not present at the start of the study * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
                                    
Comparability Criteria                                    
Study controls for age and sex * - * * * * * - * * - * - * * * * * - * - * * * - * * * * * * * * * - 
Study controls for others * * - * * * * * - * * * * * * * * - - * * * * * * * * - * * * * * * * 
                                    
Outcome Criteria                                    
Statistical test†                  X                  
Assessment of outcome - * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
Follow-up was long enough for outcomes to 
occur * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
Adequacy of follow-up of cohorts * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * - * * * 
                                    
Overall RoB Judgementa G G F G G G G G G G G G G G G G F P P G F G G G G G G G G G G F G G G 
Note. G = Good; F = Fair; P = Poor. 
†Statistical test must be clearly described and appropriate before assessing the other items under the Outcome category. a Good rating is given when there are 2 to 3 stars in Selection category (Representativeness of  
Sample must be fulfilled) AND 1 to 2 stars in Comparability category AND 2 to 3 stars in Outcome category; Fair rating is given when there are 1 to 2 stars in Selection category AND 1 to 2 stars in Comparability 
category AND 2 to 3 stars in Outcome category; Poor rating is given when there are 0 star in Selection category OR 0 star in Comparability category OR 0 to 2 stars in Outcome category. 
“*” Study satisfies the criteria; “-” Study did not satisfy the criteria; “” Statistical test is clearly described and appropriate; “X” Statistical test is not described, incomplete or inappropriate. 
NB:  Articles highlighted in light grey are combined studies (see Table 3-2 with similar highlights) and articles highlighted in dark grey are cohort studies.  Those not highlighted are single articles which are also single 
studies.  
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Table 3-2. Summary of risk of bias (RoB) appraisal of included cross-sectional articles using the modified Newcastle-Ottawa Quality 
Assessment Scale (39 articles) 
 A
g
b
o
rs
an
g
ay
a
 e
t 
al
. 
(2
0
1
3
)7
0
 
B
ar
il
e 
et
 a
l.
 (
2
0
1
2
)2
8
 
B
ar
n
et
t 
et
 a
l.
 (
2
0
1
2
)7
1
  
B
o
ec
k
x
st
ae
n
s 
et
 a
l.
 (
2
0
1
5
a)
2
9
 
C
h
en
 e
t 
al
. 
(2
0
1
1
)7
2
 
D
iN
ap
o
li
 e
t 
al
. 
(2
0
1
7
)7
3
 
F
o
rm
ig
a 
et
 a
l.
 (
2
0
1
1
b
)3
6
  
G
al
en
k
am
p
 e
t 
al
. 
(2
0
1
1
)4
5
 
G
ar
in
 e
t 
al
. 
(2
0
1
4
)7
4
 
G
ly
n
n
 e
t 
al
. 
(2
0
1
1
)1
0
  
G
u
n
n
 e
t 
al
. 
(2
0
1
2
)7
5
 
H
an
m
er
 e
t 
al
. 
(2
0
1
0
)7
6
 
H
u
 e
t 
al
. 
(2
0
1
7
)7
7
 
Is
aa
cs
 e
t 
al
. 
(2
0
1
4
)7
8
 
K
o
ji
m
a 
et
 a
l.
 (
2
0
1
1
)4
6
 
K
ri
st
en
se
n
 e
t 
al
. 
(2
0
1
4
)7
9
 
L
ap
i 
et
 a
l.
 (
2
0
1
5
)8
0
 
L
aw
so
n
 e
t 
al
. 
(2
0
1
3
)8
1
 
L
i 
et
 a
l.
 (
2
0
1
6
)8
2
 
M
ar
en
g
o
n
i 
et
 a
l.
 (
2
0
1
1
)8
3
 
M
cD
ai
d
 e
t 
al
. 
(2
0
1
3
)8
4
 
M
u
g
g
ah
 e
t 
al
. 
(2
0
1
2
)4
4
 
M
u
ji
ca
-M
o
ta
 e
t 
al
. 
(2
0
1
5
)3
 
N
ae
ss
en
s 
et
 a
l.
 (
2
0
1
1
)8
5
 
Ø
st
er
g
aa
rd
 a
n
d
 F
o
ld
ag
er
 (
2
0
1
1
)8
6
 
P
et
er
s 
et
 a
l.
 (
2
0
1
8
)8
7
 
R
an
st
ad
 e
t 
al
. 
(2
0
1
4
)8
8
 
R
en
n
e 
an
d
 G
o
b
b
en
s 
(2
0
1
8
)8
9
 
R
y
u
 e
t 
al
. 
(2
0
1
5
)9
0
 
S
h
ad
m
i 
et
 a
l.
 (
2
0
1
1
)9
1
 
S
ib
le
y
 e
t 
al
. 
(2
0
1
4
)9
2
 
S
u
ll
iv
an
 e
t 
al
. 
(2
0
1
2
)9
3
 
U
b
al
d
e-
L
o
p
ez
 e
t 
al
. 
(2
0
1
6
)9
4
 
v
an
 d
en
 B
u
ss
ch
e 
et
 a
l.
 (
2
0
1
4
)4
8
 
v
an
 O
o
st
ro
m
 e
t 
al
. 
(2
0
1
4
)9
5
 
V
o
s 
et
 a
l.
 (
2
0
1
3
)9
6
 
W
ei
 e
t 
al
. 
(2
0
1
8
)9
7
 
W
ik
m
an
 e
t 
al
. 
(2
0
1
1
)9
8
 
W
is
te
r 
et
 a
l.
 (
2
0
1
5
)9
9
 
Selection                                        
Representativeness of the sample * * * - * * * * * * * * - * - * * * * * * * * - - * * * * * * * * * * - * * * 
Ascertainment of Multimorbidity * - * * * * * * * * - - * * * * * * - * * * - * * - * - - * * * * * * * * * * 
Sample size * * * - * * - * * * * * - * - * * * * * * * * * * * * - * * * * * * * - * * * 
Non-respondents - * * - * * * - - * - - * * - * * * - - - * - * - - * - * * - - * * * * * * - 
                                        
Comparability                                        
Study controls for age and sex * * * * * * - * * * * * * - * * * * - * * - * - - * * * * * * * - * * - * * * 
Study controls for others * * * * * * * - * * * * * - * * * * - * * - * - - * * * * * - * * * * - * * - 
                                        
Outcome                                        
Statistical test†              X                          
Assessment of outcome *  * * * * * * * * * * * * * * * * * * * * * * * * * * * * - * * * * * * * * 
                                        
Overall RoB Judgementa G G G P G G G G G G F F F P P G G G P G G P F P P F G P G G P G G G G P G G G 
 
Note. G = Good; F = Fair; P = Poor. 
†Statistical test must be clearly described and appropriate before assessing the other items under the Outcome category. a Good rating is given when there are 3 to 4 stars in Selection category (Representativeness of  
Sample must be fulfilled) AND 1 to 2 stars in Comparability category AND 1 star in Outcome category; Fair rating is given when there are 2 stars in Selection category AND 1 to 2 stars in Comparability category 
AND 1 star in Outcome category; Poor rating is given when there are 0 to 1 star in Selection category OR 0 star in Comparability category OR 0 star in Outcome category. 
“*” Study satisfies the criteria; “-” Study did not satisfy the criteria; “” Statistical test is clearly described and appropriate; “X” Statistical test is not described, incomplete or inappropriate. 
NB:  Articles highlighted in light grey are combined studies (see Table 3-1 with similar highlights).  Those not highlighted are single articles which are also single studies.  
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Table 3-3. Summary of included articles with good risk of bias judgement (47 studies including 53 articles) 
  
Author (Year), 
Country 
 
Study Design 
Population 
source 
(Sample size) Age 
Multimorbidity Measurement 
Outcomes measured Results Measure (s) used 
Definition of chronic disease 
included in the scale 
Number of conditions 
(MM cut-off) 
         
Agborsangaya 
et al. (2013)70, 
Canada 
Cross-sectional General 
Population 
(N = 4,946) 
≥ 18 a. DC 
 
NS a. 16 (2) 1. HRQoL 
 
1. Number of conditions negatively 
associated with HRQoL* 
         
Barile et al. 
(2013)27, USA 
 
 
Cohort 
- Same study as 
Barile et al. 
(2012)28  
General 
Population 
(N = 27,334) 
≥ 65 a.     DC 
 
NS a. 11 (2) 1. ADL limitations 
 
 
2. Number of 
physically unhealthy 
days 
 
3. Number of mentally 
unhealthy days 
1. DC positively associated with ADL 
limitations*** 
 
2. DC positively associated with 
physically unhealthy days*** 
 
 
3. DC positively associated with 
mentally unhealthy days*** 
         
Barile et al. 
(2012)28, USA 
Cross-sectional 
- Same study as 
Barile et al. 
(2013)27 
General 
Population 
(n = 64,428) 
≥ 65 a. DC NS 1. 11 (4) 1.    Physical HRQoL 
 
 
 
2.    Mental HRQoL 
1. Number of conditions positively 
associated with number of 
physically unhealthy days 
 
2. Number of conditions positively 
associated with number of mentally 
unhealthy days 
         
Barnett et al. 
(2012)71, UK 
 
 
Cross-sectional Primary Care 
(N = 
1,751,841) 
≥ 0 a. DC Chronic diseases selected are 
those recommended as core 
for any multimorbidity 
measure by systematic 
review in QOF of the UK GP 
contract and long-term 
disorders identified as 
important by NHS Scotland 
1. 40 (2)  1.    Presence of mental  
       health disorder 
1. Presence of mental health disorder 
was positively associated with the 
number of physical disorders that an 
individual had* 
         
Biehl et al. 
(2016)49, USA 
 
 
Cohort Primary Care 
(N = 9,872) 
≥ 65 a. ERA 
b. CCI 
Chronic disease as identified 
in ICD-9 
a. 9 (NS) 
b. NS (NS) 
1. Presence of critical 
illness 
1a. Both measures positively associated 
with critical illness*** 
 
1b. CCI performed better in predicting 
critical illness 
 (Continued on next page)  
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Table 3-3. Summary of included articles with good risk of bias judgement (47 studies including 53 articles) (Continued) 
  
Author (Year), 
Country 
 
Study Design 
Population 
source 
(Sample size) Age 
Multimorbidity Measurement 
Outcomes measured Results Measure (s) used 
Definition of chronic disease 
included in the scale 
Number of conditions 
(MM cut-off) 
         
Brilleman et al. 
(2014)31, UK 
 
Cohort 
- Same study 
as Brilleman 
& Salisbury 
(2013)32 
Primary Care 
(N = 86,100) 
≥ 18 a. QOF count 
b. CCI 
c. EDC count 
d. ACG 
e. RUB 
Measure (a): Chronic disease as 
identified in the clinical domain 
of the UK QOF pay for 
performance scheme 
 
Measure (b): Chronic disease 
that are predictive of mortality 
a. 17 (NS) 
b. 17 (NS) 
c. 114 (NS) 
d. 68 categories (NS) 
e. 6 categories (NS) 
1. Primary healthcare 
cost 
1a. All measures positively associated 
with outcome* 
1b. EDC count has the best 
performance on the goodness of fit  
         
Brilleman & 
Salisbury 
(2013)32, UK 
 
 
Cohort 
- Same study 
as Brilleman 
et al. (2014)31 
Primary Care 
(N = 95,188) 
≥ 18 a. QOF count 
b. CCI 
c. EDC count 
d. ACG 
e. RUB 
f. Prescribed 
drugs count 
NS a. 17 (NS) 
b. 17 (NS) 
c. 114 (NS) 
d. 68 categories (NS) 
e. 6 categories (NS) 
f. NS (NS) 
1. Mortality  
(3-years period) 
 
 
2. Number of primary 
care consultations 
(3-years period) 
1. Best performing model was drugs 
count followed by ACG, EDC 
count, RUB, QOF count, and CCI 
 
2. Best performing model was CCI 
followed by drugs count, QOF 
count, EDC count, and RUB 
         
Carey et al. 
(2013)50, UK 
 
 
Cohort Primary Care 
(n = 335, 904) 
≥ 60 a. Standard 
QOF 
b. Extended 
QOF 
c. CCI (Khan) 
Measure (a): Based on QOF 
disease definition from UK GP 
contract 
 
Measure (b): Based on QOF 
disease definition and 
additional 5 severe subgroups 
of standard QOF conditions 
 
Measure (c): Chronic diseases 
selected based on Read code 
list created by Khan 
a. 9 (NS) 
b. 14 (NS) 
c. 17 (NS) 
1. Mortality 
(1-year period) 
1a. All measures positively associated 
with 1-year mortality risk* 
 
1b. Fitting the weighted score as a 9-
level variable, extended QOF score 
outperformed the rest of the 
measures in overall model 
performance 
         
Chapman et al. 
(2015)51, UK 
 
Cohort General 
Population 
(n = 3,237) 
≥ 18 a. CCI 
b. CCI-PSR 
NS a. 9 categories (NS) 
b. 9 categories and 5 
psycho-social 
factors (NS) 
1. Mortality 
(5, 10, 15, 20, 25-
years period) 
1. CCI-PSR showed substantially 
better discrimination across all time 
horizons*** 
 (Continued on next page)  
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Table 3-3. Summary of included articles with good risk of bias judgement (47 studies including 53 articles) (Continued) 
Author (Year), 
Country 
 
Study Design 
Population 
source 
(Sample size) Age 
Multimorbidity Measurement 
Outcomes measured Results Measure (s) used 
Definition of chronic disease 
included in the scale 
Number of conditions 
(MM cut-off) 
         
Chen et al. 
(2011)72, USA 
 
 
Cross-sectional General 
Population 
(n = 430,912) 
≥ 18 a. DC NS a. 8 (NS) 1. General Health 
 
 
2. Mental Distress 
 
 
3. Physical Distress 
 
 
4. Activity 
limitations 
1. Higher DC associated with poorer 
general health* 
 
2. Higher DC associated with higher 
prevalence of mental distress* 
 
3. Higher DC associated with higher 
prevalence of physical distress* 
 
4. Higher DC associated with more 
frequent activity limitations* 
         
Crane et al. 
(2010)52, USA 
 
 
Cohort Primary Care 
(N = 12,650) 
≥ 60 a. ERA Chronic diseases identified 
from ICD-9 and selected 
based on consensus 
discussion regarding their 
known risk for recurrent 
hospitalization and greater 
complexity of care 
a. NS (NS) 1. Number of 
hospital visits  
(1-year period) 
 
2. Number of ED 
visits 
(1-year period) 
 
 
3. Number of 
hospital 
admissions 
(1-year period) 
 
4. Days hospitalised 
(1-year period) 
1a. AUC = 0.705 
 
1b. Increased with increasing ERA 
score** 
 
2a. AUC = 0.64 
 
2b. Increased with increasing ERA 
score** 
 
3. Increased with increasing ERA 
score** 
 
 
4. Increased with increasing ERA 
score** 
         
Crooks et al. 
(2016)33, UK 
 
 
Cohort 
- Same study as 
Crooks et al. 
(2015)34 
 
Primary Care 
(n = 328,636) 
20 
to 
100 
a. Co-morbidity 
linked score 
b. CCI 
c. Elixhauser Index 
Measure (a): Chronic 
diseases identified from 
primary care in the CPRD 
and diagnostic ICD-10 from 
secondary care in English 
HES 
a. NS (NS) 
b. NS (NS) 
c. NS (NS) 
1. Mortality 
(1-year period) 
1. Linked score improved 
discrimination and fit compared to 
CCI and Elixhauser Index 
 (Continued on next page) 
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Table 3-3. Summary of included articles with good risk of bias judgement (47 studies including 53 articles) (Continued) 
Author 
(Year), 
Country 
 
Study Design Population 
source 
(Sample size) Age 
Multimorbidity Measurement 
Outcomes 
measured Results Measure (s) used 
Definition of chronic disease 
included in the scale 
Number of 
conditions 
(MM cut-off) 
         
Crooks et al. 
(2015)34, UK 
 
 
Cohort 
- Same study as 
Crooks et al. 
(2016)33 
 
 
Primary Care 
(N = 657,264) 
≥ 20 a. CCI (Read) 
b. CCI (ICD-10) 
c. CCI (Read and 
ICD-10) 
NS a. 19 (NS) 
b. 19 (NS) 
c. 19 (NS) 
1. All-cause 
mortality (1-5 
years) 
1. No large difference in the discrimination 
of model for overall survival, whichever 
codes used to derive CCI 
         
DiNapoli et 
al. (2017)73, 
USA 
 
 
Cross-sectional Primary Care 
(n = 34,786) 
≥ 50 a. Organ 
systems with 
chronic 
disease 
 
NS a. NS (NS) 1. Presence of 
depressive or 
anxiety disorder 
1. Odds of having depressive and/or anxiety 
disorder increased with each additional 
organ system with chronic disease** 
         
Formiga et 
al. (2013)53, 
Spain 
 
Cohort 
 
Primary Care 
(N = 328) 
85 a. CCI NS a. Assumed 
17 (NS) 
1. Mortality 
(3-years period) 
1. Patients who did not survive had 
significantly higher CCI score***  
         
Formiga et 
al. (2011a)54, 
Spain 
 
 
Cohort 
 
General 
Population 
(including 
those in 
institutions)  
(N = 186) 
90 
to 
99 
a. CCI NS a. NS (NS) 1. Mortality 
(5-years period) 
1. Patients who did not survive had 
significantly higher CCI score*** 
         
Formiga et 
al. (2011b)36, 
Spain 
Cross-sectional 
- Same study as 
Formiga et al. 
(2016)35 
 
Primary Care 
(n = 328) 
85 a. CCI NS a. NS (NS) 1. Successful 
aging 
1. Successful aging was associated with 
lower values on the CCI* 
         
Formiga et 
al. (2016)35, 
Spain 
Cohort 
- Same study as 
Formiga et al. 
(2011b)36 
Primary Care 
(N = 328) 
85 a. CCI NS a. NS (NS) 1. Mortality 
(5-years period) 
1. Patients who survived after 5-year 
follow-up had significantly lower CCI 
score***  
 (Continued on next page)  
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Table 3-3. Summary of included articles with good risk of bias judgement (47 studies including 53 articles) (Continued) 
Author (Year), 
Country 
 
Study Design 
Population 
source 
(Sample size) Age 
Multimorbidity Measurement 
Outcomes measured Results Measure (s) used 
Definition of chronic disease 
included in the scale 
Number of conditions 
(MM cut-off) 
         
Fraccaro et al. 
(2016)55, UK 
 
 
Cohort Primary Care 
(N = 287,459) 
≥ 18 a. CCI (Khan) 
 
Chronic disease selected 
from a validated list of Read 
diagnostic codes for 
calculating CCI in UK 
primary care from Khan et al. 
(2010) 
a. 22 (NS) 
 
1. Mortality 
(1, 5, 10-years 
period) 
 
2. Mortality 
(3, 6, 12-months 
period) 
1. Mortality odds ratio positively 
associated with change in CCI at 1, 
5, and 10 years follow-up* 
 
2. Model consisting of sex, time-
dependent age, CCI, and CCI 
change over consecutive time 
windows had the best fit to the data 
         
Galenkamp et 
al. (2011)45, 
The 
Netherlands 
Cross-sectional General 
Population 
(N = 2,046) 
57 to 
98 
a. DC Selection of chronic diseases 
was based on their 
prevalence in the 55+ age 
group in The Netherlands 
a. 7 (NS)  1. SRH 1. SRH declines with each increase in 
number of co-occurring diseases*** 
         
Garin et al. 
(2014)74, Spain 
 
 
Cross-sectional General 
Population 
(N = 3,625) 
≥ 50 a. DC NS a. 11 (NS) 1. QOL 
 
 
2. Disability 
 
1. QoL decreased with increasing 
number of chronic conditions*** 
 
2. Disability increased with increasing 
number of chronic conditions*** 
         
Glynn et al. 
(2011)10, 
Ireland 
Cross-sectional Primary Care 
(n = 3,309) 
> 50 a. DC Health problems that require 
ongoing management over a 
period of years/decades 
a. 147 (2) 1. Primary Care 
Consultations 
(1-year period) 
 
2. Hospital 
outpatient visits 
(1-year period) 
 
3. Hospital 
admissions 
(1-year period) 
 
4. Healthcare cost 
1. Mean primary care consultations 
increased with increasing number of 
conditions*** 
 
2. Mean outpatient visits increased 
with increasing number of 
conditions*** 
 
3. Higher number of conditions 
increased the odds of hospital 
admissions** 
 
4. Total healthcare cost increased 
significantly with increasing 
number of chronic conditions*** 
 (Continued on next page) 
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Table 3-3. Summary of included articles with good risk of bias judgement (47 studies including 53 articles) (Continued) 
Author 
(Year), 
Country 
 
Study Design 
Population 
source 
(Sample size) Age 
Multimorbidity Measurement 
Outcomes measured Results Measure (s) used 
Definition of chronic disease 
included in the scale 
Number of conditions 
(MM cut-off) 
         
Haas et al. 
(2013)56, 
USA 
 
 
Cohort Primary Care 
(N = 83,187) 
≥ 18 a. ACG 
b. Minnesota 
Health Care 
Home Tiering 
c. HCC 
d. ERA 
e. CCC 
f. CCI 
g. Hybrid Model 
NS a. 93 categories (NS) 
b. 5 levels (NS) 
c. 70 (NS) 
d. NS (NS) 
e. 6 categories (NS) 
f. 17 (NS) 
g. NS (NS) 
1. Hospitalisation 
(1-year) 
 
 
2. ED visits  
(1-year) 
 
3. Readmission 
within 30 days  
(1-year) 
 
4. Healthcare 
expenditure 
(1-year) 
1. ACG model outperformed other 
models when predicting 
hospitalisation 
 
2. ACG model outperformed other 
models when predicting ED visits 
 
3. ACG model outperformed other 
models when predicting 30-days 
readmissions 
 
4. ACG model outperformed other 
models when predicting healthcare 
expenditure 
         
Hwang et al. 
(2015)57, 
USA 
 
 
Cohort General 
Population 
(N = 42,038) 
≥ 0 a. ACE-27 
b. ACE-27 
count 
Measures (a) and (b) consist 
of 26 common patient 
conditions 
a. 26 (NS) 
b. 26 (NS) 
 
1. Healthcare 
expenditure 
 
 
1a. Increasing number of comorbidity 
(Φc = 0.36) and comorbidity 
severity (Φc = 0.30) increased the 
likelihood of being persistent high 
healthcare users 
 
1b. Exploratory predictive model of 
persistent high-user group reported 
an AUC value of 0.923 
         
Kristensen et 
al. (2014)79, 
Denmark 
Cross-sectional Primary Care 
(N = 139,527) 
> 0 a. RUB 
 
NS a. 6 levels (NS) 1. Fee-for-services 
expenditures 
1. RUB explained about 18% of the 
variance in expenditures 
         
Lapi et al. 
(2015)80, 
Italy 
 
 
Cross-sectional Primary Care 
(n = 26,903) 
≥ 15 a. HSMI Chronic disease is defined as 
being diagnosed with 1 of 
the selected conditions in the 
study at least once in an 18-
month period 
a. 73 (NS)  1. Total mean 
healthcare cost per 
year 
1. HSMI explained 50.17% of the 
variation in costs 
 (Continued on next page) 
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Table 3-3. Summary of included articles with good risk of bias judgement (47 studies including 53 articles) (Continued) 
Author 
(Year), 
Country 
 
Study Design 
Population 
source 
(Sample size) Age 
Multimorbidity Measurement 
Outcomes measured Results 
Measure (s) 
used 
Definition of chronic disease included in 
the scale 
Number of conditions 
(MM cut-off) 
         
Lawson et 
al. (2013)81, 
UK 
Cross-sectional General 
Population 
(n = 7,054) 
≥ 20 a. DC Chronic conditions that are 
longstanding, as defined by “anything 
that has troubled you over a period of 
time” 
a. 40 (2) 1. Preference_ 
Weighted 
HRQoL 
1. Increasing number of 
conditions was associated with 
reduction in Preference 
Weighted HRQoL scores*** 
         
Lemke et 
al. (2012)61, 
USA 
 
 
Cohort General 
Population  
(n = 
4,707,001) 
≥ 0 a. CCI 
b. ACG 
 
NS  a. 17 (NS) 
b.    NS (NS) 
1.    Inpatient     
       Hospitalisations 
 
 
1. ACG-based models were 
superior to the prior 
hospitalization model and 
Charlson inpatient 
hospitalization model (AUC 
0.80 vs 0.75 vs 0.78) 
         
Marengoni 
et al. 
(2011)83, 
Sweden 
 
 
Cross-sectional General 
Population 
(n = 1,099) 
≥ 75 
(baseline) 
 
≥ 77 
(follow-up) 
a. DC Disease was classified as chronic if it 
met 1 or more of the following 
characteristics: (1) state of permanence, 
(2) caused by non-reversible 
pathological alternation, (3) requiring 
rehabilitation and (4) requiring a long 
period of care 
a. 30 (2) 1. Disability 
 
 
1. Increasing number of diseases 
was associated with increasing 
prevalence of disability*** 
         
McDaid et 
al. (2013)84, 
Ireland 
 
 
Cross-sectional General 
Population 
(N = 6,159) 
≥ 50 a. DC NS a. 8 (2) 1. Disability 
 
2. QoL 
 
 
3. SRH 
1. Higher DC associated with 
higher risk of disability*** 
2. Higher DC associated with 
poorer QoL*** 
3. Higher DC associated with 
poorer SRH*** 
         
Payne et al. 
(2014)37, 
UK 
 
 
Cohort 
- Same study as 
Payne et al. 
(2013)38 
 
Primary Care  
(N = 180,815) 
≥ 20 a. DC 
 
Conditions established by clinical expert 
consensus, sought to include morbidities 
recommended as core for any 
multimorbidity measure by a previous 
systematic review, diseases included in 
the UK primary care ‘payment-for-
performance’ contract (QOF) and those 
considered important for health service 
planning by NHS Scotland. These 
conditions may significantly impact 
quality of life. 
a. 40 (NS) 
 
1. Unplanned 
hospital 
admissions 
(1-year period) 
 
 
1. Number of clinical conditions 
positively associated with 
unplanned hospital admissions 
in a 12-month follow-up 
period***  
 (Continued on next page)  
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Author (Year), 
Country 
 
Study Design 
Population 
source 
(Sample size) Age 
Multimorbidity Measurement 
Outcomes measured Results Measure (s) used 
Definition of chronic disease 
included in the scale 
Number of conditions 
(MM cut-off) 
         
Payne et al. 
(2013)38, UK 
 
 
Cohort 
- Same study 
as Payne et 
al. (2014)37 
 
Primary Care 
(N = 180,815) 
≥ 20 a. DC 
 
NS a. 40 (NS) 
 
1. Unplanned 
hospital admission 
(1-year period) 
 
2. Potentially 
preventable 
unplanned 
admission 
(1-year period) 
1. Number of physical conditions 
positively associated with unplanned 
admission in a year*** 
 
 
2. Number of physical conditions 
positively associated with preventable 
admission in a year*** 
         
Quail et al. 
(2011)62, 
Canada 
 
 
Cohort General 
Population 
(N = 662,423) 
≥ 20 a. DC 
b. CCI (Quan) 
c. Elixhauser 
(Quan) 
d. Number of 
different 
dispended 
drugs 
e. CDS 
NS a. NS (NS)  
b. 17 (NS) 
c. 31 (NS) 
d. NS (NS)  
e. NS (NS)  
1. Mortality 
(1-year period) 
 
 
 
2. One or more 
hospitalisations 
 
3. Two or more 
hospitalisations 
1. The addition of Elixhauser Index (Quan) 
to the base model yielded the largest 
improvement in c-statistic, followed by 
CCI (Quan) in predicting mortality  
 
2. DC performed best in predicting one 
more or hospitalisations  
 
3. DC performed best in predicting two or 
more hospitalisations 
         
Ranstad et al. 
(2014)88, 
Sweden 
 
 
Cross-
sectional 
General 
Population 
(N = 151,731) 
≥ 0 a. RUB 
 
NS a. NS (NS) 1. Registered active 
listing in primary 
care  
 
 
 
 
 
2. Registered active 
listing in all 
healthcare  
1a. Patients of high multimorbidity level are 
more likely to be actively listed in 
primary care* 
 
1b. Multimorbidity level predicted active 
listing in primary care, significantly 
increasing for RUB 0-4*** 
 
2a. Patients of high multimorbidity level are 
more likely to be actively listed in all 
healthcare* 
 
2b. Multimorbidity level predicted active 
listing in all healthcare significantly*** 
increasing for RUB 0-4 
 (Continued on next page)  
108 
 
 
 
Table 3-3. Summary of included articles with good risk of bias judgement (47 studies including 53 articles) (Continued) 
Author 
(Year), 
Country 
 
Study Design  Population 
source 
(Sample size) Age 
Multimorbidity Measurement 
Outcomes measured                                                                                                                        ResultsMeasure (s) used 
Definition of chronic 
disease included in the        
scale 
Number of conditions 
(MM cut-off) 
         
Reyes et al. 
(2014)63, 
Spain 
 
Cohort Primary Care 
(Men only) 
(N = 186,171) 
≥ 65 a. CCI NS a. 17 (NS) 1. Hip fractures                          1. Patients with CCI ≥ 3 had increased 
risk of hip fracture as compared to 
patients without co-morbidities*** 
         
Ryu et al. 
(2015)90, 
USA 
Cross-sectional Primary Care 
(N = 21,736) 
≥ 18 a. DC NS a. 80 (NS) 1. Deficits of perceived 
general health 
 
 
2. Depressive 
symptoms 
1. Disease burden was associated with 
higher risk of deficits in perceived 
general health* 
 
2. Disease burden was associated with 
higher risk of deficits in depressive 
symptoms* 
         
Salisbury et 
al. (2011)11, 
UK 
 
 
Cohort Primary Care 
(N = 99,997) 
≥ 18 a. QOF count 
EDC count 
Measure (b): Chronic 
disease defined as one 
that normally lasts ≥ 6 
months 
a. 17 (2) 
b. 114 (NS) 
1. Primary Care 
consultation rates 
(3-years period) 
 
2. Continuity of care 
(3-years period) 
1. Number of QOF conditions positively 
associated with consultation rates*** 
 
 
2. QOF morbidity inversely associated 
with continuity of care* 
         
Saver et al. 
(2014)64, 
USA 
 
 
Cohort General 
Population 
(N = 106,930) 
≥ 65 a. CCI (Romano) 
+ Hypertension 
NS a. 19 (NS) 1. Acute ACSH 
 
 
 
2. Chronic ACSH 
 
1. Models containing flags for 
comorbidity showed greater 
predictive power for acute ACSH 
 
2. Models containing flags for 
comorbidity showed greater 
predictive power for acute ACSH 
         
Shadmi et 
al. (2011)91, 
Israel 
 
 
Cross-sectional General 
Population 
(n = 279,241) 
≥ 18 a.   ADG 
b. CCI 
NS a. 32 (NS)  
b. 19 (NS) 
1. Number of primary 
care physician visits 
 
2. Number of specialist 
visits 
 
3. Number of 
hospitalisation 
1. ADGs explained 23% to 54% of the 
variance in health care resource 
utilization as compared to CCI, which 
explained only 11%-18%.  
  
 (Continued on next page)  
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Table 3-3. Summary of included articles with good risk of bias judgement (47 studies including 53 articles) (Continued) 
Author (Year), 
Country 
 
Study Design  Population 
source 
(Sample size) Age 
Multimorbidity Measurement 
Outcomes measured Results Measure (s) used 
Definition of chronic disease 
included in the scale 
Number of 
conditions 
(MM cut-off) 
         
Stanley & Sarfati 
(2017)65, New 
Zealand 
 
 
Cohort Primary Care 
(n = 
1,000,166) 
≥ 18 a. M3 Index 
b. CCI 
c. Elixhauser 
     (van  
     Walraven) 
Measure (a): Chronic diseases 
were identified from ICD-10 
and based on the impact on 
quality and quantity of life, 
requiring complex healthcare 
management for coordination, 
and lasting for ≥ 3 months 
a. 55 (NS) 
b. 17 (NS) 
c. 31 (NS) 
1. Mortality 
(1-year period) 
 
 
2. Overnight 
hospitalisation 
(1-year period) 
1. M3 Index improved predictive 
performance for 1-year mortality risk 
over CCI and Elixhauser 
 
2. M3 Index improved predictive 
performance for overnight 
hospitalisation over CCI and Elixhauser 
         
Streit et al. 
(2014)66, 
Switzerland 
 
 
Cohort Primary Care 
(N = 1,002) 
50 
to 
80 
a. CCI 
b. DC 
Measure (b): Derived list of 
chronic diseases based on a 
large study by Higashi et al. 
(2007) and the CCI. Psychiatric 
conditions were also included 
based on consensus 
a. 19 (NS) 
b. 17 (NS) 
1. Quality of 
cardiovascular 
preventive care 
 
2. Quality of 
preventive care 
1. No association found between 
multimorbidity measures and outcome 
 
2. No association found between 
multimorbidity measures and outcome 
         
Sullivan et al. 
(2012)93, USA 
 
Cross-
sectional 
General 
Population 
(N = 47,178) 
≥ 18 a. DC CCC of ICD-9 codes  
- Chronic conditions is defined 
as lasting for more than 1 year 
a. 118 (2) 1. Preference-based 
HRQoL 
1a. The number of chronic conditions was 
negatively associated with EQ-5D-5L 
scores*** 
 
1b. Inclusion of chronic co-morbidity to the 
baseline models explained more 
variance in EQ-5D-5L index scores than 
did age or other socio-demographic 
characteristics  
         
Takahashi et al. 
(2016)67, USA 
 
 
Cohort Primary Care 
(n = 42,368) 
≥ 18 a. Minnesota 
Tiering 
(ACG) 
b. Enhanced 
model 
 
NS a. 42 (NS) 
 
b. 42 (NS) 
1. Hospitalisation / 
ED visits 
1a. Patients identified as high-risk in the 
enhanced model were much more likely 
to experience hospital utilization than 
those in the Minnesota medical tiering 
model*** 
 
1b. Enhanced model (AUC = 0.711) is 
better at predicting hospitalization/ED 
visits as compared to Minnesota 
Medical Tiering (AUC = 0.667)  
(Continued on next page)  
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Table 3-3. Summary of included articles with good risk of bias judgement (47 studies including 53 articles) (Continued) 
Author (Year), 
Country 
 
Study Design  
Population 
source 
(Sample size) Age 
Multimorbidity Measurement 
Outcomes measured Results Measure (s) used 
Definition of chronic disease 
included in the scale 
Number of conditions 
(MM cut-off) 
         
Takahashi et al. 
(2012)47, USA 
 
 
Cohort Primary Care 
(N = 12,650) 
> 60 a. ERA 
 
NS a. 7 (NS) 1. Mortality 
(2-years period) 
 
 
 
2. Nursing home 
placement 
(2-years period)  
1. Being in the uppermost quartile 
of the ERA index significantly 
increased the risk for mortality in 
the subsequent 2 years*** 
  
2. Being in the uppermost quartile 
of the ERA index significantly 
increased nursing home 
placement in the subsequent 2 
years*** 
         
Ubalde-Lopez 
et al. (2016)94, 
Spain  
 
 
Cross-sectional General 
Population 
(N = 372,370) 
Female 
(Mean): 
35.9 
 
Male 
(Mean): 
37.9 
a. MDMS 
 
 
NS a. 14 (2) 
 
1. Sickness 
absence 
episodes taken 
in last 2 years 
1a. Higher risk of new episodes was 
observed among men as MDMS 
levels increased* 
 
1b. Similar trend was observed 
among women but trend was 
statistically significant 
         
van den 
Bussche et al. 
(2011)48, 
Germany 
Cross-sectional Primary Care 
(N = 123,224) 
≥ 65 a. DC Chronicity of conditions was 
assessed using the “Expert 
Report for the Selection of 50 
to 80 Diseases to be included 
in the morbidity based risk 
adjustment scheme” in the 
German Statutory Health 
Insurance. A person was 
defined as chronically ill if 
she/he had at least one of the 
46 chronic conditions in at 
least three quarters within the 
one-year observation period 
2004.   
a. 46 (3) 1. Frequency of 
contacts with 
physicians (1-
year) 
 
2. Number of 
different 
ambulatory 
physicians 
contacted (1-
year) 
1. Number of chronic conditions is 
positively associated with the 
number of contacts with 
physicians*** 
 
2. Number of chronic conditions is 
positively associated with the 
number of physicians 
contacted*** 
 (Continued on next page) 
  
111 
 
 
 
Table 3-3. Summary of included articles with good risk of bias judgement (47 studies including 53 articles) (Continued) 
Author (Year), 
Country 
 
Study Design 
Population 
source 
(Sample size) Age 
Multimorbidity Measurement 
Outcomes measured Results Measure (s) used 
Definition of chronic disease 
included in the scale 
Number of conditions 
(MM cut-off) 
         
van Oostrom et 
al. (2014)95, 
The 
Netherlands  
 
 
Cross-sectional Primary Care 
(N = 32,583) 
≥ 55 a. DC NS a. 28 (2)  1. Number of 
contacts with 
general practice 
 
 
2. Number of 
medications 
prescribed 
 
3. Number of 
referrals 
1. The number of chronic diseases 
was positively associated with the 
number of contacts for all types of 
contacts in the general practice*** 
 
2. The number of chronic diseases 
was positively associated with the 
number of medications 
prescribed*** 
 
3. The number of chronic diseases 
was positively associated with the 
number of referrals*** 
         
Wallace et al. 
(2016a)39, 
Ireland 
 
 
Cohort 
- Same study as 
Wallace et al. 
(2016b)40 
 
Primary Care 
(N = 862) 
≥ 70 a. Pra tool 
b. Modified 
Pra tool 
NS a. NS (NS) 
b. NS (NS) 
1. Emergency 
hospital admission 
(1-year period) 
1. Both measures demonstrated poor 
discrimination performance in 
predicting emergency hospital 
admission in a year 
         
Wallace et al. 
(2016b)40, 
Ireland 
 
Cohort 
- Same study as 
Wallace et al. 
(2016a)39 
Primary Care 
(N = 862) 
≥ 70 a. DC 
b. Barnett 
conditions 
DC 
c. CCI 
d. Prescribed 
drugs count 
e. RxRisk-V 
Measure (a): ICPC-2 definition of 
chronic disease was used 
 
Measure (b): Chronic conditions 
were selected based on health 
impact and prevalence 
a. NS (2) 
b. 40 (2) 
c. 19 (NS) 
d. NS (NS) 
e. N3S (NS) 
1. Emergency 
admission 
(2-years period) 
 
2. Functional decline 
(2-years period) 
1. All measures demonstrated poor 
discrimination for the emergency 
admission in 2 years 
 
2. All measures demonstrated poor 
discrimination for functional 
decline 
 (Continued on next page) 
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Wei et al. 
(2018)97, USA 
 
 
Cross-sectional General 
Population 
(N = 20,509) 
≥ 51 a. MWI NS a. 81 (NS) 1. Subjective 
physical 
functioning 
 
2. Grip strength 
 
3. Gait speed 
 
 
4. Cognitive 
performance 
 
 
5. ADL limitations 
 
6. IADL limitations 
1. MWI negatively associated with 
physical functioning*** 
 
2. MWI negatively associated with 
grip strength*** 
 
3. No association found between 
MWI and gait speed 
 
4. Higher MWI associated with 
poorer cognitive performance*** 
 
5. Higher MWI associated with 
increased ADL limitations*** 
 
6. Higher MWI associated with IADL 
limitations*** 
         
Wei & 
Mukamal 
(2018)69, USA 
Cohort General 
Population 
(N = 219,950) 
≥ 36 a. MWI 
b. DC 
c. CCI 
NS a. 81 (NS) 
b. 81 (2) 
c. 19 (NS) 
1. Mortality 
(10-years period) 
 
 
 
 
 
 
 
 
2. Future physical 
functioning 
1a. All three measures of 
multimorbidity were positively 
associated with mortality*** 
 
1b. MWI performed best in predicting 
mortality as compared to DC and 
CCI in all three cohorts as well as 
combined cohorts 
 
2. All three measures of 
multimorbidity were negatively 
associated with future physical 
functioning*** 
 
 (Continued on next page) 
                                                 
 The youngest participant was from the NHS II cohort, aged 25 in 1989. Data collection for this study started in 2000 (NHS and HPFS cohorts) and 2001 (NHS II cohort) and hence, the age of the participants 
recruited in this study is 36 years old and above. 
Author (Year), 
Country 
 
Study Design 
Population 
source 
(Sample size) Age 
Multimorbidity Measurement 
Outcomes measured Results Measure (s) used 
Definition of chronic disease 
included in the scale 
Number of conditions 
(MM cut-off) 
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Table 3-3. Summary of included articles with good risk of bias judgement (47 studies including 53 articles) (Continued) 
Author (Year), 
Country 
 
Study Design  
Population 
source 
(Sample size) Age 
Multimorbidity Measurement 
Outcomes measured Results Measure (s) used 
Definition of chronic disease 
included in the scale 
Number of conditions 
(MM cut-off) 
         
Wikman et al. 
(2011)98, UK 
 
 
Cross-
sectional 
General 
Population 
(n = 11,532) 
≥ 50 a. DC NS a. 8 (NS) 1. QoL 
 
 
 
2. Affective well-
being 
1. Number of chronic conditions 
was negatively associated to 
QoL*** 
 
2. Number of chronic conditions 
was negatively associated to 
affective well-being*** 
         
Wister et al. 
(2015)99, 
Canada 
 
 
Cross-
sectional 
General 
Population 
(n = 16,369) 
≥ 65 a. Multimorbidity 
additive scale 
b. Multimorbidity 
weighted by HUI3 
c. Multimorbidity 
weighted by ADL 
Scale 
d. Multimorbidity 
weighted by HUI3 
betas 
Conditions that are slow in 
progression, long in duration, 
and typically limit function, 
productivity and quality of 
life. 
a. 19 (NS) 
b. 19 (NS)  
c. 19 (NS) 
d. 19 (NS) 
 
1. Life satisfaction 
 
 
 
2. Perceived health 
status 
 
 
1. All measures are negatively 
associated with life 
satisfaction*** 
 
2. All measures are negatively 
associated with perceived health 
status*** 
 
Note. ACE-27 = Adult Comorbidity Evaluation-27; ACG = Adjusted Clinical Groups; ACSH = Ambulatory Care Sensitive Hospitalisation; ADG = Aggregated Diagnosis Groups; ADL = Activities of Daily Living; 
AUC = Area Under the Curve; BI = Barthel Index; CCC = Chronic Condition Count; CCC (of ICD-9 codes) = Clinical Classification Categories; CCI = Charlson Comorbidity Index; CCI-PSR = Charlson Comorbidity 
Index-Psychosocial Risk; CDS = Chronic Disease Score; CPRD = Clinical Practice Research Datalink; DC = Disease Count (Unweighted); ED = Emergency Department; EDC = Expanded Diagnosis Clusters; EMR = 
Electronic Medical Record; EQ-VAS = EuroQoL-Visual Analogue Scale; EQ-5D-5L = EuroQoL-5 Dimensions; ERA = Elder Risk Assessment; GP = General Practice; HCC = Hierarchical Condition Categories; 
HRQoL = Health-related Quality of Life; HUI3 = Health Utility Index; IADL = Instrumental Activities of Daily Living; ICD-10 = International Classification of Diseases, Tenth Revision; ICD-9 = International 
Classification of Diseases, Ninth Revision; ICPC-2 = International Classification of Primary Care, second edition; MDMS = Multidimensional Multimorbidity Score; MM = Multimorbidity; MWI = Multimorbidity-
Weighted Index; NHS = National Health Service; NS = Not Stated; Pra tool = Probability of repeated admission risk prediction tool; QOF = Quality and Outcomes Framework; QoL = Quality of Life; RUB = Resource 
Utilisation Band; RxRisk-V = A Veterans Association adapted pharmacy-based case-mix instrument; SRH = Self-Rated Health; UK = United Kingdom; Φc = Cramer’s V 
 
* p ≤ .05. ** p ≤ .01. *** p ≤ .001. 
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Table 3-4. Summary of included studies with poor and fair risk of bias judgement (20 studies including 21 articles) 
Author (Year), 
Country 
 
Study Design  Population source 
(Sample size) Age 
Multimorbidity Measurement 
Outcomes measured Measure(s) used 
Definition of chronic disease included in 
the scale 
Number of conditions 
(MM cut-off) 
        
Boeckxstaens et 
al. (2015a)29, 
Belgium 
Cross-sectional 
- Same study as 
Boeckxstaens 
et al. (2015b)30 
Primary Care 
(N = 567) 
≥ 80 a. DC 
b. CCI 
c. CIRS 
NS a. 22 (3) 
b. 19 (5) 
c. 58 (3) 
1. Disability 
2. Frailty 
        
Boeckxstaens et 
al. (2015b)30, 
Belgium 
Cohort 
- Same study as 
Boeckxstaens 
et al. (2015a)29 
Primary Care 
(N = 567) 
≥ 80 a. DC 
b. mCCI 
c. CIRS 
NS a. 22 (3/4) 
b. 19 (5/4) 
c. 58 (3/3) 
1. Mortality 
(3-years period) 
 
2. Hospitalisation 
(3-years period) 
 
3. Functional decline 
(19-months period) 
        
Gunn et al. 
(2012)75, 
Australia 
Cross-sectional Primary Care 
(n = 7,620) 
18 
to 
76 
a. DC Chronic diseases selected were the 
commonly seen chronic physical 
conditions seen in Australian GP and the 
National health priority areas 
a. 12 (2) 1. Depressive symptoms 
        
Hanmer et al. 
(2010)76, USA 
Cross-sectional General 
Population 
(n = 94,794) 
22 
to 
106 
a. Additive 
b. Minimum 
c. Multiplicative 
Models 
Chronic disease defined as conditions that 
are chronic in nature and should affect the 
respondent’s health at the point when they 
completed the survey 
a. 15 (NS) 
b. 15 (NS) 
c. 15 (NS) 
1. SF-6D health utility 
        
Hu et al. 
(2017)77, 
Canada 
Cross-sectional Primary Care 
(N = 265) 
≥ 65 a. Age-adjusted 
CCI 
NS a. NS (NS) 1. Frequency of family physician visits 
        
Isaacs et al. 
(2014)78, South 
Africa 
Cross-sectional Primary Care 
(N = 4,184) 
18 
to 
101 
a. DC Any condition requiring long-term (> 1 
month) medication with repeat 
prescriptions 
a. NS (2) 1. Prescription cost 
        
Jennings et al. 
(2015)58, USA 
Cohort Primary Care 
(N = 1,776) 
≥ 75 a. Elixhauser 
Comorbidity 
Count 
NS a. NS (NS) 1. Number of fall-related injuries in 2 years 
(Continued on next page) 
                                                 
 Multimorbidity cut-off of the multimorbidity measure in relation to hospitalisation in 3-years period. 
 Multimorbidity cut-off of the multimorbidity measure in relation to mortality risk in 3 years. 
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Table 3-4. Summary of included studies with poor and fair risk of bias judgement (20 studies including 21 articles) (Continued) 
Author (Year), 
Country 
 
Study Design  Population source 
(Sample size) Age 
Multimorbidity Measurement 
Outcomes measured 
Measure(s) 
used 
Definition of chronic disease included in the 
scale 
Number of conditions 
(MM cut-off) 
        
Jia and 
Lubetkin 
(2016)59, USA 
Cohort General 
Population 
(N = 2,380) 
≥ 65 a. DC Chronic diseases are selected based on their 
inclusion in other national data sets, prevalence 
among elderly, being a leading cause of death 
and having a high mortality rate 
a. 9 (NS) 1. QALY 
        
Jia et al. 
(2018)60, USA 
Cohort General 
Population 
(N = 96,481) 
≥ 65 a. DC NS a. 15 (NS) 1. QALY 
        
Kojima et al. 
(2011)46, Japan 
Cross-sectional Primary Care 
(N = 262) 
≥ 65 a. DC NS a. 7 (NS) 1. Fall tendency 
        
Li et al. 
(2016)82, UK 
Cross-sectional General 
Population 
(N = 27,806) 
16 
to 
68 
a. DC Conditions can range across different long-
term, illnesses, and health problems 
a. 13 (2) 1. HRQoL 
        
Md Yusof et al. 
(2010)43, UK 
Cohort General 
Population 
(N = 113) 
64 
to 
85 
a. CCI 
b. CMI 
c. Count of 
prescribed 
drugs 
NS a. 19 (NS) 
b. NS (NS) 
c. NS (NS) 
1. Mortality 
(7-years period) 
 
        
Muggah et al. 
(2012)44, 
Canada 
Cross-sectional General 
Population 
(N = 9,901,410) 
≥ 20 a. DC NS a. 9 (NS) 1. Ambulatory care use 
        
Mujica-Mota et 
al. (2015)3, UK 
Cross-sectional Primary Care 
(n = 831,537) 
≥ 18 a. DC NS a. 13 (2) 1. HRQoL 
        
Naessens et al. 
(2011)85, USA 
Cross-sectional General 
Population 
(N = 33,324) 
18 
to 
64 
a. DC Chronic diseases as identified in ICD-9 a. NS (NS) 1. Healthcare cost 
        
Østergaard and 
Foldager 
(2011)86, 
Denmark 
Cross-sectional Primary Care 
(n = 4,271) 
≥ 18 a. CGI-S 
b. DC 
NS a. 3 levels (NS) 
b. 9 (2) 
1. Presence of major 
depressive episode 
 (Continued on next page) 
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Table 3-4. Summary of included studies with poor and fair risk of bias judgement (20 studies including 21 articles) (Continued) 
 
Author (Year), 
Country 
 
Study Design  Population source (Sample 
size) Age 
Multimorbidity Measurement 
Outcomes measured Measure(s) used 
Definition of chronic disease included 
in the scale 
Number of conditions 
(MM cut-off) 
        
Peters et al. 
(2018)87, UK 
Cross-sectional Primary Care 
(N = 848) 
18 
to 
101 
a. DC NS a. 11 (NS) 1. QoL 
        
Renne and 
Gobbens 
(2018)89, The 
Netherlands 
Cross-sectional  Primary Care 
(N = 241) 
≥ 70 a. DC Chronic diseases selected were the 
most frequently present in the older 
Dutch population 
a. 9 (2) 1. QoL 
        
Sibley et al. 
(2014)92, 
Canada 
Cross-sectional General Population 
(N = 16,357) 
≥ 65 a. DC Conditions lasting for 6 months or 
more and diagnosed by a health 
professional 
a. 13 (2) 1. Self-reported falls in last 12 months 
        
Tyack et al. 
(2016)68, 
Australia 
Cohort Primary Care 
(N = 351) 
≥ 18 a. DC Chronic disease defined as requiring 
complex care management involving 
multiple providers and ideally 
coordinated care, and where they may 
be acute as well as chronic episodes 
a. 25 (NS) 1. HRQoL 
        
Vos et al. 
(2013)96, The 
Netherlands 
Cross-sectional Primary Care 
(Women only) 
(N = 315) 
70 
to 
74 
a. DC List of conditions developed under the 
auspices of Statistics Netherlands 
a. 21 (NS) 1. SRH 
 
Note. CCI = Charlson Comorbidity Index; CGI-S = Clinical Global Impression – Severity Scale; CIRS = Cumulative Illness Rating Scale; CMI = Cornell Medical Index; DC = Disease Count (Unweighted); EQ-5D-5L 
= EuroQoL 5 Dimensions 5 Levels; GP = General Practice; HRQoL = Health-related Quality of Life; ICD-9 = International Classification of Diseases, Ninth Revision; mCCI = modified Charlson Comorbidity Index; 
NS = Not Stated; QALY = Quality-adjusted Life Year; QoL = Quality of Life; SF-6D = Short-Form Six-Dimension. 
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Table 3-5. Description of instruments used for measurement of multimorbidity and the data sources and resources required 
 Category Instrument 
Instrument  
(Full Name) 
Description 
Data source(s) & 
resources required 
Number of 
studies 
using the 
instrument 
System or 
Condition 
based 
Items Weightage 
Scoring 
Method 
Score 
Range 
A COUNT OF INDIVIDUAL CONDITIONS 
A1 By Condition 
 1 DC Disease Count Condition 7 - 147 Unweighted Condition 
count 
0 to 147 EMR, GP records, Health 
service database, Hospital 
discharge abstract, 
Insurance claims or 
Questionnaires - 
telephone, face-to-face, 
mailed 
42 
A2 By Category 
 
2 CCC 
Chronic Condition 
Count 
Condition 6 categories Unweighted 
Based on 
AHRQ's 
clinical 
classification 
software and 
number of 
conditions for 
each category 
0 to 5 EMR 1 
B ORGAN OR SYSTEM-BASED APPROACHES 
 
3 CIRS 
Cumulative Illness 
Rating Scale 
System 
14 
categories 
0-4, based on 
clinical 
judgement 
Summative 0 to 56 
Structured questionnaire 
followed by encoding 
research assistants 
1 
 
4 CMI 
Cornell Medical 
Index 
System - 
Regarded 
only for 
historical 
purposes and 
for research 
since 2001. 
18 
categories 
195 yes-no 
questions 
collecting 
pertinent 
medical and 
psychiatric 
data 
Sum of 'yes' 0-195 
Self-reported 
questionnaire 
1 
 
5 
Organ - 
CDC 
Organ systems with 
chronic disease 
count 
Organ system 
17 organ 
systems 
Unweighted 
Sum of organ 
systems 
0 to 17  EMR 1 
118 
 
 
 
Table 3-5. Description of instruments used for measurement of multimorbidity and the data sources and resources required (Continued) 
 Category Instrument 
Instrument  
(Full Name) 
Description 
Data source(s) & 
resources 
required 
Number of 
studies 
using the 
instrument 
System or 
Condition 
based 
Items Weightage 
Scoring 
Method 
Score 
Range 
C WEIGHTED INDICES 
 
6 ACE-27 
Adult Comorbidity 
Evaluation 
Condition 27 conditions 
1-3, based on severity of 
most severe condition 
Highest score of 
single item 
0 to 3 
Insurance Claims' 
database 
1 
 
7 
CCI (Original 
and modified) 
Charlson 
Comorbidity Index 
Condition 
Original 17 
conditions.  
Modified - range 
from 9 conditions 
and 5 
psychosocial 
factors to 19 
conditions  
1-6; based on impact on 
1-year mortality (RR) - 
original 
Sum of 
weighted 
conditions 
0 to 37 
 
Administrative 
database (e.g., Billing, 
Insurance Claims), 
EMR (primary care or 
integrated with 
secondary care), 
Medical chart review, 
Interviews (patients, 
caregivers, nurse or 
physicians) or postal 
questionnaire. 
22 
 
8 CC-AM 
Chronic conditions 
additive modelling 
Condition 15 conditions 
Weighted based on SF-
6D   
By adding the 
health utility 
scores of the 
conditions 
Variable 
Questionnaire on 
health conditions 
1 
 
9 CC-MM 
Chronic conditions 
minimum modelling 
Condition 15 conditions 
Weighted based on SF-
6D   
By using the 
minimum single 
condition utility 
score 
Variable 
Questionnaire on 
health conditions 
1 
 
10 CC-MuM 
Chronic conditions 
multiplicative 
modelling 
Condition 15 conditions 
Weighted based on SF-
6D   
By multiplying 
the health utility 
scores of all the 
conditions 
Variable 
Questionnaire on 
health conditions 
1 
 
11 CLS 
Comorbidity Linked 
Score 
Condition 
98 combined 
codes of sub-
chapters in the 
Read code and the 
ICD10 code 
blocks 
Based on impact for 
mortality (hazard ratio) 
Sum of beta 
coefficients of 
each category 
1 to 10 
Linked patients' 
records of all primary 
care events, hospital 
admissions and causes 
of death. 
1 
 
12 EI 
Elixhauser Index 
(original and 
modified) 
Condition 
21 to 31 
conditions 
Based on impact on in-
hospital mortality 
Summing of 
beta coefficients 
-19 to 89 
Insurance Claims' or 
Medical services 
database 
3 
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Table 3-5. Description of instruments used for measurement of multimorbidity and the data sources and resources required (Continued) 
 Category Instrument 
Instrument 
(Full Name) 
Description 
Data source(s) & 
resources required 
Number of 
studies 
using the 
instrument 
System or 
Condition 
based 
Items Weightage 
Scoring 
Method 
Score 
Range 
C WEIGHTED INDICES (continued) 
 
13 ERA 
Elders Risk 
Assessment 
Condition 6 to 9 conditions 
Weighted, based 
on impact on 
future 
hospitalisation 
Sum of weighted 
regression 
coefficients 
Original: -1 
to 43. Some 
modified 
from -7 to 
43. 
EMR and administrative 
database 
4 
 
14 HCC 
Hierachical 
Condition Categories 
Condition 
70 condition 
categories 
Based on 
Medicare 
capitation 
payments for 
health 
expenditure 
The most severe 
manifestation of 
a given disease 
process 
principally 
defines 
its impact on 
costs. Therefore, 
more severe 
manifestations of 
a condition 
dominating (and 
zeroing out the 
effect of) less 
serious ones. 
Other diseases 
are summed 
additively. 
NS 
EMR & HCC software 
licensing 
1 
 
15 M3 Index 
Multi-Morbidity 
Measure Index 
Condition 55 conditions 
Weighted based 
on 1-year 
mortality 
Summing of beta 
coefficients 
0.01 to 2.47 Linked patients' records 1 
 
16 MDMS 
Multidimensional 
multimorbidity score  
Condition 
7 chronic 
conditions, 2 
health 
behaviours for 
1st dimension & 
5 symptoms for 
2nd dimension 
Weighted but 
not based on any 
specific outcome  
Sum of the value 
for the weighted 
absolute 
contributions of 
each of the 
dimensions. 
Men -  
9 to 100 
Women -  
7 to 100 
Standardised medical 
evaluation (Interviewer-
administered) 
1 
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Table 3-5. Description of instruments used for measurement of multimorbidity and the data sources and resources required (Continued) 
 Category Instrument 
Instrument  
(Full Name) 
Description 
Data source(s) & 
resources required 
Number of 
studies 
using the 
instrument 
System or 
Condition 
based 
Items Weightage 
Scoring 
Method 
Score 
Range 
C WEIGHTED INDICES (continued) 
 
17 MM by ADL 
Multimorbidity 
weighted by ADL 
Scale 
Condition 
19 
conditions 
Weighted based on 
OARS functional 
status scale 
measuring ADL 
Sum of 
weighted 
conditions 
0 to 1.8 
Face-to-face or 
telephone interviews 
1 
 
18 MM by HUI3 
Multimorbidity 
weighted by Health 
Utility Index 
Condition 
19 
conditions 
Weighted based on 
correlation with 
health utility index 
Sum of 
weighted 
conditions 
0 to 2.46 
Face-to-face or 
telephone interviews 
1 
 
19 
MM by HUI3 
betas 
Multimorbidity 
weighted by Health 
Utility Index betas 
Condition 
19 
conditions 
Weighted based on 
correlation with 
health utility index 
and adjusted for age 
and sex 
Summing 
of beta 
coefficients 
0 to 1.18 
Face-to-face or 
telephone interviews 
1 
 
20 MWI 
Multimorbidity-
Weighted Index 
Condition 
81 
conditions 
Weighted based on 
impact on SF-36 
physical functioning 
scale 
Sum of 
weights 
Variable 
Interviewer-
administered or mail 
questionnaire 
2 
 
21 QOF-E 
Extended QOF 
(weighted) 
Condition 
14 
conditions 
0-6, based on impact 
on 1-year mortality 
(RR) 
Sum of 
weighted 
conditions 
Not 
described 
EMR 1 
 
22 QOF-S 
Standard QOF 
(weighted) 
Condition 
9 
conditions 
1-3, based on impact 
on 1-year mortality 
(RR) 
Sum of 
weighted 
conditions 
0 to 17 EMR 1 
 
  
121 
 
 
 
 
Table 3-5. Description of instruments used for measurement of multimorbidity and the data sources and resources required (Continued) 
 Category Instrument 
Instrument 
(Full Name) 
Description 
Data source(s) & 
resources required 
Number of 
studies 
using the 
instrument 
System or 
Condition 
based 
Items Weightage 
Scoring 
Method 
Score 
Range 
D OTHER APPROACHES 
D1 Case-Mix 
 
23 ACG 
Adjusted Clinical 
Groups 
Condition 
93 mutually 
exclusive 
ACGs. Some 
are modified to 
68 ACGs 
Incorporated into 
ACGs based on 
impact on resource 
use (proprietary) 
Variable N/A 
EMR & ACG software 
licensing 
3 
 
24 ADG 
Aggregated 
Diagnostic Groups 
Condition 32 groups 
Based on duration, 
severity, diagnostic 
certainty, aetiology, 
and need for 
specialty care 
Variable NS 
EMR & ACG software 
licensing 
1 
 
25 HM 
Hybrid Model (MN 
Tier + ERA) 
Condition NS 
Only MN tier 4 + 
MN tier 3 with 
ERA > 10 
Variable NS 
EMR, HCC software 
licensing & administrative 
data 
1 
 
26 HSMI 
Health Search 
Morbidity Index 
Condition 
73 chronic and 
acute conditions 
Based upon yearly 
health care costs 
directly derived 
from primary care 
setting 
Sum of 
regression 
coefficients 
(range 
from -0.06 
to 1.04) 
Variable EMR 1 
 
27 MN Tier Minnesota Tiering Condition NS 
Grouping patients 
into 'complexity 
tiers' based on the 
number of major 
condition categories 
Condition 
count 
Tier  
0 to 4 
EMR or administrative 
data & MN Tiering 
software licensing 
2 
 
28 RUB 
Resource 
Utilisation Band 
Condition 
6 mutually 
exclusive bands 
Based upon ACG 
algorithm on impact 
on resource use 
(proprietary) 
Variable N/A 
EMR & ACG software 
licensing 
3 
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Table 3-5. Description of instruments used for measurement of multimorbidity and the data sources and resources required (Continued) 
 Category Instrument 
Instrument 
(Full Name) 
Description Data 
source(s) & 
resources 
required 
Number of 
studies 
using the 
instrument 
System or 
Condition 
based 
Items Weightage Scoring Method 
Score 
Range 
D OTHER APPROACHES (Continued) 
D2 Pharmaceutical-based 
 
29 CDS 
Chronic Disease 
Score 
Condition 17 conditions Weighted 1-5  
Sum of weights 
based on 
pharmacological 
database 
0 to 35 
Prescription 
drug database 
1 
 
30 Drug Count Drug Count NA 
Variable.  
Some may be 
based on 
pharmacologi
c-therapeutic 
classification 
system 
Weighted Medication count Variable 
Self-reported 
questionnaire 
4 
 
31 Modified Pra 
Modified Pra tool 
using RxRisk-V 
NA 
Pra tool + 
RxRisk-V 
Weighted due 
to RxRisk-V 
4 categories 0 to 1 
GP medical 
record + linked 
pharmacy 
claims database 
1 
 
32 RxRisk-V RxRisk-V NA 
WHO-ATC 
classification 
system 
Weighted 
according to 
the diagnostic 
group of drugs 
to predict 
future health 
care costs 
Sum of weights NA 
GP medical 
record + linked 
pharmacy 
claims database 
1 
D3 Clinical Judgement 
 
33 CGI-S 
Clinical Global 
Impression - 
Severity Scale 
NA NA 
1-6; based on 
clinical 
judgement of 
GP 
Rating of severity 
was only carried out 
for physical illness 
in general and not 
for each individual 
disease 
1 to 6 
GP 
Questionnaire 
1 
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3.3  Description of all the instruments used 
 
Table 3-6 summarised all the 27 instruments that were identified from the studies with low risk 
of bias. 
 
3.3.1 Count of Individual Conditions 
 
Disease count was based on the unweighted count of all the conditions an individual had 
usually from a pre-specified number of chronic conditions.  It was used in 42 out of the 67 
studies (62.7%).  Disease counts were positively associated with activity limitations, continuity 
of care, disability, healthcare cost, healthcare utilisation, medications, mental disorders, and 
mortality; and negatively associated with general health, physical function, quality of life, and 
self-rated health.  The only outcome that was not associated with disease count was preventive 
care66 (Table 3-6). 
 
The data sources and resources used ranged from medical records (manual to electronic) or 
administrative records like billing reports to insurance reports, self-administered questionnaires 
by using mail, or telephone to interviewer-administered questionnaires.  As such, information 
collected could be from participants’ recall or medical records (Table 3-5). 
 
Under the category of count of individual conditions, Chronic Condition Count56 (CCC) was a 
unique instrument.   The difference between disease count and CCC was that although the 
number of conditions was counted for CCC, they were further divided into six categories based 
on a clinical classification software developed by the United States government agency. The 
score ranged from zero to five.  Only one study used this instrument, and the investigators 
retrieved all the information from the electronic medical records. 
 
3.3.2 Organ or system-based approaches 
 
There were three instruments in this category.  They were Cumulative Illness Rating Scale 
(CIRS)29,30, Cornell Medical Index (CMI)43, and Organ Systems with chronic disease count 
(Organ-CDC)73 represented by one study each. 
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The CIRS is a system-based instrument divided into 14 categories100.  Weightage is applied to 
each category with a scoring of zero to four based on clinical judgement.  The score ranges 
from 0-56 and requires the summation of individual scores from each category. 
 
Cornell Medical Index was created in 1949 and has been declared by the Cornell Medical 
Centre to be no longer of clinical use since 2001.  It was a self-reported questionnaire.  
(https://library.weill.cornell.edu/archives/about-us/cornell-medical-index) 
 
The Organ-CDC has 17 organ systems summed to form a score range of zero to seventeen.  
Data were collected from electronic medical records.  The instrument was found to be 
associated with the presence of depressive or anxiety disorder73. 
 
The two studies that used the instruments CIRS and Cornell Medical Index were not rated 
‘good’ after the risk of bias assessment, and therefore the outcomes being examined in these 
two studies were not reported in our summary Table 3-6.  The outcomes examined for these 
two instruments were disability29,30, frailty29,30, functional decline29,30, and mortality30,43. 
 
3.3.3 Weighted Indices 
 
There were seventeen unique weighted instruments found in the included studies.  The original 
Charlson Comorbidity Index (CCI) with its different modifications was the most frequently 
used instrument and was found in 22 studies.  Trailing behind were four studies using the Elder 
Risk Assessment (ERA), three studies using Elixhauser Index (EI), and two studies using 
Multimorbidity-Weighted Index (MWI).  The other 13 studies had a unique weighted index 
each.  Some of these indices were used in prediction models. 
  
The CCI was based on disease count, but the 17 conditions were weighted originally based on 
its impact on one-year mortality101.  The final score was derived by the summation of all the 
weighted conditions.  The score ranges from 0-37.  There were many variations and 
modifications of the score including the addition of psychosocial factors.  The data sources and 
resources used ranged from medical records (manual to electronic), or administrative records 
like billing reports or insurance reports, to self-administered questionnaires by using mail, 
telephone, or interviewer-administered.  As such, information collected could be from 
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participants’ recall or from medical records.  The instrument was found to be associated with 
multiple outcomes other than one-year mortality (Table 3-6). 
 
The ERA was based on disease count, but the conditions were weighted based on the impact 
on future hospitalisation52.  The instrument had six to nine conditions, and the final score was 
derived from the sum of the weighted regression coefficients.  The data sources were obtained 
from electronic medical records or administrative data.  The instrument was found to be 
associated with critical illness49, healthcare expenditure56, mortality47, and  readmission56. 
 
The EI was developed from large administrative inpatient datasets102.  It was based on disease 
count with conditions ranging from 21 to 31 due to its many variations.  The conditions were 
weighted based on hospital mortality.  The final score was also from the sum of the weighted 
regression coefficients.  Like the above two indices, association with outcomes other than 
hospital mortality were found. 
 
The MWI was a newer instrument that had 81 conditions weighted based on the impact on 
physical functioning97.  The final score was from the sum of the weights.  The investigators 
used an interviewer-administered or mailed questionnaire.  The instrument was also associated 
with cognitive performance97, grip strength97 , and mortality69.  There was no association found 
between MWI and gait speed97. 
 
Most of the other instruments were novel like MWI where the investigators built multivariable 
prognostic models from a set of potential predictor conditions (including non-clinical factors) 
and weighted the conditions based on an outcome of clinical interest.  The most common 
outcomes chosen were mortality and physical function.  Others included health expenditure56, 
health utility index99, and severity of the most severe condition57.  However, Multidimensional 
multimorbidity score (MDMS)94 was unique in that it was weighted but not based on any 
specific outcome. 
 
Ubalde-Lopez et al.94 used statistical methods to develop MDMS based on seven chronic 
conditions and two health behaviours.  The conditions were weighted but were not based on 
any specific outcome.  The instrument required a standardised medical evaluation.  The 
investigators reported that MDMS was found to be positively associated with sickness absence 
for males, but no association was found for females. 
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3.3.4 Other Approaches 
 
Other approaches included case-mix, pharmaceutical-based, and using clinical judgement for 
measuring the level of multimorbidity. 
   
For case-mix, Adjusted Clinical Groups (ACG) and Resource Utilisation Band (RUB) were 
the most commonly used.  Most of the case-mix instruments required proprietary software 
licenses from the United States of America.  Large data sets from electronic medical records 
or administrative data were also needed (Table 3-5). 
 
The second group in this category was related to pharmaceutical data.  The most frequent type 
was the unweighted drug count.  The other three (Chronic disease score, Modified Pra tool 
using RxRisk-V, and RxRisk-V) were all weighted indices.  Except for the drug count that was 
based on a self-report questionnaire, the rest required a prescription drug database to obtain the 
data. 
 
Clinical global impression - severity score (CGI-S) was an exceptional instrument that was not 
based on any of the above but solely based on clinical judgement of the attending physician.  
The study looked at the outcome of the presence of major depressive episode86. 
 
3.3.5 Prediction Models 
 
Twenty studies (with 23 articles) used different multimorbidity instruments together with non-
clinical predictors like social deprivation, age, sex, marital status into a multivariable regression 
analysis to predict outcomes including emergency department visits, health-related quality of 
life, hospitalisations, mortality, number of primary care consultations, primary healthcare cost, 
readmission (Appendix 3-4). 
 
The c-statistic (concordance index), area under the receiver operating curve (AUC), and the 
square of the correlation between the observed outcome and the predicted risk (R2) are the 
general statistics tests to summarise the discrimination between individuals with and without 
the outcome event in the regression model103.  Of the 20 studies (23 articles), ten articles used 
c-statistic, five articles used AUC, and four articles used R2.  Additionally, two articles used 
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Akaike information criterion (AIC) and another two used Bayesian information criterion (BIC) 
for model selection. 
 
The predictive ability of the instruments varied widely.  Performances varied according to the 
specific instrument used and the outcome measured.  The c-statistic†††† ranged from 0.55 to 
0.931. In general, models that compared different outcomes consistently showed better c-
statistic when the model was used to predict mortality33,34,62,65.  Similar variability was noted 
with AUC‡‡‡‡ that ranged from 0.640 to 0.923, and R2 §§§§ that ranged from 0.11 to 0.793.   
 
3.4 Instruments used for measuring the three core outcomes in 
intervention studies    
 
Table 3-7 identified the instruments that were used to explore the association with the three 
essential core outcomes selected for the core outcomes set of multimorbidity research 
(COSmm)6.   Three categories of instruments were used for measuring mortality. The three 
categories were counts of individual conditions (DC), weighted indices (CCI, CLS, EI, ERA, 
M3 Index, MWI, QoF-E & QoF-S), and other approaches including case-mix (ACG & RUB) 
and pharmaceutical-based approaches (CDS & Drug Count).  For mental health as an outcome, 
only two categories of multimorbidity measures were identified.  They were counts of 
individual conditions (DC), and organ or systems-based approaches (Organ-CDC).  Finally, 
for the quality of life, only counts of individual conditions (DC) was identified.  Disease count 
was the only instrument identified for all three outcomes. 
 
                                                 
†††† Concordance index (c-statistic): 0.50-0.69 (poor), 0.70-0.79 (good), >0.80 (excellent) 
‡‡‡‡ There are no recommended cut-offs for Area Under the receiver operating Curve (AUC) 
§§§§ There are no recommended cut-offs for observed outcome and the predicted risk (R2) 
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Table 3-6. Summary of multimorbidity instruments and their associations with outcomes measured 
Multimorbidity Measures 
Association between Outcomes and Multimorbidity 
Positive Association Negative Association No Association 
Count of Individual Conditions 
By Condition 
Disease Count 
(Many different groupings ranging from 7 45-47 to 147 10 
conditions and some are further categorised 56) 
 
 
 
 
 
 
 
 
 
Activities of Daily Living (ADL) limitations 27 
Activity limitations 72 
Continuity of care (3-years) 11 
Deficits of perceived general health 90 
Depressive symptoms 90 
Disability 74,83,84 
Emergency hospital admission (2-years) 40 
Frequency of contacts with physicians (1-year) 48 
Functional decline (2-years) 40 
Healthcare costs 57,57 
Hospital admissions (1-year) 37 38 62 
Hospital outpatient visits (1-year) 67 
Hospitalisation/Emergency Department Visits 67 
Mental distress 72 
Mortality (1-year) 62, (3-years) 32, (10-years) 69 
Number of contacts with general practice (1-year) 95 
Number of medications prescribed (1-year) 95 
Number of mentally unhealthy days 27,28 
Number of physically unhealthy days 27,28 
Number of different ambulatory physicians contacted (1-year) 48 
Number of primary care consultations (1-year) 32, (3-years) 32 
Number of referrals (1-year) 95 
Physical distress 72 
Presence of mental health disorder 10 
Primary care consultations (1-year period) 11, (3-years) 11 
Primary healthcare cost 31 
Potentially preventable unplanned admission (1-year period) 38 
Affective well-being 98 
Future physical functioning 69 
General health 72 
Life satisfaction 99 
Perceived health status 99 
Self-rated Health 45,84 
Quality of cardiovascular preventive care 66 
Quality of preventive care 66 
 
By Category 
Chronic Condition Count Healthcare costs 56 
Hospital admissions (1-year) 56 
Number of emergency department visits (1-year) 56 
Readmission within 30 days (1-year) 56 
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Table 3-6. Summary of multimorbidity instruments and their associations with outcomes measure (Continued) 
Multimorbidity Measures 
Association between Outcomes and Multimorbidity 
Positive Association Negative Association No Association 
Organ or system-based approaches 
Organ systems with chronic disease Presence of depressive or anxiety disorder 73 - - 
Weighted Indices 
Adult Comorbidity Evaluation-27 (ACE-27) Healthcare expenditure 57 - - 
Charlson Comorbidity Index (CCI) Ambulatory care sensitive hospitalisations (acute & 
chronic) 64 
Emergency department visits (1-year) 56 
Emergency hospital admission (2-years) 40 
Functional decline (2-years) 40 
Healthcare expenditure 56 
Hip fractures 63 
Hospitalisation (1-year) 56,61,62,65,91 
Mortality (1-year) 50,55,62,65, (5-years) 51,55, (10-years) 51,55,  
(15, 20, 25-years) 51 
Number of primary care consultations (3-years) 32 
Number of primary care physician visits (1-year) 91 
Number of specialist visits (1-year) 91 
Potentially preventable unplanned admission (1-year) 37 
Presence of critical illness 49 
Primary healthcare cost 31 
Mortality (1-year) 33,34, (3-years) 32,53, (5-years) 34,54,35, 
(10-years) 69 
Readmission within 30 days (1-year) 56 
Future physical functioning 69 
Successful aging 36 
 
Quality of cardiovascular preventive care 66 
Quality of preventive care 66 
 
Comorbidity Linked Score Mortality (1-year) 33 - - 
Elders Risk Assessment (ERA) Healthcare expenditure 56 
Mortality (2-years) 47 
Number of days hospitalised (1-year) 52 
Number of emergency department visits (1-year) 52,56 
Number of hospital admissions (1-year) 52,56 
Number of hospital visits (1-year) 52 
Nursing home placement (2-years) 47 
Presence of critical illness 49 
Readmission within 30 days (1-year) 56 
- - 
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Table 3-6. Summary of multimorbidity instruments and their associations with outcomes measure (Continued) 
Multimorbidity Measures 
Association between Outcomes and Multimorbidity 
Positive Association Negative Association No Association 
Weighted Indices (Continued) 
Elixhauser Index (Original and Modified) Hospitalisation (1-year) 62,65 
Mortality (1-year) 33,62,65 
- - 
Hierachical Condition Categories (HCC) Hospitalisation (1-year) 56 
ED visits (1-year) 56 
Readmission within 30 days (1-year) 56 
Healthcare expenditure (1-year) 56 
- - 
Multi-Morbidity Measure (M3) Index Hospitalisation (1-year) 65 
Mortality (1-year) 65 
  
Multidimensional Multimorbidity Score (MDMS) Sickness absence episodes taken in 2 years (male) 94 - Sickness absence episodes taken in 2 years (female) 94 
Multimorbidity weighted by Activities of Daily Living 
(ADL) Scale  
- Life satisfaction 99 
Perceived health status 99 
- 
Multimorbidity weighted by Health Utility Index 
(HUI3) 
- Life satisfaction 99 
Perceived health status 99 
- 
Multimorbidity weighted by Health Utility Index 
(HUI3) betas  
- Life satisfaction 99 
Perceived health status 99 
- 
Multimorbidity-Weighted Index (MWI) ADL limitations 97 
IADL limitations 97 
Mortality (10-years) 69 
Cognitive performance 97 
Future physical functioning 69 
Grip strength 97 
Subjective physical functioning 97 
Gait speed 97 
Quality and Outcomes Framework (QOF) 
(Standard) 
Mortality (1-year) 50 - - 
Quality and Outcomes Framework (QOF) 
(Extended) 
Mortality (1-year) 50   
Other Approaches 
Case-Mix 
Adjusted Clinical Groups (ACG) Hospitalisation (1-year) 61 
Mortality (3-years) 32 
Number of primary care consultations (3-years) 32 
Primary healthcare cost 31 
Readmission within 30 days (1-year) 56 
- - 
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Table 3-6. Summary of multimorbidity instruments and their associations with outcomes measure (Continued) 
Multimorbidity Measures 
Association between Outcomes and Multimorbidity 
Positive Association Negative Association No Association 
Other Approaches (Continued) 
Case-Mix (Continued) 
Aggregated Diagnostic Groups (ADG) Hospitalisation (1-year) 91 
Number of primary care physician visits (1-year) 91 
Number of specialist visits (1-year) 91 
- - 
Hybrid Model (Minnesota Tiering + ERA) Emergency department visits (1-year) 56 
Healthcare expenditure 56 
Hospitalisation (1-year) 56 
Readmission within 30 days (1-year) 56 
- - 
Health Search Morbidity Index (HSMI) Healthcare cost (primary care) 80 - - 
Minnesota Tiering (MN Tier) Emergency department visits (1-year) 56,67 
Healthcare expenditure 56 
Hospitalisation (1-year) 56,67 
Readmission within 30 days (1-year) 56 
- - 
Resource Utilisation Band (RUB) Fee-for-service expenditures 79 
Primary healthcare cost 31 
Mortality (3-years) 32 
Number of primary care consultations (3-years) 32 
Registered active listing in primary care 88 
Registered active listing in all healthcare 88 
- - 
Pharmaceutical-based    
Chronic Disease Score (CDS) Hospitalisation (1-year) 62 
Mortality (1-year) 62 
  
Prescribed drug count Emergency hospital admission (2-years) 40 
Functional decline (2-years) 40 
Hospitalisation (1-year) 62 
Mortality (1-year) 62, (3-years) 32 
Number of primary care consultations (3-years) 32 
- - 
Pra Tool Modified Emergency hospital admission (1-year) 39 - - 
RxRisk-V Emergency hospital admission (2-years) 40 
Functional decline (2-years) 40 
- - 
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Table 3-7. Summary of the three essential core outcomes* of multimorbidity and their 
corresponding instruments 
Outcomes Corresponding multimorbidity measures 
 
Mortality 
 
Counts of Individual Conditions 
Disease count 32,62,69 
 
Weighted Indices 
Charlson Comorbidity Index 32 50 51,33-35 53-55,62,65,69 
Co-morbidity linked score 33 
Elderly Risk Assessment 47 
Elixhauser Index (original and modified) 33,62,65 
Multi-Morbidity Measure (M3) Index 65 
Multimorbidity Weighted Index (MWI) 69 
Quality and Outcomes Framework (Standard and Extended) 50 
 
Other approaches 
Case-Mix 
      Adjusted Clinical Groups 32 
      Resource Utilisation Band 32 
       Pharmaceutical-based 
      Chronic Disease Score 62 
      Drug Count 32,62       
 
Mental Health 
 
 
Counts of Individual Conditions 
Disease count 72,90 
 
Organ or system-based approaches 
Organ systems with chronic disease 73 
 
 
Quality of Life 
 
Counts of Individual Conditions 
Disease count 27,28,70,74,81,84,98 
 
* The outcomes were based on the Core Outcome Set for Multimorbidity Research (COSmm) by Smith et al.6   
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4 Discussion 
 
4.1 Summary of findings 
 
Thirty-three unique instruments for measuring the level of multimorbidity were identified from 
all the included studies using the classification by Sarfati41.  The most commonly used 
instrument in the count of individual conditions category was ‘Disease Count’.  In the organ or 
system-based approaches category, three instruments were found but they were not commonly 
used.   The weighted indices category had the most variety of different instruments (up to 17), 
and within this category, Charlson Comorbidity index (with its different variations) was the 
most commonly used.  Finally, for the ‘other approaches’ category, case-mix and 
pharmaceutical-based instruments were also commonly used.  The full list and description of 
the instruments are provided in Table 3-5. 
 
Disease count is the only instrument that was associated with all three essential core outcomes 
identified for COSmm, i.e., quality of life, mental health, and mortality (Table 3-7).  In 
summary, all the study findings showed the association between the explanatory variables and 
outcomes were in the same direction and did not conflict with each other (Table 3-6).  The 
outcomes not found to have any association with the instruments for measuring the level of 
multimorbidity were preventive care66, sickness absence episodes (female)94, and gait speed97. 
 
4.2 Comparison with previous research 
 
We identified five other review articles describing the instruments for measuring the level of 
multimorbidity in the literature:  Huntley et al.16, Sharabiani et al.104, Yurkovich et al.105, 
Diederichs et al.106, and de Groot et al.13   Huntley et al.16 was mentioned in the introduction as 
the review that this study was updating.  It was also the only study that targeted participants 
from the primary care or general population.  Sharabiani et al.104 (2012) and Yurkovich et al.105 
(2015) were reviews of multimorbidity instruments using administrative data, Diederichs et 
al.106 (2011) was a review that looked specifically at weighted indices for measuring the level 
of multimorbidity, and de Groot et al.13 (2003) was the oldest study that looked at all 
instruments using all kinds of data. 
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Huntley et al.16, consistent with this systematic review, listed the most frequently used 
instruments for measuring the level of multimorbidity while the other four reviews13,104-106 
recommended the most suitable instruments.  We found the most common instruments used 
for measuring the level of multimorbidity in primary care similar to the systematic review done 
by Huntley et al.  However, several of the instruments including Duke Severity of Illness 
Checklist (DUSOI) and Functional Comorbidity Index (FCI) identified in their paper were not 
found in this systematic review.   
 
The original DUSOI has been adapted and renamed the Duke and World Organisation of 
Family Doctors Severity of Illness Checklist (DUSOI/WONCA) in 2011107.  However, a quick 
search for use of the instrument in PubMed***** showed the last publication using the 
instrument was in 2004108.  An article on FCI in chronic rhinosinusitis was published in 2016109, 
and another study showed that FCI had higher inter-rater reliability in patients with acute lung 
injury in 2012110.  The reasons for not identifying these instruments in this review may be 
because of the lack of interest on the instrument by the research community for DUSOI in the 
recent years, or that the search strategy in the review excluded studies that have an index 
condition or were not from the primary care or general population like the FCI. 
 
Under the ‘count of individual conditions’ category, disease count was found to be one of the 
most frequently used instruments in this review and Huntley et al.’s16.  For this review, there 
were multiple and variable outcomes associated with this measure.  These outcomes included 
disability, healthcare costs, hospitalisation, mental health, mortality, quality of life, and self-
rated health. 
 
Under the ‘organ or system-based approaches’ category, the Cumulative Illness Rating Scale 
was the only instrument recommended by one review13.  The outcomes were, activities of daily 
living (ADL), instrumental ADL, and medication usage.  However, the predictive validities 
were only small to fair for positive correlation. 
 
For the category on ‘weighted indices’, three instruments were highlighted by the six reviews 
(including this review): Charlson Comorbidity Index (CCI), Elixhauser Index (EI), and Elders 
Risk Assessment (ERA).  CCI was recommended by two of the reviews.  Multiple outcomes 
                                                 
***** The free search engine provided by the United States National Library of Medicine at the National Institutes of Health. 
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were found to be associated with CCI, but mortality and hospitalisation were the main ones.  
The EI was recommended by two of the reviews.  Sharabiani et al.104 recommended that EI 
was the best predictor for long-term mortality.  Yurkovich et al.105 recommended using the 
Quan and van Walraven versions of the EI, or the Romani version of CCI for measuring 
mortality.  The ERA was not found by any of the other reviews but was one of the common 
instruments found in this systematic review.  The outcomes predicted were hospitalisation and 
mortality.  Diederichs et al.106 looked exclusively at the development of weighted 
multimorbidity indices in the general population but did not make any particular 
recommendation as the authors pointed out the heterogeneity of existing indices and the need 
for a new, established instrument to assess multimorbidity.  
 
Under the ‘other approaches’ category, RxRisk-V was recommended by Yurkovich et al.105 for 
evaluating health care utilisation, in which medication data were available.  Adjusted Clinical 
Group (ACG) was a frequently used instrument for various outcomes including healthcare 
resources, health care costs, health care utilisation, hospitalisation, and mortality found in this 
study and by Huntley et al.16 
 
4.3 Advantages and disadvantages of selected instruments 
 
4.3.1 Disease count 
 
Summing the number of conditions from among a list of candidate chronic conditions provides 
an ordinal score111.  This method has the advantage of simplicity and ease of data ascertainment 
with minimal resources required.  Despite its simplicity, the disease count was not only 
associated with the three essential core outcomes (quality of life, mental health, and mortality) 
but also six others outcomes (activities of daily living, costs, health care use, physical activity, 
physical function, and self-rated health) suggested by the Core Outcome Set for Multimorbidity 
Research (COSmm) by Smith et al.6 
 
However, using disease count to measure the level of multimorbidity does not appear 
appropriate conceptually.   For example, the same category - ‘secondary malignancies’ includes 
diagnoses that have a nearly nine-fold difference in mortality, and grouping all ‘secondary 
malignancies’ into one category oversimplifies the differences within this category seen in the 
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Elixhauser Index102.  Moreover, analytic strategies often incorrectly force a linear relationship 
with the ordinal scale, ignoring the fact that an additional unit of increase in ‘disease count’ 
will most likely have a diminishing impact.  Finally, a summed measure also ignores potentially 
important relationships between diseases that might differ from their simple sum111. 
 
The other disadvantage noted in this systematic review is that many investigators using disease 
counts as an instrument did not state clearly on what basis certain chronic conditions were 
included or excluded, the total number of conditions in the multimorbidity list, and the cut-
points used to define multimorbidity.    This lack of information makes the comparison with 
other studies difficult, and also impossible to replicate or confirm previous findings. 
 
4.3.2 Weighted Indices 
 
Calculation of weights was usually based on three methods.  The first method was by directly 
getting self-reported information from patients, for example, directly asking patients whether 
a particular condition interfered with their daily activities on a Likert scale.  The second method 
was by deriving weights from the literature according to the individual impact of diseases on 
different outcomes.  This was the commonest method and utilised in prognostic models to build 
complex multivariable regression models whereby the weights were calculated from hazard 
ratios, odds ratios, or regression coefficients112.  A third method was to apply weights by 
defining specific criteria, based on clinical parameters such as fasting glucose for a physiologic 
index of comorbidity113 or cholesterol level for Chronic Disease Score (CDS)114.  In the next 
chapter of this thesis, the Chronic Disease Control Score (CDCS) used the third method as an 
independent variable for measuring the level of multimorbidity. 
 
The common weighted indices identified in this systematic review were Charlson Comorbidity 
Index, Elders Risk Assessment, Elixhauser Index and Multimorbidity-weighted Index.  All of 
them belonged to the second method of weighting diseases.  The other 13 weighted indices 
identified in this systematic review were novel and were also developed using this second 
method.  These instruments have been found by other included studies in this systematic review 
to be associated with four outcomes from the Core Outcome Set for Multimorbidity Research 
(COSmm) suggested by Smith et al.6  These outcomes included activities of daily living, costs, 
health care use, physical function. 
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The advantage of these weighted indices is that the weights allow the adaptation of an index to 
a specific outcome.  An investigator could recalibrate the correct weight by creating a 
prognostic model to produce a contextualised instrument for a different setting.  Prognostic 
models can provide clinically relevant risk stratification and help to allocate resources115. 
  
One disadvantage of such indices is the number of resources required to develop a new 
instrument.  Even adopting well-established indices would still require validation studies 
meaningful to the local context.  This is made more difficult as there is also a lack of transparent 
reporting of multivariable prediction models for individual prognosis or diagnosis 
(TRIPOD)103.  Moreover, calculated weights are greatly influenced by the population, 
outcomes used, and the instrument’s original conception and purpose.  Therefore, addressing 
different outcomes may necessitate using different instruments. 
 
4.3.3 Case-Mix 
 
The ease of obtaining and using the data needed to characterise multimorbidity make the ACG 
system a preferred method for analyses in different domains and suitable for comparison across 
areas within and between countries116.  The advantage of the instrument is its good track record 
in the United States and several other countries.  However, the instrument is proprietary, and 
the exact algorithm of the instrument is not open to the public and may not be suitable in certain 
nuance settings.  Another disadvantage is the financial costs involved in obtaining the license. 
 
4.3.4 Pharmaceutical-based instruments 
 
Medication-based indices include versions of the Chronic Disease Score114, which later became 
known as the RxRisk117, and its adaptation for use in the veteran population, the RxRisk-V118.  
The advantage of using these instruments is when prescription datasets are easily obtainable. 
 
Drug count is one of the common instruments reported in this systematic review.  Like disease 
count, the main advantage is its ease of use with minimal resources required.  In this systematic 
review, it was found to be associated with health care use and physical function.  However, it 
was also not clearly described in many studies regarding which type of drugs were counted and 
which were not. 
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4.4  Data sources 
 
Data sources for using these various instruments rely on medical record information, patient 
self-report, clinical judgment, or large administrative databases.  Regardless of the data source, 
errors can be introduced.  For patient self-report, patients with cognitive impairment may 
under-report symptoms and may be seen less frequently by their physicians, resulting in an 
under-recognition or under-treatment of conditions111.  Administrative data may not truly 
reflect the exact list of chronic conditions of patients as that is not the primary purpose of 
collecting the data.  It has been shown that health administrative data based on billing system 
underestimated the prevalence of many chronic conditions119.  
  
Some of these instruments mentioned have been developed exclusively for use with 
administrative data such as Elixhauser Index102, whereas others have been developed in other 
contexts but adapted for use with administrative data such as the Charlson Comorbidity 
Index101. Many weighted indices require medical records or administrative data which may not 
be readily available.  It is time-consuming to engage research team members in the examination 
of individual clinical notes.   
 
The available data in a particular setting may strongly influence the ultimate instrument chosen 
for multimorbidity research.  As there is currently no consensus on the gold standard for 
sources of data, it is difficult to assess which data source performs the best.  The next chapter 
of this thesis will explore the agreement between self-reported data and the electronic medical 
records. 
 
4.5  Clinical Implications 
 
Seventeen multimorbidity outcomes were identified by a Delphi panel of international experts 
of multimorbidity intervention studies6.  However, only ten out of the seventeen outcomes were 
reported in the 67 studies identified in this systematic review.  None of the other seven outcome 
measures (adherence, communications, prioritisation, self-management behaviour, self-
efficacy, shared decision-making, and treatment burden) was explored in any of the 67 studies 
included in this systematic review.  Most of these outcomes were patient-centred outcomes.  
The outcome that was investigated the most was health care utilisation.  In the search strategy 
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for this systematic review, there was no restriction on the type of studies to be included or not.  
However, we only found observation studies (cohort and cross-sectional) and did not find any 
interventional studies.  This could be the reason why the other seven outcome measures were 
not reported, but it is also reflective of the lack of interventional studies on multimorbidity in 
primary care and the general population generally. There is still much to do to improve on the 
body of knowledge of multimorbidity when most investigators in the last ten years measured 
multimorbidity without including some of the important outcome measures of multimorbidity. 
 
Ideally, a single instrument for measuring the level of multimorbidity should be able to predict 
a variety of relevant outcomes, but Byles et al.15 reported that a single index could not predict 
a variety of outcomes, in different patient groups and settings.  The investigators suggested that 
prediction of multiple outcomes within one study may not necessitate more than one instrument 
if the same instrument could still be utilised by using different weights for the same items in 
calculating the scoring systems.  Such multiple-scoring instruments may be the way forward 
for validation of prognostic models for different outcomes and different populations with 
established multimorbidity instruments.  The choice of conditions included in such an 
instrument should include those with a high prevalence in the population being served and with 
a severe impact on affected people.   The definition of high prevalence and severe impact would 
have to be defined by each health care setting or geography.  However, for pragmatic reasons, 
the final selection of the conditions to be included in such a multiple-scoring instrument may 
have to take into account the availability of relevant and reliable data. 
 
Interestingly, in a systematic review of studies on hospitalisation risk prediction models, more 
than half of the studies did not include multimorbidity in the modelling120.  However, the 
authors noted that the studies with the best-performing models were those that considered 
multimorbidity.  It was observed that well-performing prediction models were distinguished 
by taking into account multi-dimensional scales instead of multimorbidity scores alone121.  
Therefore, in building the predictor variables for the model, relevant clinical and non-clinical 
profiles should be considered on top of a level of multimorbidity measurement instrument.  
 
Multimorbidity is a complex phenomenon, and the current definition maybe overly simplistic 
and not able to ideally capture the complexity of multimorbidity.  The complex interactions of 
several co-occurring chronic conditions often include the additional consideration of social, 
psychological, and emotional factors.  Social networks and support, coping strategies, 
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individual preferences, and living conditions would have to be considered in the assessment of 
multimorbidity122. 
 
In conclusion, a certain degree of reductionism will have to be accepted because a 
multimorbidity measurement instrument will not be able to encompass all the nuances of the 
different interactions of chronic conditions on an individual living in his/her unique milieu.  
Moreover, most of the studies in this systematic review were from Europe and North America 
with very few Asian studies.  Applying the findings to the local setting of Singapore should not 
be taken wholesale.  The current instruments should not be the only tool for investigators and 
clinicians to assess all the dimensions of multimorbidity. Ultimately, the most suitable 
instrument will depend on the specified outcome of interest, the study population, and the type 
of data and resources available.  
 
4.6  Strengths and limitations of the study 
 
One of the main strengths of this systematic review was that we involved a health science 
librarian at the start of the review and had several rounds of iterations and cross-checks before 
finalising the search strategy.   
 
We also published our protocol before embarking on the review and adhere to what we 
proposed to report without changes during the systematic review process123.  We followed the 
PRISMA statement20 for systematic review of observational studies and guidance on the 
conduct of narrative synthesis in systematic reviews21 for the reporting of this systematic 
review.  
 
The systematic review had several limitations.   Grey literature was not included in this review, 
which may have introduced study selection bias124.  However, we excluded grey literature 
based on evidence suggesting that the quality of research in the grey literature is lower and 
more difficult to appraise compared with research in journal articles124.  We excluded abstracts, 
as abstracts with positive findings tend to be accepted for presentation at conferences more 
frequently than those with negative or null findings124.  Another limitation was that we only 
included articles that were published in the English language. 
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Although our search strategy was comprehensive, it was far from complete. The use of 
electronic databases has been found to retrieve only half of all relevant studies125. We did not 
contact authors directly for a suggestion of studies.  We also did not identify a list of 
instruments from the preliminary search and then perform an additional search using the same 
databases as suggested by Yurkovich et al.105  However, given the consistency of our results, 
it is unlikely that missed studies would significantly alter the main findings of our review. 
 
As there was a lack of consensus for qualitative assessment tool for observational studies126, 
we chose Newcastle Ottawa Scale (NOS) and then modified it with careful consideration after 
testing two other risk of assessment tools.  The modified NOS may not be a perfectly reliable 
tool for risk of assessment, but the Cochrane Collaboration has recommended it for assessing 
nonrandomised studies127.  
 
4.7  Conclusion 
 
In this systematic review, we found 33 instruments for measuring the level of multimorbidity 
of community-dwelling individuals that predict or explore the association with at least one 
specified outcome.  Disease count and weighted indices like the Charlson Comorbidity Index, 
the Elders Risk Assessment, and Elixhauser Index were commonly used for measuring the level 
of multimorbidity.  Other approaches to measuring the level of multimorbidity included case-
mix or pharmaceutical-based instruments.   
 
We compiled a list of these instruments and discussed the advantages and disadvantages of the 
commonly-used instruments.  A certain degree of reductionism will have to be accepted for 
each instrument as no one single instrument for measuring the level of multimorbidity will be 
able to encompass all different dimensions of multimorbidity.  There has been a rise in the 
development of novel weighted indices by using prognostic models or validation of an existing 
well-established instrument.  The reporting of such studies would need to follow the TRIPOD 
guidelines to allow potential users to replicate and confirm the findings103.   
 
There are continuing interests in measuring the level of multimorbidity with disease count and 
drug count.  A clear description of the instruments is required in the publication of 
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multimorbidity studies to counter the frequent lack of information currently seen so as to 
contribute to robust multimorbidity research in future. 
 
There is currently an absence of a gold standard for where to obtain chronic disease 
information. Most data sources are from medical record information, patient self-report, 
clinical judgment, or large administrative databases.  Ultimately, the most suitable instrument 
will depend on the specified outcome of interest, the study population, and the type of data and 
resources available. 
 
Finally, we compiled a list of instruments that were used to explore the association with the 
three essential core outcomes selected for the core outcomes set of multimorbidity research 
(COSmm)6.  Disease count was the only instrument identified for all three outcomes. 
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6 Appendices 
Appendix 3-1. Search Strategy 
Table 1.  Medline Search 1946 to August 13, 2018 
# Searches Results 
1 exp comorbidity/ or multiple chronic conditions/ 95224 
2 (multimorbid* or multi-morbid* or comorbid* or co-morbid*).ab,ti,kw. 147739 
3 ((multiple or coexist* or co-exist* or concurrent* or simultaneous*) adj2 (disease* or 
illness* or diagnos* or condition* or morbid* or disorder*)).ab,ti,kw. 
45667 
4 1 or 2 or 3 247802 
5 primary health care/ or "continuity of patient care"/ or exp general practice/ or ambulatory 
care/ or physicians, family/ or physicians, primary care/ or community health services/ or 
general practitioners/ 
229791 
6 ((ambulatory or community or general or family or primary) adj2 (care or health* or 
practi* or physician* or medicine or center* or centre* or facilit* or clinic*)).ab,ti,kw. 
350963 
7 5 or 6 461463 
8 epidemiologic measurements/ or risk assessment/ or "Outcome Assessment (Health 
Care)"/ or patient reported outcome measures/ or health status indicators/ or "severity of 
illness index"/ or sickness impact profile/ or diagnosis-related groups/ or case mix/ 
516146 
9 ((health status or risk or outcome* or sickness impact) adj2 (appraisal* or assessment* or 
evaluation* or measur* or index* or indic* or profile*)).ab,ti,kw. 
344511 
10 ((severity or burden) adj2 (illness* or diseas* or disorder* or condition* or 
diagnos*)).ab,ti,kw. 
72588 
11 (charlson comorbidity index or charlson index or charlson score or elixhauser* or 
cumulative illness rating scale* or CIRS or adjusted clinical group* or ACG* or disease 
count or Duke severity* or DUSOI or casemix or case-mix).ab,ti,kw. 
18192 
12 8 or 9 or 10 or 11 808827 
13 4 and 7 and 12 4172 
14 limit 13 to (english language and yr="2010 -Current") 2173 
 
Table 2. Embase Classic+Embase 1947 to August 13, 2018  
# Searches Results 
1 comorbidity/ or multiple chronic conditions/ 196646 
2 (multimorbid* or multi-morbid* or comorbid* or co-morbid*).ab,ti,kw. 244599 
3 ((multiple or coexist* or co-exist* or concurrent* or simultaneous*) adj2 (disease* or 
illness* or diagnos* or condition* or morbid* or disorder*)).ab,ti,kw. 
  66050 
4 1 or 2 or 3 378500 
5 primary health care/ or patient care/ or primary medical care/ or general practice/ or 
general practitioner/ or ambulatory care/ or family medicine/ or community care/ or 
community health services/ 
578870 
6 ((ambulatory or community or general or family or primary) adj2 (care or health* or 
practi* or physician* or medicine or center* or centre* or facilit* or clinic*)).ab,ti,kw. 
453501 
7 5 or 6 811904 
8 risk assessment/ or outcome assessment/ or patient reported outcome/ or health status 
indicator/ or disease activity score/ or global disease burden/ or organ dysfunction score/ 
or "severity of illness index"/ or sickness impact profile/ or general health status 
assessment/ or disease severity/ or diagnosis related group/ or charlson comorbidity index/ 
or comorbidity assessment/ or elixhauser comorbidity index/ or case mix/ 
1257685 
9 ((health status or risk or outcome* or sickness impact) adj2 (appraisal* or assessment* or 
evaluation* or measur* or index* or indic* or profile*)).ab,ti,kw. 
438484 
10 ((severity or burden) adj2 (illness* or diseas* or disorder* or condition* or 
diagnos*)).ab,ti,kw. 
106531 
11 (charlson comorbidity index or charlson index or charlson score or elixhauser* or 
cumulative illness rating scale* or CIRS or adjusted clinical group* or ACG* or disease 
count or Duke severity* or DUSOI or casemix or case-mix).ab,ti,kw. 
32221 
12 8 or 9 or 10 or 11 1613925 
13 4 and 7 and 12 9317 
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14 limit 13 to (english language and yr="2010 -Current") 6113 
Table 3. CINAHL – since inception to August 14, 2018 
# Searches Results 
1 (MH “comorbidity”) 30423 
2 multimorbid* or multi-morbid* or comorbid* or co-morbid* 49461 
3 (multiple or coexist* or co-exist* or concurrent* or simultaneous*) N2 (disease* or 
illness* or diagnos* or condition* or morbid* or disorder*) 
9374 
4 1 or 2 or 3 57381 
5 (MH “primary health care”) or (MH “family practice”) or (MH “ambulatory care") or 
(MH “ambulatory care facilities") or (MM “community health services”) or (MM 
“community health centers”) or (MH “physicians, family”) or (MH “continuity of patient 
care") 
83299 
6 (ambulatory or community or general or family or primary) N2 (care or health* or practi* 
or physician* or medicine or center* or centre* or facilit* or clinic*) 
205406 
7 5 or 6 211994 
8 (MH “risk assessment”) or (MH "Outcome Assessment") or (MH “patient-reported 
outcomes) or (MH “health status indicators”) or (MH "severity of illness indices") or (MH 
“sickness impact profile”) or (MH “diagnosis-related groups”) or (MH “case mix”) 
69377 
9 (health status or risk or outcome* or sickness impact) N2 (appraisal* or assessment* or 
evaluation* or measur* or index* or indic* or profile*) 
165689 
10 (severity or burden) N2 (illness* or diseas* or disorder* or condition* or diagnos*) 51231 
11 (charlson comorbidity index or charlson index or charlson score or elixhauser* or 
cumulative illness rating scale* or CIRS or adjusted clinical group* or ACG* or disease 
count or Duke severity* or DUSOI or casemix or case-mix) 
4820 
 
 
12 8 or 9 or 10 or 11 211895 
13 4 and 7 and 12 1454 
14 limit 13 to (english language and yr="2010 -Current") 800 
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Appendix 3-2. Coding Description for the Modified Newcastle-Ottawa Scale for Cohort Studies 
Category Description 
Selection  
1) Representativeness of the sample 
 
This item assesses the representativeness of sample in the community, not from some general population.   
a) Truly representative* (e.g., everyone from the database) 
b) Somewhat representative* (with at least 2 criteria but selection method was convincing due to random sampling) 
c) Selected group (e.g., only certain socio-economic groups or areas)  
d) No description of sampling strategy 
2) Ascertainment of multimorbidity This item assesses the method by which multimorbidity was confirmed. 
a) Secure record* (e.g., GP questionnaire) 
b) Structured interview* (e.g., interviewer-administered questionnaire) 
c) Written self-report (e.g., mailed survey, if items are unable to be confirmed by objective measure) 
d) No description / Other 
3) Demonstration that outcome of 
interest was not present at start of 
study 
A statement of no history of disease earns a star.  In the case of mortality studies, outcome of interest is still the presence of a disease, rather than 
death.   
a) Yes* 
b) No 
Comparability  
1) Study controls for age and sex Covariates must be adjusted for in the analysis. Statements of no differences between groups or that differences were not statistically significant are 
not sufficient for establishing comparability. Note: If the relative risk for the exposure of interest is adjusted for the covariates listed, then the groups 
will be considered to be comparable on each variable used. 
a) Yes* 
b) No 
2) Study controls for other factors a) Yes* 
b) No 
Outcome 
1) Statistical test Statistical test(s) must be clearly described and appropriate before assessing the other items under the Outcome category. 
a) Clearly described and appropriate 
b) Not described, incomplete or inappropriate 
2) Assessment of outcome This item assesses the method by which the outcome of interest was confirmed. For some outcomes, reference to the medical record is sufficient to 
satisfy the requirement for confirmation.  This may not be adequate for other outcomes where reference to specific tests or measures would be 
required. 
a) Independent or blind assessment* (e.g., interviewer-administered questionnaire) 
b) Record linkage* (e.g., identified through ICD codes on database records)  
c) Self-report (i.e., no reference to original medical records) 
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d) No description / Other 
3) Was follow-up long enough for 
outcomes to occur? 
An acceptable length of time was at least 1 year of follow-up. 
a) Yes* 
b) No 
4) Adequacy of follow-up of cohorts This item assesses the follow-up of the sample to ensure that losses are not related to the outcome. 
a) Complete follow-up - all subject accounted for* 
b) Subjects lost to follow-up unlikely to introduce bias* (Number lost ≤20% or description of those lost suggested no different from those followed.)  
c) Follow-up rate less than 80% and no description of those lost 
d) No statement 
 
Thresholds for converting the modified Newcastle-Ottawa scales to Good, Fair, and Poor Quality:  
• Good Quality - 2-3 stars in Selection category (Representativeness of Sample item must be fulfilled) AND 1-2 stars in Comparability category AND 2-3 stars in Outcome category. 
• Fair Quality - 1-2 stars in Selection category AND 1-2 stars in Comparability category AND 2-3 stars in Outcome category. 
• Poor Quality - 0 star in Selection category OR 0 stars in Comparability category OR 0-2 stars in Outcome category. 
 
Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Available 
from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp  
 
 
Modifications from original NOS include:  
• ‘Statistical test’ was added to the Outcome category 
• ‘Representativeness of sample’ item under Selection category and ‘Statistical test’ item under Outcome category must both be fulfilled for study to be considered Good Quality. 
• ‘Selection of the non-exposed cohort’ item was removed from Selection category as most studies did not describe a non-exposed cohort, and this review sought to compare the different 
levels of multimorbidity within the group.  
• ‘Representativeness of the exposed cohort’ item under Selection category was renamed ‘Representativeness of the sample’ since the ‘non-exposed cohort’ was removed above. 
• ‘Ascertainment of exposure’ under the Selection category was renamed as ‘Ascertainment of multimorbidity’ to specify that multimorbidity is the exposure in this review.  
• ‘Study controls for age and sex’ and ‘Study controls for other factors’ were revised to be items under Comparability category 
• The thresholds for converting the scales to quality were amended accordingly due to the above modifications. 
Consensus: 
• The study team decided that a period of one-year was a reasonable period of follow-up under ‘Was follow-up long enough for outcomes to occur?’ item under Outcome category.  
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Appendix 3-3. Coding Description for the Modified Newcastle-Ottawa Scale for Cross-sectional Studies 
Category Description 
Selection  
1) Representativeness of the sample 
 
This item assesses the representativeness of sample in the specified population, not from some general population.   
e) Truly representative* (e.g., everyone from the database, random sampling) 
f) Somewhat representative* (with at least 2 criteria but selection method was convincing due to random sampling) 
g) Selected group (e.g., only certain socio-economic groups or areas) 
h) No description of sampling strategy 
2) Ascertainment of multimorbidity This item assesses the method by which multimorbidity was confirmed. 
e) Secure record* (e.g., Clinical records, GP questionnaire) 
f) Structured interview* (e.g., interviewer-administered questionnaire) 
g) Written self-report (e.g., mailed survey, if items are unable to be confirmed by objective measure) 
h) No description / Other 
3) Sample Size  If there is no description, a reported sample size of 800 and above is satisfactory. 
c) Justified and satisfactory* 
d) Not justified 
4) Non-respondents Acceptable response rates for surveys through various methods† 
• In-person: 57% 
• Mail: 50% 
• Average: 33% 
• Email: 30% 
• Internet: 29% 
• Telephone: 18% 
• In-app: 13% 
a) Comparability between respondents and non-respondents characteristics is established, and the response rate is satisfactory.* 
b) The response rate is unsatisfactory, or the comparability between respondents and non-respondents is unsatisfactory. 
c) No description of the response rate or the characteristics of the responders and the non-responders 
Comparability  
3) Study controls for age and sex Confounders must be adjusted for in the analysis. Statements of no differences between groups or that differences were not statistically significant 
are not sufficient for establishing comparability. Note: If the relative risk for the exposure of interest is adjusted for the confounders listed, then the 
groups will be considered to be comparable on each variable used in the adjustment. 
c) Yes* 
d) No 
4) Study controls for other factors c) Yes* 
d) No 
157 
 
  
                                                                                                                                                                            
  
Outcome 
5) Statistical test Statistical test(s) must be clearly described and appropriate before assessing the other items under the Outcome category. 
c) Clearly described and appropriate 
d) Not described, incomplete or inappropriate 
6) Assessment of outcome This item assesses the method by which the outcome of interest was confirmed. For some outcomes, reference to the medical record is sufficient to 
satisfy the requirement for confirmation.  This may not be adequate for other outcomes where reference to specific tests or measures would be 
required. 
e) Independent or blind assessment* 
f) Record linkage* (e.g., identified through ICD codes on database records)  
g) Self-report (i.e., no reference to original medical records) 
h) No description / Other 
Thresholds for converting the modified Newcastle-Ottawa scales to Good, Fair, and Poor Quality:  
• Good Quality – 3-4 stars in Selection category (Representativeness of Sample item must be fulfilled) AND 1-2 stars in Comparability category AND 1 star in Outcome 
category. 
• Fair Quality - 2 stars in Selection category AND 1-2 stars in Comparability category AND 1 star in Outcome category. 
• Poor Quality - 0 star in Selection category OR 0 stars in Comparability category OR 0 stars in Outcome category. 
†Lindermann N. What’s the average survey response rate? [2018 benchmark]. SurveyAnyplace. Available from: https://surveyanyplace.com/average-survey-response-rate/.  
Alshabanat A, Zafari Z, Albanyan O, Dairi M, FitzGerald JM. Asthma and COPD Overlap Syndrome (ACOS): a systematic review and meta-analysis. PLoS ONE. 
2015;10(9):e0136065. Doi:10.1371/journal.pone.0136065.  
 
Modifications from original NOS include: 
• ‘Ascertainment of exposure’ item under Selection category was renamed as ‘Ascertainment of multimorbidity’ to specify that multimorbidity is the exposure in this review. 
• The ratings for the ‘Ascertainment of exposure’ item under Selection category were revised to ‘secure record, structured interview, written self-report, no description/other’ 
to align with the Modified NOS for cohort studies in this review.  
• ‘Study controls for age and sex’ and ‘Study controls for other factors’ items were revised to be items under Comparability category. 
• ‘Was follow-up long enough for outcomes to occur’ item under Outcome category was renamed as ‘Statistical test’. This item must be fulfilled for the study to be considered as 
Good Quality. 
• The thresholds for converting the scales to quality were amended accordingly due to the above modifications.  
Consensus: 
• The study team decided on a list of acceptable response rates for various survey methods for the ‘Non-respondents’ item under Selection category. 
• The study team decided that a sample size of 800 was reasonable under ‘Sample size’ item under Selection category. 
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Appendix 3-4. Summary of included articles where multimorbidity measures were added into prediction models (20 studies including 23 
articles) 
Author 
(Year), 
Country 
Multimorbidity 
Measurement(s) 
Outcomes 
measured Models used in the study Statistics Conclusion 
Cohort Studies 
Brilleman et al. 
(2014)31, UK 
a. ACG 
b. CCI 
c. CCI dummy 
d. EDC count 
e. EDC dummy 
f. QOF count 
g. QOF dummy 
h. RUB 
1. Primary 
healthcare cost 
Model 1: 
 
Model 2: 
 
Model 3: 
 
Model 4: 
 
Model 5: 
 
Model 6: 
 
Model 7: 
 
Model 8: 
 
Model 9: 
 
Model 10: 
 
Model 11: 
 
Model 12: 
Age and sex 
 
Age, sex, and deprivation 
 
Age, sex, and practice 
 
Age, sex, deprivation, and practice 
 
Model 4 and QOF dummy 
 
Model 4 and QOF count 
 
Model 4 and CCI dummy 
 
Model 4 and CCI 
 
Model 4 and EDC dummy 
 
Model 4 and EDC count 
 
Model 4 and ACG 
 
Model 4 and RUB 
BIC = 1320939 
 
BIC = 1320555 
 
BIC = 1322027 
 
BIC = 1321883 
 
BIC = 1302791 
 
BIC = 1305547 
 
BIC = 1310235 
 
BIC = 1311982 
 
BIC = 1295660 
 
BIC = 1302546 
 
BIC = 1308944 
 
BIC = 1312522 
1. Under OLS estimation, the EDC measures performed best 
followed by the QOF and ACG measures. The CCI measures 
had the worst performance but still improved markedly on 
models containing only age, sex, deprivation and practice 
effects. 
 
(Continued on next page)  
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Appendix 3-4. Summary of included articles where multimorbidity measures were added into prediction models (20 studies including 23 
articles)(Continued) 
Author 
(Year), 
Country 
Multimorbidity 
Measurement(s) 
Outcomes 
measured Models used in the study Statistics Conclusion 
      
Brilleman & 
Salisbury 
(2013)32, UK 
a. ACG 
b. CCI 
c. EDC count 
d. Prescribed drugs 
count 
e. QOF count 
f. RUB 
1. Mortality 
(3-years period) 
 
 
 
 
 
 
 
 
 
 
 
2. Number of 
primary care 
consultations 
(3-years period) 
Model 1: 
 
Model 2: 
 
Model 3: 
 
Model 4: 
 
Model 5: 
 
Model 6: 
 
 
Model 1: 
 
 
Model 2: 
 
Model 3: 
 
Model 4: 
 
Model 5: 
 
Model 6: 
 
Model 7: 
Age, sex, and deprivation 
 
Model 1 and QOF count 
 
Model 1 and CCI 
 
Model 1 and EDC count 
 
Model 1 and RUB 
 
Model 1 and prescribed drugs count 
 
 
Age, sex, age-by-sex interaction, 
deprivation, and GP practice 
 
Model 1 and QOF count 
 
Model 1 and CCI 
 
Model 1 and EDC count 
 
Model 1 and ACG 
 
Model 1 and RUB 
 
Model 1 and prescribed drugs count 
BIC = 20250 
 
BIC = 19854  
 
BIC = 19443  
 
BIC = 19979  
 
BIC = 19946 
 
BIC = 19693 
 
 
BIC = 650373 
 
 
BIC = 638720  
 
BIC = 644908 
 
BIC = 629766  
 
BIC = 628438 
 
BIC = 631863 
 
BIC = 620799 
1. Measures of multimorbidity made little difference to the fit of 
a model predicting 3-year mortality. Nonetheless, the CCI 
was the best performing measured followed by the number of 
prescribed drugs. 
 
 
 
 
 
 
 
 
 
2. All of the multimorbidity measures had moderate predictive 
validity in relation to consultation in primary care, in which 
the number of prescribed drugs had the greatest predictive 
validity followed by the ACG based measures (ACG, EDC 
count, and RUB). 
 
(Continued on next page) 
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Appendix 3-4. Summary of included articles where multimorbidity measures were added into prediction models (20 studies including 23 
articles)(Continued) 
Author 
(Year), 
Country 
Multimorbidity 
Measurement(s) 
Outcomes 
measured Models used in the study Statistics Conclusion 
       
Carey et al. 
(2013)50, UK 
a. Standard QOF 
b. Extended QOF 
c. CCI (Khan) 
1. Mortality 
(1-year 
period) 
Model 1: 
 
Model 2: 
 
Model 3: 
 
 
Model 4: 
 
 
Model 5: 
 
Model 6: 
 
Model 7: 
 
 
Model 8: 
 
 
Model 9: 
 
 
Model 10: 
Age and sex 
 
Age, sex, and Standard QOF count 
 
Age, sex, and Standard QOF weighted 
score 
 
Age, sex, and Standard QOF weighted 
score (9 levels) 
 
Age, sex, and CCI count 
 
Age, sex, and CCI weighted score 
 
Age, sex, and CCI weighted score (9 
levels) 
 
Age, sex, and Extended QOF count 
 
Age, sex, and Extended QOF weighted 
score 
 
Age, sex, and Extended QOF weighted 
score (9 levels) 
C-statistics = 0.776 
 
C-statistics = 0.806 
 
C-statistics = 0.823 
 
 
C-statistics = 0.826 
 
 
C-statistics = 0.809 
 
C-statistics = 0.816 
 
C-statistics = 0.818 
 
 
C-statistics = 0.813 
 
 
C-statistics = 0.826 
 
 
C-statistics = 0.829 
1. A simple count of the morbidities in each of the 
multimorbidity measurements produced significant 
improvement from a basic model adjusting for age and 
sex. 
 
2. Fitting the weighted score as a nine-level variable further 
improved discrimination, with the standard QOF score 
outperforming the Charlson index. The extended QOF 
score produced only a modest improvement in overall 
model performance. 
 
       
Chapman et al. 
(2015)51, UK 
a. CCI 
b. CCI-PSR 
1. Mortality 
(5, 10, 15, 20, 
25-years 
period) 
CCI Model: 
 
 
 
 
 
CCI-PSR 
Model: 
Age, sex, chronic asthma/emphysema, 
arthritis/rheumatism, cancer, diabetes, 
gastrointestinal disease, heart disease, 
kidney disease, and stroke 
 
CCI model, income, education, type A 
personality, communalism, and lie scale 
AUC = 0.75 (5-yrs) 
AUC = 0.74 (10-yrs) 
AUC = 0.74 (15-yrs) 
AUC = 0.76 (20-yrs) 
AUC = 0.77 (25-yrs) 
 
AUC = 0.83 (5-yrs) 
AUC = 0.83 (10-yrs) 
AUC = 0.83 (15-yrs) 
AUC = 0.84 (20-yrs) 
AUC = 0.84 (25-yrs) 
1. Across 5-, 10-, 15-, 20-, and 25-year time horizons, the 
CCI-PSR showed substantially better discrimination than 
the CCI. 
 
(Continued on next page)  
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Appendix 3-4. Summary of included articles where multimorbidity measures were added into prediction models (20 studies including 23 
articles)(Continued) 
Author 
(Year), 
Country 
Multimorbidity 
Measurement(s) 
Outcomes 
measured Models used in the study Statistics Conclusion 
       
Crane et al. 
(2010)52, USA 
a. ERA 1. Number of 
hospital visits 
(1-year period) 
 
2. Number of ED 
visits 
(1-year period) 
 
3. Number of 
hospital 
admissions 
(1-year period) 
 
4. Number of days 
hospitalised 
(1-year period) 
ERA Model: Age, marital status, number of days 
hospitalised in 2003 or 2004, 
history of diabetes, history of 
CAD/MI/CHF, history of stroke, 
history of COPD, history of cancer, 
and history of dementia 
AUC = 0.705 
 
 
 
AUC = 0.640 
 
 
 
AUC not reported 
 
 
 
 
AUC not reported 
1. Results suggest that the ERA index is an effective risk 
identification model to identify population of older, 
community-dwelling adults who are at increased risk of 
hospitalisation and ED encounters. 
 
 
       
Crooks et al. 
(2016)33, UK 
a. Co-morbidity 
linked score 
b. CCI 
c. Elixhauser Index 
1. Mortality 
(1-year period) 
Elixhauser: 
 
 
CCI: 
 
 
Linked score 
(Categorical): 
 
Linked score 
(Continuous): 
Elixhauser Index, age, sex, and 
recent hospitalisation 
 
CCI, age, sex, and recent 
hospitalisation 
 
Linked score (Categorical), age, 
sex, and recent hospitalisation 
 
Linked score (Continuous), age, 
sex, and recent hospitalisation 
C-statistics = 0.868 
 
 
C-statistics = 0.872 
 
 
C-statistics = 0.879 
 
 
C-statistics = 0.878 
 
1. The linked score had significantly improved discrimination 
and fit compared to the CCI and the Elixhauser Index 
 
(Continued on next page) 
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Appendix 3-4. Summary of included articles where multimorbidity measures were added into prediction models (20 studies including 23 
articles)(Continued) 
Author 
(Year), 
Country 
Multimorbidity 
Measurement(s) 
Outcomes 
measured Models used in the study Statistics Conclusion 
       
Crooks et al. 
(2015)34, UK 
a. CCI (Read) 
b. CCI (ICD-10) 
c. CCI (Read and 
ICD-10) 
1. All-cause 
mortality 
Model 1: 
 
Model 2: 
 
Model 3: 
 
Model 4: 
 
 
Model 5: 
 
Model 6: 
 
 
Model 7: 
 
 
Model 8: 
Sex 
 
Age and sex 
 
Age, sex, and CCI (Read) 
 
Age, sex, recent hospitalisation, 
and CCI (Read) 
 
Age, sex, and CCI (ICD-10) 
 
Age, sex, recent hospitalisation, 
and CCI (ICD-10) 
 
Age, sex, CCI (Read and ICD-10) 
 
Age, sex, recent hospitalisation, 
and CCI (Read and ICD-10) 
C-statistics = 0.513 
 
C-statistics = 0.844 
 
C-statistics = 0.861 
 
C-statistics = 0.868 
 
 
C-statistics = 0.870 
 
C-statistics = 0.872 
 
 
C-statistics = 0.869 
 
 
C-statistics = 0.873 
1. There was no large difference in the discrimination of the 
model for overall survival, whichever codes were used to 
derive the CCI. Including a marker for a recent hospital 
admission resulted in a slightly improved discrimination for 
each Charlson derivation. 
       
Fraccaro et al. 
(2016)55, UK 
a. CCI (Khan) 1. Mortality 
(6-month 
period) 
Model 1: 
 
Model 2: 
 
 
Model 3: 
 
 
Model 4: 
 
 
 
Model 5: 
Age, sex, and baseline CCI 
 
Sex, time-dependent age, and CCI 
 
Sex, baseline CCI, time-dependent 
age, and CCI 
 
Sex, baseline CCI, time-dependent 
age, and cumulative CCI change 
 
Sex, time-dependent age, CCI, and 
CCI change over consecutive time 
windows 
AIC = 362230 
 
AIC = 358054 
 
 
AIC = 357290 
 
 
AIC = 357290 
 
 
 
AIC = 357000 
1. Model 5 had the best fit to the data but had equivalent 
discrimination to the other time-dependent models. 
(Continued on next page) 
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Appendix 3-4. Summary of included articles where multimorbidity measures were added into prediction models (20 studies including 23 
articles)(Continued) 
Author 
(Year), 
Country 
Multimorbidity 
Measurement(s) 
Outcomes 
measured Models used in the study Statistics Conclusion 
       
Haas et al. 
(2013)56, USA 
a. ACG 
b. Minnesota 
Health Care 
Home Tiering 
c. HCC 
d. ERA 
e. CCC 
f. CCI 
g. Hybrid Model 
1. Hospitalisation 
 
2. ED visits 
 
3. Readmission 
within 30 days 
 
4. Healthcare 
expenditure 
ACG 
 
 
 
 
Minnesota Health Care Home Tiering 
 
 
 
 
HCC 
 
 
 
 
ERA 
 
 
 
 
CCC 
 
 
 
 
CCI 
C-statistics = 0.73 (Hospitalised) 
C-statistics = 0.67 (ED visits) 
C-statistics = 0.81 (Readmission) 
C-statistics = 0.76 (Expenditure) 
 
C-statistics = 0.71 (Hospitalised) 
C-statistics = 0.66 (ED visits) 
C-statistics = 0.79 (Readmission) 
C-statistics = 0.74 (Expenditure 
 
C-statistics = 0.67 (Hospitalised) 
C-statistics = 0.58 (ED visits) 
C-statistics = 0.74 (Readmission) 
C-statistics = 0.70 (Expenditure) 
 
C-statistics = 0.71 (Hospitalised) 
C-statistics = 0.61 (ED visits) 
C-statistics = 0.78 (Readmission) 
C-statistics = 0.72 (Expenditure) 
 
C-statistics = 0.69 (Hospitalised) 
C-statistics = 0.61 (ED visits) 
C-statistics = 0.77 (Readmission) 
C-statistics = 0.72 (Expenditure) 
 
C-statistics = 0.68 (Hospitalised) 
C-statistics = 0.59 (ED visits) 
C-statistics = 0.75 (Readmission) 
C-statistics = 0.70 (Expenditure) 
1. The ACG model outperformed the other 5 models in 
predicting hospitalisation. 
 
2. In models predicting ED visits, the ACG model had the 
best predictive ability. 
 
3. The ACG model outperformed other models when 
predicting 30-day readmissions 
 
4. When predicting healthcare expenditures for the top 10% 
high-cost users, the performance of the ACG model was 
superior to that of other models 
       
Hwang et al. 
(2015)57, USA 
1. ACE-27 
2. ACE-27 count 
1. Healthcare 
expenditure 
Exploratory predictive model consists of 
age, sex, rurality of residence, logarithms 
of total, inpatient, medication, outpatient, 
and professional expenditures, number 
and overall severity of patient conditions 
defined by ACE-27 score, and each of 
the 26 individual comorbidities in ACE-
27 
AUC = 0.923 1. The model, using year 1 data to determine if an individual 
would be classified into the persistent high-user group for 
the following 3 years, indicates a very high level of 
accuracy in predicting membership in a high-user group. 
(Continued on next page) 
164 
 
  
                                                                                                                                                                            
  
Appendix 3-4. Summary of included articles where multimorbidity measures were added into prediction models (20 studies including 23 
articles)(Continued) 
Author 
(Year), 
Country 
Multimorbidity 
Measurement(s) 
Outcomes 
measured Models used in the study Statistics Conclusion 
       
Lemke et al. 
(2012)61, USA  
a. CCI  
b. ACG  
1. Inpatient 
hospitalisations  
 
Model 1:  
 
 
 
Model 2:  
 
 
 
 
 
 
 
 
Model 3: 
 
 
 
 
  
Model 4:  
 
 
 
 
 
Model 5:  
Prior Inpatient Hospitalisation  
Age, sex, count of hospitalisations 
within the previous 12 months  
 
Charlson Inpatient Hospitalisation  
Age, sex, prior hospitalisations, 
emergency department episodes not 
resulting in inpatient hospitalisations, 
outpatient visits, markers for dialysis 
services, nursing services and major 
procedures and 17 Charlson 
comorbidities  
 
ACG Inpatient Hospitalisation 
Age, sex, diagnosis-based morbidity 
categories and disease cluster markets, 
medication-based morbidity groups, 
count of previous hospitalisations  
 
ACG ICU/CCU Hospitalisation  
Age, sex, diagnosis-based morbidity 
categories and disease cluster markets, 
medication-based morbidity groups, 
count of ICU/CCU hospitalisation  
 
ACG Extended Hospitalisation  
 Age, sex, diagnosis-based morbidity 
categories and disease cluster markets, 
medication-based morbidity groups, 
count of extended hospitalisation  
 
 
AUC = 0.75 
 
 
 
AUC = 0.78 
 
 
 
 
 
 
 
 
AUC = 0.80  
 
 
 
 
 
AUC = 0.85 
 
 
 
 
 
AUC = 0.87  
1. ACG-based predictive model for inpatient 
hospitalisation was superior to the prior 
hospitalisation model and the Charlson 
inpatient model 
 
2. The difference between the ACG and 
Charlson inpatient models was statistically 
significant (p<0.0001)  
(Continued on next page) 
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Appendix 3-4. Summary of included articles where multimorbidity measures were added into prediction models (20 studies including 23 
articles)(Continued) 
Author 
(Year), 
Country 
Multimorbidity 
Measurement(s) 
Outcomes 
measured Models used in the study Statistics Conclusion 
       
Quail et al. 
(2011)62, 
Canada 
a. DC 
b. CCI (Quan)  
c. Elixhauser Index 
(Quan)  
d. Number of 
dispensed drugs  
e. Chronic Disease 
Score 
1. Death 
2. One or more 
hospitalisations  
3. Two or more 
hospitalisations 
Model 1 
(Base Model):  
 
 
Model 2:  
 
 
 
Model 3:  
 
 
 
Model 4: 
 
 
 
Model 5: 
 
 
 
Model 6:  
Age, age2, sex, income 
quintile, and geography  
 
 
Model 1 + Number of 
different diagnoses  
 
 
Model 1 + Charlson 
Comorbidity Index (Quan)  
 
 
Model 1 + Elixhauser (Quan)  
 
 
 
Model 1 + Number of 
dispensed drugs  
 
 
Model 1 + Chronic Disease 
Score 
 
C-statistic = 0.880 (Death)  
C-statistic = 0.652 (≥1 hospitalisations) 
C-statistic = 0.706 (≥2 hospitalisations) 
 
C-statistic = 0.901 (Death)  
C-statistic = 0.722 (≥1 hospitalisations) 
C-statistic = 0.782 (≥2 hospitalisations) 
 
C-statistic = 0.905 (Death)  
C-statistic = 0.671 (≥1 hospitalisations) 
C-statistic = 0.731 (≥2 hospitalisations) 
  
C-statistic = 0.913 (Death)  
C-statistic = 0.682 (≥1 hospitalisations) 
C-statistic = 0.748 (≥2 hospitalisations) 
 
C-statistic = 0.894 (Death)  
C-statistic = 0.688 (≥1 hospitalisations) 
C-statistic = 0.744 (≥2 hospitalisations) 
 
C-statistic = 0.889 (Death) 
C-statistic = 0.672 (≥1 hospitalisations) 
C-statistic = 0.729 (≥2 hospitalisations) 
 
In predicting all outcomes, the addition of a 
comorbidity measure to the base model yielded a 
statistically significant improvement in the c-
statistic.   
 
1. Elixhauser Index (Quan) performed best in 
improving the c-statistic, followed by CCI.  
 
2. Disease count (number of different 
diagnoses) was the best performing 
comorbidity measure for one or more 
hospitalisations  
 
3. Disease count (number of different 
diagnoses) was the best performing 
comorbidity measure Disease count 
(number of different diagnoses) was the 
best performing comorbidity measure for 
two or more hospitalisations  
(Continued on next page)  
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Appendix 3-4. Summary of included articles where multimorbidity measures were added into prediction models (20 studies including 23 
articles)(Continued) 
Author 
(Year), 
Country 
Multimorbidity 
Measurement(s) 
Outcomes 
measured Models used in the study Statistics Conclusion 
       
Saver et al. 
(2014)64, USA 
a. CCI (Romano) 
+ Hypertension 
1. Acute ACSH 
 
2. Chronic ACSH 
Model 1: 
 
Model 2: 
 
 
 
 
 
 
 
 
 
Model 3: 
 
 
 
 
 
Model 4: 
Age, sex, and race 
 
Model 1, rural-urban 
residence, state of residence, 
availability of healthcare 
services, continuity of care, 
household income, 
education, original source of 
Medicare eligibility, number 
of outpatient visits in prior 
year, and previous year 
ACSHs 
 
Model 2, comorbidity flags 
(CHF, COPD, diabetes, 
hypertension and, for acute 
ACSHs, dementia), and 
precious year ACSHs 
 
Model 1 and comorbidity 
flags (CHF, COPD, diabetes, 
hypertension and, for acute 
ACSHs, dementia) 
C-statistics = 0.68 
 
C-statistics = 0.72 
 
 
 
 
 
 
 
 
 
C-statistics = 0.87 
 
 
 
 
 
C-statistics = 0.87 
1. Model with limited set of comorbidity flags (model 3 and 
model 4) had far grater predictive power for acute and 
chronic ACSHs. 
       
Stanley and 
Sarfati 
(2017)65, New 
Zealand 
a. M3 Index 
b. CCI 
c. Elixhauser  
(van Walraven) 
1. Mortality 
(1-year period) 
 
2. Overnight 
hospitalisation 
(1-year period) 
Model 1: 
 
 
Model 2: 
 
 
Model 3: 
 
 
Model 4: 
Age and sex 
 
 
Age, sex, and CCI 
 
 
Age, sex, and Elixhauser 
 
 
Age, sex, and M3 Index 
C-statistics = 0.887 (Mortality) 
C-statistics = 0.656 
(Hospitalised) 
 
C-statistics = 0.921 (Mortality) 
C-statistics = 0.683 
(Hospitalised) 
 
C-statistics = 0.922 (Mortality) 
C-statistics = 0.676 
(Hospitalised) 
 
C-statistics = 0.931 (Mortality) 
C-statistics = 0.703 
(Hospitalised) 
1. M3 Index outperformed both CCI and Elixhauser in 
predicting mortality 
 
2. M3 Index performed better than CCI and Elixhauser when 
considering overnight hospitalisation. 
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Appendix 3-4. Summary of included articles where multimorbidity measures were added into prediction models (20 studies including 23 
articles)(Continued) 
Author 
(Year), 
Country 
Multimorbidity 
Measurement(s) 
Outcomes 
measured Models used in the study Statistics Conclusion 
       
Takahashi et al. 
(2016)67, USA 
a. DC using 
Minnesota 
Medical Tiering 
(ACG) 
1. Hospitalisation / 
ED visits  
 
Minnesota 
Medical 
Tiering  
 
 
Enhanced 
Model  
 
 
 
 
 
Age, sex, BMI, marital status, 
insurance, prior ED visits, prior 
hospitalisations, more than 3 
specialists seen in 2010, mental 
health disorders, substance-related 
disorders, narcotic prescription 
order, epilepsy, hyperlipidemia, 
warfarin prescription order  
AUC = 0.667 
 
 
 
 
AUC = 0.711  
 
1. The enhanced model is better at predicting 
hospitalisation/ED visits than models that utilise only 
Minnesota medical tiering as it takes into consideration 
previous hospitalisation, specific high-risk illnesses, mental 
health conditions, and high-risk medication use (eg, 
warfarin, narcotics) that are not universally accounted for 
in other models. 
       
Wallace et al. 
(2016a)39, 
Ireland 
a. Pra tool 
b. Modified Pra tool 
1. Emergency 
hospital 
admission 
(1-year period) 
 
 
Pra tool 
 
 
 
 
 
 
Modified Pra 
Age, sex, presence of diabetes, 
presence of coronary heart disease, 
hospital admission in previous 
year, > 6 physician visits in 
previous year, self-rated health, 
and availability of an informal 
caregiver 
 
Pra tool and RxRisk-V 
C-statistics = 0.65  
 
 
 
 
 
 
C-statistics = 0.67 
1. Both models demonstrated poor model discrimination for 
the outcome for emergency admission during the 1-year 
follow-up period. 
(Continued on next page) 
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Appendix 3-4. Summary of included articles where multimorbidity measures were added into prediction models (20 studies including 23 
articles)(Continued) 
Author 
(Year), 
Country 
Multimorbidity 
Measurement(s) 
Outcomes 
measured Models used in the study Statistics Conclusion 
       
Wallace et al. 
(2016b)40, 
Ireland 
a. DC 
b. Barnett conditions 
DC 
c. CCI 
d. Prescribed drugs 
count 
e. RxRisk-V 
1. Emergency 
admission 
(2-years period) 
 
2. Functional 
decline 
(2-years period) 
 
Model 1: 
 
 
Model 2: 
 
 
Model 3: 
 
 
Model 4: 
 
 
Model 5: 
Age, sex, deprivation, and 
DC 
 
Age, sex, deprivation, and 
Barnett DC 
 
Age, sex, deprivation, and 
CCI 
 
Age, sex, deprivation, and 
RxRisk-V 
 
Age, sex, deprivation, and 
prescribed drugs count 
C-statistics = 0.61 (Admission) 
C-statistics = 0.55 (Functional) 
 
C-statistics = 0.63 (Admission) 
C-statistics = 0.55 (Functional) 
 
C-statistics = 0.58 (Admission) 
C-statistics = 0.60 (Functional) 
 
C-statistics = 0.63 (Admission) 
C-statistics = 0.61 (Functional) 
 
C-statistics = 0.62 (Admission) 
C-statistics = 0.57 (Functional) 
1. All measures demonstrated poor discrimination in 
predicting emergency admission. 
 
2. All measures demonstrated poor discrimination in 
predicting emergency admission. 
 
       
Wei and 
Mukamal 
(2018)69, USA 
a. MWI  
b. DC 
c. CCI 
1. Mortality (10-
years period)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MWI  
 
 
 
 
DC  
 
 
 
 
CCI 
 
C-statistics = 0.67 (NHS Cohort)   
C-statistics = 0.70 (HPFS Cohort) 
C-statistics = 0.64 (NHS II Cohort)  
C-statistics = 0.68 (Combined)  
 
C-statistics = 0.65 (NHS Cohort)   
C-statistics = 0.68 (HPFS Cohort) 
C-statistics = 0.62 (NHS II Cohort)  
C-statistics = 0.66 (Combined)  
 
C-statistics = 0.64 (NHS Cohort)   
C-statistics = 0.64 (HPFS Cohort) 
C-statistics = NA (NHS II Cohort)  
C-statistics = 0.64 (Combined)  
 
1. MWI performed best in predicting mortality as 
compared to DC and CCI, with the greatest C-
statistics in all cohorts as well as the combined 
cohorts.  
 
(Continued on next page) 
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Appendix 3-4. Summary of included articles where multimorbidity measures were added into prediction models (20 studies including 23 
articles)(Continued) 
Author 
(Year), 
Country 
Multimorbidity 
Measurement(s) 
Outcomes 
measured Models used in the study Statistics Conclusion 
Cross-Sectional Studies     
Kristensen et 
al. (2014)79, 
Denmark 
a. RUB 1. Fee-for-services 
expenditures 
 
 
 
Model 1: 
 
 
Model 2: 
 
Model 3: 
 
 
Model 4: 
 
 
Model 5: 
 
 
 
Model 6: 
Age, age squared, and sex 
 
Model 1 and RUB markers 
 
Model 2 and ICPC-2 
chapter markers 
 
Model 2 and chapter 
components markers 
 
Model 2, ICPC-2 chapter 
markers, and chapter 
components markers 
 
Model 5 and volume 
markers 
R2 = 0.133 
 
 
R2 = 0.316 
 
R2 = 0.437 
 
 
R2 = 0.372 
 
 
R2 = 0.444 
 
 
 
R2 = 0.793 
1. Morbidity measures were significant patient-related fee-
for-services expenditures drivers. 
 
 
       
Lapi et al. 
(2015)80, Italy 
 
a. Health Search 
Morbidity Index 
(HSMI) 
1. Total mean 
healthcare cost 
per year 
 
 
Model 1: 
 
 
 
Model 2: 
 
 
 
Model 3: 
 
 
Model 4: 
Interaction between age 
and sex, province of 
patient’s residence, and 
GP 
 
Interaction between age 
and sex, and region of 
patient’s residence 
 
Province of patient’s 
residence and GP 
 
Model 1 and cubic 
fractional polynomial 
transformation of age 
R2 = 50.17 
 
 
 
R2 = 50.16 
 
 
 
R2 = 49.71 
 
 
R2 = 50.51 
 
1. The HSMI explained 50.17% of the variation in costs. 
(Continued on next page)  
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Appendix 3-4. Summary of included articles where multimorbidity measures were added into prediction models (20 studies including 23 
articles)(Continued) 
Author 
(Year), 
Country 
Multimorbidity 
Measurement(s) Outcomes measured Models used in the study Statistics Conclusion 
Ranstad et al. 
(2014)88, 
Sweden  
RUB  1. Registered active 
listing in primary 
care 
 
2. Registered active 
listing in all 
healthcare  
 
 
 
Model 1: 
 
Model 2:  
 
Model 3:  
 
 
 
Model 4:  
Multimorbidity, primary care  
 
Multimorbidity, all healthcare 
 
Interaction between number of 
consultations and multimorbidity, 
primary care  
 
Interaction between number of 
consultations and multimorbidity, 
all healthcare  
 
AIC = 141110.9 
 
AIC = 145361.5 
 
AIC = 140007.6  
 
 
 
AIC = 144595.7 
1. Multimorbidity level predicted active listing, 
significantly increasing for RUB0-4 in primary 
care  
 
2. Multimorbidity level predicted active listing, 
significantly increasing for RUB0-4 in all 
healthcare  
 
       
Shadmi et al. 
(2011)91, Israel  
ADGs 
CCI 
 
1. Number of primary 
care physician 
visits  
 
2. Number of 
specialist visits  
 
3. Performance of 
diagnostic tests  
 
4. Number of 
hospitalisations  
 
 
Model 1:  
 
 
 
 
Model 2:  
 
 
 
 
Model 3:  
 
Age and sex  
 
 
 
 
Age, sex, CCI  
 
 
 
 
Age, sex, ADGs  
R2  = 0.13 (Primary care visits)  
R2  = 0.12 (Specialist visits)  
R2  = 0.13 (Diagnostic tests)  
R2  = 0.05 (Hospitalisations)  
 
R2  = 0.18 (Primary care visits)  
R2  = 0.13 (Specialist visits)  
R2  = 0.15 (Diagnostic tests)  
R2  = 0.11 (Hospitalisations) 
 
R2  = 0.54 (Primary care visits)  
R2  = 0.45 (Specialist visits)  
R2  = 0.37 (Diagnostic tests)  
R2  = 0.24 (Hospitalisations) 
1. ADGs explained the largest percent of variance 
or in health care resource use, ranging from 23% 
to 54% in primary care physician visits, 
specialist visits, performance of diagnostic tests, 
and hospitalisations  
 
(Continued on next page) 
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Appendix 3-4. Summary of included articles where multimorbidity measures were added into prediction models (20 studies including 23 
articles)(Continued) 
Author 
(Year), 
Country 
Multimorbidity 
Measurement(s) Outcomes measured Models used in the study Statistics Conclusion 
       
Sullivan et al. 
(2012)93, USA 
DC 1. Preference-based 
HRQoL  
 
 
 
Model 1:  
 
Model 2:  
 
 
 
Model 3:  
 
Model 4:  
Age, number of chronic conditions  
 
Age, income, sex, race, education, 
ethnicity, physical activity, 
smoking status 
 
Number of chronic conditions  
 
Age, income, sex, race, education, 
ethnicity, physical activity, 
smoking status, number of chronic 
conditions  
  
Pseudo R2  = 0.2316 
 
Pseudo R2  = 0.1462 
 
 
 
Pseudo R2  =0.1994 
 
Pseudo R2  =0.2360 
1. The inclusion of chronic co-morbidity to the 
baseline models explained more of the variance 
in EQ-5D-5L index scores than did age or other 
sociodemographic characteristics  
 
Note. ACE-27 = Adult Comorbidity Evaluation-27; ACG = Adjusted Clinical Groups; ACSH = Ambulatory Care Sensitive Hospitalisation; AUC = Area Under the Curve; BIC = Bayesian Information Criterion; CAD 
= Coronary Artery Disease; CCC = Chronic Conditions Count; CCI = Charlson Comorbidity Index; CCI-PSR = Charlson Comorbidity Index-Psychosocial Risk; CCU = Critical Care Unit; CHF = Congestive Heart 
Failure; COPD = Chronic Obstructive Pulmonary Disease; DC = Disease Count (Unweighted); ED = Emergency Department; EDC = Expanded Diagnosis Clusters; ERA = Elder Risk Assessment; GP = General 
Practice; HCC = Hierarchical Condition Categories; HSMI = Health Search Morbidity Index; ICD-10 = International Classification of Diseases, Tenth Revision; ICPC-2 = International Classification of Primary Care, 
Second Edition; ICU = Intensive Care Unit; MI = Myocardial Infarction; OLS = Ordinary Least Squares; QOF = Quality and Outcomes Framework; RUB = Resource Utilisation Band. 
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 Western University  
CHAPTER FOUR 
 A cross-sectional study on the level of Multimorbidity 
and its association with Depression, Anxiety and 
Quality of Life (MDAQ) 
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Abbreviations 
 
ADC-EMR Additional Disease Count - Electronic Medical Record 
ADC-SR Additional Disease Count - Self-reported 
BI  Bias index 
BMI  Body Mass Index 
BP  Blood pressure 
CDCS  Chronic Disease Control Score 
CMC  Chronic Medication Count 
DBP  Diastolic Blood Pressure 
EMR  Electronic Medical Records 
EQ-5D  EuroQol Office Quality of life scale 
GAD-7 Generalised Anxiety Disorder Scale 
HbA1c  Glycated Haemoglobin 
HDB  Housing Development Board 
HUDC  Housing and Urban Development Company 
IQR  Inter-quartile range 
LD  Listwise Deletion 
LDL-C Low-density lipoprotein 
MAR  Missing at random 
MCAR Missing completely at random 
MI  Multiple Imputation 
MNAR Missing not at random 
NHGP  National Healthcare Group Polyclinics 
OR  Odds ratio 
PABAK Prevalence-adjusted bias-adjusted kappa 
PHQ-9  Patient Health Questionnaire Depression Scale 
PI  Prevalence index 
SBP  Systolic Blood Pressure 
SD  Standard deviation 
SE  Standard error 
SPSS  IBM Statistical Analysis Software 
STROBE Strengthening the Reporting of Observational Studies in Epidemiology 
UI  EuroQol Office Quality of life scale - Utility Index 
VAS  EuroQol Office Quality of life scale - Visual Analogue Scale 
VIF  Variance inflation factor 
W  Width 
κ  Cohen's kappa statistic  
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1 Introduction 
 
A clear association between illness burden and psychological distress has been reported in the 
literature1.  It is believed that psychological distress arises through progressive loss of 
independence, self-esteem, and self-identity as the number of chronic conditions increase2.  
Chapter two reported that the most common co-occurring chronic conditions found in primary 
care patients in Singapore are hyperlipidaemia, hypertension, and diabetes with a prevalence 
rate of 21.9% in the primary care setting (Chapter Two Table 2-10 p54).  If every chronic 
condition is poorly-controlled in a patient with multimorbidity, it is logical to assume that the 
illness burden would have been higher or worse than a patient whose multiple chronic 
conditions were well-controlled for every condition.  Moreover, it has been shown that 
reducing numerous risks simultaneously is beneficial because risk factors for cardiovascular 
disease tend to cluster and interact which exerts a greater combined risk3.   
 
Clinical practice guidelines on the control of clinical parameters of single diseases are widely 
available in the medical literature.  Based on the guidelines of specialty societies, optimal 
thresholds for some of these clinical parameters were combined from separate clinical practice 
guidelines as composite measures for reducing cardiovascular disease and were widely 
accepted as standards of care since the end of the 20th century4.  These standards of care quickly 
became performance measures for clinicians5.  The Ministry of Health (MOH) in Singapore 
also followed suit with the MOH’s Diabetes Mellitus Clinical Practice Guidelines published in 
20066.   
 
One success story of using a composite score for both clinical outcomes of patients with 
multimorbidity and provider’s performance measures of clinicians was reported in Taiwan7. 
However, adhering to the current clinical practice guidelines in caring for an older person with 
multimorbidity may result in undesirable effects8.  There is concern that performance measures 
may direct healthcare providers’ focus on improving outcomes of single diseases, rather than 
to manage the interactions of multiple chronic conditions9.  This is made worse when clinicians 
are blind to the extent to which treatment burden can unintentionally drag people down10.   
 
Findings from a qualitative study reported that patient’s perspectives of living with 
multimorbidity speak more to lower quality of life and functional challenges than to disease-
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specific issues11.  The inverse relationship between the level of multimorbidity and quality of 
life has been reported by multiple other studies using different methodologies12-21.  Patients 
with multimorbidity were also more likely to be screened positive for depression22.  Clinical 
depression was two to three times more likely in people with multimorbidity compared to 
people without multimorbidity23-25.  However, clinically depressed patients with 
multimorbidity were inconsistently picked up in primary care26. 
 
Although multimorbidity is commonly observed in Singapore, very few investigators have 
looked into the phenomenon locally, and even fewer studies were conducted to look at patient-
reported outcomes like depression, anxiety, and quality of life.  One exception is Quah et al.27 
who surveyed older adults in the primary care setting locally and found that multimorbidity 
was associated with lower quality of life.  Many of the multimorbidity studies that contributed 
to the burgeoning literature on the topic were conducted in North America or Europe.  
However, findings reported elsewhere may not apply to the local context.  
 
The entity of ‘diseases’ used by doctors do not always explain the individuals’ illness, and 
patient needs and symptom experience are not necessarily an indication of an underlying 
disease28.  Many multimorbidity studies were conducted by directly obtaining self-reported 
medical conditions from the patients.  Several studies have reported variable concordance rates 
that were reported by patients and what were recorded in their medical notes29-31.  A growing 
body of literature has raised concerns about the reliability of respondent recall, poor respondent 
understanding, and labelling of medical conditions when self-reporting of medical conditions 
was used in such studies29,32.   
 
Therefore, in this study, we proposed to look at the association of a composite score for 
measuring the level of multimorbidity derived from clinical data among patients with the triad 
of hyperlipidaemia, hypertension, and diabetes in primary care and determine its association 
with patient-reported outcome measures like depression, anxiety and quality of life.  Our 
primary research hypothesis was that with a higher level of multimorbidity, patients would 
experience a higher degree of depression and anxiety symptoms, and a lower quality of life.  
The second objective of the study was to describe the prevalence of depression and anxiety, 
and the average score of quality of life in individuals with the commonest triad of 
multimorbidity in primary care.  Our third objective was to determine the factors associated 
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with depression, anxiety or poor quality of life for patients with the commonest triad of 
multimorbidity.  Our final objective of this study was methodological as we determine the 
concordance rate between self-reported medical conditions by patients and medical conditions 
recorded in their clinical records. 
   
2 Methods  
 
This was a cross-sectional interviewer-administered questionnaire study conducted in the 
primary care population at one of the National Healthcare Group Polyclinics (NHGP) between 
August 2014 and June 2016. The study team received approval from the ethics review board 
(National Healthcare Group Domain Specific Review Board Reference number 2013/01053) 
on 5 June 2014, and the first patient was recruited on 12 August 2014.  We followed the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
guidelines33 in reporting this study.  This study received funding from an intramural grant. 
 
2.1 Setting 
 
Hougang Polyclinic is one of the nine polyclinics in the National Healthcare Group Polyclinics 
(NHGP) in the north-eastern part of Singapore.  Hougang Polyclinic provides a comprehensive 
range of health services for the family, functioning as a one-stop health centre providing 
treatment for acute medical conditions, management of chronic diseases, women and child 
health services, and dental care.  It operates with close to 180 staff including 24 doctors and 18 
nurses servicing up to 1,200 patients daily from 8 am to 4.30 pm.  It is opened for half a day 
every Saturday and closed on Sunday. 
 
2.2  Sampling 
 
The full inclusion criteria were listed as follows:  
a. Patients who were 21 years old and below 80 years old 
b. Patients with current co-existence of at least three chronic conditions, i.e., hyperlipidaemia, 
hypertension, and diabetes mellitus Type 1 or 2 
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c. Patients who were seen in Hougang Polyclinic at least twice in the last six months††††† for   
chronic disease management (information obtained from diagnosis codes) prior to 
commencement of the study 
d. Patients who were able to understand spoken English, Mandarin, Malay or Tamil and 
provided written informed consent 
e. Patients who consented to allow the study team to access their medical notes at Hougang 
Polyclinic 
 
A random sample of the eligible population in Hougang polyclinic was selected using the IBM 
Statistical Analysis software version 21 (SPSS).  Potential participants from this selected list 
were approached before/during/after their scheduled appointments at Hougang Polyclinic and 
invited to go to a nearby interview room where the research assistant would explain the research 
study.  All eligible participants were given the opportunity to ask questions and given ample 
time to think about participation.  Informed consent was obtained when the patient was 
agreeable to participate in the study. This consent also permitted the research team to obtain 
further data like recent biomedical results, medication list and other medical conditions from 
the electronic medical records (EMR).  We excluded pregnant women and patients who were 
cognitively not capable of providing consent.  The team members excluded pregnant women 
because the outcome measures on depression, anxiety and quality of life may be strongly 
influenced by pregnancy rather than multimorbidity. 
 
2.3 Conduct of the interview 
 
All our research assistants and coordinators met regularly and practised interviewing on each 
other under the supervision of the principal investigator to ensure that the assistance provided 
and answers to anticipated questions raised by participants were standardised as much as 
possible before embarking on the actual research to reduce interviewer bias. 
 
We used all four official languages of Singapore to conduct the interviews according to the 
choice of the participants.  The principal research assistant was proficient in English and 
Mandarin only.  For Malay and Tamil-speaking participants, we made special arrangements to 
                                                 
††††† We selected patients who visited two visits in the last six months as a proxy to represent patients who have 
chosen Hougang Polyclinic as the designated polyclinic for management of their chronic medical conditions. 
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bundle the appointments together so that other research assistants proficient in those languages 
would meet potential participants at Hougang Polyclinic on a pre-arranged date and time. We 
also arranged a convenient time for participants to return to the polyclinic for the interview if 
their agendas were not able to accommodate the interview during their polyclinic scheduled 
appointments. 
 
The study questionnaire was programmed on the QuickTapSurvey (www.quicktapsurvey.com) 
app on a tablet computer. The questionnaire included all the demographic questions, outcome 
variables described in 2.4, and the independent variables described in section 2.5.  Data were 
entered by the research assistant directly into the tablet computer.  Each interview took 
approximately 30 minutes.  All patient information was de-identified upon completion of the 
relevant data collection from the EMR before analysis was commenced. 
 
2.4 Outcome variables 
 
The three outcome variables were Patient Health Questionnaire Depression Scale (PHQ-9)34,35, 
Generalised Anxiety Disorder Scale (GAD-7)36, EuroQol Office Quality of life scale (EQ-5D-
3L) Utility index (UI)37 and EuroQol Office Quality of life scale (EQ-5D-3L) Visual Analogue 
Scale (VAS)37 score.  Both EQ-5D-3L UI and VAS were continuous variables. 
 
(1) The PHQ-934 is a nine-item depression measure where respondents were asked whether 
they were bothered by a series of problems in the past two weeks and if so, how often, using 
a four-point scale from ‘not at all’ to ‘nearly every day’. Individual scores from each item 
were summed, and a higher total score indicated greater depression as shown in Appendix 
4-1.  The PHQ-9 is a valid and reliable measure of depression screening in Singapore38.  
Using the cut-off score of 10, the PHQ-9 has a sensitivity of 88% and a specificity of 88% 
for major depression35.  We chose values equal to or greater than five as being indicative 
of symptoms of depression39,40.  PHQ-9 was a dichotomous variable (‘<5’ as equivalent to 
‘minimal depressive symptoms’ and ‘>=5’ as ‘mild to severe depressive symptoms’) 
 
(2) The GAD-736 is a seven-item anxiety measure where respondents were asked whether they 
were bothered by a series of problems in the past two weeks and if so, how often, using a 
four-point scale from ‘not at all’ to ‘nearly every day’. Individual scores of each item were 
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summed, and a higher score indicated greater anxiety as shown in Appendix 4-2.  Though 
designed primarily as a screening and severity measure for generalised anxiety disorder, 
the GAD-7 also has moderately good operating characteristics for three other common 
anxiety disorders – panic disorder, social anxiety disorder, and post-traumatic stress 
disorder.  Using the threshold score of 10, the GAD-7 has a sensitivity of 89% and a 
specificity of 82% for generalised anxiety disorder36.  We chose values equal to or greater 
than five as being indicative of symptoms of anxiety to account for emotional 
morbidity39,40. GAD-7 was a dichotomous variable (‘<5’ as equivalent to ‘minimal anxiety 
symptoms’ and ‘>=5’ as ‘mild to severe anxiety symptoms’) 
 
(3a) The EQ-5D-3L37 is a standardised measure of health status comprising a descriptive 
system - Utility Index (UI) and a Visual Analogue Scale (VAS). 
 
The Utility Index (UI) assessed five domains (i.e., mobility, self-care, usual activities, 
pain/discomfort, anxiety/depression) and participants were asked to rate their health on that 
day of the interview on a three-point scale (no problem/moderate problem/extreme 
problem).  Responses to these five domains were converted into one of 243 different health 
state descriptions which ranged between no problems on all five dimensions (11111) and 
severe/extreme problems on all five dimensions (33333). (Appendix 4-3)  
 
The utility of EQ-5D health states was originally elicited using the time trade-off method 
from a representative sample of the United Kingdom general population to value a number 
of potential EQ–5D states (the time trade-off seeks to establish by how much one would be 
willing to reduce one’s life expectancy in order to obtain full health)41.  The EQ-5D-3L UI 
used in this study was based on a representative sample of a Singapore general population 
that has been validated and ranged from -0.769 to 1.00042.  Negative values represent health 
states worse than being dead, ‘0’ representing being dead, and ‘1.000’ representing a state 
of full health. 
 
(3b) The EQ-5D-3L VAS recorded the participant’s self-rated health on a vertical, visual 
analogue scale where the endpoints were labelled ‘best imaginable health state’ (100) and 
‘worst imaginable health state’ (0). (Appendix 4-4) 
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2.5 Independent variables 
 
All the demographic information was obtained during the interview.  These included the year 
of birth (age was calculated from the interview date), sex, ethnicity, first language, marital 
status, education level, housing type, ownership status of current housing, and monthly 
household income.  We obtained the body mass index (BMI) within 12 months before the 
interview as a continuous variable from the EMR.  We measured the level of multimorbidity 
in four ways – Chronic Disease Control Score (CDCS), Additional Disease Count - Self-
Reported (ADC-SR), Additional Disease Count - Electronic Medical Record (ADC-EMR) and 
Chronic Medication Count (CMC).  ‘Disease count’ and ‘Chronic Medication Count’ are 
described in the systematic review of the literature found in Chapter Three of this thesis.  We 
refer to these four measures as the ‘instruments for measuring the level of multimorbidity’ from 
hereon.  All the instruments for measuring the level of multimorbidity were not pre-existing 
clinical measurements and were created for this study by referring to the instruments listed in 
the systematic review in Chapter three.  Appendix 4-5 summarises a list of all the independent 
and outcomes variables. 
 
We grouped the independent variables into the following categories after exploring the data set 
using SPSS.  The age range was grouped into four categories‡‡‡‡‡ – ‘< 55’, ‘55-64’, ‘65-74’, 
and ‘≥ 75’ according to the Singapore population census classification43.  We grouped ‘sex’ 
into two categories – ‘Male’ and ‘Female’, and ‘ethnicity’ into two categories – ‘Chinese’ and 
‘Non-Chinese’.  ‘First language’ was grouped into four categories – ‘English’, ‘Mandarin’, 
‘Chinese dialects’, and ‘Others’.  ‘Marital status’ was grouped into two categories – ‘Married’, 
and ‘Single/Separated/Divorced/Widowed’.  ‘Education level’ was grouped into four 
categories – ‘No formal education’, ‘Primary’, ‘Secondary’ and ‘Post-Secondary’.  ‘Housing 
type’ was grouped into four categories – ‘HDB§§§§§ 1/2/3 room’, ‘HDB 4 room’, ‘HDB 5 room 
& HUDC******’, and ‘Private Housing’.  ‘Ownership status of current housing’ was grouped 
into two categories – ‘Owner’ and ‘Non-owner’.  Finally, we grouped ‘Monthly household 
                                                 
‡‡‡‡‡ Policymakers in Singapore prefer to have age as a categorical variable instead of a continuous variable 
§§§§§ Housing Development Board (public housing in Singapore) – the type of HDB flat has been used as a proxy for 
measuring socioeconomic status in Singapore.  An HDB 1-room flat is typically about 23 square metres and a HDB 5-room 
flat is typically about 110 square metres in area. 
****** Housing and Urban Development Company (for Singaporeans who can afford something better than the typical public 
housing but still find private housing unaffordable) 
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income’ into five categories – ‘< SGD†††††† 2,000’, ‘SGD 2,000-3,999’, ‘SGD 4,000-5,999’, 
‘SGD ≥ 6,000’, and ‘Income not disclosed’. 
 
The level of multimorbidity was measured in four ways.  The first was CDCS, a composite 
score on whether all three conditions – hyperlipidaemia44,45, hypertension46,45, and diabetes47,45 
were optimally controlled strictly according to each of their respective clinical practice 
guidelines.  The clinical parameters obtained were based on the last single clinical parameter 
measured that was closest to the date of the interview.  This was based on the latest single 
clinical parameter of glycated haemoglobin (HbA1c) within six months prior to the interview, 
low-density lipoprotein (LDL-c) within twelve months before or four weeks after the interview, 
systolic blood pressure (SBP), and diastolic (DBP) recorded in the electronic medical record 
(EMR) within six months before the interview.  CDCS was grouped into four categories – 
‘1’,’2’,’3’, and ‘4’ (Appendix 4-6).  ‘1’ means that all of the three conditions (hyperlipidaemia, 
hypertension and diabetes) were optimally controlled; ‘2’ means that one of the three 
conditions was sub-optimally controlled and the other two were optimally controlled; ‘3’ 
means that two of the three conditions were sub-optimally controlled and the other one was 
optimally controlled; and ‘4’ means that all three conditions were sub-optimally controlled.   
 
The second measure for the level of multimorbidity, the Additional Disease Count - Self-
Reported (ADC-SR), was based on the total number of other chronic condition (i.e., excluding 
hyperlipidaemia, hypertension, and diabetes) that was reported by the participant to the 
interviewer.   
 
The third measure for the level of multimorbidity, the Additional Disease count – Electronic 
Medical Records (ADC-EMR), was based on the total number of other chronic condition (i.e., 
excluding hyperlipidaemia, hypertension, and diabetes) that was ever coded in the EMR of that 
participant.  The list of 15 chronic conditions was based on the Chronic Disease Management 
Program‡‡‡‡‡‡ list of chronic conditions stipulated by the Ministry of Health, Singapore in 
201445 (Appendix 4-7).  This was one of the two lists of chronic conditions for measuring the 
prevalence of multimorbidity in Chapter Two of this thesis.  We used O’Halloran and 
colleagues’ definition of chronicity of a disease as lasting at least six months, having a 
                                                 
†††††† SGD – Singapore Dollar (1.00 Singapore dollare = 0.99 Canadian dollar) 
‡‡‡‡‡‡ The number of chronic conditions has increased over the years.  There were 18 conditions in 2014 and 20 conditions in 
2018.  Chapter Two used 20 conditions. 
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documented pattern of recurrence or deterioration, and having an impact on an individual’s 
quality of life48. 
 
After exploring the data set using SPSS, we found that the frequency distributions for ADC-
SR and ADC-EMR were heavily right-skewed with clustering at 0 (Appendix 4-8).  As such, 
they were grouped into three categories – ‘0’,1’, and ‘2 or more’ additional chronic conditions.  
  
The fourth measure for the level of multimorbidity, the Chronic Medication Count (CMC), was 
based on the total number of chronic medications currently prescribed in the EMR.  We 
excluded medications prescribed for acute conditions and also excluded supplements except 
for patients with known nutritional deficiency recorded in the clinical notes, e.g., iron 
supplements for patients with anaemia.  CMC was a count variable (Appendix 4-8). 
  
2.6 Sample size calculation 
 
A regression model was used to answer the primary research hypothesis on whether a higher 
level of multimorbidity was associated with a higher degree of depression and anxiety 
symptoms, and a lower quality of life.  We also used the same regression model for determining 
the association between the sociodemographic variables and the outcome variables.  We used 
the ‘rules of thumb’ for determining sample size for regression equations using six or more 
predictors49.  VanVoorhis and Morgan49 suggested that approximately 30 or more participants 
per variable would be adequate to achieve 80% power, especially when the dependent variable 
may be skewed or the effect size expected is small.  We decided to use 50 participants per 
variable to account for the above as the outcome variable (EQ-5D) is expected to be negatively 
skewed with clustering at ‘1’ for utility index and ‘80-90’ for visual analogue scale50.  
Therefore, a sample size of 700 was required for a regression with 14 independent variables.   
 
For the prevalence of depression and anxiety, the sample size calculation was based on Jani et 
al.’s22 report that the prevalence of having depressive and anxiety symptoms in a population 
with multimorbidity was 24.3% by using the Hospital Anxiety and Depression Score.  By using 
a 5% significance level and 10% total width of confidence interval with an estimated proportion 
of 25% (round up from 24.3% from Jani et al.’s study), a sample size of 288 was required to 
estimate the prevalence in this study51. 
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For the quality of life outcome, where we determined the mean score of the utility index and 
visual analogue scale of EQ-5D, the sample size calculation was based on Abdin et al.’s52 report 
that the mean EQ-5D index score for the Singapore population was 0.95 with a standard error 
(SE) of 0.002 and a total sample size of 5,594.  From the study, we calculated the standard 
deviation (SD) using the formula SD=SE*√n (i.e., SD=0.002*√5594=0.150)51.  Using a total 
width (W) of the mean EQ-5D UI score as 0.020, the standardized width would be 0.133 (i.e., 
W/SD = 0.020/0.150=0.133).  By using a confidence level of 95%, and a 0.150 standardised 
width (round up from 0.133), a sample size of 683 was required51. 
 
Finally, for determining the concordance between self-reported and medical records 
conditions, the sample size calculation was based on Wu et al.’s30 report that the concordance 
rate kappa statistic (κ) between self-reported medical conditions and those recorded in clinical 
notes ranged between 0.4 to 0.6 (fair to moderate concordance). By using table 3 from Temel 
and Erdogan’s paper53 on sample size determination in agreement studies, we required a sample 
size of 847 when we chose a confidence level of 95%, a power of 80% with a disagreement 
probability of 0.1 based on an expected κ of 0.4.  
 
The largest sample size from all the above calculations was used to account for enough power 
to answer all the research questions in the study.  Taking into account 5% missing data whereby 
listwise deletion could be safely practiced54, a sample size of 892 was considered desirable.  
While it might be decided to conduct multiple imputation, assuming listwise deletion provides 
a conservative estimate of sample size calculation.  We rounded the number up to 900 and 
assuming a 50% response rate from the respondents, we used a computerised randomisation 
program and tagged 1800 potential participants in the electronic medical records. 
 
2.7 Statistical Analysis 
 
Descriptive analysis was used to describe the characteristics of the data set.  We described the 
mean and median for continuous variables with their respective standard deviation and 
interquartile range.  For categorical variables, we described proportions.  Frequencies, 
percentages, cross-tabulations, and graphical display were used to present results. 
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Bivariate analyses were conducted to examine the associations between the outcomes and 
different instruments for measuring the level of multimorbidity without controlling for each 
other.  Non-parametric tests were used for EQ-5D UI and EQ-5D VAS as they failed the 
normality tests56 (Appendix 4-9).  CMC was considered to have a normal distribution and 
parametric test was used55 (Appendix 4-8).  
 
We used the chi-square tests to examine the association between the level of multimorbidity 
(CDCS) with depression (PHQ-9) and anxiety (GAD-7) (Table 4-7).  The Kruskal Wallis tests 
were used to examine the association between the level of multimorbidity (CDCS) with the 
quality of life (EQ-5D UI and EQ-5D VAS) (Table 4-8).  Chi-square tests were conducted to 
examine the level of multimorbidity (ADC-SR and ADC-EMR) with depression (PHQ-9) and 
anxiety (GAD-7) (Table 4-9).  The Kruskal Wallis tests were used to examine the association 
between the level of multimorbidity (ADC-SR and ADC-EMR) with the quality of life (EQ-
5D UI and EQ-5D VAS) (Table 4-10).  Student t-tests were used to examine the association 
between the level of multimorbidity (CMC) with depression (PHQ-9) and anxiety (GAD-7) 
(Table 4-11).  Spearman correlation was used to examine the relationship between the level of 
multimorbidity (CMC) with the quality of life (EQ-5D UI and EQ-5D VAS) (Table 4-11).  We 
did not adjust for multiple paired comparisons using Bonferroni adjustment as the main 
findings were explained by the multivariable regression analyses as described below. 
 
Binary logistic regression was used to test the association between the two outcomes of 
depression (PHQ-9) and anxiety (GAD-7) and the four instruments for measuring the level of 
multimorbidity (Table 4-12).  Linear regression with the log link function was used to test the 
association between the two quality of life outcomes (EQ-5D UI and EQ-5D VAS) and four 
instruments for measuring the level of multimorbidity after log transformation§§§§§§ of EQ-5D 
UI and EQ-5D VAS (Table 4-13).  We adjusted all regression analyses for age, sex, and the 
other eight independent variables including ethnicity, first language, marital status, education 
level, housing type, ownership status of current housing, monthly household income, and body 
mass index.  We measured multicollinearity for the independent variables by using the variance 
inflation factor (VIF) which assessed how much the variance of an estimated regression 
coefficient increased if the predictors were correlated with some of the other independent 
                                                 
§§§§§§ We log transformed the variables EQ-5D UI and EQ-5D VAS as both variables and their residuals failed the normality 
tests (Appendix 4-9). 
185 
 
  
                                                                                                                                                                            
  
variables57 (Appendix 4-10).  We used the lower conventional VIF cut-off of greater than five 
as suggestive for detecting multicollinearity57. 
 
Concordance for the additional chronic conditions between self-reported and those recorded in 
electronic medical records was evaluated using Cohen’s kappa statistics (κ) (Table 4-14).  This 
was a methodological section embedded within the cross-sectional study.  Cohen’s kappa is a 
measure that adjusts for the agreement that is expected by chance58.  However, on its own, a 
kappa value is not very informative and it is strongly recommended that the positive and 
negative agreements be presented together58.  Therefore, we also reported the bias index (BI), 
prevalence index (PI), and the prevalence-adjusted bias-adjusted kappa (PABAK) as the 
magnitude of κ is highly influenced by the prevalence of the condition as well as the bias 
between the two data sources59. 
 
Statistical significance was defined as p < 0.05 and confidence intervals were set at 95% for 
both bivariate and multivariable analysis.  The interpretation for kappa (κ) was based on Landis 
and Koch’s classification60. 
 
We carried out a sensitivity analysis on the multivariable regression analyses to assess the 
robustness of the results to probable departures from the missing data assumption made in the 
main analysis.  IBM SPSS version 24 was used for all statistical analysis. 
 
2.8 Handling of missing data 
 
We employed several approaches to look at the extent of missing data, the missing data 
mechanism and patterns of missing data61.  First, we used SPSS to find the variables with 
missing data and also the total number of cases with missing data.  We next conducted the 
Little’s test62 to check for the missing data mechanism to determine whether they were missing 
completely at random (MCAR).  If the missing data were not MCAR, we explored the 
missingness to make a judgement call on whether they were missing at random (MAR) or 
missing not at random (MNAR).  Finally, we looked at the patterns of missingness to see 
whether they were monotone (i.e., if a participant drops out at one point, his/her data are 
missing on subsequent measures) or arbitrary (i.e., random fashion) in nature63.  Depending on 
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the above findings, our team would consider using the conventional approach like listwise or 
pairwise deletion, or the principled method to deal with missing data like multiple imputation64. 
 
If multiple imputation was used, the number of imputations used would be higher than the 
percentage of the missing data in the analysis65 (i.e., if 7.9% of data was missing, the number 
of imputations used should be eight). 
 
2.9 Subgroup Analysis 
 
We used chi-square tests for comparing proportions to examine the difference between the 
demographic characteristics of participants who did not disclose their household income with 
those who declared. 
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3 Results 
 
Figure 4-1. Flow chart of participant recruitment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total number of patients with at least 
three of the specified chronic 
conditions  
(n=11,389) 
Total number of patients approached for 
participation  
(n=1,650)   
Total number of participants  
(n=932)   
Declined to participate (n=238)   
Other reasons (n=195)   
Withdrew (n=1)    
Not meeting inclusion criteria 
(n=284)   
Total number of patients eligible for 
participation  
(n=1,366)   
Total number of patients who fulfilled 
the age criteria  
(n=9,954) 
Total number of patients randomly 
selected 
(n=1,800)  
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3.1 Patient participation 
 
We approached 1,650 potential participants and invited them to participate in this study.  There 
were 284 of these potential participants who were deemed not meeting inclusion criteria 
leaving 1,366 eligible patients.  The main reason was due to the language barrier.  Of these 
1,366 eligible potential participants, there were 238 patients who refused to participate, 195 
patients who were not able to participate due to various reasons (mainly due to inability to get 
a scheduled appointment for interview), and one patient who withdrew the next day after 
completing the interview.  The final number of participants recruited was 932 out of 1,366 
giving a response rate of 68.2%. 
 
Four hundred and thirty-four potential participants did not join the study due to various reasons.  
We collected the de-identified information of the sex and ethnicity characteristics of all 
potential participants who declined to take part in the study to detect whether there were 
differences in characteristics between them and those who participated in the study. 
 
Table 4-1. Demographic Characteristics of patients who Declined participation and patients 
who were Recruited for the Study 
 Declined (n=434) Recruited (n=932) p-value^ 
Sex    
Male 209 (48.2%) 513 (55.0%) 0.02* 
Female 225 (51.8%) 419 (45.0%) 
Ethnicity    
Chinese 347 (80.0%) 769 (82.5%)  
0.56 Malay 33 (7.6%) 70 (7.5%) 
Indian 46 (10.6%) 77 (8.3%) 
Others 8 (1.8%) 16 (1.7%) 
 
We performed a chi-square test to explore whether there were differences between sex and 
ethnicity of those who participated and those who did not (Table 4-1).  The difference between 
the sex composition was statistically significant (p = 0.02).  There were significantly more men 
than women in the study as more women than men declined to participate. 
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3.2 Missing Values 
 
There were six variables with missing data (Figure 4-2), namely monthly household income, 
BMI, ADC-SR, CDCS due to various missing data of glycated haemoglobin (HbA1c), low-
density lipoprotein (LDL-C), and/or blood pressure (BP), housing type, and house ownership 
(Table 4-2).  In total, there were 306 participants or 32.8% of the data with missing data from 
the 932 participants (Figure 4-3). 
 
We conducted the Little’s test to check for the null hypothesis that all the missing values were 
missing completely at random (MCAR) using SPSS62. The null hypothesis was rejected*******, 
and therefore the missing data were not MCAR.  As more than 25% of participants did not 
declare their household income, we assumed that missing data of household income might not 
be missing at random (MAR).  We aggregated all those with missing data for the declaration 
of household income into one new category - ‘Income not disclosed’, and treated that as a valid 
response category in the analysis. 
 
 
Figure 4-2. Missing data by variables  Figure 4-3. Missing data by cases 
 
 
 
 
 
  
                                                 
******* The Little's MCAR test showed a Chi-Square value of 117.630 (14), p < 0.001 
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Table 4-2. Predictor Variables with Missing Data 
  
Predictor Variables 
Missing Values  
Valid N N % 
Monthly Household Income 238 25.5 694 
BMI 38 4.1 894 
ADC-SR 29 3.1 903 
CDCS 19 2.0 913 
Housing Type 2 0.2 930 
House Ownership 1 0.1 931 
 
After excluding this variable, we repeated the Little’s test, and the null hypothesis††††††† was 
again rejected despite having 9.12% (n=85) of all cases having a missing value (Figures 4-4 & 
4-5).  We explored the missingness of the data and concluded that these missing data were 
likely to be missing at random (MAR).  For example, the missing values for BMI were likely 
due to sporadic weighing machine downtime that failed to port over the values to the EMR.  
Consequently, the team concluded that listwise deletion (LD) would introduce bias and 
multiple imputation (MI) using SPSS would be used for determining the relationship between 
the level of multimorbidity and depression, anxiety and quality of life.  MI was also used to 
determine the factors associated with the three outcomes. We used MI as it is a powerful 
statistical tool for handling missing data and have an advantage of including auxiliary 
information about the missing data into the final analysis66.  With 9.12% missing data, we 
performed multiple imputation using ten imputations for all our analyses65.  For preserving the 
maximum amount of data collected from all the participants, we described the data in Tables 
4-4 and 4-5 using pairwise deletion.  We also used pairwise deletion for determining the 
concordance rate between additional chronic conditions self-reported (ADC-SR) and electronic 
medical records (ADC-EMR) (Table 4-14).   
  
                                                 
††††††† The Little's MCAR test showed a Chi-Square value of 122.372 (14), p < 0.001 
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Figure 4-4. Missing data by variables    Figure 4-5. Missing data by cases 
(excluding Monthly household income)    (excluding Monthly household income) 
 
 
 
 
 
 
Table 4-3. Predictor Variables (exclusion of Monthly Household Income) with Missing Data 
 
Predictor Variables 
Missing Values  
Valid N N % 
BMI 38 4.1 894 
ADC-SR 29 3.1 903 
CDCS 19 2.0 913 
Housing Type 2 0.2 930 
House Ownership 1 0.1 931 
 
3.3 Descriptive Data 
  
Table 4-4 summarises the sociodemographic characteristics of 932 recruited participants.  The 
median age of the participants was 65.0 years (IQR 58.0 – 71.0).  There were more male 
participants than female participants (55%:45%), and the majority of the participants were of 
Chinese ethnicity (82.5%).  More than 37% of participants used Mandarin, ¼ of them used 
English with close to another ¼ of them using Chinese dialects as their first language.  Close 
to 80% of the participants were married.  Approximately half of them had primary education 
and below; the other half had secondary education and above.  A large majority of them stayed 
in subsidised housing, and more than 80% of them owned their own homes.  The largest group 
of participants had a household income of less than SGD 2,000.  Slightly more than ¼ of the 
participants did not disclose their monthly household income. 
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Table 4-5 summarises the clinical parameters and characteristics of the study population. The 
median body mass index (BMI) was 26.0 kg/m2 (IQR 23.7 – 28.8).  Based on the Asian cut-
off of BMI at 23 kg/m2, 80.3% of the participants were overweight.  The median HbA1c was 
7.1% (IQR 6.5 – 7.8) with 57.1% of the participants having sub-optimal diabetes control 
according to the cut-off of 7.0%.  The median LDL-C level was 2.20 mmol/L (IQR 1.78 – 2.48) 
indicating that a large majority of the participants (80.2%) were optimally controlled with a 
cut-off of 2.6 mmol/L.  Blood pressure using a cut-off of 140/80 mmHg showed that 66.1% of 
the participants were optimally controlled.  Using the Chronic Disease Control Score (CDCS) 
to classify participants into the various levels of multimorbidity based on the four individual 
biomedical parameters, 235 or 25.7% of the participants had all three conditions optimally 
controlled (CDCS ‘1’).  The majority (433 or 47.4%) had at least one out of the three chronic 
conditions that was controlled sub-optimally (CDCS ‘2’). 
 
The mean number of ADC-SR by the participants was 0.7 (SD‡‡‡‡‡‡‡ 0.8), and the mean number 
identified for ADC-EMR was 1.2 (SD 1.0).  The mean number of chronic medication count 
(CMC) retrieved from the electronic medical records was 4.5 (SD 2.1). 
 
Table 4-6 summarises the proportion of participants that belonged to each category for the 
outcome variables.  The prevalence of participants reporting depressive symptoms was 12.0%.  
The prevalence of participants reporting anxiety symptoms was 11.8%.  The mean EQ-5D UI 
score for the participants was 0.890 (SD§§§§§§§ 0.190).  The median VAS score was 75.0 (IQR 
65.0 - 80.0). 
                                                 
‡‡‡‡‡‡‡ SD – standard deviation.  The mean instead of the median was presented for easier comparison between ADC-SR and 
ADC-EMR because median was 1.0 for both the variables due to the skewed frequency distribution. 
§§§§§§§ SD – standard deviation.  The mean and standard deviation was given for EQ-5D UI as the median was 1.000 due to 
the ceiling effect of the scale. 
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Table 4-4. Sociodemographic Characteristics of Recruited Participants 
Parameters and Characteristics Descriptive Statistics % 
Age   
n 932  
Mean ± SD 64.5 ± 8.5  
Median (IQR) 65.0 (58.0 – 71.0)  
<55 years old 115 12.3 
55-64 years old 330 35.4 
65-74 years old 360 38.6 
≥75 years old 127 13.6 
Sex   
n 932 100.0 
Male 513 55.0 
Female 419 45.0 
Ethnicity   
n 932 100.0 
Chinese 769 82.5 
Non-Chinese 163 17.5 
Malay 70 7.5 
Indian 77 8.3 
Others 16 1.7 
First Language   
n 932 100.0 
English 233 25.0 
Mandarin 348 37.3 
Chinese Dialects 227 24.4 
Others 124 13.3 
Marital Status   
n 932 100.0 
Married 739 79.3 
Single/Separated/Divorced/Widowed 193 20.7 
Education Level   
n 932 100.0 
No Formal Education 172 18.5 
Primary 294 31.5 
Secondary 315 33.8 
Post-Secondary 151 16.2 
Housing Type   
n 930 100.0 
HDB 1/2/3 Room 194 20.9 
HDB 4 Room 390 41.9 
HDB 5 Room/Executive/HUDC 233 25.1 
Private Housing 113 12.1 
Ownership Status of Current Housing   
n 931 100.0 
Owner 766 82.3 
Non-Owner 165 17.7 
Monthly Household Income   
n 932 100.0 
<SGD2,000 340 36.5 
SGD2,000 – SGD3,999 160 17.2 
SGD4,000 – SGD5,999 99 10.6 
≥SGD6,000 95 10.2 
Income Not Disclosed 238 25.5 
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Table 4-5. Clinical Parameters and Characteristics of Recruited Participants 
Parameters and Characteristics Descriptive Statistics % 
Body Mass Index (BMI) (kg/m2)   
n 894  
Mean ± SD 26.5 ± 4.2  
Median (IQR) 26.0 (23.7, 28.8)  
Normal (<23.0 kg/m2) 176 19.7 
Overweight (≥23.0 kg/m2) 718 80.3 
Glycated Haemoglobin (HbA1c) (%)   
n 930 100.0 
Mean ± SD 7.3 ± 1.3  
Median (IQR) 7.1 (6.5, 7.8)  
Optimal Control (<7.0%) 399 42.9 
Sup-Optimal Control (≥7.0%) 531 57.1 
Low Density Lipoprotein Cholesterol (LDLc) (mmol/L)   
n 915 100.0 
Mean ± SD 2.20 ± 0.64  
Median (IQR) 2.20 (1.78, 2.48)  
Optimal Control (<2.6mmol/L) 734 80.2 
Sup-Optimal Control (≥2.6mmol/L) 181 19.8 
Systolic Blood Pressure (SBP) (mmHg)   
n 931 100.0 
Mean ± SD 130 ± 14  
Median (IQR) 130 (120, 138)  
Optimal Control (<140mmHg) 726 78.0 
Sup-Optimal Control (≥140mmHg) 205 22.0 
Diastolic Blood Pressure (DBP) (mmHg)   
n 931 100.0 
Mean ± SD 72 ± 9  
Median (IQR) 70 (66, 78)  
Optimal Control (<80mmHg) 722 77.6 
Sup-Optimal Control (≥80mmHg) 209 22.4 
Blood Pressure (BP) (mmHg)   
n 931 100.0 
Optimal Control 615 66.1 
Sup-Optimal Control 316 33.9 
Chronic Disease Control Score (CDCS)   
n 913 100.0 
Median (IQR) 2 (1, 3)  
1 (All 3 conditions optimally controlled) 235 25.7 
2 (1 condition sub-optimally controlled) 433 47.4 
3 (2 conditions sub-optimally controlled) 197 21.6 
4 (3 conditions sub-optimally controlled) 48 5.3 
Additional Disease Count – Self Reported (ADC-SR)   
n 932 100.0 
Mean ± SD 0.7 ± 0.8  
Median (IQR) 1.0 (0.0, 1.0)  
0 467 50.1 
1 356 38.2 
2+ 109 11.7 
Additional Disease Count – Electronic Medical 
Records (ADC-EMR) 
  
n 932 100.0 
Mean ± SD 1.2 ± 1.0  
Median (IQR) 1.0 (1.0, 2.0)  
0 230 24.7 
1 385 41.3 
2+ 317 34.0 
Chronic Medication Count (CMC)   
n 932 100.0 
Mean ± SD 4.5 ± 2.1  
Median (IQR) 4.0 (3.0, 6.0)  
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Table 4-6. Outcome Variables Obtained from PHQ-9, GAD-7, EQ-5D Questionnaires of 
Recruited Participants 
Outcome Variables Frequency (n=932) % 
PHQ-9   
Mean ± SD 1.6 ± 2.7  
Median (IQR) 1.0 (0.0, 2.0)  
Minimal (0-4) 820 88.0 
Mild to Severe (5-27) 112 12.0 
GAD-7   
Mean ± SD 1.5 ± 3.0  
Median (IQR) 0.0 (0.0, 2.0)  
Minimal (0-4) 822 88.2 
Mild to Severe (5-21) 110 11.8 
EQ-5D Utility Index (UI)   
Mean ± SD 0.890 ± 0.190  
Median (IQR) 1.000 (0.850, 1.000)  
EQ-5D Visual Analogue Scale 
(VAS) 
  
Mean ± SD 73.6 ± 15.5  
Median (IQR) 75.0 (65.0, 80.0)  
 
3.4 Bivariate Analyses 
 
There were no associations found between Chronic disease count score (CDCS) and depressive 
symptoms (PHQ-9), and CDCS and anxiety symptoms (GAD-7) (Table 4-7).  There were also 
no associations found between CDCS and quality of life for both utility index (EQ-5D UI) and 
visual analogue scale (EQ-5D VAS) (Table 4-8). 
 
A higher number of self-reported additional disease count (ADC-SR) was associated with 
higher depressive symptoms (PHQ-9) (Table 4-9), and with a lower quality of life score for 
EQ-5D UI (Table 4-10).  ADC-SR was not associated with anxiety symptoms (GAD-7) (Table 
4-9) nor EQ-5D VAS (Table 4-10).  A higher number of additional disease count from the 
electronic medical records (ADC-EMR) was associated with a lower quality of life (EQ-5D 
UI) (Table 4-10). There were no associations found between ADC-EMR and depressive 
symptoms (PHQ-9), anxiety symptoms (GAD-7) and EQ-5D VAS (Table 4-9 & 4-10). 
 
Chronic medication count (CMC) was not associated with depressive nor anxiety symptoms 
(Table 4-11).  Although a weak negative correlation was noted between CMC and quality of 
life (both EQ-5D UI and EQ-5D VAS), statistical significance was not reached (Table 4-11). 
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Table 4-7. Effect of Chronic Disease Count Score on Depression and Anxiety (n=932) 
Outcome 
Chronic Disease Count Score (CDCS) 
p-value* 
1 2 3 4 
PHQ-9 n n n n  
Minimal  209 384 181 46  
0.58 Mild to Severe 30 57 21 4 
% of mild to severe depression 12.6% 12.9% 10.4% 8.0%  
GAD-7     
 
Minimal 212 390 175 45 
0.74 
Mild to Severe 27 51 28 4 
% of mild to severe anxiety 11.3% 11.6% 13.8% 8.2%  
ˢp-value was obtained from chi-square test comparing between CDCS and PHQ-9 or GAD-7.  *p<0.05 is considered 
statistically significant 
 
Table 4-8. Effect of Chronic Disease Count Score on Quality of Life (n=932) 
 
Outcome 
Chronic Disease Count Score (CDCS)  
p-value* 1 2 3 4 
EQ5D-UI      
n 239 441 202 50 0.09 
Mean Rank 452.23 479.91 442.41 514.49 
EQ5D-VAS      
n 239 441 202 50 
0.61 
Mean Rank 448.17 474.79 465.90 483.74 
ˣp-value was obtained from Kruskall-Wallis test comparing between CDCS and ED5D-UI or EQ5D-VAS.  *p<0.05 is 
considered statistically significant. 
 
Table 4-9. Effect of Additional Disease Count on Depression and Anxiety (n=932) 
 
Outcome 
Level of Multimorbidity Measures 
ADC-SR ADC-EMR 
0 1 ≥2 
p-value 
0 1 ≥2 
p-value 
n n n n n n 
PHQ-9         
Minimal 425 312 84 
<0.01* 
 
 
209 340 271 
0.16 
Mild to Severe 42 44 25 21 45 46 
% of mild to 
severe depression  9.0% 12.4% 22.9%  9.1% 11.7% 14.5%  
GAD-7         
Minimal 415 318 89 
0.07 
194 348 280 
0.08 
Mild to Severe 52 38 20 36 37 37 
% of mild to 
severe anxiety 11.1% 10.7% 18.4%  15.7% 9.6% 11.7%  
ˇp-value was obtained from chi-square test between ADC-SR or ADC-EMR and PHQ-9 or GAD-7, ˆp-value was obtained 
from t-test comparing between CMC and PHQ-9 or GAD-7; **p<0.05 is considered statistically significant. 
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Table 4-10. Effect of Additional Disease Count on Depression, Anxiety and Quality of Life 
(n=932) 
Outcome 
Level of Multimorbidity Measures 
ADC-SR ADC-EMR 
EQ5D-UI 0 1 ≥2 p-value# 0 1 ≥2 p-value# 
n 467 356 109 
<0.01* 
230 385 317 
<0.01* 
Mean Rank 518.91 434.50 346.58 499.43 485.05 420.08 
         
EQ5D-VAS         
n 467 356 109 
0.37 
230 385 317 
0.384 
Mean Rank 474.54 465.53 435.18 472.20 476.81 449.85 
# p-value was obtained from Kruskall-Wallis test comparing between ADC-SR or ADC-EMR and EQ5D-UI or EQ5D-VAS, 
*p<0.05 is considered statistically significant.   
 
Table 4-11. Effect of Chronic Medication Count on Quality of Life (n=932) 
Outcome 
Chronic Medication Count 
n Mean 
Correlation coefficient 
(Rho) 
p-value* 
PHQ-9     
Minimal 820 4.51 
NA 0.40 
Mild to Severe 112 4.69 
     
GAD-7     
Minimal 822 4.51 
NA 0.37 
Mild to Severe 110 4.68 
     
EQ5D-UI NA NA -0.054 0.10 
EQ5D-VAS NA NA -0.060 0.07 
*p-value was obtained from t-test comparing between CMC and PHQ-9 or GAD-7, and p-value was obtained from 
Spearman’s Correlation test comparing between CMC and EQ5D-UI or EQ5D-VAS.  *p<0.05 is considered statistically 
significant.   
 
3.5  Multivariable Regression Analysis 
 
We measured multicollinearity for the independent variables by using the variance inflation 
factor (VIF) which assessed how much the variance of an estimated regression coefficient 
increased if the predictors were correlated with some of the other independent variables57.  The 
VIFs obtained were around 1.000, and therefore, we retained all the independent variables in 
the regression analysis (Appendix 4-10). 
 
3.5.1 Depression and Anxiety 
 
Logistic regression was performed to assess the impact of several factors on the likelihood that 
participants would report that they had a problem with depressive symptoms (Table 4-12).  
Only two of the independent variables made a unique statistically significant contribution to 
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the model: marital status; and ADC-SR.  This indicated that participants who were 
single/separated/divorced/widowed had 1.69 times greater odds of reporting a higher score for 
depressive symptoms using the PHQ-9 scale compared to those who were married (p=0.048).  
Participants who self-reported two or more additional chronic conditions had 3.09 times greater 
odds of reporting a higher score for depressive symptoms than those who did not report any 
additional chronic conditions (p < 0.01). 
 
Another logistic regression was conducted to assess the impact of the 14 predictor variables on 
the likelihood that participants would report that they had a problem with anxiety symptoms 
(Table 4-12).  Two of the independent variables made a unique statistically significant 
contribution to the model – ADC-SR and ADC-EMR.  Participants who self-reported two or 
more additional chronic conditions had 2.07 times greater odds of reporting a higher score for 
anxiety symptoms than those who did not report any additional chronic conditions (p=0.02).  
However, participants who had one additional chronic condition recorded in their electronic 
medical records had lower odds of reporting a lower score for anxiety symptoms using the 
GAD-7 scale than those who had no additional chronic conditions recorded in their notes 
(OR=0.53, p=0.02). 
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Table 4-12. The Effect of Sociodemographic and Clinical Predictor Variables on Depression 
and Anxiety of Recruited Participants (n=932) 
 
Predictor Variables 
PHQ9 GAD7 
Odds 
Ratio^ 
95% CI^ p-value^ Odds 
Ratio^ 
95% CI^ p-value^ 
Age       
<55 years old REF   REF   
55-64 years old 1.62 0.73, 3.60 0.24 0.93 0.49, 1.79 0.84 
65-74 years old 1.14 0.50, 2.61 0.75 0.71 0.35, 1.43 0.34 
≥75 years old 1.61 0.61, 4.21 0.33 0.91 0.37, 2.23 0.84 
Sex       
Male REF   REF   
Female 0.90 0.57, 1.40 0.63 1.18 0.75, 1.85 0.47 
Ethnicity       
Chinese REF   REF   
Non-Chinese 0.92 0.33, 2.57 0.87 0.63 0.23, 1.72 0.37 
First Language       
English REF   REF   
Mandarin 0.84 0.45, 1.58 0.59 0.74 0.40, 1.36 0.33 
Chinese Dialects 0.87 0.43, 1.77 0.70 0.56 0.27, 1.16 0.12 
Others 1.41 0.48, 4.18 0.53 1.89 0.66, 5.44 0.24 
Marital Status       
Married REF   REF   
Single/Separated/Divorced/Widowed 1.69 1.01, 2.85 0.048* 1.66 0.98, 2.82 0.06 
Education Level       
No Formal Education REF   REF   
Primary 1.12 0.62, 2.04 0.71 1.09 0.58, 2.03 0.80 
Secondary 0.72 0.36, 1.42 0.34 0.53 0.26, 1.09 0.08 
Post-Secondary 0.49 0.19, 1.23 0.13 0.73 0.31, 1.74 0.48 
Housing Type       
HDB 1/2/3 Room REF   REF   
HDB 4 Room 0.68 0.40, 1.14 0.14 0.79 0.45, 1.40 0.42 
HDB 5 Room/HUDC 0.70 0.37, 1.33 0.28 1.39 0.74, 2.58 0.30 
Private Housing 0.84 0.37, 1.94 0.69 0.86 0.35, 2.09 0.73 
Ownership Status of Current 
Housing 
      
Owner REF   REF   
Non-Owner 1.11 0.64, 1.93 0.71 0.86 0.47, 1.56 0.61 
Monthly Household Income       
<SGD2,000 REF   REF   
SGD2,000 – SGD3,999 1.07 0.59, 1.95 0.83 1.58 0.88, 2.82 0.12 
SGD4,000 – SGD5,999 1.17 0.52, 2.60 0.71 0.97 0.44, 2.13 0.93 
≥SGD6,000 1.45 0.66, 3.17 0.35 1.23 0.56, 2.72 0.61 
Income not disclosed 0.63 0.35, 1.12 0.11 0.82 0.45, 1.48 0.51 
^Odds ratio, 95% CI and p-values were obtained from logistic regression; REF – reference group; *p<0.05 is considered 
statistically significant. 
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Table 4-12. The Effect of Sociodemographic and Clinical Predictor Variables on Depression 
and Anxiety of Recruited Participants (n=932) (continued) 
 
Predictor Variables 
PHQ9 GAD7 
Odds Ratio^ 95% CI^ p-value^ Odds 
Ratio^ 
95% CI^ p-value^ 
Body Mass Index (BMI) 0.97 0.92, 1.02 0.26 1.01 0.96, 1.06 0.78 
Chronic Disease Control 
Score (CDCS) 
      
1 (All 3 conditions optimally 
controlled) 
REF   REF   
2 (1 condition sub-optimally 
controlled) 
1.15 0.69, 1.91 0.59 1.06 0.62, 1.80 0.83 
3 (2 conditions sub-optimally 
controlled) 
0.83 0.43, 1.58 0.57 1.06 0.57, 1.97 0.86 
4 (3 conditions sub-optimally 
controlled) 
0.51 0.15, 1.68 0.27 0.63 0.20, 1.99 0.43 
Additional Disease Count – 
Self Reported (ADC-SR) 
      
0 REF   REF   
1 1.36 0.84, 2.20 0.21 1.05 0.65, 1.69 0.85 
2+ 3.09 1.71, 5.58 <0.01* 2.07 1.12, 3.84 0.02* 
Additional Disease Count – 
Electronic Medical Records 
(ADC-EMR) 
       
0 REF   REF   
1 1.11 0.62, 1.99 0.72 0.53 0.31, 0.90 0.02* 
2+ 1.16 0.62, 2.14 0.65 0.61 0.34, 1.07 0.09 
Chronic Medication Count 
(CMC) 
1.04 0.94, 1.16 0.43 1.06 0.95, 1.18 0.33 
^Odds ratio, 95% CI and p-values were obtained from logistic regression; REF – reference group; *p<0.05 is considered 
statistically significant. 
 
3.5.2 Quality of Life (EQ-5D UI and EQ-5D VAS) 
 
We conducted a linear regression with log link function to explore the impact of using the same 
predictor variables with the quality of life (EQ-5D UI) as the dependent variable (Table 4-13). 
 
There were four independent predictors with a statistically significant lower quality of life 
score.  Participants who were 75 years old and above were more likely to report a lower UI 
score compared to those younger than 55 years old (p=0.03).  Those who received primary 
educational level were more likely to report a lower UI score compared to those who had no 
formal education (p=0.01).  A higher body mass index was associated with a lower UI score 
(p=0.01).  Finally, participants who reported one or more additional chronic conditions were 
more likely to report a lower UI score when compared with those who did not self-report any 
additional chronic conditions (one condition, p < 0.01; and two or more conditions, p < 0.01). 
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There were two independent predictors that were associated with a statistically significant 
higher quality of life score.  Participants who stayed in private housing were more likely to 
report a higher UI score as compared to those who stayed in the smallest public housing 
(p=0.03).  Participants who had all three chronic conditions (hyperlipidaemia, hypertension, 
and diabetes) sub-optimally controlled also reported a higher UI score when compared to those 
participants who had all three chronic conditions optimally controlled (p=0.03). 
 
We conducted a second linear regression with log link function to explore the impact of using 
the same predictor variables with the quality of life (EQ-5D VAS) as the dependent variable 
(Table 4-13). There were three independent predictors with a statistically significant lower 
quality of life. 
   
Participants who had higher education were more likely to report a lower VAS score compared 
to those who had no formal education (p < 0.01 for all three categories).  The trend seemed to 
suggest that the higher the education, the lower the VAS score.  Participants who did not 
disclose their income also reported lower VAS score when compared to those who earned less 
than SGD 2,000 (p < 0.01).  A higher chronic medication count was associated with a lower 
VAS score (p=0.02).  
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Table 4-13. The Effect of Sociodemographic and Clinical Predictor Variables on Quality of Life of Recruited Participants (n=932) 
 
Predictor Variables 
EQ5D-UI EQ5D-VAS 
Unadjusted 
Mean (SD) 
Adjusted 
Mean (SE) 
Beta 
Coefficient^ 
95% CI^ p-value^ Unadjusted 
Mean (SD) 
Adjusted 
Mean (SE) 
Beta 
Coefficient^ 
95% CI^ p-value^ 
Age           
<55 years old 0.910 (0.177) 0.883 (0.021) REF   72.3 (17.1) 74.2 (1.7) REF   
55-64 years old 0.899 (0.169) 0.881 (0.016) -0.002 -0.045, 0.042 0.94 72.6 (14.8) 74.2 (1.3) -0.001 -0.045, 0.044 0.98 
65-74 years old 0.895 (0.194) 0.877 (0.015) -0.007 -0.053, 0.039 0.77 74.1 (15.6) 75.2 (1.3) 0.014 -0.033, 0.061 0.57 
≥75 years old 0.837 (0.241) 0.825 (0.020) -0.068 -0.128, -0.008 0.03* 75.9 (15.0) 76.6 (1.8) 0.032 -0.027, 0.090 0.29 
Sex           
Male 0.904 (0.192) 0.877 (0.015) REF   72.3 (14.7) 74.4 (1.2) REF   
Female 0.873 (0.190) 0.856 (0.014) -0.025 -0.053, 0.004 0.09 75.1 (16.3) 75.7 (1.2) 0.018 -0.010, 0.046 0.22 
Ethnicity           
Chinese 0.893 (0.194) 0.861 (0.015) REF   73.2 (15.2) 73.1 (1.2) REF   
Non-Chinese 0.877 (0.180) 0.871 (0.022) 0.012 -0.050, 0.073 0.71 75.4 (16.7) 77.1 (2.0) 0.054 -0.008, 0.116 0.09 
First Language           
English 0.922 (0.140) 0.877 (0.018) REF   71.3 (15.0) 74.7 (1.5) REF   
Mandarin 0.892 (0.206) 0.875 (0.019) -0.003 -0.040, 0.035 0.89 73.8 (14.6) 76.4 (1.7) 0.022 -0.017, 0.061 0.27 
Chinese Dialects 0.872 (0.212) 0.867 (0.021) -0.011 -0.056, 0.033 0.61 74.5 (15.8) 74.8 91.8) 0.000 -0.045, 0.045 0.99 
Others 0.862 (0.191) 0.846 (0.023) -0.036 -0.103, 0.031 0.29 75.7 (17.4) 74.4 (2.0) -0.005 -0.071, 0.061 0.89 
Marital Status           
Married 0.899 (0.187) 0.853 (0.017) REF   73.4 (15.2) 75.3 (1.2) REF   
Single/Separated/Divorced/Widowed 0.857 (0.206) 0.880 (0.014) -0.031 -0.067, 0.005 0.10 74.5 (16.2) 74.8 (1.4) -0.008 -0.043, 0.027 0.67 
Education Level           
No Formal Education 0.883 (0.172) 0.886 (0.020) REF   79.8 (17.2) 81.9 (1.7) REF   
Primary 0.855 (0.243) 0.839 (0.016) -0.055 -0.096, -0.014 0.01* 73.0 (16.1) 74.7 (1.4) -0.092 -0.130, -0.053 <0.01* 
Secondary 0.912 (0.155) 0.871 (0.016) -0.017 -0.061, 0.027 0.44 72.3 (13.6) 73.4 (1.3) -0.11 -0.153, -0.068 <0.01* 
Post-Secondary 0.922 (0.156) 0.869 (0.019) -0.019 -0.073, 0.035 0.49 70.3 (13.7) 70.7 (1.6) -0.147 -0.202, -0.093 <0.01* 
Housing Type           
HDB 1/2/3 Room 0.864 (0.230) 0.844 (0.017) REF   73.7 (15.8) 73.7 (1.5) REF   
HDB 4 Room 0.886 (0.183) 0.860 (0.015) 0.019 -0.018, 0.055 0.31 74.1 (14.8) 75.1 (1.3) 0.019 -0.017, 0.054 0.30 
HDB 5 Room/HUDC 0.899 (0.193) 0.866 (0.016) 0.026 -0.016, 0.068 0.23 73.4 (16.7) 75.9 (1.4) 0.029 -0.012, 0.070 0.17 
Private Housing 0.935 (0.132) 0.895 (0.021) 0.059 0.007, 0.111 0.03* 72.4 (14.6) 75.6 (1.9) 0.026 -0.027, 0.079 0.34 
^Beta coefficient, 95% CI and p-values were obtained from linear regression with log link function; REF – reference group; *p<0.05 are considered statistically significant 
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Table 4-13. The Effect of Sociodemographic and Clinical Predictor Variables on Quality of Life of Recruited Participants (n=932) (continued) 
 
 
Predictor Variables 
EQ5D-UI EQ5D-VAS 
Unadjusted 
Mean (SD) 
Adjusted 
Mean (SE) 
Beta 
Coefficient^ 
95% CI^ p-value^ Unadjusted 
Mean (SD) 
Adjusted 
Mean (SE) 
Beta 
Coefficient^ 
95% CI^ p-value^ 
Ownership Status of Current Housing           
Owner 0.899 (0.176) 0.866 (0.014) REF   73.3 (15.0) 74.6 (1.1) REF   
Non-Owner 0.849 (0.250) 0.866 (0.018) 0.000 -0.039, 0.039 0.99 74.7 (17.4) 75.6 (1.5) 0.013 -0.024, 0.051 0.49 
Monthly Household Income           
<SGD2,000 0.887 (0.198) 0.877 (0.015) REF   75.8 (15.3) 76.6 (1.3) REF   
SGD2,000 – SGD3,999 0.903 (0.140) 0.872 (0.019) -0.005 -0.045, 0.034 0.80 72.1 (15.0) 73.8 (1.6) -0.036 -0.076, 0.004 0.08 
SGD4,000 – SGD5,999 0.930 (0.140) 0.876 (0.021) 0.000 -0.048, 0.047 0.99 74.1 (13.7) 76.9 (1.9) 0.005 -0.044, 0.053 0.86 
≥SGD6,000 0.918 (0.158) 0.859 (0.022) -0.020 -0.070, 0.030 0.43 72.7 (15.0) 76.3 (2.0) -0.003 -0.054, 0.048 0.91 
Income not disclosed 0.859 (0.235) 0.847 (0.016) -0.035 -0.071, 0.001 0.06 71.6 (16.5) 71.8 (1.4) -0.065 -0.100, -0.030 <0.01* 
Body Mass Index (BMI) NA NA -0.006 -0.010, -0.002 0.01* NA NA -0.002 -0.006, 0.001 0.24 
Chronic Disease Control Score (CDCS)           
1 (All 3 conditions optimally controlled) 0.874 (0.230) 0.846 (0.016) REF   72.5 (15.6) 73.2 (1.3) REF   
2 (1 condition sub-optimally controlled) 0.901 (0.181) 0.864 (0.014) 0.022 -0.012, 0.055 0.20 73.9 (15.5) 75.4 (1.2) 0.031 -0.003, 0.064 0.07 
3 (2 conditions sub-optimally controlled) 0.878 (0.178) 0.851 (0.017) 0.006 -0.035, 0.047 0.77 73.9 (15.3) 75.8 (1.4) 0.035 -0.005, 0.075 0.08 
4 (3 conditions sub-optimally controlled) 0.940 (0.099) 0.905 (0.027) 0.068 0.006, 0.130 0.03* 74.9 (16.4) 75.9 (2.3) 0.037 -0.027, 0.101 0.26 
Additional Disease Count – Self 
Reported (ADC-SR) 
          
0 0.929 (0.145) 0.920 (0.015) REF   73.6 (15.5) 75.8 (1.2) REF   
1 0.865 (0.214) 0.871 (0.015) -0.056 -0.085, -0.026 <0.01* 73.2 (15.4) 75.3 (1.3) -0.006 -0.036, 0.024 0.72 
2+ 0.802 (0.251) 0.811 (0.020) -0.127 -0.174, -0.080 <0.01* 71.8 (15.1) 74.1 (1.7) -0.023 -0.068, 0.023 0.33 
Additional Disease Count – Electronic 
Medical Records (ADC-EMR) 
          
0 0.925 (0.120) 0.878 (0.017) REF   73.8 (15.5) 75.5 (1.5) REF   
1 0.902 (0.182) 0.874 (0.015) -0.004 -0.038, 0.029 0.79 74.2 (15.4) 75.6 (1.3) 0.001 -0.032, 0.035 0.93 
2+ 0.851 (0.235) 0.847 (0.015) -0.036 -0.074, 0.002 0.07 72.7 (15.5) 74.0 (1.3) -0.020 -0.058, 0.017 0.29 
Chronic Medication Count (CMC) NA NA -0.005 -0.012, 0.001 0.13 NA NA -0.008 -0.015, -0.001 0.02* 
^Beta coefficient, 95% CI and p-values were obtained from linear regression with log link function; REF – reference group; *p<0.05 is considered statistically significant 
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3.6 Concordance of self-reported additional chronic conditions and 
those recorded in Electronic Medical Records (EMR) 
 
We explored the agreement between self-reported additional chronic conditions and those 
recorded in the electronic medical records by using kappa statistics in SPSS (Table 4-14).  We 
excluded 29 cases with missing data in this analysis.   
 
We considered κ values of < 0.20 as slight, 0.21 - 0.40 as fair, 0.41 - 0.60 as moderate, 0.61 – 
0.80 as substantial, and 0.81 – 1.00 as almost perfect according to the Landis and Koch’s 
classification60.  Out of fifteen conditions, ten of them showed a statistically significant 
difference in the concordance rate between self-reported conditions and those reported in the 
EMR.  Stroke was the only condition that had substantial agreement with a concordance rate 
(κ) of 0.61.  Parkinson’s disease, Schizophrenia, and Asthma had a moderate agreement with 
a concordance rate (κ) of 0.44, 0.43, and 0.42 respectively.  Dementia and Major Depression 
had a fair agreement with a concordance rate (κ) of 0.31 and 0.27 respectively.  Osteoporosis, 
Anxiety, Osteoarthritis, and Chronic Kidney Disease (CKD) had a slight agreement with a 
concordance rate (κ) of 0.13, 0.10, 0.06, and 0.01 respectively.  Benign prostate hypertrophy, 
Rheumatoid Arthritis, and Bipolar Disorder had no agreement and were not statistically 
significant.  The concordance rate was not calculated for COPD and Psoriasis as no patients 
self-reported the former condition and the EMR did not record any participant for the latter 
condition. 
 
The positive agreement ranged from 0.04 to 0.65 for the ten conditions that were found to have 
a p-value for prevalence-adjusted bias-adjusted kappa (PABAK) < 0.05.  The negative 
agreement ranged from 0.58 to 1.00.  In general, κ was aligned with the positive and negative 
agreement.  However, PABAK was very different ranging from -0.18 to 0.99.  κ was 
consistently lower than PABAK with the difference ranging from 0.19 (chronic kidney disease) 
to 0.86 (anxiety). 
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Table 4-14.Concordance of Additional Disease Count between Self-Reported and Electronic Medical Records of Recruited Participants (n=903) 
 ADC-EMR Positive 
Agreement 
Negative 
Agreement 
Kappa Bias 
Index 
Prevalence 
Index 
PABAK p-value for 
PABAK  No % Yes % Total % 
Stroke        0.65 0.96 0.61 0.06 0.78 0.84 <0.01* 
ADC-SR  No 769 85.2 62 6.9 831 92.0        
 Yes 8 0.9 64 7.1 72 8.0        
 Total 777 86.0 126 14.0 903 100.0        
Parkinson’s Disease        0.44 1.00 0.44 0.00 0.99 0.99 <0.01* 
ADC-SR No 896 99.2 3 0.3 899 99.6        
 Yes 2 0.2 2 0.2 4 0.4        
 Total 898 99.4 5 0.5 903 100.0        
Schizophrenia        0.43 1.00 0.43 0.01 0.98 0.98 <0.01* 
ADC-SR No 892 98.8 7 0.8 899 99.6        
 Yes 1 0.1 3 0.3 4 0.4        
 Total 893 98.9 10 1.1 903 100.0        
Asthma        0.44 0.98 0.42 0.01 0.92 0.91 <0.01* 
ADC-SR No 847 93.8 14 1.6 861 95.3        
 Yes 26 2.9 16 1.8 42 4.7        
 Total 873 96.7 30 3.3 903 100.0        
Dementia        0.31 0.99 0.31 0.01 0.99 0.98 <0.01* 
ADC-SR No 892 98.8 9 1.0 901 99.8        
 Yes 0 0.0 2 0.2 2 0.2        
 Total 892 98.8 11 1.2 903 100.0        
Major Depression        0.29 0.98 0.27 0.02 0.95 0.93 <0.01* 
ADC-SR No 867 96.0 23 2.5 890 98.6        
 Yes 7 0.8 6 0.7 13 1.4        
 Total 874 96.8 29 3.2 903 100.0        
Osteoporosis        0.14 0.98 0.13 0.02 0.95 0.92 <0.01* 
ADC-SR No 864 95.7 28 3.1 892 98.8        
 Yes 8 0.9 3 0.3 11 1.2        
 Total 872 96.6 31 3.4 903 100.0        
Anxiety        0.11 0.99 0.10 0.01 0.98 0.96 <0.01* 
ADC-SR No 885 98.0 11 1.2 896 99.2        
 Yes 6 0.7 1 0.1 7 0.8        
 Total 891 98.7 12 1.3 903 100.0        
kappa< 0 no agreement, 0–0.20 as slight, 0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 as substantial, and 0.81–1 as almost perfect agreement. *p<0.05 is considered statistically significant.
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Table 4-14. Concordance of Additional Disease Count between Self-Reported and Electronic Medical Records of Recruited Participants 
(n=903)(Continued) 
 ADC-EMR Positive 
Agreement 
Negative 
Agreement 
Kappa Bias 
Index 
Prevalence 
Index 
PABAK p-value for 
PABAK  No % Yes % Total % 
Osteoarthritis        0.10 0.93 0.06 0.10 0.86 0.75 0.01* 
ADC-SR  No 783 86.7 102 11.3 885 98.0        
 Yes 12 1.3 6 0.7 18 2.0        
 Total 795 88.0 108 12.0 903 100.0        
CKD        0.04 0.58 0.01 0.59 0.39 -0.18 0.03* 
ADC-SR No 361 40.0 530 58.7 891 89.7        
 Yes 1 0.1 11 1.2 12 1.3        
 Total 362 40.1 541 59.9 903 100.0        
Benign Prostate 
Hypertrophy 
       0.06 0.98 0.04 0.00 0.96 0.93 0.22 
ADC-SR No 870 96.3 17 1.9 887 98.2        
 Yes 15 1.7 1 0.1 16 1.8        
 Total 885 98.0 18 2.0 903 100.0        
Rheumatoid Arthritis        0.04 0.97 0.03 0.05 0.94 0.89 0.07 
ADC-SR No 853 94.5 3 0.3 856 94.8        
 Yes 46 5.1 1 0.1 47 5.2        
 Total 899 99.6 4 0.4 903 100.0        
Bipolar Disorder        0.00 1.00 -0.002 0.00 1.00 0.99 NA 
ADC-SR No 899 99.6 2 0.2 901 99.8        
 Yes 2 0.2 0 0.0 2 0.2        
 Total 901 99.8 2 0.2 903 100.0        
COPD        0.00 0.99 NA 0.02 0.98 0.97 NA 
ADC-SR No 889 98.4 14 1.6 903 100.0        
 Yes 0 0.0 0 0.0 0 0.0        
 Total 889 98.4 14 1.6 903 100.0        
Psoriasis        0.00 1.00 NA 0.00 1.00 0.99 NA 
ADC-SR No 899 99.6 0 0.0 899 99.6        
 Yes 4 0.4 0 0.0 4 0.4        
 Total 903 100.0 0 0.0 903 100.0        
kappa< 0 no agreement, 0–0.20 as slight, 0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 as substantial, and 0.81–1 as almost perfect agreement. *p<0.05 is considered statistically significant. 
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3.7 Subgroup Analysis 
 
We examined the difference in demographic characteristics between those who did not disclose 
their household income with those who did using a chi-square test (Table 4-15).  Six of the 
eight demographic variables showed statistically significant differences. 
 
Table 4-15. Sociodemographic and Clinical Characteristics of Recruited Participants Who 
Declared or Refused to Declare Monthly Household Income 
 
 
Predictor Variables 
Declared Household 
Income (n=694) 
Refused to Declare 
Household Income 
(n=238) 
 
p-value^ 
n % n % 
Age      
<55 years old 98 14.1 17 7.1  
 
<0.01* 
55-64 years old 265 38.2 65 27.3 
65-74 years old 256 36.9 104 43.7 
≥75 years old 75 10.8 52 21.8 
Sex      
Male 411 59.2 102 42.9  
<0.01* Female 283 40.8 136 57.1 
Ethnicity      
Chinese 548 79.0 221 92.9  
<0.01* Non-Chinese 146 21.0 17 7.1 
First Language      
English 193 27.8 40 16.8  
 
<0.01* 
Mandarin 249 35.9 99 41.6 
Chinese Dialects 140 20.2 87 36.6 
Others 112 16.1 12 5.0 
Marital Status      
Married 558 80.4 181 76.1  
0.15 Single/Separated/Divorced/Widowed 136 19.6 57 23.9 
Education Level      
No Formal Education 107 15.4 65 27.3  
 
<0.01* 
Primary 205 29.5 89 37.4 
Secondary 253 36.5 62 26.1 
Post-Secondary 129 18.6 22 9.2 
Housing Type      
HDB 1/2/3 Room 146 21.0 48 20.2  
 
0.40 
HDB 4 Room 292 42.1 98 41.2 
HDB 5 Room/HUDC 178 25.6 55 23.1 
Private Housing 77 11.1 36 15.1 
Ownership Status of Current 
Housing 
     
Owner 602 86.7 164 68.9  
<0.01* Non-Owner 91 13.1 74 31.1 
^ p-values were obtained from chi-square tests; *p<0.05 is considered statistically significant. 
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Those who did not disclose their household income were more likely to be older, be women 
rather than men, be of Chinese ethnicity, use Mandarin and Chinese dialects as their first 
language, have no formal or only primary education, and more likely not to own their current 
housing.  
 
3.8 Sensitivity Analysis 
 
We carried out a sensitivity analysis by comparing the different methods of dealing with 
missing data on the multivariable regression analysis for the four outcome variables.  We 
considered the use of listwise deletion because a large enough sample was available, the 
listwise deletion method was not prone to Type 1 error, the method was simple, and it provided 
‘factual’ standard errors that reflected the actual amount of information obtained from the 
study54,67.  Furthermore, the regression analysis would have chosen listwise deletion by default 
as SPSS software would delete cases with any missing data on the variables of interest for 
complete case analysis or listwise deletion67. 
 
Therefore, regression analyses were conducted using listwise deletion.  The two tables in 
Appendix 4-11 show the full multivariable regression for complete case analysis of 847 
participants.  Multiple imputation and listwise deletion provided exactly similar analysis results 
for three outcome variables PHQ-9, GAD-7, and EQ-5D VAS.  However, for EQ-5D UI, there 
were four discrepancies.  Conflicting results are compared in Tables 4-16 & 4-17 to that found 
with multiple imputation (Tables 4-12 & 4-13). 
 
Using the multiple imputation method, age group (p=0.03) and chronic disease control score 
(CDCS) (p=0.03) were found to be associated with EQ-5D UI score but the listwise deletion 
method did not pick up these two predictor variables (Table 4-16). 
 
The listwise deletion method also picked up two other predictor variables that were negatively 
associated with EQ-5D UI.  These two variables were sex (p=0.09) and marital status (p=0.10) 
which were not picked up by the multiple imputation method (Table 4-17).  We noted that the 
mean EQ-5D UI score for male and female participants who were excluded from the listwise 
deletion method (n=85) was 0.721 and 0.842 respectively.  For the same group of participants 
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who were excluded from the listwise deletion, the mean EQ-5D UI score for those who were 
married and those who were not married were 0.764 and 0.831 respectively (Table 4-17). 
 
 
Table 4-16. Two variables where Multiple Imputation method showed significant p-value but 
not Listwise Deletion method 
 
 
Variables 
n = 932 n = 847 
EQ-5D UI 
Unadjusted 
mean 
(Multiple 
Imputation) 
Beta-
Coefficient 
p-value^ 
EQ-5D UI 
Unadjusted 
mean 
(Listwise 
Deletion) 
 
Beta-
Coefficient 
p-value^ 
Age 
< 55 years old 0.910 REF REF 0.900 REF REF 
≥ 75 years old 0.837 -0.068 0.03* 0.869 -0.039 0.15 
Chronic Disease Control Score 
1  
(All conditions 
optimally controlled) 
0.874 REF REF 0.894 REF REF 
4  
(All conditions not 
optimally controlled) 
0.940 0.068 0.03* 0.939 0.047 0.08 
^ p-values were obtained from linear regression with log link function; REF – reference group; *p<0.05 is considered 
statistically significant. 
 
Table 4-17. Two variables where Listwise Deletion method showed significant p-value but 
not Multiple Imputation method  
 
 
Variables 
n = 932   n = 847   n = 85 
EQ-5D UI 
Unadjusted 
mean 
(Multiple 
Imputation) 
Beta-
Coefficient 
p-value^ 
EQ-5D UI 
Unadjusted 
mean 
(Listwise 
Deletion) 
 
Beta-
Coefficient 
p-value^ 
EQ-5D UI 
Unadjusted 
mean 
(Excluded 
participants 
from 
Listwise 
Deletion) 
Sex        
Male 0.904 REF REF 0.922 REF REF 0.721 
Female 0.873 -0.025 0.09 0.877 -0.036 <0.01* 0.842 
Marital Status        
Married 0.899 REF REF 0.913 REF REF 0.764 
Not married 0.857 -0.031 0.10 0.859 -0.042 0.01* 0.831 
^ p-values were obtained from linear regression with log link function; REF – reference group; *p<0.05 is considered 
statistically significant.   
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4 Discussion 
 
There were four objectives to this study.  The primary objective was to determine whether a 
higher level of multimorbidity was associated with a higher degree of depression and anxiety 
symptoms, and a lower quality of life.   We found that all four different instruments for 
measuring the level of multimorbidity were variably associated with the three outcomes.  
Comparisons of our findings and the possible reasons for the associations are discussed in more 
detail in Sections 4.1 to 4.5.  
 
The second objective of the study was to describe the prevalence of depression and anxiety, 
and the average score of quality of life in individuals with the commonest triad of 
multimorbidity in primary care in Singapore.  We found that the prevalence of depression was 
12.0%, the prevalence of anxiety was 11.8%, the mean score of EQ-5D utility index score was 
0.890, and the mean score of EQ-5D visual analogue scale score was 73.6. 
 
Our third objective was to determine the factors associated with depression, anxiety or poor 
quality of life for patients with the commonest triad of multimorbidity in Singapore.  We found 
that marital status was associated with depression.  Age, education level, housing type, and 
body mass index were associated with quality of life.  Comparisons of our findings and the 
possible reasons for the associations are discussed in more detail in Sections 4.1 to 4.3. 
 
The final objective of this study was to determine the concordance rate between self-reported 
medical conditions by patients and medical conditions recorded in their electronic medical 
records.  We found that ten out of the fifteen conditions had a slight to substantial agreement.  
We will discuss this further in Section 4.6. 
 
4.1 Depression 
 
The prevalence of mild to severe depression was 12.0% in this study. This was consistent with 
rates of 6-22% which were reported in clinical trials of depression screening68.  Compared to 
the 11.4% prevalence of depression in individuals 55 years and above with coexisting medical 
comorbidity using the Geriatric Depressive Scale in the local community69, the prevalence rate 
was slightly higher in the primary care setting. 
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The only sociodemographic factor that was found to be associated with depression was marital 
status.  In our study, we found that the odds ratio of participants who were not married 
compared to those who were married was 1.69 (p = 0.048).  It has been reported that different 
marital statuses were found to be associated with depression but the strength of association was 
modified by age and sex70.    As a large majority of participants were married, our study did 
not have ample power to further differentiate whether there were differences between those 
who were single, separated, divorced, or widowed. 
 
4.2 Anxiety 
 
The prevalence of subthreshold generalised anxiety disorder reported in a systematic review 
ranged from 1.3% to 8.3% for primary care patients71 and 2.1% in the local general 
population72.  Therefore, the prevalence of 11.8% for mild to severe anxiety in this study 
indicated that anxiety level was generally higher for the most common pattern of 
multimorbidity compared to other studies that included people with and without 
multimorbidity.  No sociodemographic factors were found to be associated with anxiety. 
 
4.3  Quality of life (Utility Index) 
 
The EQ-5D UI value norms for 20 countries based on country-specific time trade-off values 
ranged from 0.855 to 0.95873.  The mean score of EQ-5D UI was 0.890 in this study population.  
This was lower than the mean score of 0.95 that was reported for the general population in 
Singapore52.  The EQ-5D UI score was 0.87 for patients with diabetes, and 0.91 for patients 
with hypertension indicating that the mean EQ-5D UI score in this study was not dissimilar in 
those with chronic conditions.   
 
Those aged 75 years and older reported lower quality of life compared with those younger than 
55 years old.   The negative correlation between age and quality of life, even after adjustment 
for the effect of chronic conditions, was supported by several studies74,75.  Hunger et al.76 
showed that the age-related decline in the quality of life was only observed from the age of 70 
years old onwards which was very similar to this study. 
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Those with primary school education reported a poorer quality of life compared to those who 
had no formal education.  Looking at the adjusted mean EQ-5D UI score, those with secondary 
education or above also seemed to have a poorer quality of life score compared to those with 
no formal education without statistical significance (Table 4-13).  This finding is more 
pronounced in the EQ-5D VAS score and will be discussed more in the next section. 
 
Using housing as a measure of socioeconomic status, we found those in private housing 
reported better quality of life compared to those who stayed in HDB 1/2/3 room flats.   Many 
other studies supported this finding of better housing being associated with better quality of 
life80-83. 
 
An increased body mass index has been found to be strongly associated with health-related 
quality of life77-79.  Our study result was consistent with this finding. 
 
4.4 Quality of life (Visual Analogue Scale) 
 
The EQ-5D VAS value norms for 20 countries based on country-specific time trade-off 
values ranged from 70.4 to 83.373.  The mean score of EQ-5D VAS was 73.6 in this study 
population.  The VAS score for the patients with diabetes was 69.9 in a 2012 local study84. 
 
Generally, international studies have shown that the amount of schooling was positively 
associated with quality of life in the physical, psychological, social and environmental domains 
across countries, culture, sex and age85.  This differs from what we found in this study.  Our 
results showed that participants who had any level of education were found to have a lower 
quality of life compared to those who had no formal education.  The trend seemed to suggest 
that the higher the education level, the lower the quality of life.  
 
Powdthavee86 in a study in 2008 found that after controlling for income and employment status, 
life satisfaction was on average lower for those with higher levels of education.  She cited a 
plausible explanation for this was that a comparison effect could be present where a higher 
education level raised the expectation of quality of life.  It is highly possible that her findings 
and explanation for the British citizens may be similar for our population in Singapore too. 
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More than 25% of participants did not disclose their household income.  This is not uncommon 
in surveys and ways to improve the response rates to this sensitive question have been 
reported87.  We found that participants who did not disclose their income reported lower VAS 
score when compared to those who earned less than SGD 2,000 (p < 0.01).  We explored the 
characteristics for participants who did not disclose their income in Table 4-15.  Those who 
did not disclose their household income were more likely to be older, be women rather than 
men, be of Chinese ethnicity, use Mandarin and Chinese dialects as their first language, have 
no formal or only primary education, and were more likely not to own their current housing.  
Answers to sensitive question are subject to normal sources of reporting errors but they also 
have an added problem whereby respondents basically do not want to tell the truth88.  As such, 
interpreting the findings from household income may not be accurate and alternative ways of 
getting such information should be considered in future studies. 
 
Six independent predictor variables were associated with EQ-5D UI while three independent 
predictor variables were associated with EQ-5D VAS.  Out of these, education was the only 
factor where the EQ-5D UI and EQ-5D VAS data was aligned.  The observed differences in 
results between EQ-5D UI and EQ-5D VAS have been reported by other studies89.  Compared 
to the EQ-5D UI where participants were asked to rate their quality of life based on five 
dimensions, the EQ-5D VAS asked for the participants’ overall rating of their health.  Any 
aspects of health-related quality of life that mattered to the participants (i.e., not just the five 
dimensions) would influence the way they rate their overall health.  Our study confirms that 
the visual analogue scale (EQ-5D VAS) measures a broader underlying construct of health 
summarising overall health that is closer to the patient’s perspective compared to the utility 
index (EQ-5D UI)89. 
 
4.5 Instruments for measuring the level of multimorbidity 
 
We included all four instruments in the same regression model and found that there was no 
multicollinearity (Appendix 4-10).  This indicated the multi-dimensional nature of 
multimorbidity as all four instruments for measuring the level of multimorbidity were 
associated with all the outcome measures (depression, anxiety and quality of life) in some way 
or another with differing results. 
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4.5.1. Chronic Disease Control Score (CDCS) 
 
No associations were found between the CDCS and depression or anxiety symptoms.  
However, CDCS showed an association with quality of life using EQ-5D UI (not EQ-5D VAS).  
Interestingly, patients classified as CDCS ‘4’ (all three chronic conditions sub-optimally 
controlled) was associated with a better quality of life when compared with those who were 
optimally controlled, i.e., CDCS ‘1’.  This was contrary to our hypothesis. 
 
There could be several explanations to this observation.  Firstly, the trajectory of living with 
chronic disease is not linear90. The period directly after newly acquiring a chronic disease may 
lead to a decreased quality of life that might diminish or disappear when a patient has adjusted 
to the newly acquired illness91.  Adaptation and resilience may be at play here where the quality 
of life is maintained or in this case, better, in the face of objectively poor health conditions92.  
Our study did not look at the duration of the chronic conditions which could have helped to 
shed more information on this phenomenon.   
 
Secondly, poor agreement between patients and doctors on their diverging views on patients’ 
suffering and quality of life is not new93-95.  It is plausible that a poorer quality of life resulted 
from the treatment burden imposed on patients when they work hard to keep all the three 
clinical parameters optimally controlled.  Conversely, those patients who chose not to be 
restrained by the treatment burden resulting in sub-optimal control of their clinical conditions 
experienced a better quality of life before illness burden became overbearing.  This explanation 
further highlights the chasm that may exist between patients and doctors’ perspectives on 
multimorbidity.   
 
4.5.2 Additional disease count – self-reported (ADC-SR) and electronic medical 
records (ADC-EMR) 
 
The association of higher disease count and poorer mental health has been well-documented96-
98.  The inverse relationship between the number of self-reported chronic conditions and quality 
of life has also been shown in multiple studies12, 15-17, 19, 99.  Our results in this study were 
consistent with these findings.  The ADC-SR was found to be positively associated with 
depressive symptoms, anxiety symptoms, and negatively associated with quality of life using 
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the EQ-5D (UI) (not EQ-5D VAS).  When more chronic conditions were self-reported, the 
more likely the patient had a lower quality of life. 
 
ADC-EMR did not show a similar result.  On the contrary, the anxiety score of patients who 
had one additional chronic condition compared to those with none was reduced.  The direction 
of the anxiety score seemed to be similar when more additional chronic conditions were 
considered even though there was no statistical significance (Table 4-12).  One explanation for 
this might be that when physicians documented conditions that mattered to the patients, their 
anxiety level dropped.  It was plausible that anxiety level went up if patients were concerned 
with certain chronic conditions but these conditions were not acknowledged and documented 
by their doctors (as in ADC-SR).  Our postulation of the above relationship between ADC-
EMR and anxiety symptoms would need to be further explored in future studies. 
 
4.5.3 Chronic medication count (CMC) 
 
A higher CMC was found to be associated with a poorer quality of life using the EQ-5D VAS 
(not EQ-5D UI).  This was consistent with findings on the effects of polypharmacy and quality 
of life in several studies100,101. 
 
4.6 Concordance 
 
There are several clinical implications for the findings from the concordance study.  First of 
all, Singapore had consistently ranked as one of the top five countries in the world with the 
highest number of end-stage renal disease102.  Alarmingly, more than half of the patients 
(58.7%) with chronic kidney disease (CKD) recorded in their EMR did not self-report about 
the condition (Table 4-14). There could be several reasons for this discrepancy.  From the 
clinicians’ perspectives, this could imply that either the doctors were downplaying the 
significance of early stage CKD and not informing patients, or they were not explaining the 
condition well to patients.  From the patients’ perspectives, it could be that they had been 
informed but did not consider the condition important enough to be reported during the 
interview, or they did not understand what was explained to them.  
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Secondly, it has been reported that patients often confused the term ‘rheumatoid arthritis’ with 
rheumatism103.  The results of this study also seemed to suggest that as ‘rheumatoid arthritis’ 
had the lowest positive agreement of only 0.04.  This was one of the three conditions where 
patients self-reported more than that recorded in the EMR.  Health literacy and communication 
between care providers and patients may be the main issue here. 
 
Thirdly, according to the kappa statistic, the majority of conditions in this study had only slight 
to fair agreement between what was self-reported by patients and what was recorded in the 
EMR.  Adjusting for the low prevalence of the conditions studied, resulted in substantially 
higher agreement coefficients as measured by PABAK, except for CKD.  However, the very 
high PABAK values with low positive agreement e.g., anxiety and osteoarthritis, raise doubt 
about its reliability as an agreement statistic.  Therefore, PABAK values should still be 
interpreted with caution and the evaluation and conclusion for the strength of agreement should 
be judged from many aspects104. 
 
Fourthly, all ten conditions that were statistically significant had a high negative agreement of 
more than 0.90 except CKD which was only at 0.58.  From the results of this study, sole reliance 
on the use of medical records may not be warranted.  This is especially so in a fee-for-service 
environment where patients may obtain multiple sources of care for different health conditions. 
Self-reporting of medical conditions allows patients to provide their perception of those 
problems that interfere more in their everyday lives and are in line with the concept of the 
evidence-based patient information105.  Therefore, self-reports may better reflect conditions 
more likely to affect patients’ mental health status and quality of life.  The discrepancy between 
the two sources of medical diagnoses is a concern for epidemiological research106. 
 
On average, patients in this study reported fewer additional chronic conditions during the 
interview than what was documented in the EMR (twelve conditions had lower self-reported 
‘yes’ compared to EMR). This was contrary to what was reported in a similar study in 2008107.   
 
The possible reasons for the lower self-reports are summarised below.  Firstly, it could be due 
to a lack of awareness on the part of the patients about the presence of a condition108.  Secondly, 
patients might consider some health conditions were not important enough to use health 
services and failed to report them.  Thirdly, because the study was conducted as a face-to-face 
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interview, the social desirability effect could be at play especially for mental disorders109.  
Fourthly, sporadic diseases from the patients’ perspective may not be reported; studies have 
reported that conditions like osteoarticular diseases tend to be reported less frequently by 
patients due to its sporadic course110. 
 
4.7 Multiple imputation and Listwise deletion 
 
We explored the reasons for the discrepancy between the results in the multivariable regression 
analysis that we found when we used the two methods of dealing with missing data as 
demonstrated in the sensitivity analysis.   
 
For the two predictors ‘age’ and ‘CDCS’, type II error was introduced due to the loss of sample 
size when listwise deletion was used (Table 4-16). The loss of data led to larger standard errors, 
wider confidence intervals, and a loss of power in hypotheses testing67.   
 
We next explored the reasons for the listwise deletion method identifying two predictor 
variables as significant – sex and marital status which the multiple imputation did not find.  The 
mean EQ-5D UI scores were lower for the male participants (0.721) and for participants who 
were married (0.764) than the mean EQ-5D UI scores for the males (0.922) and those married 
(0.913) for the complete case analysis using the listwise deletion method (Table 4-17).  As 
such, when these participants were included in the multiple imputation method, the mean EQ-
5D score was pulled down and did not achieve a significant difference for either the female 
participants or those who were not married resulting in a Type I error when using listwise 
deletion. 
 
When data were not missing completely at random, listwise deletion may have introduced bias.  
This was clearly demonstrated in our case above for selecting the EQ-5D UI as an outcome 
even though the two methods provided similar results for the other three outcomes - PHQ-9, 
GAD-7 and EQ-5D VAS. Multiple imputation is therefore advocated because it uses 
information in the incomplete cases, performs better as more variables are included in the 
analysis model, and it is valid when values were missing at random (MAR) where listwise 
deletion is biased111. 
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4.8  Strengths and Limitations of the study 
 
4.8.1 Strengths 
 
The strengths of the study include the following.  First of all, we randomly selected all patients 
known in Hougang Polyclinic that had come for follow-up of the most common triad of 
multimorbidity instead of convenience sampling.  This helps to reduce selection bias by 
including patients who made unplanned visits.  It is a known fact that patients who attend 
physician visits that are unplanned consistently have a poorer state of health112.  Second, we 
used all the official languages in Singapore to interview our participants so as not to exclude 
potential patients from the minority group.  Third, we took into account the implications of 
missing value and conducted a sensitivity analysis.  We further provided a detailed analysis of 
the possible reasons for the discrepancies noted between the two different analyses.  Fourth, 
we provided the positive and negative agreements and preference-adjusted and bias-adjusted 
kappa (PABAK) to better understand the agreement between self-reported medical conditions 
and those recorded in the EMR.  Finally, we provided the report of the study based on the 
STROBE guidelines33. 
 
4.8.2 Limitations 
 
Our study also has several limitations other than some that have been mentioned before.  First, 
this was a cross-sectional study using the point estimate of depression, anxiety, quality of life, 
and only the last single clinical parameter during and around the period of the interview.  
Causation cannot be determined because of the design of the study.  Second, the quality of 
morbidity coding in primary care consultations may be variable among diagnoses, e.g., coding 
of diabetes tended to be of higher quality than coding of asthma113.  Third, the study did not 
take into account other missing data mechanisms under which multiple imputation is biased 
and listwise deletion is not.  These mechanisms do not correspond to missing completely at 
random, missing at random or missing not at random categories, but cut across this 
classification111.  Fourth, despite the random selection of eligible participants, we found that 
there were more male to female participants and therefore the study findings may not be 
generalisable.  Lastly, we did not include lifestyle behaviours that may have impact on the three 
outcomes including smoking, physical activity, diet and sleep. 
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4.9  Conclusion and future 
 
Out of the four instruments for measuring the level of multimorbidity, only Additional Disease 
Count - Self-Reported (ADC-SR) was positively associated with depression and anxiety 
symptoms, and negatively associated with quality of life (Utility Index).  Patients with all three 
chronic conditions that were sub-optimally controlled reported a higher score for quality of life 
compared to those who were optimally controlled (Chronic Disease Control Score).  A higher 
chronic medication count was also associated with a poorer quality of life.  Finally, a higher 
number of additional chronic conditions using electronic medical records was associated with 
a lower score for anxiety symptoms reported by participants.  These findings together with the 
finding that, for the majority of chronic conditions, there was only slight to fair concordance 
between ADC-SR and AC-EMR further highlights the discrepancy of the source of chronic 
conditions reported by patients and those reported by the doctors i.e., medical records. 
 
The prevalence of depressive symptoms was 12.0% and the prevalence of anxiety symptoms 
was 11.8% for patients with the most common triad of multimorbidity in primary care; both 
prevalence rates were higher than the general population in Singapore.  The average score of 
quality of life using the EQ-5D utility index for patients with multimorbidity in primary care 
was 0.890 which was lower that of the general population but comparable to those with chronic 
diseases.  The average score of quality of life using the EQ-5D visual analogue scale was 73.6 
which was higher than 69.9 reported by patients with diabetes in Singapore. 
 
Factors found in our study that were associated with depression, anxiety and quality of life 
were largely consistent with those found in the current literature.  These included older age of 
75 years and above, participants living in small public housing, and those with higher body 
mass index being associated with poorer quality of life; and unmarried participants being 
associated with higher levels of depressive symptoms.  Contrary to most other studies, a higher 
education level was associated with a poorer quality of life. 
 
We found that only the condition, stroke showed substantial agreement between patients’ self-
reported medical conditions and the electronic medical records (EMR).  The majority of 
chronic conditions had only slight to fair concordance, and this study further highlights the 
incongruency of the source of chronic conditions reported by patients and those reported by 
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the doctors, i.e., medical records.  In general, patients self-reported fewer conditions than what 
was recorded in the EMR.  More than half of the patients with chronic kidney disease (58.7%) 
recorded in their EMR did not self-report about the condition. 
 
Understanding the patients’ expectations and experiences of multimorbidity would improve 
the alignment of goals of clinicians and patients in the documentation of medical conditions 
that truly matter to the patients, and may alleviate health care systems’ and clinicians’ obsession 
with surrogate clinical parameters.  It is essential to include the perspective of patients 
themselves who are the real experts in the day-to-day reality of living with multimorbidity 
thereby potentially embracing patient-centredness and reducing treatment burden.  Better 
communication with patients could also improve patient knowledge of their actual conditions. 
Future studies should look at the psychological process underlying patient adjustment to 
multimorbidity because of its potential to predict clinical, quality of life, and mental health 
outcomes. 
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6 Appendices 
Appendix 4-1. PHQ-9 Questionnaire 
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Appendix 4-2. GAD-7 Questionnaire 
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Appendix 4-3. EQ-5D Utility Index 
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Appendix 4-4. EQ-5D Visual Analogue Scale 
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Appendix 4-5. A summary list of all the outcome and independent variables 
 Variable name Abbreviation Type 
1 Age Age Categorical (4) 
2 Sex Sex Dichotomous 
3 Ethnicity Ethnicity Dichotomous 
4 First language Language Categorical (4) 
5 Marital status Marital status Categorical (4) 
6 Education level Education Categorical (4) 
7 Housing type Housing Categorical (4) 
8 Ownership status Ownership  Dichotomous 
9 Monthly household income Income Categorical (5) 
10 Body Mass Index BMI Continuous 
11 Chronic Disease Control Score CDCS Categorical (4) 
12 Additional disease count – self-reported ADC-SR Categorical (3) 
13 Additional disease count – electronic medical 
records 
ADC-EMR Categorical (3) 
14 Chronic medical count CMC Count 
15 Depression score PHQ-9 Dichotomous 
16 Anxiety score GAD-7 Dichotomous 
17 Quality of life – utility index EQ-5D UI Continuous 
18 Quality of life – visual analogue scale EQ-5D VAS Continuous 
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Appendix 4-6. Chronic Disease Condition Score (CDCS) 
Table 1 – Clinical control of chronic conditions based on Chronic Disease Management  
    Program Handbook45 
 
Chronic Condition Optimally controlled Sub-optimally controlled 
Diabetes47 HbA1c < 7.0% HbA1c ≥ 7.0 % 
Hyperlipidaemia44 LDL-c < 2.6mmol/L LDL-c ≥ 2.6 mmol/L 
Hypertension46 SBP < 140mmHg and  
DBP < 80mmHg 
SBP ≥ 140mmHg or  
DBP ≥ 80mmHg  
 
Table 2 – Chronic Disease Condition Score (CDCS) definition 
Score Explanation and remarks 
1 All three conditions were optimally controlled 
2 One of the three conditions was sub-optimally controlled and the other two were optimally controlled 
3 Two of the three conditions were sub-optimally controlled and the other one was optimally 
controlled 
4 All three conditions were sub-optimally controlled 
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Appendix 4-7. List of additional disease counts for ADC-SR & ADC-EMR 
List of Other Chronic Conditions for determining Additional Disease Count – self-reported and 
Additional Disease Count – Electronic Medical Record 
1. Stroke 
2. Asthma 
3. Chronic Obstructive Pulmonary Disease (COPD) 
4. Major Depression 
5. Schizophrenia 
6. Dementia 
7. Bipolar Disorder 
8. Anxiety 
9. Parkinson’s Disease 
10. Chronic Kidney Disease 
11. Benign Prostate Hypertrophy 
12. Osteoarthritis 
13. Rheumatoid Arthritis 
14. Osteoporosis 
15. Psoriasis 
16. Others, please specify:  _____________ 
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Appendix 4-8. Normality tests for independent variables - BMI, CMC, ADC-SR & EMR 
BMI (Body Mass Index)      
 
 
Variable 
Kolmogorov-Smirnov test Shapiro-Wilk test 
Statistic df Sig. Statistic df Sig. 
BMI .063 866 .000 .970 866 .000 
From visual inspection, the variable BMI was considered not to be normally distributed as the frequency 
distribution showed right skewness, and the Q-Q plot did not form a straight diagonal line55. Moreover, both the 
Lilliefors corrected Kolmogorov-Smirnov and Shapiro-Wilks’s tests were statistically significant (p < 0.05).  
Therefore, the variable BMI was not normally distributed. 
CMC (Chronic Medication Count) 
 
 
Variable 
Kolmogorov-Smirnov test Shapiro-Wilk test 
Statistic df Sig. Statistic df Sig. 
CMC .105 866 .000 .977 866 .000 
The variable CMC was considered to be normally distributed as the frequency distribution and the Q-Q plot 
satisfied the visual methods for assessing normality despite having significant test results for both the Lilliefors 
corrected Kolmogorov-Smirnov and Shapiro-Wilks’s tests55.   
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Appendix 4-8. Normality tests for independent variables - BMI, CMC, ADC-SR & EMR 
(Continued) 
ADC-SR     ADC-EMR 
(Additional Disease Count – Self-Reported)  (Additional Disease Count – Electronic Medical Record) 
 
The distribution frequency of ADC-SR and ADC-EMR were both positive skewed with clustering at ‘0’.  
Therefore, the two variables were changed to categorical variables with three categories of ‘0’, ‘1’, ‘2 and 
more’. 
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Appendix 4-9. Normality tests for dependent variables – EQ-5D UI & EQ-5D VAS 
EQ-5D Utility Index 
  
 
Variable 
Kolmogorov-Smirnov test Shapiro-Wilk test 
Statistic df Sig. Statistic df Sig. 
EQ-5D UI .314 932 .000 .615 932 .000 
From visual inspection, the variable EQ-5D UI was considered not to be normally distributed as the frequency 
distribution showed left skewness with clustering at ‘1.000’, and the Q-Q plot did not form a straight diagonal 
line55. Moreover, both the Lilliefors corrected Kolmogorov-Smirnov and Shapiro-Wilks’s tests were statistically 
significant (p < 0.05).  Therefore, the variable EQ-5D UI was not normally distributed. 
EQ-5D Visual Analogue Scale 
  
 
Variable 
Kolmogorov-Smirnov test Shapiro-Wilk test 
Statistic df Sig. Statistic df Sig. 
EQ-5D VAS .122 932 .000 .957 932 .000 
From visual inspection, the variable EQ-5D VAS was considered not to be normally distributed as the frequency 
distribution showed left skewness, and the Q-Q plot did not form a straight diagonal line55. Moreover, both the 
Lilliefors corrected Kolmogorov-Smirnov and Shapiro-Wilks’s tests were statistically significant (p < 0.05).  
Therefore, the variable EQ-5D VAS was not normally distributed.   
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Appendix 4-9. Normality tests for dependent variables – EQ-5D UI & EQ-5D VAS 
(Continued) 
EQ-5D UI Residual  
    
 
From visual inspection, the EQ-5D UI residuals showed left skewness in the frequency distribution, and the P-P 
plot did not form a straight diagonal line55.  Therefore, the residuals of EQ-5D UI was not normally distributed. 
 
 
EQ-5D VAS Residual     
 
From visual inspection, the EQ-5D VAS residuals showed left skewness in the frequency distribution, and the 
P-P plot did not form a straight diagonal line55.  Therefore, the residuals of EQ-5D VAS was not normally 
distributed. 
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Appendix 4-10. Multicollinearity Tests 
 
Variance Inflation Factor 
Variables VIF 
First Language Constant 
Marital Status 1.141 
Education Level 1.205 
Housing Type 1.212 
Ownership Status of Current Housing 1.192 
Monthly Household Income 1.078 
 
Variables VIF 
CDCS Constant 
ADC-SR 1.062 
SDC-EMR 1.071 
CMC 1.136 
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Appendix 4-11. Multivariable Regression Analysis using listwise deletion (n=847) 
 
Table 1A:  The Effect of Sociodemographic and Clinical Predictor Variables on Depression and Anxiety of 
Recruited Participants (n=847) 
 
Predictor Variables 
PHQ9   GAD7   
Odds 
Ratio^ 
95% CI^ p-value^ Odds 
Ratio^ 
95% CI^ p-value^ 
Age       
<55 years old REF   REF   
55-64 years old 1.29 0.57,2.94 0.55 0.87 0.44,1.73 0.70 
65-74 years old 1.08 0.46,2.51 0.86 0.68 0.33,1.42 0.30 
≥75 years old 1.47 0.53,4.07 0.46 1.02 0.40,2.63 0.96 
Sex       
Male REF   REF   
Female 0.95 0.59,1.53 0.84 1.24 0.78,1.99 0.37 
Ethnicity       
Chinese REF   REF   
Non-Chinese 1.02 0.33,3.12 0.98 0.73 0.26,2.03 0.54 
First Language       
English REF   REF   
Mandarin 0.90 0.46,1.79 0.77 0.68 0.36,1.27 0.22 
Chinese Dialects 1.17 0.55,2.50 0.69 0.56 0.26,1.21 0.14 
Others 1.92 0.60,6.13 0.27 1.70 0.58,4.99 0.34 
Marital Status       
Married REF   REF   
Single/Separated/Divorced/Widowed 2.05 1.19,3.55 0.01* 1.66 0.95,2.90 0.08 
Education Level       
No Formal Education REF   REF   
Primary 1.05 0.56,1.98 0.87 1.26 0.65,2.47 0.50 
Secondary 0.74 0.36,1.52 0.41 0.63 0.29,1.35 0.23 
Post-Secondary 0.59 0.22,1.54 0.28 0.88 0.35,2.17 0.77 
Housing Type       
HDB 1/2/3 Room REF   REF   
HDB 4 Room 0.76 0.43,1.32 0.33 0.78 0.43,1.42 0.41 
HDB 5 Room/HUDC 0.71 0.36,1.41 0.33 1.40 0.73,2.69 0.31 
Private Housing 0.67 0.27,1.67 0.39 0.79 0.32,1.98 0.61 
Ownership Status of Current 
Housing 
      
Owner REF   REF   
Non-Owner 0.88 0.48,1.61 0.67 0.80 0.42,1.52 0.50 
Monthly Household Income       
<SGD2,000 REF   REF   
SGD2,000 – SGD3,999 1.11 0.59,2.10 0.74 1.56 0.85,2.86 0.16 
SGD4,000 – SGD5,999 1.01 0.42,2.41 0.98 0.90 0.40,2.06 0.81 
≥SGD6,000 1.73 0.78,3.82 0.18 1.28 0.57,2.86 0.55 
Income not disclosed 0.55 0.30,1.02 0.06 0.78 0.43,1.45 0.44 
^Odds ratio, 95% CI and p-values were obtained from logistic regression; REF – reference group; *p<0.05 is considered 
statistically significant. 
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Table 1A:  The Effect of Sociodemographic and Clinical Predictor Variables on Depression and Anxiety of 
Recruited Participants (n=847) (continued) 
 
Predictor Variables 
PHQ9 GAD7 
Odds Ratio^ 95% CI^ p-value^ Odds 
Ratio^ 
95% CI^ p-value^ 
Body Mass Index (BMI) 0.96 0.90,1.01 0.13 1.00 00.94,1.05 0.87 
Chronic Disease Control 
Score (CDCS) 
      
1 REF   REF   
2 1.33 0.77,2.30 0.31 1.12 0.64,1.96 0.69 
3 0.91 0.46,1.78 0.78 1.10 0.58,2.09 0.78 
4 0.48 0.13,1.73 0.26 0.69 0.22,2.20 0.53 
Additional Disease Count – 
Self Reported (ADC-SR) 
      
0 REF   REF   
1 1.35 0.82,2.23 0.24 0.98 0.59,1.61 0.93 
2+ 2.86 1.53,5.34 0.001* 2.08 1.10,3.91 0.024* 
Additional Disease Count – 
Electronic Medical Records 
(ADC-EMR) 
      
0 REF   REF   
1 0.99 0.54,1.83 0.99 0.55 0.32,0.96 0.034* 
2+ 1.02 0.53,1.95 0.95 0.62 0.34,1.12 0.11 
Chronic Medication Count 
(CMC) 
1.06 0.95,1.19 0.31 1.06 0.95,1.19 0.30 
^Odds ratio, 95% CI and p-values were obtained from logistic regression; REF – reference group; *p<0.05 is considered 
statistically significant. 
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Table 1B: The Effect of Sociodemographic and Clinical Predictor Variables on Quality of Life of Recruited Participants (n=847) 
 
Predictor Variables 
EQ5D-UI EQ5D-VAS 
Unadjusted 
Mean (SD) 
Adjusted 
Mean (SE) 
Beta 
Coefficient^ 
95% CI^ p-value^ Unadjusted 
Mean (SD) 
Adjusted 
Mean (SE) 
Beta 
Coefficient^ 
95% CI^ p-value^ 
Age           
<55 years old 0.900 (0.186) 0.870 (0.018) REF   71.3 (17.1) 73.1 (1.8) REF   
55-64 years old 0.907 (0.156) 0.877 (0.013) 0.007 -0.031,0.046 0.71 72.6 (14.7) 73.8 (1.3) 0.010 -0.037,0.058 0.67 
65-74 years old 0.908 (0.151) 0.876 (0.013) 0.007 -0.033,0.047 0.74 74.3 (15.4) 74.7 (1.3) 0.023 -0.026,0.072 0.37 
≥75 years old 0.869 (0.173) 0.837 (0.018) -0.039 -0.090,0.013 0.15 75.5 (14.2) 75.3 (1.8) 0.030 -0.032,0.091 0.34 
Sex           
Male 0.922 (0.142) 0.880 (0.013) REF   72.0 (14.4) 73.3 (1.3) REF   
Female 0.877 (0.178) 0.849 (0.012) -0.036 -0.061,-0.012 0.004* 75.3 (16.1) 75.2 (1.3) 0.025 -0.004,0.054 0.09 
Ethnicity           
Chinese 0.908 (0154) 0.863 (0.013) REF   73.5 (15.0) 72.8 (1.3) REF   
Non-Chinese 0.868 (0.186) 0.866 (0.019) 0.003 -0.050,0.057 0.91 73.7 (16.4) 75.6 (2.0) 0.038 -0.028,0.103 0.26 
First Language           
English 0.927 (0.138) 0.876 (0.016) REF   71.3 (15.1) 74.3 (1.6) REF   
Mandarin 0.909 (0.156) 0.880 (0.017) 0.005 -0.027,0.037 0.77 74.1 (14.5) 75.7 (1.7) 0.019 -0.021,0.059 0.35 
Chinese Dialects 0.893 (0.162) 0.872 (0.018) -0.004 -0.043,0.034 0.82 74.6 (15.5) 73.9 (1.8) -0.004 -0.051,0.042 0.85 
Others 0.850 (0.197) 0.830 (0.020) -0.053 -0.112,0.006 0.08 73.9 (17.1) 73.0 (2.0) -0.017 -0.087,0.054 0.65 
Marital Status           
Married 0.913 (0.150) 0.883 (0.012) REF   73.3 (15.1) 74.8 (1.2) REF   
Single/Separated/Divorced/Widowed 0.859 (0.191) 0.846 (0.014) -0.042 -0.073,-0.011 0.009* 74.1 (16.0) 73.7 (1.4) -0.015 -0.051,0.022 0.43 
Education Level           
No Formal Education 0.892 (0.152) 0.878 (0.017) REF   80.5 (16.3) 81.7 (1.8) REF   
Primary 0.876 (0.187) 0.845 (0.014) -0.039 -0.074,-0.004 0.03* 72.6 (16.0) 73.5 (1.5) -0.106 -0.146,-0.067 <0.0001* 
Secondary 0.922 (0.133) 0.874 (0.014) -0.005 -0.042,0.033 0.80 71.9 (13.4) 72.1 (1.3) -0.124 -0.168,-0.081 <0.0001* 
Post-Secondary 0.919 (0.160) 0.861 (0.016) -0.019 -0.066,0.027 0.41 70.6 (13.9) 70.1 (1.6) -0.153 -0.209,-0.097 <0.0001* 
Housing Type           
HDB 1/2/3 Room 0.889 (0.176) 0.851 (0.015) REF   73.2 (15.2) 72.7 (1.5) REF   
HDB 4 Room 0.891 (0.161) 0.854 (0.013) 0.004 -0.027,0.035 0.81 73.8 (14.8) 74.0 (1.3) 0.018 -0.019,0.055 0.33 
HDB 5 Room/HUDC 0.910 (0.159) 0.863 (0.014) 0.014 -0.022,0.050 0.45 73.7 (16.5) 75.3 (1.4) 0.035 -0.008,0.078 0.11 
Private Housing 0.940 (0.127) 0.891 (0.018) 0.046 0.002,0.091 0.04* 72.6 (14.5) 75.0 (1.9) 0.031 -0.024,0.085 0.27 
^Beta coefficient, 95% CI and p-values were obtained from linear regression with log link function; REF – reference group; *p<0.05 are considered statistically significant 
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Table 1B: The Effect of Sociodemographic and Clinical Predictor Variables on Quality of Life of Recruited Participants (n=847) (continued) 
 
Predictor Variables 
EQ5D-UI EQ5D-VAS 
Unadjusted 
Mean (SD) 
Adjusted 
Mean (SE) 
Beta 
Coefficient^ 
95% CI^ p-value^ Unadjusted 
Mean (SD) 
Adjusted 
Mean (SE) 
Beta 
Coefficient^ 
95% CI^ p-value^ 
Ownership Status of Current Housing           
Owner 0.910 (0.148) 0.865 (0.012) REF   73.3 (14.7) 73.9 (1.2) REF   
Non-Owner 0.866 (0.206) 0.864 (0.015) -0.001 -0.034,0.033 0.97 74.6 (17.4) 74.6 (1.5) 0.010 -0.029,0.049 0.62 
Monthly Household Income           
<SGD2,000 0.900 (0.168) 0.877 (0.013) REF   75.4 (15.1) 75.6 (1.3) REF   
SGD2,000 – SGD3,999 0.903 (0.135) 0.862 (0.016) -0.017 -0.051,0.017 0.33 71.7 (14.8) 72.7 (1.6) -0.039 -0.081,0.002 0.06 
SGD4,000 – SGD5,999 0.936 (0.135) 0.878 (0.018) 0.002 -0.038,0.043 0.92 74.5 (13.5) 76.5 (1.9) 0.012 -0.037,0.061 0.63 
≥SGD6,000 0.913 (0.162) 0.849 (0.019) -0.032 -0.075,0.011 0.14 72.8 (14.9) 75.3 (2.0) -0.004 -0.056,0.048 0.88 
Income not disclosed 0.884 (0.173) 0.857 (0.014) -0.023 -0.053,0.007 0.14 72.0 (16.3) 71.1 (1.4) -0.061 -0.097,-0.025 0.001* 
Body Mass Index (BMI) NA NA -0.003 -0.006,0.000 0.023* NA NA -0.002 -0.006,0.001 0.20 
Chronic Disease Control Score (CDCS)           
1 (All 3 conditions optimally controlled) 0.894 (0.171) 0.854 (0.014) REF   72.7 (15.1) 72.6 (1.4) REF   
2 (1 condition sub-optimally controlled) 0.914 (0.149) 0.866 (0.012) 0.014 -0.014,0.042 0.33 73.8 (15.4) 74.5 (1.2) 0.030 -0.004,0.064 0.09 
3 (2 conditions sub-optimally controlled) 0.875 (0.179) 0.843 (0.014) -0.014 -0.048,0.02 0.43 74.0 (15.0) 75.6 (1.4) 0.040 0.000,0.081 0.05 
4 (3 conditions sub-optimally controlled) 0.939 (0.101) 0.895 (0.023) 0.047 -0.006,0.100 0.08 73.4 (15.8) 74.1 (2.4) 0.021 -0.045,0.086 0.54 
Additional Disease Count – Self 
Reported (ADC-SR) 
          
0 0.934 (0.136) 0.914 (0.013) REF   73.8 (15.4) 74.7 (1.2) REF   
1 0.885 (0.164) 0.871 (0.013) -0.048 -0.073,-0.023 <0.0001* 73.4 (15.3) 74.2 (1.3) -0.007 -0.037,0.023 0.64 
2+ 0.817 (0.201) 0.811 (0.017) -0.119 -0.159,-0.079 <0.0001* 72.8 (14.6) 73.8 (1.7) -0.012 -0.057,0.032 0.59 
Additional Disease Count – Electronic 
Medical Records (ADC-EMR) 
          
0 0.924 (0.122) 0.869 (0.015) REF   73.4 (15.5) 74.4 (1.5) REF   
1 0.911 (0.162) 0.869 (0.013) 0.000 -0.029,0.029 0.99 74.1 (15.1) 74.8 (1.3) 0.006 -0.029,0.041 0.75 
2+ 0.875 (0.179) 0.854 (0.013) -0.017 -0.050,0.015 0.29 72.9 (15.3) 73.5 (1.3) -0.012 -0.051,0.026 0.53 
Chronic Medication Count (CMC) NA NA -0.004 -0.009,0.002 0.24 NA NA -0.008 -0.015,-0.001 0.024* 
^Beta coefficient, 95% CI and p-values were obtained from linear regression with log link function; REF – reference group; *p<0.05 is considered statistically significant 
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1 Introduction 
 
The major gaps in multimorbidity research concern the immaturity of the different 
measurements of multimorbidity: prevalence, levels of morbidity burden, and outcomes.  
Therefore, this thesis aimed to narrow these gaps by providing a uniform definition for 
multimorbidity in order to define the prevalence of multimorbidity in the primary care 
population in Singapore, identifying a list of instruments to measure the levels of 
multimorbidity and exploring some patient-reported outcomes and their association with 
different levels of multimorbidity. 
 
Three studies were conducted to achieve the above aims.  Chapter Two reported the first study 
on the prevalence and patterns of multimorbidity:  the title is ‘The Prevalence and the common 
patterns of multimorbidity in Singapore:  An Epidemiological Study based on Administrative 
Data’  (PESAD); Chapter Three reported the systematic review and the title is ‘A Systematic 
review on the Instruments used for measuring the level of multimorbidity’ (SIM); Chapter Four 
reported the study of the outcomes of multimorbidity and the title is ‘Multimorbidity and its 
association with depression, anxiety and quality of life’ (MDAQ). 
  
The thesis has met these aims.  In Chapter Two (PESAD) on prevalence and patterns of 
multimorbidity, the study compared the standardised prevalence rates of multimorbidity based 
on two different multimorbidity lists (CDMP and Fortin lists) with two different cut-points, 
and identified the Fortin list with ‘three or more’ chronic conditions as a better definition of 
multimorbidity in the primary care population.  The systematic review, Chapter Three (SIM), 
found 33 different instruments reported since January 2010 to August 2018 that were used to 
measure the levels of multimorbidity for specific outcomes in the primary care and general 
population.  Finally, Chapter Four (MDAQ), a study of outcomes of multimorbidity, found that 
the outcomes depressive symptoms, anxiety symptoms, and quality of life of patients with 
multimorbidity were associated with different levels of multimorbidity. 
 
Section 2 of this concluding chapter will elaborate further on these results and synthesise what 
was learnt from the findings reported in Chapters Two, Three and Four.  Section 3 discusses 
the importance of considering age, sex and ethnicity when studying multimorbidity.  Based on 
all the findings reported in Chapters Two, Three and Four, some new insights are shared in 
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Sections 4, 5 and 6 where the future directions in the conceptualisation of multimorbidity, 
future directions in multimorbidity research, and future directions in clinical practice will be 
discussed. 
 
2 The measurement of multimorbidity 
 
2.1  Defining multimorbidity 
 
The fundamental reason for a wide variety of prevalence rates among multimorbidity studies 
is the contentious issues related to the definition of multimorbidity.  On top of using reporting 
guidelines like RECORD1 for Chapter Two (PESAD) on the prevalence and patterns of 
multimorbidity and STROBE2 for Chapter Four (MDAQ) for the cross-sectional study on the 
outcomes of multimorbidity, five components of the definition of multimorbidity were also 
identified and included in both chapters.  These five components were: 
a) the types of conditions selected to form the multimorbidity list;  
b) the total number of conditions considered in the multimorbidity list;  
c) the data sources of the chronic conditions;  
d) the cut-points used to define multimorbidity; and  
e) the reference population. 
 
When data were extracted for the included articles for the systematic review in Chapter Three 
(SIM), the provision of these five components were purposefully searched from each article.  
Only 34.3% of the included studies provided at least a brief statement of what a chronic 
condition was.  The total number of conditions considered in the multimorbidity list ranged 
from seven to 147 diseases in this review but only slightly more than half of them, i.e., 56.7% 
of the studies, provided a full list of the conditions.  Finally, only 34.3% of the studies stated 
clearly the cut-points they used to define multimorbidity.  In total, only 20.9% of the studies 
included all three components, i.e., the definition of chronic condition, list of conditions and 
cut-points used to define multimorbidity.  The data sources of the chronic conditions and the 
reference population were the only two components that were stated in all the included studies. 
 
In Chapter Two (PESAD), different definitions of multimorbidity for determining the 
prevalence of multimorbidity in the Singapore primary care population were explored and it 
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was found that Fortin’s list with a cut-off of ‘three or more’ conditions was clinically more 
meaningful.  However, using ‘three or more’ conditions as a cut-off was not commonly used 
in multimorbidity studies.   For the included studies in the systematic review in Chapter Three 
(SIM) where the cut-points was mentioned, only two studies used the cut-off of ‘three or more’ 
conditions3-5.  The MDAQ study reported in Chapter Four used a cut-off of three specific 
chronic conditions as the inclusion criteria. 
 
2.2  Measuring multimorbidity 
 
Lefevre et al.6 listed four common methods of measuring multimorbidity as described in 
Chapter One.  They are: by simple counts of chronic diseases from a list of individual 
conditions (i.e., disease count), by grouping chronic diseases into dyads or triads (i.e., dyad and 
triad patterns), by identifying homogeneous groups of people with common disease and 
characteristics (i.e., non-random association patterns), and by using an index of variable 
complexity (i.e., weighted indices).  However, this classification does not clearly explain the 
different purposes of measuring multimorbidity7.  
 
It is important to establish the purpose of measuring multimorbidity and to note that the 
same instrument can serve different purposes8.  According to de Vet et al.8, the three main 
purposes of measurement in medicine are for diagnosis, evaluation of intervention and 
prediction of outcome.  Discriminant measurement is for diagnosis, evaluation measurement 
is for evaluation after an intervention, and predictive measurement is to predict a specific 
outcome.  The studies conducted in this thesis have improved on the terminology of 
measuring multimorbidity based on Lefevre et al.’s6 classification.  Therefore, it is proposed 
that explicitly described measurements of multimorbidity should be upfront in all 
multimorbidity studies and should  include the purpose, i.e., discriminant, evaluative or 
predictive, using de Vet et al.’s8 framework.  As the studies in this thesis did not involve 
intervention studies, the types of measurement of multimorbidity described in this thesis 
were mainly discriminant and predictive measurements. These two types of measurements 
are described below. 
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2.2.1 Discriminant measurement 
 
Measuring the prevalence of multimorbidity is a discriminant measurement and using disease 
count is a common practice as used in Chapter Two (PESAD).  For understanding the patterns 
of multimorbidity, ‘dyads and triads’ of combinations and random associations of chronic 
conditions are frequently used, and these are also discriminant measurements.  ‘Dyads and 
triads’ was used in Chapter Two (PESAD) and distinct differences in patterns of 
multimorbidity between the different ethnic/sex groups were found. 
 
Multimorbidity is common.  Comparing the outcomes between patients with multimorbidity 
and no multimorbidity has already been well-established as described in Chapter One (Section 
4.1 to 4.3 p5-6).  However, in this thesis, measuring different levels of multimorbidity in 
Chapters Three (SIM) and Four (MDAQ) were also done.  The frequent instruments used for 
measuring the level of multimorbidity include disease count, weighted indices of varying 
complexity, case-mix, and drug counts as reported in the systematic review.    Chronic disease 
control score, additional disease count-self-reported, additional disease count-electronic 
medical records, and chronic medication count were used in Chapter Four (MDAQ).  In de Vet 
et al.’s8 framework, these instruments are also discriminant measurements as they distinguish 
among the different levels of multimorbidity. 
 
Out of the four different instruments used in Chapter Four (MDAQ) that comprises of chronic 
disease control score (CDCS), additional disease count-self-reported (ADC-SR), additional 
disease count-electronic medical records (ADC-EMR), and chronic medication count (CMC), 
only CDCS was not found in the list of instruments identified in the systematic review in 
Chapter Three (SIM). 
 
2.2.2 Predictive measurement 
 
Chapters Three (SIM) and Four (MDAQ) also looked at the specific outcomes that were 
predicted******** by the different levels of multimorbidity.  In this case, the different levels of 
multimorbidity were used as predictive measurements for specific outcomes like depressive 
                                                 
******** The term ‘predicted’ is used here to mean ‘associated with’ as the MDAQ study is a cross-sectional study 
whereby causal relationships cannot be ascertained. 
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symptoms, anxiety symptoms and quality of life in Chapter Four.  However, when focusing on 
the independent variables, the differentiation of multimorbidity into different levels is a 
discriminant measurement as mentioned in Section 2.2.1 above. 
Four different instruments in Chapter Four (MDAQ) were used to predict the outcomes of 
patients with multimorbidity in primary care using an observational interviewer-administered 
questionnaire.  The study found that poorer disease control was associated with a better quality 
of life which was contrary to the hypothesis.  It was postulated that when patients worked hard 
to keep all the three clinical parameters for each of the chronic diseases optimally controlled, 
the resultant treatment burden imposed on them led to a poorer quality of life.  Conversely, 
those patients who chose not to be restrained by the treatment burden resulting in sub-optimal 
control of their clinical conditions experienced a better quality of life before illness burden 
became overbearing.  This finding was interpreted based on the conceptual framework of 
minimally disruptive medicine that is described further in Section 4 later. 
 
In summary, the work done in this thesis has improved the description and terminology of 
measurements of multimorbidity based on Lefevre et al.’s6 classification.  Authors should make 
it clear to readers whether investigators are discriminating between patients with 
multimorbidity or no multimorbidity, or among patients with different levels of 
multimorbidity.  The same instrument, i.e., disease count, can be used as a prediction 
instrument for specific outcomes, or an evaluation instrument if there were an intervention. De 
Vet et al.8 suggested to speak of discriminative, predictive or evaluative applications than of 
instruments because the same instrument can be used for different purposes. 
 
2.3 Disease count by self-report or electronic medical records 
 
In Chapter Three (SIM), out of the 33 instruments identified in the systematic review for 
measuring the level of multimorbidity, 21 of them were obtained from administrative or 
medical records, 12 of them were self-reported by participants of the studies, and two of the 
studies obtained data from both medical records and self-reports of participants.  Despite the 
different sources of data on chronic conditions in these studies, the outcomes associated with 
the different levels of multimorbidity were all aligned. 
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However, in the study of outcomes of multimorbidity in Chapter Four (MDAQ), additional 
disease count-self reported (ADC-SR) and additional disease count-electronic medical record 
(ADC-EMR) were associated in different directions for the patient-reported outcome of anxiety 
symptoms.  A higher number of ADC-SR was associated with a higher level of anxiety, but a 
higher number of ADC-EMR was associated with a lower level of anxiety. (Chapter Four 
Table 4-12 p199). 
 
Additionally, there was, at the most only, moderate agreement between the two data sources 
for 15 chronic conditions.  The one exception was for the condition ‘stroke’ where there was 
substantial agreement.  The patient-reported outcomes (depressive symptoms, anxiety 
symptoms, and quality of life) associated with ADC-SR were aligned with the findings of the 
systematic review in Chapter Three (SIM) but not ADC-EMR.  The implications of this 
disparity are discussed further in Section 4. 
 
3 Age, sex and ethnicity 
 
This section looks at the significance of considering age, sex and ethnicity when studying 
multimorbidity especially in a multi-ethnic society of Singapore that comprises the three main 
ethnic groups of Chinese, Malay and Indian.   
 
3.1 Age 
 
Age was related to the standardised prevalence rates of multimorbidity in Chapter Two 
(PESAD) in much the same way as in the literature9-16 with a rise in the prevalence rates with 
advancing age.  Similarly, in Chapter Four (MDAQ), it was found that being in the oldest age 
group was associated with a lower quality of life (EQ-5D utility index) compared to those less 
than 55 years old, which was consistent with previous literature17,18. 
 
3.2 Sex 
 
Although the evidence of an association between multimorbidity and sex has not been 
consistent across studies19,  investigators who conducted multimorbidity studies in primary 
care found no sex differences in the prevalence of multimorbidity20-24.  Similarly, in Chapter 
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Two (PESAD), no sex differences in the standardised prevalence rates of multimorbidity was 
found.  Sex was also not found to be associated with depressive symptoms, anxiety symptoms, 
or quality of life in the MDAQ study (Chapter Four). 
 
3.3 Ethnicity 
 
The literature on race or ethnic group in relation to multimorbidity is sparse as shown by the 
systematic review in Chapter Three (SIM) finding that only two25,26 of 22  studies using 
prognostic models included race. Therefore, the addition this thesis makes to the literature is 
somewhat original and potentially important. In the descriptive study on the prevalence and 
patterns of multimorbidity in Chapter Two (PESAD), the standardised prevalence rates were 
not found to be clinically different among the three major ethnic groups of Singapore (Chinese, 
Malay, and Indian) for those age from 0 to 99.  However, different distinct patterns of dyads 
and triads of multimorbidity were noted between the different ethnic/sex groups for those ages 
45 years old and above. The latter finding indicates how potentially important it will be for 
future studies in multi-ethnic communities to identify any clinically important differences in 
the patterns of dyads and triads, to prepare clinicians to provide appropriate care, hopefully 
using relevant guidelines developed for the unique communities of patients. Ethnicity was not 
found to be associated with depressive symptoms, anxiety symptoms, or quality of life in 
Chapter Four (MDAQ). 
 
4 Future directions in the conceptualisation of multimorbidity 
 
Chapter One introduced two concepts/frameworks of relevance to multimorbidity: the Patient-
Centred Clinical Method (PCCM); and Minimally Disruptive Medicine (MDM). The thesis 
findings resonate well with PCCM because the variable that was the most strongly associated 
with patient-reported outcomes was the patient self-reported count of chronic conditions.  In 
other words, the patient’s perspective, i.e., the measure of patients’ self-reported conditions, 
was the most valid in terms of its relationship with outcomes.  Once again, as has been found 
before in the literature, patient perceptions are the key to patient outcomes27. 
 
Minimally disruptive medicine (MDM) emphasises the importance of balancing the capacity 
of patients with the workload experienced by patients with multimorbidity.  The workload of 
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such patients is imposed both by the treatment rendered by the health care providers (treatment 
burden) and the demands of life which are outside the control of health care providers28.  The 
concept of MDM was used to explain the unexpected finding in the MDAQ study reported in 
Chapter Four where patients with multimorbidity that have poorer disease control were 
associated with a better quality of life.  Buffel du Vaure et al.29 reported that the potential 
workload for patients with multimorbidity in applying different clinical practice guidelines was 
too arduous and not practical for patients and inevitably induced poor adherence, wasted 
resources and poorer outcomes29.  Similarly, the capacity of coping with multimorbidity was 
overwhelmed by the treatment burden imposed such that poorer surrogate outcomes (i.e., 
control of individual chronic conditions) were observed in patients who chose not to adhere to 
the clinical advice and therefore reported better quality of life. 
 
While both concepts PCCM and MDM have been used to interpret the findings in Chapter Four 
(MDAQ), the prevalence study in Chapter Two (PESAD) highlighted the importance of 
individual chronic conditions that when combined, constituted the phenomenon of 
multimorbidity.  The literature supports considering multimorbidity as an entity of 
interdependent parts which the PCCM advocates in its language about understanding the whole 
person.  Cassel talks of this  interdependence30 and Koestler31 described the ‘wholes’ that 
simultaneously are ‘parts’ of other ‘wholes’ as ‘holons’.  Single conditions are the ‘parts’ of 
multimorbidity (‘whole’), and the same multimorbidity is also a ‘part’ or ‘holon’ of the overall 
health (‘whole’). 
 
The new insights obtained from looking at how multimorbidity is formed from single 
conditions suggested that multiple conditions within an individual, are not necessarily caused 
by independent mechanisms32.  A common underlying physiological disease process(es) may 
be at play.  These underlying process(es) affect the whole individual across the molecular, 
personal and social domains of life and physiologically lead to a new state of objective and 
subjective adaptation.  Recognising that multimorbidity reflects an underlying disturbance in a 
network of interlinked neuroendocrine, immunological and cellular processes allows clinicians 
and scientists to view an individual with multimorbidity as both a ‘whole’ and a ‘part’ of the 
bigger scheme of life. 
 
Future directions should consider the notion of ‘interdependence with an underlying unifying 
mechanism’ together with PCCM and MDM in the conceptualisation of multimorbidity. 
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5 Future directions in multimorbidity research 
 
The results of this thesis have led to the recognition of two important directions for 
multimorbidity research: involvement of patients in multimorbidity research; and the creation 
of the most appropriate data sources for the measurement of multimorbidity. 
 
Involving the individuals with multimorbidity in priority setting and preferences in a resource-
scarce climate in healthcare is both rational and ethical.  The finding in this thesis, that patient 
self-reported measure of multimorbidity was the most highly associated with outcomes, 
supports this thrust.  Besides, research into patients’ perspectives on how multimorbidity 
affects their health, well-being, and clinical care is pertinent lest one falls into the McNamara 
fallacy†††††††† of focusing on certain metrics of measuring multimorbidity and neglecting the 
less easily quantifiable attributes of health care such as self-management behaviour and 
treatment burden33.  The shift to involve patients in multimorbidity research will encompass 
abandoning a linear, reductionist view of the world to an integrated understanding of the 
complexity of multimorbidity and its management moving from ‘what is the matter?’ to ‘what 
matters?’34 to the patient. 
 
The lack of a ‘gold standard’ data source in obtaining accurate medical conditions is a hurdle 
in multimorbidity research.  There have been advocates in the scientific community to adopt 
real-world data (RDW) such as electronic medical records and administrative data for the 
evaluation of epidemiology and burden of disease, treatment patterns, adherence, persistence, 
and health outcomes of different treatments35.  However, there are also concerns about their 
use36,37, with similar apprehensions being echoed from findings in this thesis.  Fundamentally, 
the problem lies in the messy evolvement of our medical records that have grown cumbersome 
for serving too many purposes38.  A re-conceptualisation and further research work on how we 
document chronic conditions for patient care and clinical research is urgently needed.  Until 
issues related to the re-conceptualisation of our current documentation of chronic conditions 
                                                 
†††††††† “The first step of McNamara’s fallacy is to measure whatever can easily be measured. This is OK as far as it goes. 
The second step is to disregard that which can’t be easily measured or to give it an arbitrary quantitative value. 
This is artificial and misleading. The third step is to presume that what can’t be measured easily really isn’t 
important. This is blindness. The fourth step is to say that what can’t be easily measured really doesn’t exist. This 
is suicide.” (O'Mahony S. Medicine and the McNamara fallacy. J R Coll Physicians Edinb 2017;47(3):281-87.) 
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are addressed such that the documentation truly captures patients concerns, chronic conditions 
self-reported by patients would be the preferred data source for multimorbidity research for 
now. 
 
Finally, researchers studying multimorbidity should aim to make their work reproducible by 
reporting their work transparently to allow direct and conceptual replication.  All the work done 
for multimorbidity to improve the body of knowledge on the subject should be incremental and 
useful to the world literature.  In preparing this thesis, it was found that most researchers were 
not as transparent as they should be, making it difficult to achieve the above aim.  This is an 
area of improvement in multimorbidity research that should not be trivialised. 
 
6 Future directions in clinical practice 
 
System-level rationing is the norm in the current model of care where ageing and 
multimorbidity threatens the sustainability of many health care systems40.  The findings in this 
thesis point to paying closer attention to the patients’ perceptions of their morbidity as these 
are the measures that were related to the outcomes of interest and therefore the best solution 
for sustainability at the patient, clinician, and system level.   
 
Care is better when it recognises what patients’ defined problems are rather than focusing only 
on what the diagnoses are41.  Health care providers should aim to provide minimally disruptive 
medicine by not focusing solely on improving clinical parameters as recommended by 
individual clinical practice guidelines42.  The overall aim is to provide patient-centred care as 
described by Stewart et al.43, the ‘willingness to become involved in the full range of difficulties 
individuals bring to their doctors, and not just their biomedical problems’.  However, medical 
education in the last few decades has concentrated on the latter and promoted reductionism, 
specialisation, mechanistic models of disease, and faith in a definitive cure44.  The way we 
deliver caregiving will have to be revamped in both undergraduate, postgraduate training and 
daily practice especially in our management of individuals with multimorbidity.   
 
Although there were no clinically significant differences in the prevalence rates of 
multimorbidity between the different sexes and among the different ethnic groups, but 
importantly distinct patterns of multimorbidity were identified in the different ethnic and sex 
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groups in our population.   Kastner et al.’s systematic review on effective interventions for 
managing multimorbidity in older adults also found the occurrence of commonly occurring 
diseases dyads like diabetes and cardiovascular diseases, and urged researchers to investigate 
the potential impact of interventions on these clusters of chronic conditions45.  As such, primary 
care physicians should partake in the development of guidelines for the most common 
combinations of chronic conditions that are personalised to each subgroup.  Ideally, the payoff 
time framework‡‡‡‡‡‡‡‡ should be included in the guidelines and preferably in electronic form 
individualised to each patient46. 
 
7 Conclusion 
 
The research work undertaken in this thesis has added to the body of knowledge on the 
definition of multimorbidity and suggested the most appropriate data source for multimorbidity 
research pertaining to patient-reported outcomes in a multi-ethnic country.  The thesis has also 
helped to improve on the terminology used in measuring multimorbidity and provided an 
updated list of instruments for measuring the level of multimorbidity in community-dwelling 
adults with multimorbidity bearing in mind that the same instrument may have several 
applications. 
 
Developing strategies to manage individuals with multimorbidity on what truly matters to them 
will need further work.  These will include the identification of the unifying underlying 
mechanism(s) in the development of multimorbidity, involvement of patients in multimorbidity 
research, and development of multimorbidity clinical practice guidelines targeting specific 
sex/ethnic groups for health care providers.  
                                                 
‡‡‡‡‡‡‡‡ The earliest time when cumulative incremental benefits attributable to a clinical guideline exceed cumulative 
incremental harms attributable to that guideline. 
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